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Abstract
For this project I aimed to identify and investigate genes which regulate an invasive 
phenotype in thyroid carcinomas. To investigate this aim, I utilised an established in 
vitro model system which involves the introduction of the oncogenes RASV12, 
BRAFV600E and RET/PTC1 by retroviral infection into normal primary thyrocytes to 
represent the in vivo tumour situation. I adopted Affymetrix microarray gene 
expression profiling of the oncogene infected primary thyrocytes to identify candidate 
genetic markers facilitating thyroid invasion. In parallel I performed a literature 
analysis to identify additional markers of invasion. The genes identified from this 
analysis were Slug and Osteopontin. Osteopontin is over-expressed and enhances 
papillary carcinoma invasion in a Fisher rat cell line model of thyroid carcinoma. In 
tissue samples, Slug is over-expressed in papillary carcinomas. Currently, there is 
limited research on how Slug and Osteopontin regulate thyroid tumour invasion. I 
have investigated the role of Slug and Osteopontin in tumour invasion through the 
employment of RNA interference. I have analysed the role of Slug and Osteopontin 
in a number of invasive mechanisms. The mechanisms analysed included 
degradation of the extracellular matrix, cell motility, regulation of the actin 
cytoskeleton during cell migration, cell-matrix interactions and cell-cell interactions. 
The results indicate that Osteopontin influences the actin cytoskeleton by possibly 
regulating the formation of contractile stress fibres required for forward movement. 
Slug mediates tumour invasion by deregulating the cell-cell interactions which are 
important for maintaining normal epithelial architecture.
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PART I
1.0 Background
1.1 The Thyroid Gland
The thyroid gland is located on the anterior surface of the trachea at the base of the 
neck. It is comprised of lobules which contain spherical follicles which are lined with 
follicular epithelial cells. The follicles contain colloid, a store for thyroglobulin which is 
a precursor of the thyroid hormones, L-triodothyronine (T3) and L-thyroxine (T4). 
These hormones are regulated by the release of thyrotrophin-releasing hormone 
from the hypothalamus which induces the release of thyroid-stimulating-hormone 
(TSH) from the anterior pituitary gland. This stimulates the synthesis and secretion of 
T3 and T4 from the thyroid (Kondo et al. 2006) (Figure 1). Calcitonin producing C- 
cells are present at the junction of the upper and middle third of both thyroid lobes, 
and are situated within the follicles.
A
Co«o.J t oMinnj 10dm*. 
t h x o g U x i m  T ) « h jT 4  J
T h y r e a d
i  Figure 1. A, Representation of the 
thyroid gland detailing localisation and 
|  cells (Kondo et al. 2006). B, 
U Histological section of a normal thyroid
gland detailing follicles, epithelial cells
and colloid (D'Alessandro, 2005).
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Methods to investigate thyroid neoplasms prior to thyroidectomy include ultrasound 
imaging, nuclear scan and fine needle aspiration biopsy (FNA). The FNA offers the 
best preoperative diagnostic approach, with a reliability of 95% for the diagnosis of 
papillary thyroid carcinoma (PTC) (Zhao et al. 2008). This diagnostic approach is 
limited as it cannot differentiate follicular adenoma (FA) from follicular thyroid 
carcinoma (FTC) as these lesions have overlapping pathological features making a 
differential diagnosis difficult. Patients with indeterminate or suspicious tumours 
undergo thyroidectomy, and up to 80% of these particular surgeries are determined 
as FA (Nunez and Mendelsohn 1989). The sole criterion for the diagnosis of FTC is 
the demonstration of capsular or vascular invasion, ascertained by histological 
examination following thyroidectomy (Lewinski et al. 2000). There is a need for 
further improvements to diagnose and to identify differential genetic makers which 
may distinguish FTC from FA.
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1.2 Thyroid Neoplasia
Approximately 90% of thyroid tumours are derived from follicular epithelial cells, 
whilst the rest are derived from other cell types (DeLellis 2006). These epithelial 
tumours are classified as either follicular adenomas, follicular or papillary carcinomas 
(differentiated thyroid carcinomas) and anaplastic carcinomas (undifferentiated 
thyroid carcinomas).
1.2.1 Follicular Adenoma (FA)
Follicular adenomas are benign tumours which are distinguished from the 
surrounding parenchyma by a ‘well-defined’ intact fibrous tissue capsule. The tissue 
capsule is a thin connective tissue layer comprising a mixture of adipose and 
connective tissues with a variable thickness (Mete et al. 2010). Thyroid FAs are 
associated with haemorrhage, cystic degeneration, ossification, calcification and 
fibrosis (Suster 2006).
1.2.2 Follicular Thyroid Carcinoma (FTC)
Defined by the World Health Organisation (WHO), follicular carcinomas are 
malignant epithelial tumours with evidence of follicular cell differentiation and 
comprise of 10-15% of all thyroid malignancies, with a higher incidence in women 
(DeLellis 2006). FTCs derive from FA, and are also encapsulated comprising of 
follicles or follicular cells arranged in a follicular, solid or trabecular pattern. FTCs 
displaying transcapsular and/or limited vascular invasion are classified as minimally 
invasive FTC. Those FTCs which display wide spread capsular and vascular
4
invasion are classified as widely invasive FTCs (Baloch and Livolsi 2002). The 
presence of limited capsular invasion is an indicative risk factor for metastasis and 
recurrence. The risk is increased in FTCs with limited capsular and vascular 
invasion, and these widely invasive FTCs are associated with a significant increase 
in mortality and morbidity (DeLellis 2006). Metastasis occurs through the 
haematopoietic system to secondary sites such as the brain, liver and lungs 
(Mazzaferri 1999). The presence of capsular and/or vascular invasion in FTC are the 
only histopathological differences which distinguish FTCs from FAs.
1.2.3 Papillary Thyroid Carcinoma (PTC)
Papillary carcinomas are defined as malignant tumours which derive from follicular 
cells. They comprise -90% of all thyroid malignancies, occurring mainly in women at 
a ratio of 4-5:1 (DeLellis 2006). The diagnostic features of PTC include characteristic 
papillae where the papillary cores are covered by neoplastic cells. They lack a 
tumour capsule and possess distinct histopathological features including nuclear 
enlargement and irregularity with finely dispersed chromatin, a highly folded nuclear 
membrane and an abnormal nuclear contour. Metastasis of PTC occurs through the 
lymphatic system (Al-Brahim and Asa 2006). Variants of classical PTC have been 
identified and these tumours present a diagnostic challenge as they may be 
encapsulated or possess nuclear features as seen with conventional PTC.
Papillary carcinomas may also present as ‘microcarcinomas’, and these are defined 
as papillary lesions measuring less then 1cm in size with gross extension beyond the 
capsule. This type of lesion is common, occurring in up to 24% of thyroidectomies 
unrelated to papillary carcinoma and in up to 30% of autopsies. Most well
differentiated tumours have good prognosis and with an increased survival rates as 
they are slow growing.
1.2.4 Poorly differentiated and undifferentiated carcinomas
Poorly differentiated tumours (insular thyroid carcinomas) are defined as follicular 
cell carcinomas with limited follicular cell differentiation. They occupy an 
intermediate position between differentiated carcinomas and undifferentiated thyroid 
carcinomas. Cytologically, these tumours have high cellular smears, scanty or no 
colloid. The cells appear singly and in syncytial with irregular aggregates. Nuclear 
overlapping and overcrowding, poorly formed micro-follicles, a high nuclear to 
cytoplasmic ratio, necrosis are common features (Kondo et al. 2006). 
Undifferentiated anaplastic thyroid carcinomas (ATC) are rare tumours occurring 
primarily in individuals above the age of 60. Typically, ATCs have a survival rate of 
less than 1 year. More than half of patients have a previous or coexisting 
differentiated thyroid carcinoma. ATC presents with widespread local invasion and 
distant metastases in other organs of the body (Lewinski et al. 2000).
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1.3 Molecular events involved with thyroid cancer
There have been significant advances in the molecular mechanisms involved with 
thyroid neoplasia. The knowledge of genetic alterations which are implicated in the 
tumourigenesis provides the basis of the signalling activities within the thyroid 
tumour types. Of which, the MAPK pathway contains within it key signalling 
molecules which are initiating events in FA and PTC. The pathway and the 
oncogenic events identified in thyroid tumours are detailed below.
1.3.1 Mitogen-activated protein kinase (MAPK) signalling pathway
The MAPK signalling cascade is a key pathway which leads to multifaceted cellular 
responses controlling cell proliferation, differentiation and survival in response to 
environmental conditions. The pathway is activated by extracellular stimuli through 
receptor tyrosine kinases to illicit a cellular response. Receptor tyrosine kinase 
activation triggers inactive Ras to exchange GDP to GTP to become active, and to 
recruit Raf to the plasma membrane. By phosphorylation, activation of MEK1 and 
MEK2 occurs which leads to the activation of ERK. This proceeds to the activation of 
numerous targets, which include kinases, phosphatases, transcription factors and 
cytoskeletal proteins. This pathway is particularly prevalent in cancer, with 
constitutive activation of the pathway caused by genetic alterations affecting the 
signalling cascade.
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1.3.1.1 RET
RET (Rearranged during transfection) proto-oncogene is a transmembrane receptor 
tyrosine kinase localised on chromosome 10q11.2 and contains 21 exons. Its natural 
ligand is the glial cell derived neurotrophic factor (GNDF), and it normally functions in 
the development of the kidney and the enteric nervous system (Takahashi 1988; 
Schuchardt et al. 1994). RET activates multiple cell signalling cascades mediating a 
number of cellular functions including cell survival, differentiation, proliferation, 
migration and chemotaxis. RET chromosomal rearrangements are implicated in the 
oncogenesis of papillary carcinomas. Targeted expression of RET/PTC1 in 
transgenic mice developed PTC (Cho et al. 1999). RET expression is normally 
restricted to calcitonin-producing C-cells but not follicular cells of the thyroid. The 
fusion of intracellular RET tyrosine kinase domain to the N-termini of certain thyroid 
specific genes generates chimeric oncogenes leading to expression in follicular cells. 
These fusion proteins are designated RET/PTC. There are 12 RET/PTC 
rearrangements currently identified in papillary carcinomas (Ichihara et al. 2004) 
(Table 1.0). The most prevalent, RET/PTC1, involves the chromosomal inversion of 
the tyrosine-kinase domain of RET on chromosome 10q11.2 which juxtaposes with 
the promoter region and first exon of the gene H4(D10S170). The cloning and 
sequencing revealed that H4 shares no homology to any known genes. However it 
does contain a SH3 binding domain highlighting a role in protein interaction (Grieco 
et al. 1994; Celetti et al. 2004). Functional characterisation of H4 has highlighted its 
role in PTCs. It was found to have prominent roles in the formation of the RET 
heterodimer which is crucial for the constitutive activation and transforming ability 
(Tong et al. 1997). Restored expression of H4 in a RET/PTC1 positive cell line 
induced apoptosis. This indicates a role of H4 in cell survival and the pathogenesis
8
of cancer. RET/PTC rearrangements are localised in the cytoplasm where ligand 
independent dimerisation and constitutive activation takes place (Figure 2). 
RET/PTC rearrangements are found in 5-40% of PTC, and are more prevalent in 
sporadic PTC (13-44%) and cancers associated with exposure to radiation (50-90%) 
(Jhiang 2000).
GNDF
I
B
1
Cell membrane
Figure 2. Normal RET and oncogenic RET/PTC1. A, Normal RET. Upon GNDF ligand 
binding RET receptors dimerise and initiate signalling. B, Oncogenic RET/PTC1 fusion 
causes ligand independent constitutive phosphorylation of residues in the kinase domain. 
(Ichihara et al. 2004).
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Rearrangement RET fusion 
partner
Mechanism and 
location
Reference
RET/PTC1 H4 (D10S170 
locus)
Inversion 
(chromosome 10) 
(q11.2;q21)
(Celetti et al. 
2004)
RET/PTC2 PRKAIRA T ranslocation 
(chromosome 10:17) 
(q11.2;q23)
(Sozzi et al. 
1994)
RET/PTC3 and 
RET/PTC4
Nuclear Receptor 
Coactivator 4 
(NCOA4)
Inversion 
(chromosome 10) 
(q11.2)
(Bongarzone et 
al. 1994; 
Santoro et al. 
1994)
RET/PTC5 Golgi Autoantigen 
5 (RFG5)
Translocation 
(chromosome 10:14) 
(q11.2;q)
(Klugbauer et 
al. 1998)
RET/PTC6 Tripartite Motif- 
containing 24 
(TRIM24)
T ranslocation 
(chromosome 7:10) 
(q32;q11.2)
(Klugbauer et 
al. 1996)
RET/PTC7 Tripartite Motif- 
containing 33 
(TRIM33)
Translocation 
(chromosome 1:10) 
(p13;q11.2)
(Klugbauer et 
al. 1996)
RET/PTC8 Kinectin 1 (KTN1) Translocation 
(chromosome 10:14) 
(q11.2;q22.1)
(Salassidis et 
al. 2000)
RET/PTC9 RFG9 Translocation 
(chromosome 10:18) 
(q11.2;q21-22)
(Klugbauer et 
al. 2000)
ELKS-RET ELKS/RAB6- 
interacting (ELKS)
Translocation 
(chromosome 10:12) 
(q11.2;p13)
(Nakata et al. 
1999)
PCM 1-RET Pericentriolar 
Material 1 (PCM1)
Translocation 
(chromosome 8:10) 
(p21-22;q11.2)
(Corvi et al. 
2000)
RFP-RET Tripartite Motif- 
containing 27 
(TRIM27)
Translocation 
(chromosome 6:10) 
(P21;q11.2)
(Saenko et al. 
2003)
Table 1.0. RET rearrangements with fusion partners which are found in thyroid cancers. 
RET/PTC1 represents the most common rearrangement found in PTC (Putzer and Drosten 
2004; Arighi et al. 2005; Prensner and Chinnaiyan 2009).
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1.3.1.2 Ras
In humans, the RAS superfamily is categorised into 6 families, Ras, Rho, Arf, Rab, 
Ran and Rad. The Ras family are encoded by 3 Ras genes which comprise Harvey- 
Ras (H-Ras) located on chromosome 11, Neuroblastoma-Ras (N-Ras) located on 
chromosome 1 and two splice variants of Kirsten-Ras (K-Ras) which are located on 
chromosome 12. Their mechanism of activation involves cycling between an inactive 
state when bound to GDP, and an active state when bound to GTP (Takai et al.
2001). The GTP-GDP cycle is regulated by cell surface receptors comprising of 
receptor tyrosine kinases, heterotrimeric G protein-coupled receptors, cytokine 
receptors and integrins. Peptides like the Epidermal Growth Factor (EGF) binds to 
cell surface receptors resulting in receptor tyrosine dimerisation and activation of 
their kinase domains. This leads to their autophosphorylation and release of cryptic 
binding sites for the binding of proteins containing Src homology 2 (SH2) domains. 
The SH2 containing She protein is tyrosine-phosphorylated inducing its interaction 
with Grb2. This complex binds to the Ras nucleotide exchange factor Sos, forming 
the Shc-Grb2-Sos complex which localises to the plasma membrane. Mediated by 
the interaction of She with the phosphorylated receptor, cycling of GDP to GTP on 
Ras takes place (Figure 3A). The Guanine-nucleotide exchange factors (GEFs) 
promote the release of bound GDP to aid in the binding of GTP (Cherfils and 
Chardin 1999), whilst GTPase activating proteins (GAPs) deactivates the activity of 
Ras supporting the binding of GDP (Donovan et al. 2002). The active GTP state of 
Ras interacts with wide range of effector proteins, of which, the best characterised 
are the Raf family of kinases (Dhillon et al. 2002) and the phosphatidylinositol 3- 
kinases (PI3K) (Wymann et al. 2003). All Ras proteins undergo post-translational 
modifications which comprise of farnesylation of a cysteine residue in the C-terminus
l i
of Ras, proteolysis of the last 3 amino acid residues and methylation of C-terminal 
carboxylic acid group (Giehl 2005). The H-Ras and N-Ras are palmitoylated at their 
final cysteine residues. These modifications allow Ras to localise to the inner side of 
the plasma membrane where they are active (Hancock 2003). Mutations at codons 
12, 13 and 61 of Ras are found in 30% of all tumours. In thyroid lesions, Ras 
mutations are prevalent in ~85% in follicular adenomas (Vasko et al. 2003). Mutation 
of valine for glycine in codon 12 (designated RasV12) occurs within the GTP binding 
domain of the H-Ras isoform. The lack of dissociation of GTP causes accumulation 
of Ras-GTP, causing constitutive activity independent of external stimuli (Vasko et al.
2003) (Figure 3B).
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Figure 3. Ras activation and signalling. A, Normal activation and signalling. Receptor tyrosine kinase 
dimerise following ligand binding. This results in the autophosphorylation of the receptor kinase domain 
which in turn induces the interaction with She. The interaction of Grb2 to She recruits Sos to the plasma 
membrane leading to Ras-GDP to Ras-GTP cycling. Ras signalling activates the MAPK signalling 
cascade. This involves the phosphorylation of RAF, which in turn activates MEK to activate ERK inducing 
a multitude of cellular functions. B, Aberrant Ras signalling. RasV12 mutation of RasGTP prevents 
GTPase hydrolysis leading to Ras-GTP accumulation independent of external stimuli.
Effector proteins
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1.3.1.3 RAF family
The first identified Raf oncogene, v-Raf functions as the transforming gene of the 
mouse sarcoma virus 3611 which induces fibrosarcomas and erythroleukemia in 
newborn mice and C-Raf (Raf-1) was identified as its proto-oncogene homolog 
(Rapp et al. 1983). A-Raf was next discovered from screening a mouse spleen cDNA 
library with a v-Raf probe. B-Raf, the final discovery is the homolog of the chicken C- 
Rmil transforming gene in the retrovirus which causes spontaneous ovarian tumours 
(Eychene et al. 1992; Calogeraki et al. 1993)
In mammals, the Raf family of genes consist of A-Raf located on chromosome Xp11, 
B-Raf located on chromosome 7q32 and Raf-1 located on chromosome 3p25. Each 
of these genes encode cytosolic proteins termed A-Raf, B-Raf and Raf-1 
respectively. The Raf proteins share 3 conserved regions, termed CR1, 2 and 3. 
CR1 contains the Ras binding domain, which localises the kinase to the cell 
membrane, and a regulatory cysteine rich domain. The CR2 domain is less defined 
but is rich in serine/threonine residues which aid in protein interactions. CR3 
comprises the kinase domain and contains the activation loop and the negatively 
charged regulatory region (Figure 5). The Raf kinases differ based on their 
expression in tissues and kinase activity.
Mutational status of the RAF family of proteins in colorectal cancer revealed the B- 
Raf gene was frequently mutated whilst analysis of A-Raf and Raf-1 revealed rare 
germline polymorphisms, the majority of which were intronic and therefore unlikely to 
be important in the development of colorectal cancers (Fransen et al. 2004). In 
addition, mutational status of A-Raf in human cancers including ovarian epithelial 
tumours, colorectal carcinomas, gastric adenocarcinomas and acute leukemias 
failed to identify any A-raf mutations in the tumour samples (Lee et al. 2005). These
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findings allude to the observation that B-Raf is the key ERK activator in the MAPK 
pathway (Mercer and Pritchard 2003). Indeed, in a resting state, Raf-1 is localised in 
the cytoplasm where it is phosphorylated on S259 and S621 inducing binding to 14- 
3-3 proteins to retain an inactive Raf-1 conformation. For Raf-1 activation, the 
phosphorylation of Y341 and S338 and de-phosphorylation of S621 are required 
(Mercer and Pritchard 2003). The constitutive activation of S446 in B-Raf 
(constituting to S338 in Raf-1) together with the D448 contributes to the high level of 
basal kinase activity which is 50-20 times higher than Raf-1 (Mason et al. 1999). This 
also means the activation required for A-Raf and Raf-1 is much more complex then 
BRAF. This also highlights why B-Raf is selected as an oncogene whilst A-Raf and 
Raf-1 are not.
Expression of B-Raf is restricted to neural, testicular, splenic, and hematopoietic 
tissues. Activation of B-Raf is dependent upon Ras-GTP binding and 14-3-3 
displacement. The displacement of 14-3-3 is induced by phosphorylation of S259 
leading to an open conformation and exposure of the MEK binding site (Dhillon et al.
2002). In comparison, Raf-1 and A-Raf undergo a complex series of phosphorylation 
events to become active, whereas B-Raf has a constitutively active S445 residue. 
Binding of Ras-GTP at the cell membrane phosphorylates B-Raf inducing an active 
conformation. The phosphorylation of S365, located in the CR2 domain and S429 
induces a downregulation of B-Raf activity by inducing the docking of 14-3-3 proteins 
(Guan et al. 2000).
Alternative splicing of B-raf gives rise to multiple isoforms (Figure 4). In mice,
alternative splicing encodes at least 10 isoforms of B-Raf with tissue-specific
expression. The isoforms arise from the alternative splicing of exon 10 (9b), exon 8b
and exons 1/2. The presence of exon 10 increases the basal kinase activity and
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affinity towards MEK, whilst exon 8b decreases kinase activity (Hmitou et al. 2007). 
Exons 1/2 promote dimerisation with Raf-1 providing an additional level of kinase 
activity. These spliced exons modulate the kinase activity of B-Raf which may relate 
to its biological activity.
Signalling of the MAPK pathway through B-Raf induces sustained ERK activation 
and cellular differentiation by phosphorylation of dual-specificity kinases MEK1 and 2 
which phosphorylate ERK1 and 2. The phosphorylation events shuttles ERK to the 
nucleus which induces the multitude of biological effects. Occurring in the cytosol, an 
additional level of activity is provided by the heterodimerisation of B-Raf with Raf-1, 
in a Ras dependent manner (Weber et al. 2001; Garnett et al. 2005). In this instance 
the activation of Raf-1 requires activation region and S621 phosphorylation (Figure 
5).
Exon 8b Exon 10Exon 1/2
Full Length
A Exon 10
8b 10
V V
A Exon 8b, 10
1/2
A Exon 1/2, 10
1/2
A Exon 1/2, 8b, 10
Presumed molecular 
mass
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69 kDa
88/82 kDa
86/79 kDa
96/99 kDa
Figure 4. Schematic representation of B-Raf isoforms. Spliced exons are highlighted by 
black triangles. Exon 1/2 is highlighted in green, exon 8b in blue and exon 10 in orange. 
Apparent molecular mass of the B-Raf isoforms was previously determined by a different 
group. This was determined by immunological characterisation with the different sera from 
experiments using transfected COS-1 cells or mouse tissues (Barnier et al. 1995).
16
ClL “j
Y302 
S214 S299
• JU__
T455
T452 S582
U ________ I
CR3 (Kinase Dom ain)
1  _ZL
B
T199
T373 T440
S365 T401 S429
iL -J
S605
S602
S579 T599 S729T753
L L
V 1
ATG
V600E
K601E
S43
_L
S259
S233
lK
S494
T491
r-rV-r
CR3 (Kinase Dom ain)
Figure 5. Schematic diagram of the RAF family of proteins, displaying conserved domains 
with phosphorylation sites. Green boxes signify activation steps. Red box is constitutively 
active. Mutations of B-Raf are signified by a Black box. A. A-Raf B. B-Raf and C, Raf-1.
B-raf remains the only Raf kinase to be frequently mutated in human cancer with the 
highest incidence occurring in malignant melanoma (27%-70%), papillary thyroid 
carcinoma (36%-53%) and colorectal carcinoma (5%-22%) (Garnett and Marais 
2004). Low frequency mutations are also present in a variety of other cancers (1%- 
3%) (Garnett and Marais 2004). Missense mutations of B-Raf have been identified in 
24 different codons, and a majority of these are in low occurrence. Only 2 mutations 
have been identified in human thyroid lesions, the K601E and V600E (Figure 5). The 
K601E B-Raf mutation is rare and was only found in 3 cases follicular-variants of 
papillary carcinoma (Trovisco et al. 2004) and 2 cases of benign adenoma (Soares 
et al. 2003). Situated between T599 and S602, the K601E mutation has 2.5x lower 
kinase activity then the V600E mutation. The more prevalent mutation is the T1799A 
transversion which induces the V600E mutation of B-Raf. This mutation accounts for
17
~90% of all B-Raf mutations in thyroid cancers (Garnett and Marais 2004). This 
mutation mimics T599/S602 phosphorylation rendering B-Raf constitutively active. 
Transfection of BRAFV600E in NIH3T3 cells transforms cells approximately 667-fold 
more efficiently then wild-type B-Raf and induces constitutive ERK activation (Davies 
et al. 2002). In PCCL3 rat thyroid cells, BRAFV600E induces DNA synthesis, 
apoptosis, dedifferentiation and chromosomal instability (Mitsutake et al. 2005). 
Maintenance of proliferation and transformation by BRAFV600E was demonstrated in 
human papillary carcinoma cell lines (Liu et al. 2007). The BRAFV600E mutation is 
associated with aggressive characteristics including lymph node metastasis, 
extrathyroidal invasion and recurrence (Namba et al. 2003; Palona et al. 2006). 
Interestingly, the BRAFV600E mutation is also present in occult micro-papillary 
carcinomas (Ugolini et al. 2007). These lesions are designated <10mm in size and 
are typically discovered post-operative procedures for benign lesions following 
histological examination. Microcarcinomas exhibit features consistent with papillary 
carcinomas, but little is known about their potential to progress into papillary 
carcinoma. This indicates a prominent role of the B-raf oncogene, and in particular 
the BRAFV600E mutation in the initiation and progression of papillary carcinoma.
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1.4 Gene expression profiling of thyroid lesions
Microarrays are rapidly advancing, powerful tools to simultaneously analyse gene 
expression of thousands of genes. Although an expensive technology, it remains a 
widely utilised tool in research. There are many perspectives, considerations and 
limitations for microarrays, (reviewed by Eszlinger et al. 2007) and it has been used 
to elucidate various aspects of thyroid tumourigenesis. This chapter will review 
recent studies which use the microarray platform to gain new perspectives on 
malignant and benign thyroid lesions, highlighting aims, methods, results, 
perspectives and limitations.
1.4.1 Differentiating Thyroid Tumours
The best method of diagnosis remains the fine needle aspiration biopsy which can 
diagnose papillary carcinoma with an accuracy of 95%. However, tumours of 
follicular origin (FA and FTC) are not as easy to distinguish. Suspicious lesions are 
subjected to thyroidectomy, and subsequently histologically examined for capsular 
invasion. This forms the basis of many thyroid studies which use the microarray 
platform to distinguish FA from FTC. The microarray expression profiling offers a 
means to detect markers to distinguish tumour types together with key biological 
background information.
Global gene expression analysis offered a means of dissecting the minimal number 
of genes that have a role in FTC progression, providing new markers for therapy and 
differentiating FTC from FA (Weber et al. 2005). With sample consisting of 12 FTCs 
and 12 FAs, this study identified 96 probe sets corresponding to 80 genes, which
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were categorised based on their histological groups. Following fold-change ranking 
of the probe sets, 11 genes were returned as significant. The top two ranking genes 
confirmed by quantitative RT-PCR were Cyclin D2 and growth differentiation factor 
15. Interestingly, these genes have not previously been associated with thyroid 
carcinogenesis and thus remain unique to this study. This study showed like other 
studies that FTCs can be differentiated by a select number of genes (Aldred et al. 
2004). The Aldred et al. study differentiated FTC from PTC using 5 genes. The 
structure of the experiment was conducted by profiling FTC and PTC independently 
and combining the datasets to highlight the similarities and differences. Compared to 
normal thyroid, PTCs displayed two distinct clusters of genes including Cbp/p300- 
interacting transactivator 1, Claudin-10 and Insulin-like growth factor binding protein- 
6. FTCs did not express Claudin-10 and had a decreased expression of Insulin-like 
growth factor binding protein-6, Caveolin-1 and Caveolin-2. The datasets were 
analysed using hierarchical clustering and analysed using t-tests to observe the 
overlap in change calls and gene expression levels of PTC when compared with 
FTC. Consistent with other studies, galanin3 (GAL3) was over-expressed in both 
PTC and FTCs (Lubitz et al. 2006). Although these genes are differentially 
expressed in the tumour types, their potential roles as prognostic and therapeutic 
markers remain to be defined.
An early study used a cDNA microarray platform containing 5,760 probes for 
diagnostic and clinical implications profiling 6 normal thyroid samples, 4 FAs, 3 FTCs 
and 2 PTCs, and 3 follicular variant of PTC (FVPTC) samples (Chevillard et al.
2004). This study showed consistency with a number of other studies. There were 
165 differentially expressed genes in FA, 222 in FTC and 172 in PTC. The biological 
function of the 165 genes were classified into categories of cytoskeleton, cell
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adhesion, cellular matrix related, signal transduction and immune-response, a finding 
consistent with other profiling studies (Giordano et al. 2005; Melillo et al. 2005; Delys 
et al. 2007; Vasko et al. 2007). The data also showed that FA can be differentiated 
for FTC by a set of 43 genes, 10 of which were previously reported (Barden et al.
2003). A set of 23 and 52 genes could differentiate PTC from FA and FTCs. These 
genes were composed of members belonging to protein metabolism/catabolism 
(15%), intracellular trafficking (12%), ion/metal binding and transport (10%) and 
transcription (12%). In general, the expression signatures of PTC and FTC showed 
common features, but individual genes including dual specificity phosphatase 6 
(DUSP6), dual specificity phosphatase 5 (DUSP5), milk fat globule-EGF factor 8 
protein were identified as differentiation markers between the tumour types, and this 
is a finding repeated in other studies (Delys et al. 2007). Many of these genes have 
not been associated with thyroid development and may lend themselves to potential 
diagnostic and prognostic markers. In summary, this study showed gene expression 
data correlated with classification of thyroid lesions, and identified genes that can 
differentiate between the tumour types. From a technological stand point, the 
microarray platform used contained very few probes compared to today’s platforms. 
Microarray platforms are able to differentiate tumour types, however differences in 
platform and analysis makes each study unique, and it is difficult to directly compare 
similar studies.
Improvement on the methods for diagnosing malignancy from fine needle aspirates 
is an issue which required further investigation. Instead of tumour tissue samples, 
which require invasive procedures FNA biopsies were profiled on a microarray 
platform with an aim to assess the feasibility for diagnosing malignancy from FNA 
(Lubitz et al. 2006). To elucidate this aim, tissue samples were profiled and
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compared with FNA. The tumour samples included FA and hyperplastic nodules 
which were compared with PTC and FVPTC. Profiling was conducted on the 
Affymetrix U133 gene chips using tissue samples. Differential expression revealed a 
set of 25 genes which included thyroid peroxidase, transcription termination factor 
RNA polymerase I I I , GAL3, fibronectin (FN), TIMP metalloproteinase inhibitor 1 
(TIMP1) and keratin 19, which correlated with other studies (Huang et al. 2001; 
Giordano et al. 2005; Prasad et al. 2005). The FNA categorised as either 
preoperative diagnosis or as a final histological diagnosis were compared. Of these 
cases, 16 of the 17 were predicted by the microarray to be benign or malignant 
which was confirmed by pathological analysis. Preoperative analysis was less 
conclusive with 13 of 17 (76%) of cases confirmed to be correctly diagnosed. This 
study represents a breakthrough for using microarray technology as a platform to 
improve diagnosis. More importantly, the study shows consistency of the Affymetrix 
microarray platform, the use of alternative sample material, correlation with other 
studies and the use of a microarray as a useful diagnostic tool albeit its high cost and 
technical complexity.
There are atypical thyroid tumours which are difficult to determine by histological 
analysis, in particular the diagnosis of FVPTC which represents a challenge as it 
retains features of both benign and malignant lesions. An expression profile was 
generated for malignancy in PTC to identify discriminating genes to distinguish the 
subtypes of PTC (Finn et al. 2007). A differentially cluster of 173 genes were 
identified from the datasets. In conjunction with other studies genes including soluble 
galactoside-binding lectin 3, v-yes-1 Yamaguchi sarcoma viral related oncogene 
homolog, TTF3, cellular retinoic acid binding protein 1, BCL2-associated X protein, 
mitogen-activated protein kinase 4, CD44, TIMP1, fibroblast growth factor receptor 2
and S100A11 also displayed significant expression (Delys et al. 2007). The 
unsupervised clustering of FVPTC and PTC did not reveal any independent 
clustering highlighting the close relationship between the tumour types. However, 15 
genes were differentially expressed in FVPTC compared to benign and classical 
PTC. The cathepsin family of genes were all highly upregulated in FVPTC. The 
authors highlight the close biology of PTC and FVPTC, however the identification of 
a cohort of genes in FVPTC may improve diagnosis of this lesion. This study has 
similarities with other unique studies where proteases including MMP-2 have been 
highlighted.
1.4.2 Molecular characterisation of thyroid tumours
Detailed molecular characterisation of thyroid tumours have been a primary aim for a 
number of studies. One such study was performed to determine novel clinical 
markers (Zhao et al. 2006). Gene expression profiles using filter-based high-density 
cDNA arrays in a series of thyroid tissues which included 17 normal thyroid, 16 
PTCs, 13 FTCs. These cDNA arrays contained 12,000 known genes and 63,000 
expressed sequence tags (EST). ANOVA analysis revealed 1,950 cDNA targets 
displaying significant expression differences between FTC, PTC and normal thyroid. 
Occurring in >40% PTC and/or FTC, 603 genes were 2-fold under-expressed and 
176 genes 2-fold over-expressed. Despite the differential expression of the tumours 
when compared to normal thyroid, there were minimal differences seen between 
FTC and PTC. The most frequent over-expressed genes in >60% of FTC and/or 
PTC were functionally categorised into cell cycle control, signal transduction, growth 
factor receptors (EGF receptor) transcriptional factors and cell interaction. These
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processes are consistent with involvement of protease activity identified in other 
studies (Melillo et al. 2005; Delys et al. 2007; Vasko et al. 2007). Consistent with 
other studies thyroid specific markers including thyroglobulin and paired box 8 were 
under-expressed in both PTC and FTC (Melillo et al. 2005; Delys et al. 2007). FN 
had increased expression in 81% of PTCs and 33% of FTCs and BSG was over­
expressed in FTC but not in PTC (Prasad et al. 2005; Vasko et al. 2007). Significant 
expression variation revealed 123 genes (45 known, 78 unknown) which were 
identified to be differentially expressed between PTC and FTC. The most 
differentially expressed genes identified by permutation 2-sample t-test were over­
expressed in PTC and under-expressed in FTC. They concluded the similar gene 
expression profile between PTC and FTC reflects a close histological and biological 
relationship. However, the differences between PTC and FTC may contribute to the 
progression of the carcinomas along different pathways.
PTCs are commonly associated with lymph node metastases, and this occurs in 
30% to 65% of cases at initial diagnosis. PTCs with metastasis are phenotypically 
more aggressive, and are characterised by lymphatic invasion, increased resistance 
to treatment and increased mortality. Microarray profiling has been used to identify 
biomarkers related to PTC with aggressive metastases (Cerutti et al. 2007). This 
analysis also highlighted invasive processes and genes involved with PTC. Using an 
individual patient with metastatic PTC, serial analysis of gene expression (SAGE) 
was conducted due to its ability to produce consistent gene profiles from small 
samples, and allows for easy comparison with data from other studies. 
Retrospective comparison of the data obtained from 4 different SAGE libraries 
revealed 31 out of 498 transcripts were highly expressed in the metastatic libraries 
but not in the patient tumour, whilst 47 transcripts were highly expressed in the
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tumour but not in the libraries. Transcripts were chosen based on their fold induction 
were chosen from the libraries, as they have the greatest potential as prognostic 
markers, together with S100 calcium binding protein A11 (S100A11), LSM7 and met 
proto-oncogene (cMET) which have been previously implicated in tumours with 
metastatic potential. These were validated using quantitative PCR and compared 
with the levels associated with normal thyroid physiology. The gene ontology was 
related to transport and cell signalling. The SAGE and quantitative PCR were 
compared using the matched samples of normal thyroid, primary PTC and lymph 
node metastasis to generate libraries. Specifically, protein tyrosine phosphatase 
receptor type C was found to be over-expressed in all metastases analysed. LIM 
domain containing 2 (LIMD2) and the CD48 molecule were only expressed in lymph 
node metastases whilst lymphotoxin beta and ATP-binding cassette sub-family C 
member 3 were over-expressed in lymph node metastases, at lower levels in PTC 
and normal thyroid samples. The previously reported genes (S100A11 and cMet) 
were all found to concur with other studies (Finn et al. 2007). Although further 
investigation is required, the authors show that for the first time, LIMD2 is associated 
with the metastatic process of PTC. The authors also conclude the identification and 
validation of genes associated with lymph node metastases from PTC may be 
helpful in providing new targets for therapy, and earlier detection of metastasis. What 
is clear from this study to the identification of novel genes not highlighted in the other 
studies, which may be linked to the metastases and not the primary tumour, and this 
is the case for other tumour variants.
In parallel, PTC remains the most frequent endocrine malignancy and represents up 
to 80% of all malignant thyroid tumours (Delys et al. 2007). Gene expression profiling 
have provided tumour type signatures and elucidated tumour cell metabolism for
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PTC (Baris et al. 2005; Giordano et al. 2005). The majority of gene profiling studies 
fail to explore the underlying mechanisms in detail. Microarray datasets from 
different experiments were combined to analyse the regulation of the numerous 
signalling pathways and processes involved in PTC (Delys et al. 2007). Their 
analysis generated a gene list with 451 upregulated and 233 downregulated genes. 
Gene ontology analysis revealed the genes to be related to immune response, cell 
adhesion, extracellular matrix, cell-cell adhesion, integrin, collagen, peptidase activity 
and the EGFR signalling pathway.
Hurthele cell carcinomas are malignant thyroid tumours which present with 
accumulations of dilated mitochondria. A hypothesis that high mitochondrial content 
may be linked to the malignant progression of PTC was investigated (Baris et al.
2005). The comparison between 6 oncocytic follicular carcinomas and 6 
mitochondrial-rich papillary carcinomas revealed a set of genes which can 
distinguish oncocytic FTC from PTCs. Genes over-expressed in PTCs included 
DUSP6, cyclin D1, TIMP1, CD44 molecule (CD44) and matrix metalloproteinase 2 
(MMP-2). In oncocytic tumours, there were a number of different over-expressed 
genes. Gene ontology of the 59 PTC over-expressed genes was related to cellular 
physiological process (52.94%) and cell communication (43.14%). A total of 24 
genes over-expressed in the oncocytic follicular carcinomas were involved in the 
metabolism (83.33%) and stress response (21.05%). This suggested a higher rate of 
oxidative metabolism in oncocytic tumours compared with PTCs. The respiratory 
chain complexes III and IV were over-expressed in oncocytic tumours which may 
modulate the production of reactive oxygen species. They conclude that oxidative 
metabolism and reactive oxygen species distinguishes oncocytic tumours from
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PTCs. The over-expression of the respiratory chain proteins seems to be essential to 
the development of oncocytic FTCs.
The malignant phenotype of PTC is primarily caused by Epithelial to mesenchymal 
transition (EMT), and genes which regulate the process of EMT were profiled by 
analysing the invasive front of PTC (Vasko et al. 2007). They characterised the 
biological processes involved with PTC invasion and observed the expression of 
genes in invasive regions compared to central regions of papillary carcinomas. In 
addition to identifying BRAFV600E and RET/PTC genetic alterations, the invasive 
regions of PTCs revealed over-expression of genes relating to TGFp cell signalling, 
integrin cell signalling, Notch signalling, NFkB signalling and PI3K signalling. 
Quantitative RT-PCR was conducted on a select number of genes known to be 
involved with EMT (FN, runt-related transcription factor 2 (RUNX2), prickle homolog 
1 and slit homolog 1). Immunohistochemistry was conducted on RUNX2, FN and 
vimentin to assess the expression of the genes in PTC. Osteopontin (OPN) is also in 
part regulated by RUNX2, and expression of osteopontin was also confirmed in the 
PTCs. There are many invasive processes and genes which have been highlighted 
by these studies. Consistent with other studies they found the over-expression of 
genes including CITED1, FN (Delys et al. 2007), extracellular matrix protein 
1 (ECM1), mucin 1 (MUC1) and S100 calcium binding protein A4 (S100A4) (Zou et 
al. 2005) in PTC, with reduced expression of genes regulating thyroid hormone 
production. Consistent with immunohistochemical studies (Shin et al. 2004), genes 
encoding activators of the JNK pathway were over-expressed in the dataset, 
suggesting a possible role of the JNK pathway. The over-expression of dual 
specificity phosphatase 4 (DUSP4), DUSP5 and DUSP6 was seen in the dataset 
(Chevillard et al. 2004). These are known inhibitors of the MAPK pathway may
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account for the JNK pathway activation. Over-expression of many proteases was 
also observed. Known mediators which regulate the remodelling the extracellular 
included matrix metalloproteinase 1, matrix metalloproteinase 7 and matrix 
metalloproteinase 11, serine proteases cysteine proteases including urokinase 
plasminogen activator and aspartyl proteases including cathepsin B.
A number of studies have highlighted the genetic alterations of PTC in a microarray 
platform. The oncogenic Ras and B-Raf mutations with RET/PTC rearrangements 
are known to be mutually exclusive in thyroid lesions. The genetic alterations were 
genotyped in thyroid tumours (Giordano et al. 2005) and the link verified between the 
3 oncogenes in a thyroid cell culture model (Melillo et al. 2005). This model uses a 
differentiated thyroid follicular cell line (PCCL3) derived from Fischer rats. A mixture 
of 6 hormones are required to induce proliferation and transfection of RET/PTC1, 
BRAFV600E and RASV12 to induce hormone independent growth of the cell line. 
Genes modified by cell transformation included the upregulation of G1 cyclins and 
downregulation of thyroid markers. 786 probes in total were upregulated in RET/PTC 
and 146 of these were found to be significant. Of these 146 probes 80 were also 
induced by RASV12 and 70 were induced by BRAFV600E. Overall 60 probes were 
induced by all three oncogenes and were related to structure and adhesion (S100A4 
and S100 calcium binding protein A6) and proteolysis (matrix metalloproteinase 13, 
matrix metalloproteinase 10, matrix metalloproteinase 12 and matrix 
metalloproteinase 3). Additionally, the intermediate filament protein, vimentin was 
also upregulated, data which showed consistency with other studies (Vasko et al. 
2007). Of 2517 probes, 338 probes were downregulated in RET/PTC1, 148 probes 
were downregulated in RASV12 and 121 probes were downregulated in BRAFV600E. 
Genes relating to thyroid differentiation (Thyroid peroxidise (TPO) and
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thyroglobulin (TG)), adhesion, signalling and metabolism were also downregulated. 
To observe the role of the MAPK pathway in the expression regulation induced by 
RET/PTC3 transformed cells, quantitative PCR of 37 selected genes from the 
genetic profiling data revealed that with the use of the MEK inhibitor U0126 or siRNA 
directed towards BRAF, 22 of the 37 genes were altered by BRAF knock-down. This 
highlighted the integral role of the MAPK pathway in the expression profile of 
transformed cells. In addition, there are a number of genes which overlap between 
cells transformed by RET/PTC3, BRAFV600E or RASV12, and most of these genes 
were regulated by the MAPK pathway.
As a comparison, combined transcriptional expression profiles of 51 papillary 
carcinomas with their known morphology and their RET/PTC, B-Raf and Ras 
mutational status was analysed in order to improve the understanding of papillary 
carcinoma and the relationship between the gene expression profiles, morphology 
and oncogenic events (Giordano et al. 2005). The relationship between mutation and 
gene expression revealed distinct gene clusters which were dependent on RAS or 
BRAF mutation or RET/PTC rearrangement. There was a strong correlation between 
mutation and gene expression compared to the gene expression and morphology. 
Application of increased stringent analysis criteria resulted in a total of 132 (100 
upregulated, 32 downregulated) probe-sets of RET/PTC, 82 (31 upregulated, 51 
downregulated) probe-sets for B-Raf and 571 (165 upregulated, 406 downregulated) 
probe-sets for RAS. This indicated the increased number of downregulated genes for 
RAS with a similar number in B-Raf and RET/PTC indicates the thyroid carcinoma 
pathologies are dependent on the oncogenic event. The mutation specific expression 
of cMet and TIMP1 was confirmed in PTC. Genes relating to immune response were 
also differentially expressed in a mutation specific manner. The expression of TPO
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was decreased 18.9 fold in PTC compared with normal thyroid, a result consistent 
with another study (Melillo et al. 2005). The authors conclude the reduced TPO 
expression suggests decreased thyroid hormone synthesis and radioiodine uptake, 
increasing the resistance of the B-Raf mutant tumours to radioiodine treatment. The 
greatest difference was found in B-Raf tumours compared to Ras and RET/PTC 
tumours. This may relate to the specific signalling cascades involved with the 
oncogenic events as B-Raf mutations follow a more aggressive course. Since the 
aims of these particular studies are unique and utilise different sample material, the 
datasets cannot be direct compared but they do indicate a number of similarities in 
gene expression with thyroid differentiation, proteolysis and immune response all 
consistent throughout.
1.4.3 Genetic Profiling of thyroid tumour cell lines
Thyroid tumour cell lines derived from different pathologic origin have been 
developed over past years. The unlimited replicative potential and the existence of 
only one cell type allows for a more accurate interpretation. The in vitro properties of 
thyroid tumours were investigated by using thyroid tumour derived cell lines which 
included 1 FA (KAK-1), 2 FTC (FTC133 and WRO), 3 PTC (BCPAP, TPC-1 and 
KAT-10) and 2 ATC (KAT-1 and 8505C) (van Staveren et al. 2007). The gene 
expression of the cell lines were compared with normal human thyrocytes from 
primary cultures. The hierarchical clustering confirmed by bootstrap analysis, 
revealed the cell lines did not cluster based on their origin. The KAK-1, KAT-4 and 
KAT-10 cell lines were highly similar, all containing a point mutation in E-Cadherin 
and a heterozygous BRAFV600E mutation. Regardless of origin, comparison of
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these cell lines with a panel of in vivo solid tumours showed the cell lines resembled 
in vivo ATCs. The gene expression profiles of the in vivo tumours showed that the 
adenomas clustered together but were distinct from ATCs. The FTCs and PTCs 
clustered in between adenoma and the ATCs. RT-PCR confirmed the mRNA 
expression of thyroid differentiation markers. The cell lines were found to have lost 
the expression of a number of thyroid markers (thyroid stimulating hormone 
receptor (TSHR), sodium iodide symporter member 5 (NIS), TG and TPO). The 
authors conclude the cell lines cultured in the absence of thyroid stimulating 
hormone may account for partial loss of differentiation. This also highlights the 
limitations of using cell lines in a gene profiling study as the study raises the issue of 
origin of the cell line. They also speculate that cell lines derived from in vivo tumours 
may have arisen from cancer stem cells or adapt to the in vitro environment which 
they are cultured in.
Other models discussed in this chapter include the transfectable rat cell line PCCL3 
model (Melillo et al. 2005), which would circumvent the background noise with 
primary tissue profiling but being derived from a different species, raised the 
question if this would alter the gene expression. The use of cell lines derived from 
human tumour tissue would provide a species-relevant expression profile and being 
a pure culture would minimise the background noise seen with tumour tissue 
samples. However, their transformed nature and unlimited proliferative potential may 
affect the gene expression. In addition, evidence has emerged that the majority of 
cell lines resemble anaplastic tumours regardless of where they were derived from 
(van Staveren et al. 2007). Clearly, there are positive and negatives associated with 
all the different sample material for profiling, but raise the question of consideration 
of selection of the sample material to create an accurate and precise study reflecting
31
the true tumour situation. The majority of profiling studies discussed all have 
overlapping genes, pathways and processes which are known to be involved in 
thyroid tumourigenesis, and have been used to assess the validity of a given study. 
The involvement of individual genes would provide the greatest confirmation of 
precision and accuracy and this is an adopted method of confirmation by a number 
of studies.
1.4.4 Overall perspectives
A key goal of many studies is to distinguish between tumour types and to provide 
detailed molecular characterisation. This essentially provides an insight into tumour 
progression and identifies potentially markers to facilitate diagnosis and thereby 
guide treatment. Essentially, each microarray gene profiling study is unique based 
on the type of sample, the platform and the analysis method utilised. Despite these 
variables there is consistency between the studies. For instance a number of genes 
were identified as distinguishing markers. GAL3 was found overexpressed in both 
FTC and PTCs (Aldred et al. 2004; Lubitz et al. 2006). FN was also identified in a 
number of studies. This gene was overexpressed in a large percentage of PTCs and 
FTCs (Prasad et al. 2005; Vasko et al. 2007; Zhao et al. 2006). S100A4, a marker of 
thyroid malignancy was also identified in PTCs (Giordano et al. 2005; Melillo et al. 
2005; Zou et al. 2005). A number of studies also identified TIMP1 malignant thyroid 
tumours (Chevillard et al. 2004; Vasko et al. 2007; Baris et al. 2005; Lubitz et al.
2006). The dual specificity phosphatise were also identified in a number of studies 
(Chevillard et al. 2004; Vasko et al. 2007).
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There is a clear indication that despite differences in methodology there is some 
consistency between studies. However, the type of sample, the platform and 
analysis method ultimately has an impact on the profiling data, and this requires 
careful consideration for future studies.
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1.5 In vitro models of thyroid neoplasia
My group have established in vitro models representing FA and PTC. Normal 
primary thyrocytes have a low proliferative rate (3-4 population doublings), and 
retroviral induction of mutated H-RASV12 enhances proliferation and develops a 
phenotype consistent with in vivo benign follicular adenomas. The enhanced 
proliferation is not definite in thyrocytes, with growth ceasing after 15-25 population 
doublings, resembling replicative senescence (Bond et al. 1994; Jones et al. 2000). 
This finding is consistent with in vivo data as FAs appear to reach a self-limiting 
quiescent state. Retroviral transduction of RASV12 results in a distinctive expanding 
pattern of growth with distinct colony margins, a phenotype consistent with FA. 
Conversely, the retroviral transduction of RET/PTC1 and BRAFV600E also results in a 
self-limiting growth response, with the resulting colonies showing a different pattern 
of growth. The RET/PTC1 and BRAFV600E cells are capable of migrating over and 
between the surrounding cells, a phenotype reminiscent of in vivo PTC.
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1.6 Aims, Objectives and Experimental strategies
Thyroid tumours are diagnosed with pathological examination of FNA, an invasive 
procedure. This diagnostic technique is not absolute and is unable to differentiate 
invasive FTC from benign FA.
Much work has been conducted to identify additional markers of malignancy. 
Microarray gene profiling offers an alternative method for defining malignancy in 
thyroid tumours. Currently, microarray gene profiling has been used to characterise 
malignancy, differentiate tumour types and define biological information in thyroid. 
These studies either use cell lines which have restricted biological complexity or 
primary tumours which possess a high signal to noise ratio.
My group has established in vitro primary models of PTC and FA which represent 
the in vivo situation. The infection of the RASV12 oncogene in thyroid epithelial cells 
results in a phenotype consistent with FA. Conversely, introducing the BRAFV600E 
and RET/PTC1 oncogenes results in a phenotype consistent with PTC. These 
models represented a major incentive to study malignant behaviour in thyroid cancer 
using a microarray platform. Firstly, this is the only study to utilise this type of sample 
in a microarray platform. Secondly, the in vitro primary models offer a closer 
representation to in vivo tumours compared to cell lines and on a microarray 
platform, a lower signal to noise ratio compared to primary tumour samples.
The major aims of the thesis were to use a microarray platform using the previously 
established in vitro primary models of PTC and FA to identify novel markers 
associated with tumour invasion. I next aimed to investigate if the markers were of 
therapeutic value by genetic manipulation. These aims would not only elucidate the 
biological background of thyroid tumours in relation to tumour invasion and
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progression, but also provide evidence of additional therapeutic markers which could 
be used in diagnostic and therapeutic approaches.
The following are the major aims of the thesis:
Identification of novel markers of tumour invasion using a microarrav platform
1) Defining the BRAFV600E mutation in thyroid cell lines
The B-Raf oncogene is known to be alternatively spliced giving rise to multiple 
isoforms. I wanted to define these isoforms in thyroid cancer cell lines and analyse 
the B-Raf oncogenic mutation in the isoforms. This was of importance to future 
investigations which use the BRAFV600E oncogene. To achieve this aim the following 
objectives were accomplished:
1. Characterisation of B-Raf isoforms in thyroid cell lines
2. Define the mutational status in thyroid cell lines
2) Identification of genetic markers involved in tumour invasion
The microarray platform offers genome-wide analysis of gene expression. Profiling of 
the in vitro models not only accomplished the primary aim of identifying novel 
markers which define an invasive phenotype but also provided relevant biological 
information. To accomplish this aim the following objectives were carried out:
1. Infecting primary epithelial cells with the RASV12, BRAFV600E and RET/PTC1 to 
formulate the primary in vitro models
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2. Processing primary models for the use in a microarray platform
3. Conduct the genetic profiling using the microarray platform
4. Analysis of the datasets to identify a gene cluster implicated in invasive behaviour
5. Identify genetic markers using a literature analysis
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2.0 Materials and
Methods
This material and methods section describes the assay procedures for producing the 
in vitro models and the one-cycle eukaryotic labelling of gene chips. After I extracted 
total RNA from samples the one-cycle eukaryotic labelling for the Microarray analysis 
was conducted by the in-house Microarray service provided by the Cardiff University 
CBS department.
2.1 Generation of oncogene expression infected thyroid colonies
2.2.1 Cell culture
Monolayer cultures of primary human epithelial cells were previously prepared by 
from surgical samples of histologically normal thyroid tissue by collagenase B and 
Dispase II (Roche, Germany) protease digestion with mechanical disaggregation 
(Williams et al. 1988). Cultures were judged as >99% epithelial by cytokeretin 
staining (Bond et al. 1994). Primary cultures were placed in liquid nitrogen storage 
until ready for use.
Frozen primary epithelial cells were thawed and maintained in a 1:1 mixture of 
Dulbecco’s modified Eagles’ medium and Hams’ F12 supplemented with 10% foetal 
calf serum (Autogen Bioclear, London, UK), Penicillin and Streptomycin (Sigma- 
Aldrich, UK) with glutamine. Cells were grown in a humidified atmosphere containing 
3 % 0 2> 5 % C02 and 92% N2 at 37°C.
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2.2.2 Preparation of viral supernatants
All procedures during viral infection were undertaken with significant caution with 
accordance with the advisory committee on Genetic Modification (ACGM) guidelines. 
All procedures involving the transfer and filtration of viral supernatants were 
conducted using a sterile plastic kwill and syringe in a class II containment facility. All 
pipette tips and stripettes were rinsed with bleach after use. All viral waste was 
placed in a special designated metal container and autoclaved before disposal.
2.2.2.1 Preparation of Retroviral supernatants
M'-CRIP-DOEJ producer cells were used to produce retrovirus encoding RASV12. 4*- 
CRIP-RET/PTC1 producer cells were used to produce retrovirus encoding 
RET/PTC1. Both constructs have been previously described (Bond et al. 1994). For 
4^-CRIP-DOEJ and M^-CRIP-RET/PTCI cells were grown to 95% confluency in 
selective medium (Table 2.0). 24 hours prior to infection the medium was removed 
and the cells replenished with a minimal amount of selective-free medium 
appropriate for the target cells containing freshly added glutamine. This medium 
containing the retroviral particles was harvested for retroviral infection by collecting 
with a pipette and kwill into a 15mL centrifuge tube and centrifuging at 100 rpm for 5 
minutes to sediment any cell debris.
For retrovirus encoding BRAFV600E the phoenix producer cell line was used 
(Morgenstern and Land 1990; Kinsella and Nolan 1996). To prepare BRAFV600E 
retrovirus phoenix cells were plated at a density of 8x106 per T 7 5 -  flask (Nalge Nunc, 
Intl.). After 24 hours, 10pg of BRAFV600Epbabeneo plasmid DNA was diluted in a total
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of 405|jL of sterile water. Using the calcium chloride method of transfection the 
plasmid DNA was introduced into the phoenix cells.
This involved re-feeding phoenix cells with 15 ml_ of medium and in a separate 
microtube adding 45pL of CaCI2 to the diluted DNA, mixing and add drop wise to the 
HEPES-buffered saline solution (HeBs) while passing bubbles through the (HeBs). 
The mixture was vortexed for 2 seconds and left to incubate at room temperature for 
exactly 20 minutes. Fifteen minutes into the incubation, chloroquine at a 
concentration of 25pM was added to the phoenix cells. The transfection mix was 
then added after the final 5 minute incubation. The mixture was added whilst swirling 
the flask and incubated overnight in an incubator set at 37°C overnight. The following 
day the flasks were incubated at 35°C overnight. The next day the supernatant 
containing the BRAFV600E retrovirus was harvested. The supernatant was carefully 
removed and spun at 1000 rpm for 5 minutes to pellet any cell debris. The 
supernatant was then aliquoted and flash frozen in liquid nitrogen and stored at - 
80°C.
2.2.3 Viral infections
Primary epithelial were plated at 5x105 per 60mm-dish without selection. After 2 
days, 1 hour prior to infection cells were refed with medium containing 8pg/mL 
polybrene. The dishes were aspirated to remove the medium and replaced with the 
retroviral supernatant containing 8pg/mL polybrene. After 5 hours, additional medium 
was added to the dishes, where the dishes were returned to the incubator. After 24 
hours, cells were refed with non-selective medium and returned to the incubator. 
After 3 days, cells were passaged using non-selective medium into fresh dishes. 
After 24 hours, the dishes were refed with selective medium. Every 2 days dishes
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were refed with selective medium for 3 weeks at which point colonies had been 
established.
Oncogene/plasmid Producer cells Selection
^-CRIP-DOEJ-RASV12 MJcripDOEJ G418
BRAFVBUUtpbabeneo Phoenix G418
'V-CRIP-RET/PTC1 ^cripRET/PTCI G418
Table 2.0. Retroviral plasmids, producer cells and selection
2.3 Total RNA extraction
Cells were grown to 70% confluency in 100mm dishes and washed with pre-warmed 
Hanks Balanced Salt Solution (Sigma-Aldrich, Dorset, UK). To each dish, 1.5mL of 
TRIzol reagent (Invitrogen, Paisley, UK) was added and left to incubate for a 
maximum of 30 minutes to lyse the cells. Cells were scraped from the 100mm dishes 
using a Nunc cell scraper (Nalge Nunc, Intl.). The cell lysates were pippetted and 
aspirated to ensure homoginisation. The fractions were divided into 175pL aliquots 
and transferred into 1.5mL RNase-free centrifuge tubes, to which 175pL of 
chloroform was added. In parallel, Heavy Phase Lock Gel™ (PLG; Eppendorf) tubes 
were equilibriated by centrifugation at 13,000g for 25 seconds. The 
TRIzol/chloroform mixture was transferred to the phase lock gel tube and centrifuged 
at 13,000g for 2 minutes. The upper aqueous solution was transferred to a fresh 
eppendorf tube and the RNA precipitated by addition of 500pL of isopropanol and 
5mg/mL of glycogen with a brief vortex and an incubation at room temperature for 
10> minutes. The solution was centrifuged at 12,000g at 4°C for 10 minutes. The
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supernatant was discarded and the pellet washed twice with 80% ethanol vortexing 
between each wash and centrifuging at 7,500g at 4°C for 5 minutes. The 
supernatant was discarded and samples resuspended in a total volume of 200pL of 
sterile water for irrigation and heated at 65°C for 10 minutes. Samples were 
incubated between 30 and 60 minutes on ice. After this period, samples were 
quantified using a Nanodrop ND-1000 spectrophotometer (Nanodrap Technologies, 
Rockford, IL, USA), and 1/10th volume of 3M Sodium Acetate, 2.5 times the volume 
of 100% ethanol and 5mg/mL of glycogen (Ambion, Austen, TX, USA) was added, 
followed by a brief vortex and incubation at -20°C for 24 hours. The mixture was 
centrifuged at 12,000g at 4°C for 30 minutes, and the pellet washed twice with 80% 
ethanol with centrifugation at 12,000g at 4°C for 10 minutes following each wash. 
The supernatant was discarded and using the quantification values previously 
obtained the RNA sample was resuspended in the desired volume of sterile water to 
obtain a final concentration of 2pg/mL. To aid resuspension, the RNA sample was 
incubated at 65°C for 10 minutes. The sample was re-quantified on the Nanodrop 
ND-1000 spectrophotometer to determine the final concentration of the RNA.
2.4 Sequencing of B-Raf
Following RT-PCR with B-Raf specific primers (Section 5.11) sequencing of exon 15 
was conducted using 1pL of the exon 15 sequencing primer 5- 
GTGAGGGCTCCAGCTTGTATC-3 (3.3pmol/pL), 1pL of the B-Raf PCR products, 
4pL BigDye3.1 kit (Applied Biosystems) and 4pL H20. A PCR program of 95°C for 30 
seconds, 50 °C for 10 seconds and 60°C for 4 minutes for 40 cycles was used. This 
was then cleaned with the Dye Ex 2.0 Spin kit (Quigen) using 20pL volumes. DyeEx
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Kits are designed for the removal of unincorporated dye terminators directly from 
sequencing reactions. The resin in the spin column was vortexed for resuspension. 
The cap of the column was loosened a quarter of a turn to avoid a vacuum inside the 
spin column. At the bottom of the spin column the closure plastic was snapped off 
and placed in the 2mL collection tube. This was then centrifuge for 3 minutes at 101 g 
using a Micro centaur bench-top centrifuge (Sanyo). The spin column was transfer to 
a clean centrifuge tube and the sequencing reaction (20pL) applied drop-wise 
directly onto the centre of the slanted gel-bed surface to the to the gel bed. The 
sequencing reaction product was collected by further centrifugation for 3 minutes at 
101g using the Micro centaur bench-top centrifuge. The spin column was discarded 
and the eluate in the micro-centrifuge tube contained the purified DNA. Sequencing 
reactions were sent to the ‘in house’ Central Biotechnology Service (CBS) where 
sequence analysis was undertaken using the automated ABI PRISM 3100 Genetic 
Analyser.
2.5 One-cycle eukaryotic labelling of gene chips
2.5.1 Sample preparation
For each gene chip a 60mm dish was used. This equated to 4 dishes for RASV12, 4 
dishes for BRAFV600E and 4 dishes for RET/PTC1 since the microarray experiment 
was conducted in quadruplicate. I processed all the dishes for total RNA isolation 
and purification in an RNase-free environment (section 2.3). Following the isolation 
of total RNA from samples, the following procedure involving labelling of gene chips 
were conducted by the in-house Affymetrix service which is part of the CBS facility. 
This method describes the experimental procedures conducted by the CBS facility.
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Total RNA was first reverse transcribed using a T7-Oligo(dT) Promoter Primer in the 
first- strand cDNA synthesis reaction. Following RNase H-mediated second-strand 
cDNA synthesis, the double stranded cDNA was purified and used as the template in 
the in vitro transcription (IVT) reaction. The IVT reaction was carried out with the T7 
RNA polymerase and a biotinylated nucleotide ribonucleotide mix for complementary 
cRNA amplification and biotin labelling. These cRNA targets were then cleaned up, 
fragmented and hybridised to gene expression arrays. All reagents are supplied from 
Affymetrix (High Wycombe, UK), unless detailed otherwise.
2.5.2 Quantification of RNA
RNA was quantified by spectrophotometric analysis on the basis that 1 absorbance 
unit at 260nm equals 40pg/ml_ RNA. The absorbance was checked at 260nm and 
280nm to determine RNA concentration and purity, and a A260/A280 ratio close to 
2.0 indicates pure RNA. The integrity of RNA was also assessed using an Agilent 
2100 Bioanalyzer, which produces an electropherogram displaying two well defined 
peaks which correspond to the 18S and 28S ribosomal RNAs, with a ratio of 2:1 for 
the 18S and 28S bands.
2.5.3 One-cycle cDNA synthesis
Poly-A RNA controls for the one-cycle cycle cDNA synthesis were first prepared. 
These controls provide exogenous positive controls to monitor the entire eukaryotic 
target labelling process. Each eukaryotic gene chip probe array contained dilutions. 
These were amplified and labelled with the samples, and were used to examine the
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hybridisation intensities on the arrays by monitoring the labelling process 
independent of the starting RNA samples. For 5pg of total RNA, 2pL of the Poly-A 
Control Stock was diluted in 38pL of the Poly-A Control Dilution Buffer for a 1:20 
dilution (first dilution). After mixing, centrifugation and the lower aqueous phase 
collected, 2pL was further diluted in 98pL of the Poly-A Control Dilution Buffer, 
producing a 1:50 dilution. This like previously, was mixed, centrifuged and the lower 
aqueous phase collected and 2pL was diluted in 18pL of the Poly-A Control Dilution 
Buffer to give a 1:10 dilution. After mixing, centrifugation and collection of the lower 
aqueous phase, 2ul of the final dilution was added to 5pg of total RNA sample.
2.5.4 First-strand cDNA synthesis
After thoroughly mixing the RNA samples, diluted poly-A controls and the T7- 
Oligo(Dt) primer, the total RNA (1pg-15pg) was added to 2ul of the diluted Poly-A 
RNA controls and 2pL of 50pM T7- Oligo(Dt) primer. RNase free water was finally 
added to a total volume of 12pL and the tube was mixed and pulsed briefly to collect 
the reaction mix at the bottom of the tube. The reaction mix was incubated for 10 
minutes at 70°C and briefly cooled at 4°C for -2  minutes. In a separate tube the first 
strand master mix was assembled (Table 2.1). This mixture was transferred to each 
RNAsample/T7-Oligo(Dt) primer mix, thoroughly mixed and incubated at 42°C for 2 
minutes. Depending on the amount of total RNA, Superscript II was added (1pL for 
1-8pg RNA or 2pL for 8.1-15pg RNA), thoroughly mixed an incubated at 42°C for 1 
hour, followed by cooling the samples at 4°C for at least 2 minutes.
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Component Volume
5X 1st Strand Reaction Mix 4pL
0.1M DTT 2pL
10mMdNTP 1pL
Table 2.1. First-Strand Master Mix
2.5.5 Second-strand cDNA synthesis
In another tube the second-strand master mix was assembled (Table 2.2) and 
thoroughly mixed. To each first-strand master mix 1 30jjL of the second strand 
master mix was added and incubated at 16°C for 2 hours. After which, 2pL of T4 
DNA polymerase was added to each sample and incubated at 16°C for 5 minutes. 
Following this incubation, 10pL of 0.5M EDTA was added.
Component Volume
RNase-free water 91 pL
5X 2nd Strand Reaction Mix 30pL
10mMdNTP 3pL
E.coli DNA ligase 1pL
E.coli DNA Polymerase 1 4pL
RNase H 1pL
Table 2.2. Second-Strand Master Mix
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2.5.6 Cleanup of Double-Stranded cDNA
To the double-stranded cDNA 600|jL of cDNA Binding Buffer was added and 
vortexed briefly. To a cDNA Cleanup Spin Column sitting in a 2mL collection tube 
500pL of the sample was applied and centrifuged for 1 minute at >8000g, and the 
flow through discarded. The remaining sample mixture was applied and centrifuged 
and the flow through discarded as before. The spin column was transferred to a new 
2mL collection tube and 700pL of the cDNA wash buffer was added to the column, 
which was centrifuged for 1 minute at £8000g and the flow through discarded. The 
spin column was then centrifuged for 5 minutes at maximum speed with the cap 
open and any flow through discarded as before. The spin columns were transferred 
into a 1.5mL collection tube, to which 14pL of cDNA elution buffer was added to the 
spin column membrane and incubated for 1 minute at room temperature and 
centrifuged for 1 minute at maximum speed for elution to occur.
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2.5.1 Synthesis of Biotin-labelled cRNA
For this section the gene chip IVT labelling kit was utilised. The amount of cDNA to 
be used for each IVT reaction was calculated (Table 2.3) and transferred to RNase- 
free tubes.
Starting RNA Material Volume of cDNA for 
IVT
10 to 100ng 12pL
1 to 8pg 12pL
8.1 to 15pg 6pL
Table 2.3. IVT reaction set-up
Components from the IVT labelling kit were added (Table 2.4) and centrifuged briefly 
and incubated at 37°C for 16 hours.
Component Volume
Template cDNA Variable
RNase-free water variable
10X IVT Labelling Buffer 4pL
IVT Labelling NTP mix 12pL
IVT Labelling Enzyme Mix 4pL
Table 2.4. IVT labelling kit components
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2.5.8 Cleanup and quantification of Biotin-Labelled cRNA
To each IVT reaction 60pL of RNase-free water was added and briefly vortexed. To 
this 350|jL of IVT cRNA Binding Buffer was added and again briefly vortexed. 250jjL 
of ethanol (96-100%) was then added, mixed followed by the application of 700pL of 
the sample to an IVT cRNA Cleanup Spin Column which is sat in a 2mL collection 
tube. The columns were centrifuged for 15 seconds at >8000g, and the flow through 
and collection tube discarded. The spin columns were transferred to a new collection 
tube and 500pL of the IVT cRNA Wash Buffer was applied onto the spin column. The 
column was centrifuged for 15 seconds at £8000g, and the flow through discarded. 
To the column 500pL of 80% (v/v) ethanol was applied and centrifuged for 15 
seconds at >8000g, and the flow through and collection tube discarded. The columns 
were then transferred to 1.5mL collection tubes and 11 pL of RNase water was added 
and centrifuged for 1 minute at maximum speed. A further 10pL of RNase-free water 
was added directly to the spin column membrane and the column centrifuged 1 
minute at maximum speed. Spectrophotometric analysis was then utilised to 
determine the cRNA yield and purity.
2.5.9 Fragmentation of the cRNA for Target Preparation
Fragmentation of the cRNA target before hybridisation onto gene chip probe arrays 
is crucial to obtain optimal assay sensitivity. The Fragmentation Buffer has been 
optimised to break down full length cRNA to 35 to 200 base fragments by metal 
induced hydrolysis. The fragmentation reaction mix was formulated (Table 2.5), 
incubated at 94°C for 35 minutes and then cooled on ice. An aliquot was saved for 
testing on the Agilent Bioanalyzer to check the fragmentation procedure.
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Component Volume
cRNA 20pg
5X Fragmentation Buffer 8pL
RNase-free water Make up to 40pL
Table 2.5. Fragmentation Mix components
2.5.10 Eukaryotic Target Hybridisation
The hybridisation cocktail was mixed together (Table 2.6) and the probe arrays 
equilibrated at room temperature.
Component Volume
Fragmented and labelled cRNA 20pg
Control Oligonucleotide B2 (3mM) 8pL
20X Eukaryotic Hybridisation Controls (bioB, bioC, ere) 15pL
2X Hybridisation Mix 150pL
DMSO 30pL
Nuclease-free water Make to 300pL
Table 2.6. Hybridisation Cocktail Mix
The hybridisation cocktail was heated to 99°C for 5 minutes and during this 
incubation, the array was immersed with 200pL of Pre-Hybridisation Mix through one 
of the septa. The array was incubated with the pre-hybridisation mix at 45°C for 10
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minutes with constant rotation. The hybridisation cocktail was then heated to 45°C 
for 5 minutes and centrifuged at maximum speed in a microcentrifuge. Te array was 
removed from rotation, and the pre-hybridisation mix removed and replaced with the 
hybridisation cocktail. This was left to hybridise to the array at 45°C for 16 hours on a 
rotation of 60rpm.
2.5.11 Washing, staining and scanning the array
After hybridisation, the array was vented and the hybridisation cocktail removed and 
washed with 250pL of Wash buffer A. The automated protocol for washing and 
staining was performed by the Fluidics Station 450 (Table 2.7)
Step
Post hybridisation wash #1 10 cycles of 2 mixes/cycle with Wash buffer A at 30°C
Post hybridisation wash #2 6 cycles of 15 mixes/cycle with wash buffer B at 50°C
1st stain 5 minutes with stain cocktail 1 at 35°C
Post stain wash 10 cycles of 4 mixes/cycle with wash buffer A at 30°C
2na stain 5 minutes with stain cocktail 2 at 35°C
3ra stain 5 minutes with stain cocktail 3 at 35°C
Final wash 15 cycles of 4 mixes/cycle with wash buffer A at 35°C
Filled with Array Holding Buffer
Table 2.7. Automated protocol for scanning and staining
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Scanning the array was performed by the GeneArray Scanner 3000 at a pixal value 
of 3pm and a wavelength of 570nm. This was followed by quality control analysis 
also conducted by CBS.
2.6 Invasion Assay
Growth factor reduced BD Matrigel™ Matrix (BD Biosciences, Bedford, UK) 
containing reduced amounts of EGF (<0.5 ng/mL), IGF-1 (5ng/mL), PDGF (<5 
ng/mL) and TGFp (1.7ng/mL) was thawed overnight at 4°C. The stock Matrigel™ 
was diluted in 1%FCS media at a concentration of 500 pg/mL. In a sterile 24 plate, 
BD Biocoat™ Matrigel™ invasion chambers (BD Biosciences, Bedford, UK) were 
placed and 100pL of the diluted Matrigel™ was plated into each chamber. The plate 
was incubated in an oven for 4 hours at 37°C. Each chamber was then rehydrated 
using 100pL of 1%FCS cell culture media and incubated for 1 hour. Cells to be used 
in the assay were trypsinised and counted using a haemocytometer. A cell 
concentration of 3x105/mL was obtained and cells resuspended in media containing 
1%FCS. To each invasion chamber 3x105 cells were plated and 900pL of 1%FCS 
cell culture media was placed in the outer section of the invasion chamber. The plate 
was incubated at 37°C, 5% CO2 for the required length of time (24 hours or 48 
hours). After the invasion period, each chamber was removed and the inner cleaned 
with tissue. Any invaded cells which would be present on the underside of the PET 
membrane of the invasion chamber were fixed in methanol/acetic acid (3:1) for 10 
minutes, left do air dry and stained with GIEMSA (VWR International, Poole, UK) for 
30 minutes. Stained inserts were photographed at x20 magnification and 5 fields per
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insert counted, with the average cell number determined. This was subsequently 
converted to percentage invasion.
54
3.0 Results
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3.1 The status of BRAFV600E mutation in thyroid cell lines
Alternative splicing of B-raf gives rise to multiple isoforms. In mice, alternative 
splicing encodes at least 10 isoforms of B-Raf with tissue-specific expression. The 
isoforms arise from the alternative splicing of exon 10 (9b), exon 8b and exons 1/2. 
The presence of exon 10 increases the basal kinase activity and affinity towards 
MEK, and exon 8b decreases kinase activity, the mechanisms of which remain 
unknown (Hmitou et al. 2007). Exons 1/2 promote dimerisation with Raf-1 providing 
an additional level of kinase activity. This allows for the modulation of kinase activity 
which may relate to its biological activity.
The T1799A transversion mutation induces the V600E mutation of B-Raf. This 
mutation accounts for ~90% of all B-Raf mutations in thyroid cancers and renders B- 
Raf constitutively active (Garnett and Marais 2004). Transfection of BRAFV600E in 
NIH3T3 cells induces transformation with constitutive ERK activation (Davies et al. 
2002). The T1799A mutation present in exon 15 was analysed in the full length and 
a shorter isoform (excluding exon 10), and this was conducted in a number of cell 
lines derived from thyroid tumours.
I aimed to characterise the alternative splicing mechanism in my panel of thyroid 
cancer cell lines. In addition, I also aimed to determine the mutational status, an 
important consideration for future experiments.
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3.1.1 Objectives
1. To define the mutational status of B-Raf in the panel of cell lines
2. To identify B-Raf isoforms in a panel of thyroid cell lines
3.1.2 Multiple BRAF isoforms are detected in thyroid cell lines
The regulation of kinase activity by B-Raf is complex, and alternative splicing of B- 
Raf is known to occur giving rise to multiple isoforms (Hmitou et al., 2007, Barnier et 
al., 1995). An important consideration for future experiments is establishing the B- 
Raf mutational status in thyroid cancer cell lines (Table 3.0). To conduct this 
investigation, a number of cell lines derived from various thyroid tumours were 
analysed by western blot analysis. The B-Raf antibody which I used was raised 
against a KLH-conjugated synthetic peptide corresponding to 754-765 amino acids 
of the human B-Raf with an N-terminal cysteine. This sequence is common to all B- 
Raf isoforms, and so the antibody is able to detect the full length recombinant B-Raf 
and B-Raf splice isoforms.
In the thyroid cancer cell lines SW1736, Hth74, FTC133, TT and UCLA-R082 there 
are multiple bands detected, indicating that multiple isoforms of B-Raf are present. 
Predominantly detected was a shorter 74kDa isoform which corresponded to 
AExonlO. Interestingly, in all the cell lines the full length isoform is expressed at a 
significantly lower level then the shorter isoforms of B-Raf indicating the dominant 
presence of a shorter isoform of B-Raf (Figure 6).
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Cell Line Mutational Status Origin
ORI3 None SV40 Transformed, 
immortalized
SW1736 br a fV600E +/- Anaplastic Carcinoma
Hth74 Unknown Anaplastic Carcinoma
BCPAP BRAFV600E +/- Papillary Carcinoma
K1 b r a fV600E +/- Papillary Carcinoma
FTC133 Unknown Follicular Carcinoma
K5 Unknown Papillary Carcinoma
TT None Medullary Carcinoma
UCLA-R082 Unknown Follicular Carcinoma 
(metastasis)
Table 3.0. Thyroid cell lines with associated origin and mutational status. +/- represents 
heterozygous BRAFV600E mutation and +/+ represents homozygous BRAFV600E mutation.
Full Length
AExonlO
AExon8b,10
coI£  AExon1/2,10 ■
m
^
•250 kDa 
•150 kDa
•100 kDa 
•75 kDa
■50 kDa 
■37 kDa
•25 kDa
“ 20 kDa
Actin
Figure 6. B-Raf isoforms identified by Western blot. Thyroid cell lines were probed with a B- 
Raf specific antibody detecting different isoforms of B-Raf. The lower molecular weight 
bands are deemed to be too small to be a B-Raf isoform and maybe either a non-specific 
artifact or due to protein degradation of the sample. To observe loading the western blot was 
stripped and re-probed for Actin.
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3.1.3 The BRAFV600E mutation is detected in the BCPAP and K1 papillary 
carcinoma cell lines.
A number of cell lines were selected to analyse the oncogenic mutation in the 
transcribed functional form of B-Raf. Using RT-PCR, cDNA was generated from 
mRNA extracted from the cell lines, thereby eliminating genomic non-coding regions 
of B-Raf. Exon 10 is present in the wild-type isoform of B-Raf and is spliced out of 
the shorter isoforms. Amplifying the region of exons 10-18 isolated the wild-type 
isoform since the forward primer is specific for exon 10 and would only anneal to the 
cDNA of the wild-type B-Raf isoform (Figure 7). For the detection of a shorter isoform 
of B-Raf, RT-PCR was conducted on the region between exons 8-18 These two RT- 
PCR reactions were sequenced to determine the presence of the BRAFV600E 
mutation in exon 15 of the full length isoform (exons 10-18) and shorter isoform 
(exons 8-18).
Full length
□mu□ D Exons
Sequence
AExon 10
m D D Exons
Sequence
Figure 7. Methodology of RT-PCR sequencing for the full length and shorter isoforms of B- 
Raf.
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The normal epithelial cell line ORI-3, displayed a red trace indicating a Thymine at 
the site of the point mutation confirming the presence of a valine codon (GTG), and 
therefore no BRAFV600E mutation. This was consistent for both the full length and 
short isoforms of B-Raf. The SW1736, Hth74 and TT cell lines displayed similar 
traces, highlighting the lack of the BRAFV600E mutation. Based on literature, the 
SW1736 cell line should contain a heterozygous BRAFV600E mutation. Since no 
mutation was detected, this indicates that the lab stock of this cell line is 
compromised. The mutation of B-Raf can either be present on both maternal and 
paternal alleles (homozygous) or on a single allele (heterozygous). The BCPAP 
papillary carcinoma cell line harbours a homozygous mutation in the full length 
isoform of B-Raf, indicated by a green trace which designates an Adenine base, and 
a Glutamic Acid codon (GAG). A heterozygous mutation in the full length B-Raf 
isoform was demonstrated in K1 indicated by the overlapping Thymine and Adenine 
bases at the point mutation. This demonstrates that only one B-Raf allele possesses 
the mutation in the full length isoform. The results were also consistent in the 
amplified region of exon 8-18 which also harboured the point mutation (Figure 8).
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Figure 8. Sequencing data of selected cell lines observing BRAFV600E mutation. Region 
containing the mutated codon is highlighted in pink. GTG represents wild-type B-Raf codon 
(Valine). GAG represents mutated codon (Glutamic Acid). Black arrows highlight the 
presence of an Adenine base highlighting the BRAFV600E mutation.
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3.1.4 Summary
Alternative splicing of B-raf gives rise to multiple isoforms. In mice, alternative 
splicing encodes at least 10 isoforms of B-Raf with tissue-specific expression. The 
isoforms arise from the alternative splicing of exon 10 (9b), exon 8b and exons 1/2. 
The presence of exon 10 increases the basal kinase activity and affinity towards 
MEK, and exon 8b decreases kinase activity (Hmitou et al. 2007). Exons 1/2 
promote dimerisation with Raf-1 providing an additional level of kinase activity. 
These spliced exons modulate the kinase activity of B-Raf to mediate different 
biological effects (Barnier et al. 1995).
Signalling of the MAPK pathway through B-Raf induces sustained ERK activation 
and cellular differentiation by phosphorylation of dual-specificity kinases MEK1 and 2 
which phosphorylate ERK1 and 2. The phosphorylation events shuttles ERK to the 
nucleus which induces the multitude of biological effects. Occurring in the cytosol, an 
additional level of activity is provided by the heterodimerisation of B-Raf with Raf-1, 
in a Ras dependent manner (Weber et al. 2001; Garnett et al. 2005). In this instance 
the activation of Raf-1 requires activation region and S621 phosphorylation. When B- 
Raf becomes activated, Raf-1 may bind in a 14-3-3 dependent manner, which 
activates Raf-1 to signal to MEK1/2. The dimerisation may provide B-Raf with subtle 
modulation of its kinase activity, which may relate to the biological outcome.
Analysis of B-Raf isoforms in my panel of thyroid cell lines revealed multiple 
isoforms. There was a prominent shorter isoform which based on current literature I 
determine to be the AExon 10 isoform. There is however a discrepancy in size of B- 
Raf isoforms which I identified and the isoforms identified in the literature. The study 
by Barnier et al. was conducted in murine cells, and this may not fully recapitulate
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the situation in human thyroid. In addition, modifications such as phosphorylation 
may be a probable cause of why the sizes do not match.
The T1799A transversion induces the BRAFV600E mutation. This accounts for -90% 
of all B-Raf mutations in thyroid cancers (Hmitou et al. 2007). BRAFV600E mimics 
T599/S602 phosphorylation rendering B-Raf constitutively active. Ectopic expression 
of BRAFV600E in NIH3T3 cells transforms cells with a 667-fold increase in kinase 
activity compared to wild-type B-Raf and induces constitutive ERK activation (Davies 
et al. 2002). In PCCL3 rat thyroid cells, BRAFV600E induces DNA synthesis, 
apoptosis, dedifferentiation and chromosomal instability (Mitsutake et al. 2005). In 
contrast, transformation by BRAFV600E with maintenance of proliferation was 
demonstrated in human papillary carcinoma cell lines (Liu et al. 2007). The 
difference in species and experimental conditions may provide an indication as to 
why BRAFV600E has a different effect in these studies. The BRAFV600E mutation is 
associated with aggressive characteristics including lymph node metastasis, 
extrathyroidal invasion and recurrence (Namba et al. 2003; Palona et al. 2006). 
Recent evidence has emerged suggesting that a homozygous mutation is correlated 
with increased aggression in thyroid cancer (Baitei et al. 2009). The aggressive 
nature of a homozygous mutation is highlighted by the BCPAP cell line and this was 
also shown to invade to a high degree in vitro.
In addition, it was shown that the phosphorylation sites of T599 and S602, where the 
BRAFV600E mutation occurs were not present in spliced variants. Instead these 
variants did not possess the N-terminal auto-inhibitory domain and only contained 
the C-terminal kinase domain resulting in constitutive activation. This indicates the 
shorter isoforms of B-Raf do not contain the V600E mutation and the mutation is 
restricted to the full length isoform only (Baitei et al. 2009). My investigation identified
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mutations in all isoforms of B-Raf which is in contrast to the Baitei et al study. In the 
authors study it appears the variant isoforms which were detected were not the same 
ones I identified in my investigations. Further work is required to analyse if the auto- 
inhibitory domain is lacking in the variant isoforms which I identified, and if the 
mechanism of constitutive B-Raf activation proposed by Baitei et al. is applicable to 
the thyroid cell lines I used.
This investigation was conducted to characterise B-Raf alternative splicing and the 
status of BRAFV600E. For future experiments, it was important to check if the full 
length isoform of B-Raf was the correct one to use for the in vitro model of PTC. I 
therefore aimed to select an appropriate isoform of B-Raf containing BRAFV600E. The 
full length isoform was not the most prevalent; however, the full length isoform 
contains exon 10 and 8b to modulate the basal kinase activity and affinity towards 
MEK and exons 1/2 which are required for heterodimerisation with Raf-1.
This means the chosen B-Raf isoform has the full array of biological activity. The 
presence of the mutation is not a factor for selection since the mutation is present in 
all isoforms. For the production of the BRAFV600E PTC model the full length isoform 
of BRAFV600E was utilised in a retroviral vector.
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3.2 Microarray Expression Gene Profiling
To identify candidate genes involved in invasive behaviour in thyroid cancer I utilised 
the Microarray platform to achieve this aim. Young human primary thyrocytes 
infected with the respective oncogenes (RASV12, BRAFV600E and RET/PTC1) were 
genetically profiled in quadruplicate on an Affymetrix microarray platform using U133 
PLUS 2.0 gene chips by the in-house Affymetrix service. This particular array 
contains 47400 transcripts, totalling 38500 genes and 54000 probe sets allowing for 
comprehensive analysis of genome-wide expression on a single array. The primary 
aim for this experiment was to identify potential candidate genes regulating the 
invasive phenotype of thyroid cancer. The microarray study was also used to 
observe the genetic profiles and highlight the molecular mechanisms the each 
oncogene infected thyrocytes, providing further insight into the biology of FA and 
PTC. The microarray study was subjected to statistical analyses conducted by Dr. 
Peter Giles who specialises in bioinformatic analysis and is a member of the in- 
house Affymetrix array service.
3.2.1 Objectives
1. Prepare oncogene infected thyrocytes for Microarray gene profiling
2. Conduct Microarray gene profiling quality control metrics
3. Analyse Microarray datasets to identify markers of tumour invasion
4. Identify candidate genes from literature analysis
5. Characterise invasive ability of oncogene expressing thyrocytes
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3.2.2 Preparation of oncogene infected thyrocytes
As detailed in the materials and methods, the in vitro models of RASV12, BRAFV600E 
and RET/PTC1 infected thyrocytes were produced by plating primary thyrocytes 
derived from a single patient into 12x60mm dishes (4 dishes per model). This 
effectively provided me with a model for FA (RASV12) and two models for PTC 
(BRAFV600E and RET/PTC1). Total RNA was extracted and the one-cycle eukaryotic 
labelling of gene chips followed by quality control metrics was conducted. Each 
model was conducted in quadruplicate to give the microarray experiment adequate 
power.
3.2.3 Microarray quality control metrics
Microarray technology is a rapidly advancing, expensive yet Informative biological 
technology. There are a number of variables which require careful consideration, and 
may affect the result, precision and accuracy. The starting sample material is crucial, 
as samples may display variable RNA quality. The use of quality control metrics 
assures accurate replication within sample sets and technical variation within the 
experiment ensuring consistency with accurate and precise gene expression data.
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3.2.3.1 Spatial Artefacts
To highlight physical imperfections and defective hybridisation within each gene chip, 
the gene chips were pseudo coloured to observe signal intensity. This quality control 
metric contains a localised scaling factor which is defined as a multiplication factor 
applied to every signal value in each chip. Scaling factors should be consistent within 
a sample set, highlighted by a prominent yellow colour. Poor quality is highlighted by 
indicated by extreme colours (blue/red). This forms the basis for the detection of 
hybridisation and physical chip defects. In this Microarray experiment, a prominent 
yellow colour with consistent scaling factors was observed for the gene chips 
indicating no physical imperfections or defective hybridisation (Figure 9).
Gene Chip 1 Gene Chip 2 Gene Chip 3 Gene Chip 4
CM
oo
LL
Figure 9. Spatial artifact quality control analysis. Gene chips used in the microarray study 
were pseudo-coloured to observe signal intensity for the detection of physical chip defects. 
The scaling factor is indicated below each gene chip.
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3.2.3.2 RNA degradation
RNA degradation plots observe the difference in the quality of RNA for each 
replicate. The degradation of RNA initiates at the 5’ end and terminates at the 3’ end 
of the RNA molecule, and the plots display the expression of the 5’ to 3’ position of 
probes, random degradation and ployA-primed synthesis. The average intensity of 
the probes is classified in the order of their proximity to the 5’ end of the gene for 
each gene chip. Each line displayed corresponds to an array, and the slope indicates 
the potential RNA degradation of the material hybridised to the array. In general, the 
greater the slope the more degraded the sample and overall decreased quality of 
data (Figure 10), but consistency is the most important factor. A single gene chip, 
RET/PTC1 chip 3 displayed a higher trend indicating increased degradation and 
poor quality of RNA, and therefore this particular chip was excluded from further 
analysis.
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Figure 10. RNA Degradation plots of RASV12, BRAFV600E and RET/PTC1 genechips. A, RASV12 gene chips. B, BRAFV600E and 
RET/PTC1 gene chips. The average intensity of the probes were classified in the order of their proximity to the 5’ end of the gene for 
each gene chip. Each line displayed corresponds to each gene chip with the slope indicating the potential RNA degradation of the 
material hybridised to the array.
69
3.2.3.3 Percent present genes and internal control genes
Percent present genes is defined as a fraction of probe sets ‘expressed’ in relation to 
the entire array, as produced by the Affymetrix MAS 5.0 statistical algorithm. This 
algorithm works by taking a set of Perfect Match (PM) and Mis-Match (MM) probes, 
and using these to generate a single value representing the estimated amount of 
transcript. To do this, files containing array images were processed to produce 
measured intensities for each probe on the array. The values depend on multiple 
factors including cell/tissue type, biological or environmental stimuli, probe array type 
and overall RNA quality. Logically, replicate arrays should have similar values, and in 
the experiment all gene chips had similar values (Figure 11). The absolute % present 
values were also similar between the gene chips.
To assess sample and assay quality the internal control genes GAPDH and P-actin, 
which are ubiquitously expressed were used. The signal values of the 3’ probe sets 
for GAPDH and probe sets were compared with signal values of the corresponding 
5’ probe sets. Since the gene chips contain separate probe sets against the 3’, mid 
and 5’ regions of the GAPDH transcript, a high ratio may indicate presence of 
truncated transcripts which may occur due to RNA degradation. Both GAPDH 3’-5’ 
(circles) and p-actin (triangles) were plotted for each gene chip. The GAPDH ratios 
were <1 which is the suggested maximum value of 1.25. The p-actin ratios were 
well within the limit of 3 (as stated by Affymetrix) for all the gene chips (Figure 11).
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Figure 11. Percent present genes and internal control genes analysis of RASV12, BRAFV600E and RET/PTC1 genechips. A, RASV12 
and B, BRAFV600E and RET/PTC1 gene chips. The percent present genes are highlighted in blue. The GAPDH internal control gene 
ratio is highlighted by the blue circles, and the (3-actin ratio is highlighted by the blue triangles.
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3.2.3.4 Q C Summary
Following the QC metrics, only the RET/PTC1 gene chip 3 revealed increased RNA 
degradation which would affect its hybridisation and display a variability within the 
sample dataset, and so was subsequently removed from further analysis. All the 
other gene chips displayed consistency quality control analyses with percent present 
and internal control genes all within the desirable limits.
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3.2.4 Microarray Analysis Design
As a general rule, microarray data can be analysed in 2 different ways. (1) Analysing 
the data to find the answer to a set hypothesis. (2) Analysing the data in order to find 
interesting biological information within the dataset. Using both principles, I analysed 
the datasets for my microarray experiment to obtain a thorough analysis. This will 
allow me to identify novel genetic markers and to observe any other relevant 
biological information associated with the oncogenic transformation of RASV12, 
BRAFV600E and RET/PTC1. To conduct this, the experiment was analysed using 2 
separate statistical tests; a t-test to determine the hypothesis and an Analysis of 
Variance (ANOVA) test to identify relevant biological information.
3.2.5 Gene Profiling Analyses
I chose to use the U133 PLUS2.0 microarray gene chip array since it offers complete 
coverage of the Human Genome U133 Set plus 6,500 additional genes for analysis 
of over 47,000 transcripts. This array offers the best solution for this investigation. It 
is also the first time that this array has been used with oncogene infected thyrocytes, 
as the genetic backgrounds of the oncogenic conditions have not previously been 
studied in this manner.
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3.2.5.1 Statistical t-test analysis ofRASV12, BRAFV600E and RET/PTC1.
The RASV12 oncogene is present in most benign non-invasive FA. In contrast, 
BRAFV600E and RET/PTC1 are both present most in invasive PTC, including occult 
micro PTC. To highlight specific genes involved with invasive behaviour of PTC, the 
BRAFV600E and RET/PTC1 datasets were combined and compared with the RASV12 
dataset using a t-test This test is designed to identify the genes which are 
statistically differentially expressed between the invasive and non-invasive models. 
The method of Benjamini and Hochberg (1995) False Discovery Rate (FDR) was 
conducted. This method correct for multiple testing and false discovery rates among 
the significant values obtained (p=0.05, 95% chance of differential gene expression 
and 5% chance of a false positive). In this experiment the FDR was set to 0.1% for 
the t-test, which significantly reduces the amount of false positives within the data. 
The data was subjected to hierarchical clustering, using the Euclidean distance 
measure. By definition, the Euclidean distance measures the absolute distance 
between two genes and can be visualised by a dendrogram, where the shorter the 
distance the greater the similarity. To visualise this concept, heat maps were 
produced using a colour coded matrix, where red signifies high expression, green 
low expression and the median expression as black (created using logs transformed 
median centred data). The heat maps observing the significant differential gene 
expression were produced using the R Package For Statistical Computing. This 
complete method of applying FDR, hierarchical clustering and generating heat maps 
were applied to the other statistical tests. For the t-test a probe set of 705 
differentially expressed genes was identified (FDR=0.1%), displaying 2 unique 
clusters (Appendix Figure 1). Cluster 1 contained 334 up-regulated genes in 
RASV12, with genes either down-regulated or at median expression in both
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BRAFV600E and RET/PTC1. Cluster 2 contains 334 down-regulated genes in RASV12 
with genes up-regulated or at median expression in BRAFV600E and RET/PTC1 
conditions.
To analyse the clusters in further detail, the primary biological functions were 
analysed. This would provide an insight into any processes which are present in the 
oncogenic models with correlation with malignancy. In order to gain an insight into 
the key biological information in each cluster and thereby present key information 
pertaining to invasion and tumourigenesis in the oncogenic conditions, over­
representation analysis was conducted using the Metacore™ analysis suite 
(GeneGo; http://portal.qeneqo.com). The package as a whole offers the storage and 
annotation of probe sets incorporating high quality curated databases of human 
protein-protein and protein-DNA interactions, transcription factors, signalling and 
metabolic pathways and effects of bioactive molecules. The incorporation of these 
databases facilitates detailed genetic background of a single gene together with its 
interaction with other genes and pathways. Within the software package, the 
GeneGo pathway map folder enrichment tool was used. This is a collection of 
manually created pathway maps, grouped hierarchically into folders according to 
main biological processes in the interrogated gene list. Interrogating cluster 1 
(Appendix Figure 2) and cluster 2 (Appendix Figure 3) respectively revealed a 
distinct set of biological functions elucidating the key phenotypes in each of the 
clusters. By default, this analysis tool specifies an FDR of 0.05 which lists the 
significant processes containing no more than 5% of false positive results. The 
orange bars representing experiment mappings that do not pass through this level 
are light orange/opaque, whilst the dark orange bars are deemed significant 
(Appendix Figure 2 and 3).
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The 334 differentially regulated probe sets (Appendix Table 1.0) represented gene 
transcripts from a diverse range of functional categories that regulate a multitude of 
biological functions. Cluster 1 had an expression pattern of up-regulation in RASV12 
and median/down-regulation in BRAFV600E and RET/PTC1. The map folder tool 
identified vascular development (angiogenesis) as the most significant process 
(Appendix Figure 2). Further analysis revealed the upregulation of the VEGFA, a 
potent mediator of angiogenesis. The expression of FN was found expressed highly 
in the RASV12 model. FN is associated with EMT and is utilised as a differential 
marker of thyroid malignancy. The identification of FN and VEGFA is indicative of a 
malignant phenotype in this particular cluster (Appendix Figure 2).
The analysis also highlighted an EMT response as ‘Regulation of epithelial-to- 
mesenchymal transition (EMT)’, ‘TGF-beta-dependent induction of EMT via MAPK’ 
and TGF-beta-dependent induction of EMT via RhoA, PI3K and ILK’ were identified. 
RhoA expression was highly up-regulated in the RASV12 oncogenic condition. The 
upregulation of this gene in RASV12 implies a migratory phenotype. Rho regulates 
the rear of the cell by stimulating the formation of stress fibers critical for actin- 
myosin mediated cell contraction (Wu et al. 2004). This forms the mechanism 
together with other GTPases to induce cellular movement.
The enrichment analysis identified an inflammatory response in the RASV12 model 
with the Cell adhesion-Chemokines and adhesion pathway highlighted. The genes 
associated with this pathway and upregulated in RASV12 included CD44, 
interleukin-8, VEGFA, FN, syndecan-2 and caveolin-2 upregulation. The VEGFA and 
FN genes have been previously associated with other pathways; however, genes 
can participate in multiple pathways thus explaining why genes are identified more 
than once.
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The analysis also identified the Tissue remodeling and wound repair' process as a 
significant hit. The pathways identified in this process included ‘Cell adhesion-ECM 
remodeling’, ‘Cell adhesion_Alpha-4 integrins in cell migration and adhesion’ and 
‘Development-EGFR signaling via PIP3’. The genes which I found interesting with 
this process include the EGF receptor and PTEN tumour suppressor protein, which 
were both up-regulated in RASV12. Integrins a4 and (31 were also up-regulated in 
RASV12, and these are essential for cell migration and polarity in certain cell types. 
PTEN is a negative regulator of the Akt pathway, and plays an important role in cell 
cycle arrest and apoptosis. RASV12 transformation results in increased activity of 
Akt and subsequently a natural increase in PTEN expression. The PI3K pathway is 
one of the effector pathways of RASV12 transformation, which explains the increase 
of Akt and PTEN in my analysis. The increase in PTEN may be an apparent cellular 
mechanism to counter the effects of increased Akt signalling.
The final significant process identified in cluster 1 was apoptosis, and within this 
process ‘Apoptosis and survival-Endoplasmic reticulum stress response pathway’ 
was identified. A specific gene relating to this pathway was the heat shock protein 70 
which was up-regulated in RASV12. The upregulation of this gene is linked to stress 
stimuli/signaling, and the MAPK pathway is central to the regulation of heat shock 
protein 70, and therefore is in concordance with the MAPK signalling cascade which 
RASV12 functions in.
Cluster 2 had 334 genes which were down-regulated in the RASV12 model and up- 
regulated in BRAFV600E and RET/PTC1 model (Appendix Table 2.0). The map folder 
enrichment of cluster 2 identified tissue remodelling and wound repair as the most 
significant (Appendix Figure 5). In this process, the role of ACM3 and ACM4 in 
keratinocyte migration was identified. Keratinocyte migration plays a key role in re-
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epithelialisation of skin wounds. Central mediators of this process are the muscarinic 
cholinergic receptors (ACM).
The calcium signalling process was also enriched in cluster 2, and the calmodulin 
genes are important in this process. These genes act as mediators of many enzyme 
and calcium ion channel function. Calcium can regulate the actomyosin-based 
contractile forces and the formation and disassembly of cell-matrix adhesions. 
Calcium sensitive actin binding proteins regulate the structure and dynamic 
behaviour of the cytoskeleton and cell migration (Lee et al. 1999). In addition, 
calcium is essential for thyroid hormone synthesis. TSH produced by the anterior 
pituitary gland fine-tunes calcium signals in the thyroid.
The second enriched process identified in cluster 2 was apoptosis. Within this 
process the ,‘DNA damage-Role of SUMO in p53 regulation pathway’ was 
highlighted. The genes regulating this pathway include Akt1, PML and SAE1. p53 
acts as an inducible, sequence-specific transcription factor on genes whose products 
regulate cell-cycle progression and apoptosis. PML functions as a transcription factor 
and tumour suppressor and its expression is cell-cycle related and functions to 
regulate the p53 response to oncogenic signals. Its upregulation in BRAFV600E and 
RET/PTC1 affects the expression of p53 gene expression. Akt1 upregulation may be 
a contributing factor inducing increased expression of PML and p53. The Akt 
pathway may also be attributed to protein synthesis where oncogenic transformation 
induces an increase in protein synthesis, a process which was also highlighted in the 
cluster 2 (Bader and Vogt 2004).
The enrichment of protein degradation process contained the ‘Proteolysis-Putative 
ubiquitin pathway’, ‘Development-WNT signaling pathway’ and ‘Degradation of beta- 
catenin in the absence WNT signalling pathway’.
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In cluster2, immune response and inflammatory response were identified. Although 
separate processes, a synergistic relationship between inflammation and an immune 
response is common in a number of cellular contexts including tumour progression. 
The pathways highlighted in the inflammatory process included ‘Immune response- 
inhibitory action of Lipoxins on pro-inflammatory TNF-alpha signalling’, ‘Cell 
adhesion-Chemokines and adhesion’, ‘Immune response-CD28 signalling’ and 
‘Immune response_IL-6 signalling pathway. The pathways highlighted in the immune 
system response process included ’Immune response-lL-15 signalling via JAK-STAT 
cascade’, ‘Development-GM-CSF signalling’, ‘Immune response-IFN alpha/beta 
signalling pathway’, ‘Immune response-CD28 signalling’ and ‘Immune response-IFN 
gamma signalling pathway. These responses are often observed within a tumour 
environment where the immuno-survaillence mechanisms mediate the immune 
responses.
A number of processes were identified in both clusters for example, amino acid 
metabolism and its regulation, apoptosis, mitogenic signalling and tissue remodeling 
and wound repair. However, the genes regulating these processes are unique to 
cluster 1 and cluster 2 respectively.
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3.2.5.2 Analysis of Variance (ANOVA) analysis
To identify any genetic signature changes between the 3 oncogenic conditions the 
statistical ANOVA test was utilised. This method calculates the probability of finding 
the observed differences in means between two or more conditions. It is important to 
consider the effect of multiple testing of each probe array where there is a probability 
of 5% of making a false positive error if the P-value is set at 0.05. The p-values 
obtained from the ANOVA analysis were subjected to FDR correction, which was set 
at 0.01% to reduce the amount of false positives within the data. The data was then 
subjected to hierarchical clustering, using the Euclidean distance measure. Heat 
maps were produced observing the differential gene expression of the probe sets for 
each sample. Visualisation of the heat maps was conducted using the web-based 
Microarray Data Review and Annotation System (MADRAS; 
http://madras.uwcm.ac.uk). developed in-house by the Microarray Bioinformatics 
Group at Cardiff University was utilised.
Significant changes in transcriptional modulation were observed in the RASV12, 
BRAFV600E and RET/PTC1 respectively. This ANOVA analysis identified 690 
differentially expressed genes (FDR of 0.01%) with consistent replication and a clear 
differential expression pattern for each oncogenic condition (Appendix Figure 4). To 
digest the data, heat maps were produced and the gene list was split (using the first 
5 significant bands on the dendrogram) into 5 individual clusters displaying 
modulation of expression between each oncogenic condition (Table 3.1).
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Cluster Number of 
Probe sets
RASV12 BRAFveoot RET/PTC1
1 121 Median/low High Low
2 96 Median/low Median/low High
3 142 Low Median High
4 209 High Median Low
5 34 High Low Median
Table 3.1. Details of hierarchical clustering of genotype-specific genes in RASV12, 
BRAFV600E and RET/PTC1 oncogene infected thyrocytes. Columns correspond to the 
oncogene and the rows to each gene transcript. Red signifies up-regulation and green 
signifies down-regulation. Table displays number of probe sets in each cluster with overall 
expression pattern corresponding to each oncogenic condition.
The probe sets identified for each cluster were categorised according to biological 
function. The 5 clusters represented differential patterns of expression with a diverse 
range of biological functions, analysed by the pathway map tool provided by 
GeneGo. The unique modulation of genes within each oncogenic condition indicates 
that the oncogenic event dictates a unique genetic profile. The pattern although 
unique show distinct similarities, and is observed when looking at the probe sets 
contained within each cluster and the respective integral pathway responses.
The 121 probe sets in cluster 1 had an expression pattern of low/median expression 
in RASV12 and RET/PTC1 with up-regulation in BRAFV600E (Appendix Figure 5). The 
enrichment of the biological processes contained within the cluster strongly identified 
tissue remodelling and wound repair. The pathways contained within this process 
included ‘Cell adhesion-Gap junctions’, ‘Development-BMP signaling’, ‘Development- 
TGF-beta receptor signaling’ and ‘Cell adhesion-Cadherin-mediated cell adhesion’. 
The genes which were up-regulated in the BRAFV600E model included Plakoglobin, 
cingulin, ZO-3, SMURF1 and SMURF2. Plakoglobin is a component of desmosomes
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and adherence junctions. This implies a role of desmosomes and/or adherence 
junctions in the BRAFV600E model. Also identified were the tight junction proteins, ZO- 
3 and cingulin implying that tight junctions are a component of BRAFV600E colonies. 
Taken together the identification of cell-cell contacts in the BRAFV600E model 
indicates epithelial architecture. It also reinforces the notion that BRAFV600E colonies 
maintain epithelial differentiation markers despite expressing the BRAFV600E 
oncogene.
The ANOVA cluster 2 containing 96 probes had only one significant process which 
was an immune system response (Appendix Figure 6). This cluster contained probes 
up-regulated in the RET/PTC1 model with down/median expression in RASV12 and 
BRAFV600E models. The immune system response pathways regulated by 
RET/PTC1 oncogene included ‘Immune response-Classical complement pathway’, 
‘Immune response-Lectin induced complement pathway’, ‘Immune response- 
Alternative complement pathway’ and Immune response-Antigen presentation by 
MHC class II’. These significant findings highlight the initiation of the complement 
pathway within this cluster with the upregulation of C1S, C3 and SERPING1 genes 
in the RET/PTC1 model.
The ANOVA cluster 3 containing 142 genes down-regulated in the RASV12 model, 
median expression in the BRAFV600E model and up-regulated in the RET/PTC1 
model (Appendix Figure 7). Pathways identified within this cluster included ‘Cell 
cycle-Nucleocytoplasmic transport of CDK/Cyclins’, ‘Cell cycle-Regulation of G1/S 
transition (part 2)’, ‘Cell cycle-Start of DNA replication in early S phase’, ‘Cell cycle- 
Spindle assembly and chromosome separation’, ‘Cell cycle-Regulation of G1/S 
transition (part 1)’ and ‘Cell cycle-Role of 14-3-3 proteins in cell cycle regulation’. 
These pathways were highlighted under the cell cycle and its regulation process.
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Other map folder processes included Cardiac Hypertrophy, Protein synthesis, DNA- 
damage response, Inflammatory response, Myogenesis regulation, Apoptosis and 
Immune system response. These pathways recapitulate the findings from the t-test 
cluster 2 (Appendix Figure 5).
Cluster 4 contained 209 probes with upregulated probes in the RASV12 model. This 
cluster recapitulates the processes and pathways which were identified in t-test 
cluster 1 (Appendix Figure 4). This cluster contained genes regulating ‘vascular 
development (angiogenesis)’, ‘Cell differentiation’, Tissue remodeling and wound 
repair”, ‘Mitogenic signaling’ and ‘Inflammatory response’ (Appendix Figure 8). These 
were all observed in the t-test cluster, and shows although the test is different, the 
general expression pattern remains relatively consistent.
Cluster 5 containing 34 probes also displayed up-regulated probes in RASV12, did 
not reveal any significant map folders or individual pathways (Appendix Figure 9). 
The ‘Apoptosis and survival-Endoplasmic reticulum stress response pathway’ was 
identified as the highest ranked pathway (Appendix Figure 9). Only heat shock 
protein 70 and protein disulfide isomerase family A genes were identified. In cluster 
2 of the t-test (Appendix Figure 5) Apoptosis was also identified. This expression 
pattern recapitulates these results observed in the t-test cluster.
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3.2.6 Invasive behaviour of the in vitro models
To investigate whether microarrays could be utilised to identify candidate genes 
involved in invasion, I sought to characterise the invasive capability of my primary 
models. This would thereby link mRNA expression to the invasive behaviour of the 
PTC models.
To do this I had established an invasion assay using a modified boyden chamber 
using negative control cell lines ORI-3, MCF10A and invasive cell lines FTC236 and 
MDAMB231 (data not shown). In an ideal situation, the assay would be performed 
three times with triplicate chambers. However, there is a limited supply of primary 
thyroid cells. I therefore conducted a single experiment to indicate the invasive 
capability of the RASV12, BRAFV600E and RET/PTC1 models. The RASV12 cells 
were highly invasive, a finding which was unexpected, as RASV12 was assumed to 
be a model for non-invasive FA. Both BRAFV600E and RET/PTC1 also displayed 
invasive capability but at a decreased level (Figure 12). The RET/PTC1 oncogenic 
condition was significantly decreased when compared with the RASV12 model 
(p=0.04). The decreased invasion in both BRAFV600E and RET/PTC1 may be 
explained by their proliferative rates. Although BRAFV600E and RET/PTC 1 oncogenes 
display decreased proliferative rates compared with RASV12, they retain their 
invasive behaviour in the invasion assay. This is consistent with in vivo PTCs which 
also display a low proliferative rate.
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Figure 12. Representative view and the number of invaded cells of the RASV12, BRAFV600E 
and RET/PTC1 models. Each oncogenic condition was assayed in triplicate. Invasion was 
conducted for 24 hours with a Matrigel concentration of 50pg/pl. After invasion, inserts were 
fixed and stained with G IEMSA to visualise invaded cells. Cells were counted and the 
average number of invaded cells calculated. T-test analysis was conducted by comparing 
RASV12 with the BRAFV600E model and RASV12 with the RET/PTC1 model. Significance 
between RASV12 and RET/PTC1 (p=0.04) is highlighted by a black star.
With the discovery that RASV12 transformed cells invade Matrigel, the identification 
of novel candidate genes could not be achieved since there is no appropriate non- 
invasive control within the profiling experiment. Without comparing an invasive model 
with a benign model, identification of genes involved with invasion is not possible at 
this stage. Further microarray gene profiling of a benign model such as normal 
follicular epithelial cells would provide a non-invasive model to compare against.
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However, I conducted a literature analysis for potential candidates and profiled their 
expression using my microarray experiment to provide an indication that they may be 
involved in invasive behaviour.
3.2.7 Identification of candidate genes
To further explore the genes which may regulate this invasive phenotype in these 
cells, an extensive literature search revealed a number of genes which mediate an 
invasive phenotype. In addition, many studies conduct a robust check of a number of 
genes to determine that datasets obtained from the analysis are both accurate and 
precise and are in conjunction with the biology of FA and PTC or benign vs. 
malignant thyroid tumours. There are a number of studies which have indicated a 
selection of genes which show a consistent genetic profile in benign or malignant 
tumours of the thyroid.
There are however, inherent factors which are taken into consideration. These are 
the variability in the microarray platform, methods of analysis, sample type and 
preparation means. The gene expression signatures are most likely to differ 
between studies, however a select few genes which are known to be associated with 
either specific tumours or malignancy. A number of studies investigating thyroid 
neoplasia corroborate their data with genes analysed through other experimental 
procedures and studies. Visualisation was conducted using a web-based Microarray 
Data Review and Annotation System (MADRAS) which provides expression values 
of individual probes for the each of the gene chips.
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In the process of tumour invasion ECM degradation/remodelling is extremely 
important. MMPs degrade ECM products and are associated with cancer invasion. 
The primary MMPs which have been implicated in thyroid invasion are the 
membrane bound MMP (MT1-MMP), MMP-2 and MMP-9 (Hofmann et al. 1998; 
Buergy et al. 2009). The expression of MT1-MMP on average was up-regulated in 
RASV12 compared with BRAFV600E and RET/PTC1. The expression of MMP-2 was 
detected at median expression, whilst RET/PTC1 showed up-regulation and 
BRAFV600E was slightly down-regulated. The expression of MMP-9 was increased in 
the RASV12 model, whilst both BRAFV600E and RET/PTC1 had reduced expression 
(Figure 13).
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Figure 13. Expression profiles of Matrix 
Metalloproteinases determined in MADRAS. A. 
MT1-MMP B, MMP-2 and C, MMP-9. Red 
signifies up-regulation, green signifies down- 
regulation and black signifies median expression
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In parallel, from the literature analysis I identified genes which have a potential role 
in thyroid tumourigenesis. The expression of these potential targets in my model 
systems were observed using MADRAS.
1) Profilins are a low molecular weight family of proteins, of which there are multiple 
isoforms and function to regulate the actin cytoskeleton. Proflin-1 was described 
initially as a G-actin binding protein, and has a primary role in sequestering actin, 
inhibiting actin polymerization. However, profilin can also promote actin assembly 
through the nucleotide ADP to ATP exchange, shuttling ATP-bound actin to the free 
barbed ends of actin filaments. It is therefore highly significant in mediating a motile 
phenotype. The polymerisation of actin is required for the formation and extension of 
actin protrusions including lamellipodia, invadopodia and filopodia which all aid in the 
process of cell movement and tumour invasion (Li et al. 2008). Proflin-1 induces 
lamellipodia in a growth factor impendent manner by increasing the nucleotide 
exchange of ADP-actin for ATP-actin. In addition, genetic studies revealed that 
disruption of Profilin-1 gene attenuated growth and motility in single cells (Ding et al. 
2006). However, below a threshold level, Profilin-1 correlated with the tumourigenic 
state of breast carcinoma cells (Zou et al. 2007). In contrast, in malignant melanoma 
cells Profilin-1 is upregulated which indicates a tumour specific role of Profilin-1 (Li et 
al. 2008). Its role in the progression of malignant thyroid lesions remains to be 
investigated. In this instance profilin-1 was down-regulated in RASV12 and 
upregulated in BRAFV600E and RET/PTC1 models. This implies a role of profilin in 
PTC tumourigenesis (Figure 14).
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Figure 14. Expression analysis of Profilin-1 using MADRAS. Red highlights up-regulation, 
green down-regulation and black median expression
2) The S100 proteins are a family of small acidic calcium binding proteins which 
have a broad range of intracellular and extracellular functions including regulating 
protein phosphorylation and enzyme activity, calcium homeostasis, regulation of 
cytoskeletal components and regulation of transcription factors. They all contain 2 
helix-loop-helix motifs, one of which is conserved amongst all S100 proteins and the 
other which conveys its specific biological function (Bjornland et al. 1999).
S100A4 has emerged as an important protein with the capacity to promote invasion 
and metastasis of numerous human tumours including PTC (Bjornland et al. 1999). It 
regulates a number of cellular processes including growth, motility, cell cycle, 
transcription and differentiation. Observing expression of S100A4 in MADRAS 
revealed basal level expression in RASV12 with increased expression in both 
BRAFV600E and RET/PTC1 models (Figure 15). This indicates a potential role of 
S100A4 in PTC.
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Figure 15. Expression analysis of S100A4 using MADRAS. Red highlights up-regulation, 
green down-regulation and black median expression
3) Tenascin C is an extracellular matrix glycoprotein which functions in the process 
of EMT. It belongs to the matricellular class of proteins which include 
thrombospondins and SPARC (secreted protein acidic and rich in cysteine) and can 
exist in soluble or insoluble forms. Tenascin C contains many repeats which share a 
similar homology to EGF, and fibronectin. Alternative splicing of Tenascin C gives 
rise to several isoforms, which may have independent roles in the extracellular 
matrix, although this remains to be investigated. Its expression is limited to specific 
developing tissues and tissues undergoing remodelling such as in wounds and 
tumours indicating a prevalent role of tenascin C in cell migration.
The mRNA expression of Tenascin C and fibronectin are highly upregulated in 
invasive malignant melanomas (llmonen et al. 2004). The simultaneous expression 
of fibronectin implies a synergistic role in carcinogenesis, a role which as yet remains
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S100A4
to be elucidated. Under normal conditions, fibronectin acts as an antagonist to 
tenascin C, with fibronectin promoting adhesion, whilst Tenascin C interferes with 
fibronectin-cell interactions. It is unclear if this antagonistic role by Tenascin C and 
fibronectin is present in thyroid lesions. In thyroid lesions, immunohistochemical 
analysis revealed that Tenascin C was devoid in normal and benign lesions, whilst 
being intensively expressed in papillary carcinomas, highlighting a potential role in 
malignant tumour progression (Tseleni-Balafouta et al. 2006). In my microarray 
profiling experiment, Tenacin-C was expression at relatively high levels with RASV12 
displaying a marginal increase in expression level (Figure 16).
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Figure 16. Expression analysis of Tenacin-C using MADRAS. Red highlights up-regulation, 
green down-regulation and black median expression
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4) The Slug transcriptional repressor in recent years has become a potential target in 
many cancers. In normal conditions Slug expression is restricted to developmental 
processes during embryogenesis. In tumours it is a known transcriptional repressor 
of E-cadherin, which can lead to Epithelial to Mesenchymal Transition (EMT) (Hajra 
et al. 2002). In thyroid tumours research pertaining to Slug is limited and could be 
expanded upon. In my microarray profiling study the expression of Slug was 
detected at a median level in RASV12. RET/PTC1 also had median expression, 
although the RET/PTC1 (1) gene chip had double the level of expression. 
Expression of Slug in BRAFV600E was decreased 3-fold compared to the other 
models (Figure 17). In addition, the array only contained a single probe for Slug, 
therefore issues such as hybridisation may have compromised the probe. Further 
characterisation of Slug expression using alternative methods is required.
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5) Osteopontin (OPN) is a secreted phosphoprotein supporting numerous cellular 
functions. OPN overexpression is observed in numerous malignant tumours (Wai 
and Kuo 2008). OPN is overexpressed in PTCs, however the mechanistic 
requirements of OPN in invasion requires further investigation (Guarino et al. 2005). 
In the microarray profiling study the expression of OPN was increased in RASV12. 
The expression was slightly lower the both BRAFV600E and RET/PTC1 (Figure 18).
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down-regulation and black median expression
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3.2.8 Summary
In this section, microarrays were used to identify novel candidate genes involved 
with tumour invasion in BRAFV600E and RET/PTC1 models of PTC, by comparison 
with the RASV12 model of FA. There are many studies which utilise the microarray 
platform to distinguish tumour types i.e. FA from FTC. PTC can be diagnosed with 
95% accuracy from FNA biopsy. My aim therefore was not to distinguish between 
tumour types, but rather to identify novel diagnostic markers which are implicated in 
tumour invasion. I conducted a microarray study using primary model systems for 
PTC and FA. This would provide a lower signal to noise ratio compared to primary 
tumours, and increased biological complexity compared to cell lines. I also aimed to 
provide additional biological information pertaining to the primary models.
In general, a microarray study contains a number of variables which can affect the 
overall outcome of experimentation and these require careful consideration when 
conducting profiling studies. The use of different types of platforms and gene chips 
may yield different expression profiles. The different use of gene chips contain within 
them different number of probes which therefore represent varying amounts of the 
human genome. The Affymetrix 133A gene chip offers 22,283 probes is compatible 
with its successor, the U133 PLUS 2.0 Affymetrix gene chips which were used in my 
experiment. These next generation gene chips offer the greatest comprehensive 
number of probes for human genome with an extra 6,500 genes in addition to the 
22,283 probes on the 133A gene chips. This makes comparison of datasets using 
either of these gene chips comparable between studies. A number of studies utilise 
primary tumour samples or cell lines, my microarray profiling study is novel in this 
respect. This is the first time where transforming primary thyrocytes with respective
oncogenes creating an in vitro cell culture model of FA and two models of PTC. Our 
group is unique in our approach, and therefore is superior to cell lines and with 
respect to genetic profiling primary tumour samples as well. The use of cell lines 
offers unlimited proliferative potential with a low signal to noise ratio. The biological 
relevance to primary tumours is restricted as primary cells do not possess an 
unlimited proliferative potential, making their use as true models for primary tumours 
restricted, however, they remain a powerful tool in cancer research. Since primary 
tumour samples are taken from the said tumour, the majority of profiling studies use 
primary tumour tissue as the sample. However, the tumour contains a number of 
other cell types, in addition to the transformed tumour cells. This in effect would 
create ‘background noise’ in the experiment, perhaps masking the true profile of 
transformed tumour cells. The use of my group’s unique primary tumour model offers 
an intermediate, with increased biological complexity and accuracy compared to a 
cell line, but decreased background noise compared to primary tumour tissue 
samples. In general, microarray data was analysed using 2 different approaches, the 
first, analysing the data by addressing the aim of the study, in this instance to identify 
genes which may regulate an invasive phenotype and secondly, to identify any other 
biological information contained within the dataset. For the identification specific 
genes which may regulate an invasive phenotype the t-test was used to compare the 
benign non-invasive with the invasive models BRAFV600E and RET/PTC1 which were 
combined for this analysis. The different kinetics in gene expression revealed by 
transcription expression profiling reflect the complexity of FA and PTC, represented 
by the RASV12 FA model, BRAFV800E PTC model and the RET/PTC1 PTC model. 
The second method utilised was an ANOVA test which determines differential 
expressed genes across all the models. This in particular displayed 5 clusters with
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modulation of gene expression unique to the RASV12, BRAFV600E and the 
RET/PTC1 model respectively.
Since the overall aim of the microarray study was to identify novel markers mediating 
invasion, each oncogenic condition was analysed for their invasive behaviour using a 
well established in vitro invasion assay system. Since samples were in short supply, 
this particular experiment could not be conducted to its full replication with 3 
separate experiments, which would normally be conducted for studies involving 
invasion assays. Therefore, a single experiment was conducted to represent the 
invasive capability of each respective model. In my hands, I found the RASV12 
model displayed an invasive capability. This finding was surprising as FAs are non 
invasive tumours which are well known within the literature (Kondo et al. 2006). 
Indeed, profiling of the oncogene infected models determined a genetic profile of 
pathways, processes and genes which may propagate the invasive response 
observed in all the models.
This is the first time oncogene infected thyrocytes have been used for profiling and 
invasion assays. Therefore, comparisons with other studies cannot be performed. 
However, the normal epithelial thyrocytes which are isolated from primary tissue 
invariably contain multiple cell types. Although much of the unwanted cells are 
removed, one cannot rule out the possibility that more than one cell type is present in 
culture. Within the RASV12 model, our group have found a sub-culture of epithelial 
like cells within the primary culture. Although these cells have not been thoroughly 
characterised, they do display a high proliferative capacity (Bond, Wyllie et al. 1993). 
It is unknown if it is this sub-culture of cells which are invading the Matrigel. It is 
probable that the retroviral induction of RASV12 into this sub-culture conveys an 
invasive phenotype. Since there is no definitive detection method to determine the
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invaded cell type, this can only be proposed at this stage. Introduction of mutant 
Ras in culture induces clonal expansion without morphological transformation, which 
closely represents FA in vivo. There has been extensive evidence which has found 
that introduction of mutant Ras in epithelial cells results in growth stimulation whilst 
in fibroblasts results in growth arrest (Gire, Marshall et al. 1999). This evidence 
suggests that introduction of RASV12 has different effects in different cells
Another possible explanation may be due to the culture conditions. Typically cells 
are cultured in culture media supplemented with 10% FCS. The presence of serum 
is crucial to maintain cell cycle progression, where lack of serum results in the cell 
cycle arrest in Go phase of the cell cycle. It is also known that serum invariably 
contains numerous factors including growth factors. The effect of growth factors may 
lead the activation and signalling of pro-invasive pathways. In the presence of serum 
the induction of the RASV12 oncogene may be masked by growth factors which 
induce the invasive phenotype which RASV12 transduced cells appear to have.
The profiling of the oncogene infected thyrocytes could not determine novel markers 
of invasion. This was due to the RASV12 model displaying invasive processes as 
determined by the microarray gene profiling experiment. Gene profiling offers an 
indication of processes and pathways which are implicated in invasion. In addition, in 
the future probable negative controls may be profiled and combined with the 
datasets to elucidate the aim of identifying novel markers of invasion. From the t-test 
analysis, the test is able to group both up- and down-regulated genes in the RASV12 
model to compare with the combination of BRAFV600E and RET/PTC1 models. This 
method provided extensive gene lists, and to interrogate the lists enrichment 
analysis was conducted. The GeneGo Map folder and pathway map tools were 
utilised for the enrichment analysis. Cluster 1 which displayed probes up-regulated in
RASV12, a number of genes associated with a malignant phenotype were identified. 
FN is utilised as a immunohistochemical tumour marker and is found in a large 
percentage of carcinomas, but a small degree of adenomas also (Prasad, Pellegata 
et al. 2005). Detection of FN is only an indication of malignancy and cannot be 
considered absolute. The second gene which was identified was the pro-angiogenic 
factor VEGF which was also highly expressed in RASV12. VEGF has role in both 
physiological and pathological angiogenesis, and its expression is associated with 
carcinomas (de la Torre, Buley et al. 2006). Its identification in the RASV12 model 
implies an angiogenic response. EGFR, another gene which was expressed highly in 
the RASV12 model is overexpressed in anaplastic carcinomas, however, it appears 
posttranslational modifications convey EGFR as a differential marker for FA 
(Westermark, Lundqvist et al. 1996). The identification of pathways involving Rho 
implies a migratory phenotype for RASV12. Rho is known to be associated with 
cytoskeletal reorganisation which is important for cell migration and invasion. The 
upregulation of this gene does in fact imply that RASV12 does not have a phenotype 
that represents FA. The expression of Caveolin 2 cannot determine benign or 
malignant phenotype in RASV12. A previous study showed Caveolin2 was not a 
differentiating marker of malignancy (Aldred, Huang et al. 2004).The identification of 
these genes indicate that RASV12 has a unique profile in that there are genes which 
are associated with FA, whilst a small number of genes that are associated with 
malignancy. It is this small proportion of genes which may contribute to the invasive 
phenotype of RASV12.
Genetic profiling does in part indicate why the RASV12 cells invade in the in vitro 
assay. To further expand upon this, the datasets for each oncogenic cluster were 
interrogated for individual probes targeted against MT1-MMP, MMP-2 and MMP-9
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using MADRAS software suite. This gave a profile of MMP activity in each oncogenic 
condition, elucidating proteinase activity. MT1-MMP is a master regulator of MMP-2 
and this was up-regulated in the RASV12 oncogenic model. Observing the 
expression of MMP-2, there is an indication of involvement in all the models since 
expression levels were comparable. Perhaps most interesting is the significant 
detection of MMP9 which was increased in the RASV12 oncogenic model. In 
immortalised keratinocytes the induction of RASV12 increases MMP-9 gene 
expression and promoter activity (Iyer, Pumiglia et al. 2005). Although the cellular 
context may be altered evidence exists which link RASV12 to MMP-9 expression, 
and this may explain the involvement of the protein degradation process. Although 
MMP gene expression was identified, the analysis does not differentiate between 
latent and active enzymes.
Enrichment analysis observing the map folders provided a view of the main 
processes and pathways occurring in each oncogenic condition. The identification of 
an immune response is common within the tumour microenvironment, where host 
tissue cells have an active participating role in tumourigenesis. The immune 
response links with an inflammatory response. The inflammatory response involves 
the influx of leukocytes and secretion of inflammatory mediators including cytokines, 
chemokines, growth factors and proteinases (Le Bitoux and Stamenkovic 2008).
The inflammatory process was identified in all the oncogenic models; however, a 
normal thyroid negative control is required to observe if the involvement of 
inflammation and immune system response is involved in invasion. Tumours whether 
malignant or benign, are subject to the host immune-surveillance. This is where the 
host immune system responds to transformed cells by inducing an immune 
response, as they are deemed a foreign entity. Although this may occur tumours also
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possess mechanisms to evade the host immune response. Deficiencies in key 
immunological molecules may convey the identification of the immune system 
response and inflammation in the analysis.
I also sought to determine the expression levels of targets I had identified within the 
literature. Based on my extensive literature analysis and expression profiling 
experiment I aimed to select a couple of candidates to take forward for further 
experimentation.
From the literature analysis I had selected a number of genes. These included the 
transcription factor Slug, OPN, profilin-1, Tenacin-C and S100A4. All of these genes 
have a role in tumourigenesis, or are linked to invasive processes. The S100A4 
protein is a small calcium binding protein that is associated with metastatic tumours 
and appears to be a molecular marker for clinical prognosis. The expression of 
S100A4 is therefore a good indication of an invasive phenotype. Since it is 
associated with thyroid cancer, it is not only a probable candidate for genetic 
manipulation, but also an indicator of the gene profile of the oncogenic models. 
S100A4 is highly expressed in the PTC models, a result which is consistent with the 
models and the literature. There has been a vast amount of work conducted with the 
S100A4 in thyroid cancer, and in my opinion investigating this particular gene would 
not provide much novel work for this thesis.
Profilin-1 was highly expressed in my PTC models, however, in breast cancer cells 
profilin-1 acts as a suppressor of tumourigenesis (Janke, Schluter et al. 2000). 
Therefore this gene is not a strong choice for genetic manipulation. Tenascin-C 
expression in the in vitro models revealed similar levels. In melanoma, tenascin-C is 
associated with tumour progression (Fukunaga-Kalabis, Martinez et al.). Without
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significant differential expression tenascin-C remains a weak candidate for further 
investigation.
However, OPN is known to be overexpressed in PTC (Guarino, Faviana et al. 2005) 
and details regarding the invasive mechanisms regulated by OPN remain elusive. 
The genetic profile of OPN revealed a low level of detection in the models. This 
implies the PTC models do not have an ‘exact’ genetic profile to the in vivo situation. 
The expression profile of OPN was also variable with differing degrees of detection 
between each chip. There was only a single probe for OPN on the gene chip and 
this may explain the variable result seen. From the literature genetic manipulation of 
OPN has not been conducted before, therefore the scope for elucidating OPN in 
thyroid tumour invasion is great.
The Slug transcription factor is well established in tumours and has been implicated 
in thyroid tumourigenesis (Nieto 2002). Genetic manipulation of this gene has not 
been conducted before, and observing expression levels in the models revealed 
median expression in both RASV12 and RET/PTC1. The levels were similar 
between the models, and all had displayed an invasive capability, therefore this gene 
is a strong contender for genetic manipulation.
Taken together, genes which were identified in the extensive literature search were 
selected as candidate markers for thyroid invasion. The OPN and Slug genes were 
selected as candidates for genetic manipulation based on their implicated role in 
thyroid tumourigenesis, and their scope for future work. Although the expression 
values obtained in MADRAS are an indicator of a possible role, this cannot be taken 
as absolute without a control displaying a non-invasive phenotype, or re-confirming 
the expression using real-time quantitative PCR.
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PART II
4.0 Background
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4.1 The SNAIL family of transcriptional repressors
In vertebrates, the Snail family of zinc finger transcription factors consists of 3 genes, 
snail (snail), snai2 (slug) and snai3 (smuc). The Snail zinc finger transcription factor 
was first identified in Drosophila melanogaster, where it is required for mesoderm 
development (Boulay, Dennefeld et al. 1987; Alberga, Boulay et al. 1991). The 
family all have a conserved carboxy- terminal containing 4-6 zinc fingers to function 
as DNA binding motifs, with a diverse amino-terminal domain. The consensus 
binding site for snail-related genes is identical to the E-box binding site, a core 
binding site for basic-helix-loop-helix binding transcription factors (Nieto 2002). The 
binding of the E-box by Snail family members relies upon the zinc finger domains 
and the SNAG domain contained within the amino terminal (Nakayama, Scott et al.
1998). The central domain is a divergent serine/proline rich region, where the Slug 
protein contains a so-called Slug domain within this region. Within the Snail protein, 
the central portion contains a regulatory nuclear export signal (NES) domain and a 
destruction box domain (Peinado, Olmeda et al. 2007).
The process of EMT is important for early development during gastrulation and 
neural crest cell migration which require motile cells that differentiate into specialised 
structures. In addition in the context of tumour progression in general, EMT is 
initiated through the disruption of cell-cell contacts which include adherent, tight and 
desmosomal junctions that link epithelial cells to one another. This is followed by 
cytoskeletal reorganisation and degradation of basement membranes and stroma 
together with an enhanced growth rate (Kurrey, K et al. 2005). The repression of the 
adherent Epithelial-cadherin (E-cadherin) protein is important for EMT. It functions as 
a calcium dependant adhesion protein and facilitates cell-cell communication and is
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regarded as a tumour suppressor. The cytoplasmic domain of E-cadherin interacts 
with a and p and p120ctn catenins and this complex interacts with the actin 
cytoskeleton. The extracellular domain binds to adjacent adherent junctions on 
neighbouring cells. P-catenin is associated with cell-cell adhesion but is also a well 
established mediator of the Wnt signalling pathway. Disruption of cell-cell adhesion 
includes the downregulation of E-cadherin, and this is considered as a progressive 
step in conferring invasive potential of carcinomas. E-cadherin is repressed by the 
snail family of transcription factors, which can interact with E-box elements on the E- 
cadherin promoter (Cano, Perez-Moreno et al. 2000). Indeed, Snail is expressed in 
the developing skin of mice, where the skin cells lose E-cadherin expression during 
the formation of hair follicle buds (Jamora, Lee et al. 2005). Also, Snail mutant mice 
die at gastrulation which highlights the critical role Snail in EMT (Sefton, Sanchez et 
al. 1998). Snail silencing has also been shown to inhibit tumour growth (Olmeda, 
Jorda et al. 2007). The event of Snail overexpression in Madin Darby canine kidney 
(MDCK) epithelial cells leads to an invasive phenotype (Cano, Perez-Moreno et al. 
2000). Snail expression has been highlighted in an increasing number of human 
carcinoma and melanoma cell lines (Peinado, Portillo et al. 2004), and is expressed 
at the invasive front of epidermoid carcinomas (Cano, Perez-Moreno et al. 2000) and 
has been correlated to lymph node invasion of ductal breast carcinomas and 
hepatocarcinomas (Blanco, Moreno-Bueno et al. 2002; Sugimachi, Tanaka et al.
2003). The high expression of the Snail transcription factors implies a role in thyroid 
carcinogenesis. Increased expression was detected in thyroid papillary carcinoma 
cell lines, with lack of expression in normal thyroid tissue or normal tissue derived 
cell lines. This particular study demonstrated this was due to the downregulation of 
E-cadherin (Hardy et al., 2007).
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The second member of the Snail transcription factors, Slug has an overlapping role 
with Snail but also has been linked with additional EMT processes. Slug has been 
documented to be a repressor of E-cadherin (Hajra, Chen et al. 2002; Uchikado, 
Natsugoe et al. 2005), but also has been shown to convey other cellular processes 
which are important for EMT. Indeed, cell survival is conveyed by Slug during 
epithelial morphogenesis (Leroy and Mostov 2007) and has been shown to function 
as a survival factor in myeloid progenitor cells, where Slug repressed the p53- 
induced apoptotic gene puma, conferring cell survival (Wu, Heinrichs et al. 2005). In 
addition to E-cadherin repression, Slug in numerous pathological contexts has been 
shown to be responsible for desmosome dissociation where E-cadherin was not 
repressed (Savagner, Yamada et al. 1997). In epithelial ovarian cancers, in addition 
to the downregulation of E-cadherin, Snail transcription factors also repress other 
junctional proteins including Claudin, Occludin and ZO-1 (Bolos, Peinado et al. 2003; 
Ikenouchi, Matsuda et al. 2003; Ohkubo and Ozawa 2004) and regulation of other 
epithelial markers including cytokeratin 18 and Mucin-1 have been demonstrated 
(Guaita, Puig et al. 2002; Tripathi, Misra et al. 2005). Cytokeratins are intermediate 
filament proteins present on epithelial cells and their downregulation indicates 
biochemical and morphological changes often seen in carcinomas. Slug has also 
been shown to decrease the expression of integrins a3, p i and p4 in cultured 
epidermal keratinocytes (Turner, Broad et al. 2006). In an ovarian epithelial cancer 
cell line both expression of Slug and E-cadherin was detected, indicating an 
alternative role of Slug in tumourigenesis (Kurrey, K et al. 2005). It seems then, that 
Slug expression is dependent on the pathology of the tumour and its associated 
EMT process. In the context of bone formation or osteoblast maturation, Slug 
positively correlated with osteoblast markers including Runx2, OPN, collagen type I
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and Wnt signalling mediators and the knockdown of Slug weakened the Wnt 
signalling cascade, as well as reducing the other osteoblastic markers (Lambertini, 
Lisignoli et al. 2009). This highlights the broad range of functions in which Slug 
mediates and partakes.
From embryogenesis, Snail appears to be regulated by the NFkB and the FGF 
receptor. Transcription of Snail requires ERK signalling, indicating the MAPK 
pathway as the transcription can be influenced by MEK inhibitors (Barbera, Puig et 
al. 2004). The PI3K pathway has also been shown to regulate Snail expression, 
although it may not have such an integral role (Barbera, Puig et al. 2004). The 
repression of E-cadherin induces translocation of (3-catenin to the nucleus where it 
binds to the Lcf transcription factor to aid in EMT (Conacci-Sorrell, Simcha et al. 
2003; Medici, Hay et al. 2008). In addition, TGFpl and TGFP2 have both been 
shown to promote Snail transcription, highlighting the upstream elements of Snail 
and Slug. Also, TGFp3 was shown to induce Lcf, which highlights the crossover 
between the TGFp and Wnt signalling pathways (Medici, Hay et al. 2008). 
Correlating with these findings TGFpl was shown to induce Snail expression in 
epithelial cell lines (Peinado, Quintanilla et al. 2003). This also applies to Slug, where 
treatment of TGFpi induced Slug expression in lens and epithelial cells in vitro, and 
Slug expression was reduced with MEK inhibitors (Choi, Park et al. 2007). This 
indicates that both Snail transcriptional repressors function on the same pathway
Matrix metalloproteases (MMPs) have important roles in the degradation of the ECM, 
aiding invasion and tumour progression. The expression of MMP-2, which degrades 
type IV collagen is prevalent in Slug-transfected cells (Shih, Tsai et al. 2005). In 
malignant mesothelioma, Snail protein expression was significantly associated with
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the expression of MT1-MMP (Sivertsen, Hadar et al. 2006). Snail has also been 
reported to increase the expression of MMP-2 (Yokoyama, Kamata et al. 2003).
4.2 Osteopontin (OPN)
Osteopontin (OPN) or secreted phosphoprotein 1 is localised on chromosome 4 and 
belongs to the family of small integrin binding ligand N-linked glycoproteins, which 
also includes in addition to OPN, bone sialoprotein, dentin matrix protein 1, dentin 
sialoprotein and matrix extracellular phosphoglycoprotein (Wai and Kuo 2004). OPN 
was first characterized as a phosphoprotein secreted by transformed epithelial cells 
(Senger, Wirth et al. 1979). OPN is expressed in multiple species and in multiple cell 
lines including osteoclasts, osteoblasts, epithelial cells, nerve cells, vascular smooth 
muscle cells and endothelial cells (Wai and Kuo 2004). Its expression has also been 
highlighted in activated immune cells including T-cells, macrophages and natural 
killer (NK) cells (Wai and Kuo 2004). Human OPN maps to chromosome 4q13 and 
contains 7 exons, with the secreted form between 44 kDa -  75 kDa in size. This is 
thought to be due to posttranslational modifications by O-glycosylation, sulfation, 
phosphorylation and enzymatic cleavage, allowing secreted OPN to support its 
numerous cellular functions. There is evidence for the alternative splicing of the OPN 
gene, where 3 cDNAs have been identified. These include the full length OPN (a) 
gene, OPN (b) lacking exon 5 and OPN (c) lacking exon 4. The functional 
significance of these deletions is currently unknown (Figure 19).
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4.2.1 Structure of OPN
A protease sensitive site within OPN separates its binding domains with integrins 
and CD44. Its thrombin cleavage motif contains a conserved sequence known as 
RSK. Thrombin cleaves OPN at this motif releasing two receptor binding domains. 
The secreted OPN protein is incorporated in the matrix in mineralised connective 
tissue but also is detected in biological fluids including bile, urine sweat and semen 
(Ramaiah and Rittling 2008); (Senger, Perruzzi et al. 1988); (Senger, Perruzzi et al. 
1989); (Bautista, Denstedt et al. 1996).
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F ig u r e  19. A. Genomic structure highlighting OPN spliced isoforms. B Schematic 
representation of the domain structure of OPN with binding ligands (black boxes). 
(Rangaswami, Bulbule et al. 2006); (Denhardt, Noda et al. 2001); (Ramaiah and Rittling 
2008).
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OPN has been characterised as a secreted glycoprotein, however an intracellular 
form of OPN exists. This was detailed in plasmacytoid dendritic cells (Shinohara, 
Kim et al. 2008), fetal fibroblasts (Zohar, Suzuki et al. 2000) and periotoneal 
macrophages (Zhu, Suzuki et al. 2004). This isoform is not subjected to post- 
transcriptional modifications and is synthesised independently of secreted OPN 
(Zohar, Suzuki et al. 2000). Intracellular OPN can interact with CD44. This 
interaction indicates a probable role in increased cell migration, as disruption of 
intracellular OPN or CD44 causes a reduction in chemotaxis (Zhu, Suzuki et al. 
2004).
The main integrin binding sites are situated on the N-terminal cleaved fragment of 
OPN. The RGD domain is a binding site for numerous integrins av/p3, av/p1, a5/p1, 
a8/p1 and av/p5, whilst the SWYGLR domain can bind a9/pi and a4/p1 integrins. 
The SWYGLR domain is cryptic and is only accessible when OPN is cleaved by 
thrombin. It is also a substrate for MMP-3 and MMP-7 cleavage, providing an 
additional level of signalling capability (Ramaiah and Rittling 2008). It is currently 
unreported which isoforms of OPN are secreted.
i n
4.2.2 OPN receptors
4.2.2.1 CD44
The CD44 family of molecules are single chain glycoproteins encoded by a single 
copy gene which is located on the short arm of chromosome 11 p13 and is composed 
of 20 exons (Jothy 2003). Its function include cell adhesion affecting aggregation and 
migration, lymph node homing, myelopoisis and lymphopoiesis, angiogenesis and 
release of cytokines (Sneath and Mangham 1998). The protein size vary between 
80 and 200 kDa, which is due to post-transcriptional modifications including 
glycosylation and alternative splicing (Marhaba and Zoller 2004). The formation of 
exons 1-5 and 16-20 forms the ubiquitously expressed standard isoform of CD44 
(CD44s) (Goodison, Urquidi et al. 1999). Indeed the alternative splicing allows the 
insertion of variable exons between exons 5 and 16 located within the extracellular, 
membrane proximal region of CD44 (Marhaba and Zoller 2004) and are designated 
CD44v giving further diversity to the functional regulation of CD44. The human 
CD44 mRNA, unlike mouse does not contain exon 6 due to the presence of a stop 
codon, post-transcriptional splicing may result in up to 10 isoforms of CD44 (Figure 
20).
________________________EC______________________TM 1C
Exon 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20nm  _ jj in in r i i1 1 1 1 1 1 I I I I I I I I IIBII
s1 s2 s3 s4 s5 v1 v2 v3 v4 v5 v6 v7 v8 v9 v10 s6 s7 s8 s9 s10
Variable region
F ig u r e  20. Exon map of CD44 displaying spliced exons and conserved exons. Spliced 
variants are named according to the corresponding v exon splicing. Exons v6, v7 and v 10 
are prominent in malignancy.
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The principle ligand for CD44 is hyaluronic acid (HA) which is ubiquitous component 
of the ECM. There are a total of 3 binding domains for HA on CD44 at the exon 2 link 
domain and 2 domains encoded by exon 5 (Goodison, Urquidi et al. 1999). Mutation 
studies have shown that the binding sites consist of basic amino acid clusters with 
arginine residues (Bajorath, Greenfield et al. 1998). In some instances in response to 
an external stimulus CD44 can bind other molecules including galectin-8, collagen, 
fibronectin, laminin, fibrinogen, chondroitin sulphate, mucosal vascular addressin, 
serglycin/gp600 and OPN (Naor, Wallach-Dayan et al. 2008). The C-terminal 
fragment of OPN interacts with CD44, with an interaction also shown to occur at the 
N-terminal fragment independent of the RGD domain of OPN (O'Regan 2003).
The expression of variant isoforms of CD44 have been implicated in tumour 
progression (Jothy 2003). However, this seems to be tumour specific, for example, in 
prostate carcinoma the down-regulation of CD44v6 correlates with metastasis (Ekici, 
Ayhan et al. 2002), and invasion and migration is inhibited through the 
overexpression of CD44s and knockdown of CD44v7-10 (Omara-Opyene, Qiu et al.
2004). Although CD44v are membrane bound, there is evidence that they exist in 
soluble forms in the serum of gastrointestinal carcinomas, cervical carcinomas and 
malignant lymphomas (Guo, Liu et al. 1994; Kainz, Tempfer et al. 1995; Ristamaki, 
Joensuu et al. 1997). Indeed serum levels correlate with tumour burden in colon 
cancer and malignant lymphoma making soluble CD44 a prognostic marker in 
certain tumours. Soluble CD44 is formed by proteolytic cleavage or CD44 shedding. 
Shedding of CD44 occurs through proteolytic cleavage of its ectodomain, and 
release of the extracellular domain (Okamoto, Kawano et al. 1999). CD44 shedding 
has been highlighted in numerous tumours in vivo (Okamoto, Kawano et al. 1999). 
The cleavage of CD44 was detected in 58% of gliomas, 67% breast carcinomas,
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45% of non-small cell lung carcinomas, 90% of colon carcinomas and 25% of 
ovarian carcinomas (Okamoto, Tsuiki et al. 2002). Proteolytic cleavage of CD44 was 
also found to occur in highly aggressive melanoma cell lines and may confer an 
invasive phenotype (Goebeler, Kaufmann et al. 1996). In cervical cancer cells, CD44 
is known to interact with the EGF Receptors, erbB2 and erbB3 enhancing their 
signalling during cervical carcinoma progression by constitutive activation (Wobus, 
Kuns et al. 2001).
The shedding of CD44 is mediated by membrane bound matrix metalloproteinases. 
Furthermore, ADAM metalloproteinases have also been shown to induce CD44 
cleavage (Nakamura, Suenaga et al. 2004). This is triggered in response to 
numerous stimuli including protein kinase C signalling activation, calcium influx, Ras 
and Rac GTPase activity (Okamoto, Kawano et al. 1999) and EGF (Palyi-Krekk, 
Barok et al. 2008). With respect to Ras involvement, it was shown that H-Ras 
transformation in NIH3T3 fibroblasts results in increased CD44 cleavage increasing 
cell migration and invasion of the ECM (Kawano, Okamoto et al. 2000). In breast 
cancer, the shedding of CD44v6 is associated with increased tumour size, lymph 
node metastasis and resistance to chemotherapy. The cytoplasmic tail of CD44 can 
interact with many cytoskeletal proteins, namely the band 4.1 family of proteins 
which are ezrin-radixin-moesin (ERM) family and merlin. The ERM proteins are 
integral to the regulation of cell migration, cell shape and protein resorting at the 
plasma membrane. This complex rests in an inactive state, and become activated to 
link the transmembrane proteins with the actin cytoskeleton (Marhaba and Zoller
2004).
Proteolytic cleavage occurs in the extracellular domain which produces an 
extracellular CD44 fragment, it is followed by cleavage of the CD44 intracellular
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domain, mediated by y-secretase, a membrane bound protease complex (Steiner, 
Fluhrer et al. 2008). This leads to translocation to the nucleus which interacts with 
the p300/cAMP responsive element to initiate the transcription of a number of genes 
including CD44 itself, thus providing a positive feedback loop (Nagano and Saya
2004). The adenomatous polyposis coli (APC) gene mutation in colorectal cancer 
mutation is well known. This gene is integral to the WNT signalling cascade 
interacting with p-catenin and indirectly interacts with cadherin molecules (Wielenga, 
Smits et al. 1999). In intestinal epithelial cells, mutation leads to constitutive 
transcription of the Tcf-4. The activation of Tcf-4 signalling which occurs with APC 
mutations is associated with CD44 overexpression. Targeted blockade of Tcf-4 
abrogates CD44 expression (Wielenga, Smits et al. 1999). This interaction implies 
Tcf-4 either directly or indirectly regulating CD44 expression in colorectal cancer 
(Wielenga, Smits et al. 1999). Inhibition of CD44 in mammary cancer cells induces 
apoptosis highlighting a role of CD44 in the process of programmed cell death, and 
overexpression may lead to a counteraction of this process (Yu, Toole et al. 1997).
The interaction of OPN and CD44 has been shown to confer increased cell survival 
(Lin, Huang et al. 2000; Lee, Wang et al. 2007) . In H-RasV12 transformed cells, 
both OPN and CD44 are upregulated inducing an autocrine feedback loop, and this 
autocrine loop is directly related to H-RasV12 cell invasion in the system (Teramoto, 
Castellone et al. 2005). CD44v6 and 7 are reported to interact with OPN (Katagiri, 
Sleeman et al. 1999; Lee, Wang et al. 2007). This interaction was shown to correlate 
with the clinical outcome of laryngeal dysplasia (Staibano, Merolla et al. 2007) and 
confer cell survival in gastrointestinal cancer cells (Lee, Wang et al. 2007). This type 
of interaction has also been established in other carcinomas (Ponta, Sherman et al. 
2003). The OPN-CD44 is not strictly exclusive, since in rat pancreatic carcinoma p1
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integrins cooperate with CD44v to promote OPN-dependent cell motility and 
chemotaxis (Katagiri, Sleeman etal. 1999).
4.2.2.2 av(3 Integrins
OPN can bind to avp3, avpi, avp5 integrin through the RGD domain. The pi 
integrins have been shown to cooperate with CD44v mediated OPN to increase cell 
motility and chemotaxis (Katagiri, Sleeman et al. 1999). Integrinp3 is consistently 
detected in breast cancer, and mediates OPN migration and invasion of tumour cells. 
VEGF, a pro-angiogenic factor can induce OPN and avp3 expression in 
microvascular endothelial cells to promote angiogenesis (Wai and Kuo 2004). OPN- 
p3 integrin interaction mediates cellular adhesion of a number of cell types (Wai and 
Kuo 2008). This interaction also detected in breast cancer metastasis, and mediates 
invasion and cell migration of tumour cells (Furger, Allan et al. 2003).
The distribution of integrin avp3 is polarised towards the cell front in migrating 
fibroblasts (Woods, White et al. 2004). In epithelial cells integrin avp3 is persistently 
expressed and appears to be the result of Rac activation (Danen, van Rheenen et al.
2005). The overexpression of integrin avp3 increases Rac activity and lamellipodium 
formation, increasing actin stress fibre formation. Engagement of integrin avp3 
results in integrin clustering and the formation of Rac-dependent focal complexes 
which are important for cell migration (Kiosses, Shattil et al. 2001).
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4.2.3 Regulation of OPN expression
4.2.3.1 Ras
Direct transcriptional regulation of OPN is mediated by Ras, a GTPase which 
primarily activates the MAPK pathway. An increase in OPN transcription is observed 
in Ras-transformed cells, and knockdown of OPN in these cells resulted in a reduced 
ability to form tumours and metastasise (Denhardt, Mistretta et al. 2003). Conserved 
among species, the (murine) OPN promoter contains a Ras-activated enhancer 
domain and confers increased transcriptional activity of the OPN gene in Ras- 
transformed 3T3 cells (Zhu, Denhardt et al. 2005). In addition, the haematological 
malignancy chronic myeloid leukaemia (CML) is caused by the constitutive active 
fusion gene Bcr-Abl. In response to high levels of Bcr-Abl, a fusion gene product in 
self-renewing haematopoietic stem cells OPN is upregulated. The signalling 
pathways mediating this response require Ras, atypical PKC, MEK and Raf-1 
activation in CML (Hickey, England et al. 2005).
4.2.3.2 Rous sarcoma oncogene (Src)
The proto-oncogene, Src is a non receptor tyrosine kinase which has roles in 
proliferation, adhesion and survival (El-Tanani, Campbell et al. 2006). Src actively 
regulates OPN in tumour and non-tumour cells, where v-Src and c-Src induce OPN 
expression in transformed NIH3T3 mouse fibroblasts (Tezuka, Denhardt et al. 1996). 
This is almost certainly to be due to a v-Src response element in the murine OPN 
promoter (Blobel and Hanafusa 1991). The v-Src tyrosine kinase induces several
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genes including collagens, TGFp, c-fos and MMP-9, and may aid the process of 
tumour invasion and metastasis (Wai and Kuo 2008).
4.2.3.3 Tcf-4
The Wnt signalling pathway has key roles in development, homeostasis and tumour 
progression (Hatsell, Rowlands et al. 2003). Detailed description of the pathway has 
been provided earlier. Briefly, the pathway is activated by Wnt proteins which bind 
and activate the membrane bound Frizzled receptors, which mediate the 
phosphorylation of dishevelled (Dsh). p-catenin is a key regulator of the Wnt 
signalling pathway. When phosphorylated by the APC/axin/GSK3p complex, it is 
primed for destruction. Unphosphorylated p-catenin translocates to the nucleus to 
bind the Lcf/Tcf family of transcription factors to initiate activation of a host of genes 
including c-myc, cyclinDI and OPN. In the absence of p-catenin Tcf-4 binds to 
A/TA/TCAAAG sequences in the OPN promoter inhibiting OPN protein expression. 
In the presence of p-catenin the effect is opposite with OPN promoter activation and 
protein expression (El-Tanani, Barraclough et al. 2001). Deregulation of the Wnt 
pathway has been identified in colorectal cancer, which results in increased active p- 
catenin levels in both the cytoplasm and nucleus, and OPN expression significantly 
correlates with this expression highlighting that the Wnt pathway is largely 
responsible for OPN activation and expression (Rohde, Rimkus et al. 2007).
4.2.3.4 AP-1
The AP-1 transcription factor is a dimeric complex which mediates transformation in 
a number of cellular contexts including bone, skin and in lung tumours. The OPN
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promoter also contains a binding site for AP-1 in its promoter region (Renault, Jalvy 
et al. 2003). AP-1 can induce expression of OPN by binding to its promoter (El- 
Tanani, Platt-Higgins et al. 2004). A positive feedback mechanism exists where OPN 
can stimulate AP-1 transactivation and DNA binding mediated by av(33 integrin and 
ERK signalling (Das, Mahabeleshwar et al. 2004). The binding of av(33 integrin 
activates integrin linked kinase (ILK) which leads to the binding of AP-1 to the 
proteinases MMP-2 and uPA promoters and an increase in promoter activity (Mi, 
Guo et al. 2006).
4.3.4 OPN and proteinase activity
OPN has important roles in many physiological cellular functions, including 
mineralisation, blood vessel formation and inflammation. Cumulative evidence has 
highlighted the role of OPN in tumourigenesis and metastasis. The remodelling of 
the cytoskeleton represents a major event during tumour invasion. OPN mediates 
the regulation of proteinases to regulate the degradation of the extracellular matrix. 
The urokinase plasminogen activator (uPA) has a role in tumour progression through 
regulation of cell motility and extracellular matrix degradation. OPN has been shown 
to induce uPA secretion and subsequent activation of plasmin, thereby regulating 
tumour cell migration, motility and extracellular matrix degradation in breast cancer 
cells. The induction of uPA occurs via c-Src, PI3K and MAPK signalling (Das, 
Mahabeleshwar et al. 2003). In addition, OPN mediates the expression of proMMP-2 
during tumour invasion in an NFKB-dependent manner in melanoma cells (Philip, 
Bulbule et al. 2001). In chrondrasarcoma cells, OPN mediates the expression of 
MMP-9 through a number of signalling mechanisms including av(33 integrin, FAK and
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MAPK signalling, all of which indicate a role in mediating the expression of MMP-9 
and cell migration (Chen, Wei et al. 2009). In prostate cancer, OPN regulates MMP- 
2 and COX-2 expression to mediate invasion and motility in vivo (Jain, Chakraborty 
et al. 2006). COX is an integral membrane bifunctional enzyme which metabolises 
arachidonic acids to active eicosanoids including PGE2 (Jain, Chakraborty et al.
2006). Increased COX-2 expression has been detected in a number of tumour 
pathologies including colorectal, gastric, pancreatic and breast and others (Wallace 
2002) and generation of PGE2 contributes to the promotion of angiogenesis, invasive 
potential, motility and survival (Surh and Kundu 2005).
4.2.5 The Hepatoctye Growth Factor (HGF)-cMet system
One of the mechanisms that OPN confers a migratory phenotype in tumour cells is 
through the HGF-cMet system. The cMet tyrosine kinase receptor is predominantly 
expressed on epithelial and endothelial cells, its ligand, hepatocyte growth factor 
(HGF) is produced by motile mesenchymal cells. The interaction leads to a number 
of physiological functions including development of epithelial organs, tissue 
regeneration, angiogenesis and wound healing (Birchmeier and Gherardi 1998). In 
an in vitro setting, HGF is a potent stimulus for cell growth, motility and 
morphogenesis. Deregulation of this signalling system is implicated in numerous 
human cancers (Ariztia, Subbarao et al. 2003). Mutation of cMet may cause ligand 
independent receptor activation and cMet expression (Ariztia, Subbarao et al. 2003). 
OPN is prominent in HGF-dependent tumourigenesis, and inhibition of OPN 
expression in vitro and in vivo attenuates the HGF-induced (Medico, Gentile et al. 
2001; Ariztia, Subbarao et al. 2003). This is an indication that OPN is a necessity for
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HGF-induced tumour invasion. CD44 variant isoforms are able to induce the 
amplification of HGF induced invasion. OPN can interact with CD44v together with 
(31 integrins to induce receptor pair clustering (van der Voort, Taher et al. 1999). This 
mechanism is thought to occur in a number of possible ways, firstly, both CD44v and 
P1 integrins binding OPN in a cooperative manner; secondly, signalling via CD44v 
mediating the OPN-P1 integrins; and finally, by interacting with p1 integrins and 
stabilising the CD44v interaction (Ariztia, Subbarao et al. 2003). In addition, the 
CD44v6 and CD44v7 have been shown to bind to OPN to enhance the migratory 
phenotype of rat fibrosarcoma cells (Katagiri, Sleeman et al. 1999).
4.2.6 OPN in thyroid cancer
In thyroid cancer, OPN is overexpressed and enhances papillary carcinoma 
invasiveness in RET/PTC transformed rat thyroid cells. In thyroid tumours OPN 
expression correlates with aggressive clinicopathological features of papillary 
carcinoma, presence of lymph node metastases and tumour size. OPN-integrin 
binding directly mediates migration and invasion of tumour cells (Angelucci et al.,
2002), and is known to enhance thyroid papillary carcinoma invasiveness (Guarino, 
Faviana et al. 2005). Moreover, in RET/PTC transformed cells, an autocrine loop 
sustaining proliferation and invasiveness initiated by OPN-CD44 signalling was 
discovered (Castellone, Celetti et al. 2004).
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4.3 Tumour Invasion and Metastasis
Growth of primary tumour is often followed by the metastasis of tumour cells and 
formation of secondary tumours to distant sites of the body. For this to occur, a 
number of events need to occur for tumour cells to invade and disseminate 
neighbouring tissues, and for the tumour cells persist and progress in secondary 
sites. The progression of cancers may be considered as a collection of cellular 
processes converging together to induce invasion, a prominent feature of cancers 
and their metastases. The metastatic process consists of a series of events which 
must occur for a cancer to progress (Chambers, Groom et al. 2002). As a primary 
tumour grows, angiogenesis needs to occur so the tumour can support its metabolic 
needs and to provide a metastatic route. Cells in the primary tumour invade the 
surrounding tissue stroma and migrate towards blood/lymphatic systems. 
Intravasation into blood vessels allows the tumour cells to disseminate to distant 
parts of the body using the host circulatory system. Here the cancerous cells may 
persist in the vessels or extravasate and invade other organs.
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4.3.1 Epithelial to mesenchymal transition (EMT)
In normal conditions, cell migration and motility are essential for tissue development 
and homeostasis. Tumour cells acquire these processes to further their progression 
to aid invasion, metastasis and survival. The epithelial-mesenchymal transition 
(EMT) naturally features during embryogenesis (Hugo, Ackland et al. 2007) wound 
healing, (Desmouliere 1995) placental formation (Vicovac and Aplin 1996) and 
production of fibroblasts during inflammation (Iwano, Plieth et al. 2002). It essentially 
brings a change in cellular morphology to allow cells to have a migratory phenotype. 
Alteration of an epithelial cell to have mesenchymal properties requires 
morphological, architecture, adhesion and migratory changes. Normal epithelial cells 
form a tight monolayer and their movement is restricted and provide tissues with 
mechanical rigidity. The presence of cell-cell junctions and adhesive molecules holds 
the cells tightly together and inhibits the movement of individual cells. In contrast, 
mesenchymal cells do not possess the epithelial junctions and their adhesive 
properties are less strong allowing for greater motile capacity. They form structures 
which are irregular in shape and not uniform in structure or density. The morphology 
of mesenchymal cells is irregular as they possess leading edge polarity. The 
difference between epithelial and mesenchymal cells defines an essential dynamic 
process for tumour progression, and EMT is a crucial event for this to occur. The 
transition involves a change in the adhesive qualities of the cell, remodelling of the 
cytoskeleton, and proteolytic degradation of the extracellular matrix.
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4.3.2 Cell adhesion and cytoskeletal rearrangement
Cell migration has an integral role in a diverse range of biological functions including 
development, immune regulation, and tumourigenesis (Dikeman, Rivera Rosado et 
al. 2008). In the context of tumour progression, tumour cells need to detach from the 
primary tumour mass, inhibit cytokinesis, initiate protrusion formation, cell migration 
and remodelling the surrounding ECM through by physical and chemical means.
4.3.2.1 Cell Adhesion
A) Integrins
For directional movement of cells the spatial and temporal coordination of membrane 
protrusions and retraction with cell adhesion are required. Indeed, cell migration is 
coordinated by numerous proteins which regulate cell-matrix and cell-cell 
interactions, formulating structural linkages or adhesions with cytoskeletal proteins to 
become organised protein complexes. Central to interactions are the family of 
integrins which formulate the bridge between the ECM and the actin cytoskeleton of 
the cell. Integrins are multifunctional heterodimeric adhesion receptors consisting of 
non-covalently bound a- and p- subunits. Currently, there are 18 different a- subunits 
and 8 p- subunits forming a total of 24 distinct heterodimers (Al-Jamal and Harrison 
2008). The general structure of an integrin subunit consists of a large ectodomain, a 
transmembrane domain and a short cytoplasmic tail. The globular head is devoid of 
kinase activity and binds ECM components.
The activation of integrins is important for cellular processes involving anchorage 
such as cell polarity of migrating cells and ECM assembly (Ginsberg, Partridge et al.
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2005). Integrins can undergo conformational changes and clustering which can 
influence ligand binding. This is important for functionality as conformation of the 
heterodimers and clustering of heterodimers into oligomers is likely to be dependent 
on the integrin, cell type and biological context (Shattil et al. 2010). In the majority of 
integrins, the amino-terminal domain of a- and P- subunits form a non-covalent bond 
to form a globular head and a ligand binding site. The ectodomains can exist in a 
bent ‘closed’ conformation, an intermediate extended conformation with a ‘closed’ 
head and an extended ‘open’ conformation.
Integrin clustering is defined as the interaction of heterodimers to form hetero­
oligomers. This action is integral for outside-in signalling, integrin recycling formation 
of cell-matrix adhesive structures. Clustering may be caused by the inside-out 
signalling which recruits protein complexes to the integrin cytoplasmic domains. It 
can also be caused by the binding of multivalent extracellular ligands to integrin 
ectodomains or the release of integrins leading to free diffusion of integrins.
The globular head of the extracellular domains of integrin bind ECM components, 
and interestingly the subunits have no catalytic kinase activity. Instead, signals are 
transduced through the binding of effector proteins, some of which link directly with 
the actin cytoskeleton. Together, the integrins with the effector proteins form a multi- 
protein complexes forming dynamic cell-matrix adhesions (Wiesner, Legate et al.
2005). These adhesions are formulated around activated integrin clusters, and these 
are essential for cell motility and migration. Adhesion structures must form, 
disassemble or mature at the leading edge of the cell and disassemble at the rear of 
the cell for the cell to conduct cell migration.
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Inside-out activation of integrins is mediated by the binding of talin to the cytoplasmic 
domain of the p-integrin subunit, and is a crucial step in integrin p i and integrin p3 
activation (Tadokoro, Shattil et al. 2003). Talin also links integrins to Filamentous 
actin (F-actin) and other actin binding proteins. This provides the link between the 
actin cytoskeleton of the cell and the ECM. The talin-integrin interaction is mediated 
by RAP1, a Ras subfamily member, which is activated by the RAP1 effector protein, 
RAIM (Boettner and Van Aelst 2009) (Figure 21).
Active open’ 
integrin
Inactive ‘dosed’ 
integrin
0-subunit
a-subunit
Activation
Plasma membrane
RAP1RAP1 RAP1 RAP1K ^RAP1
RAIM,RAIM,
RAIM
Figure 21. Schematic diagram of integrin activation. RAP1 is converted from its inactive 
GDP state to an active GTP state. Activation of RAP1 leads to the recruitment of RAIM and 
its binding partner talin to the plasma membrane.
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B) Cell-matrix interactions
Cell-matrix adhesive structures can be characterized based on their subcellular 
location, size and composition. There are 4 types of clearly defined adhesive 
structures which are focal complexes, focal adhesions, fibrillar adhesions and 
podosomes. Focal complexes contain talin and vinculin and are small, dot like 
structures concentrated at membrane protrusions. These either turn-over or mature 
into focal adhesions. Maturation into focal adhesions occurs with the recruitment of 
FAK, paxillin, a-actinin, Src, p130Cas and Crk to the complex (Galbraith, Yamada et 
al. 2002). These dynamic structures in a 2-Dimensional surface are found at the cell 
periphery and in more central areas and act as attachment points for actin stress 
fibres (Wozniak, Modzelewska et al. 2004). They display a slower turn-over rate 
compared to focal complexes and are associated with less motile cells. Fibrillar 
adhesions are generally more elongated then focal adhesions and specifically 
contain a5p1 integrin and tensin (Pankov, Cukierman et al. 2000). These adhesive 
structures arrange extracellular fibronectin in a parallel formation with actin stress 
fibres.
For cell migration to occur the cell must constantly remodel focal complexes into 
focal adhesions and back again to effectively migrate. This is a dynamic process 
which involves more than 50 cytoplasmic proteins which present in cell-matrix 
adhesion structures. Integrins form the link between the ECM and the actin 
cytoskeleton. They do not possess enzymatic activity and so they recruit signalling 
proteins to control adhesion-dependent processes. These proteins include integrin 
binding proteins, adaptor and/or scaffold proteins and enzymes.
127
Talin is considered to be integral in coupling integrins to the actin cytoskeleton. It is 
also important in focal complexes/adhesions. Talin self-associates to form a dimer, 
where the tail region of talin contains binding domains for p1, (32, (33, (35 and p7 
integrins (Pfaff, Liu et al. 1998). Talin also contains binding domains for Focal 
Adhesion Kinase (FAK), non integrin transmembrane receptors, vinculin and actin 
(Wiesner, Legate et al. 2005). Vinculin is recruited to the early focal adhesion 
complexes causing an enlargement of focal adhesions by inducing and stabilising 
‘open’ conformation integrin clustering (Wiesner, Legate et al. 2005). The talin- 
vinculin interaction is integral for vinculin activation (Ziegler, Liddington et al. 2006). 
Cells with depleted amounts of vinculin have decreased adhesion and increased 
migratory ability (Saunders, Holt et al. 2006). Vinculin functions as an adaptor protein 
at focal adhesions. It comprises of 3 domains, an N-terminal head, a flexible proline 
rich hinge region and a C-terminal tail domain (Humphries, Wang et al. 2007). 
Paxillin is recruited to the focal adhesion by binding to the vinculin C-terminal tail 
domain. Like vinculin, it functions as an adaptor protein recruiting other signalling 
proteins to the focal adhesion. Paxillin may also be recruited by other proteins 
including parvin, Focal Adhesion Kinase (FAK) and Integrin-Linked Kinase.
Present in the focal adhesion complex, FAK functions as an tyrosine kinase 
(Brakebusch and Fassler 2003). Since FAK can strongly bind paxillin and talin, it 
indicates that the interaction with integrins may occur in an indirect manner 
(Hildebrand, Schaller et al. 1995). However, co-precipitation experiments have 
revealed that FAK can bind to the integrinpl tail region in a direct manner (Schaller, 
Otey et al. 1995).
The autophosphorylation of FAK at Y397 is induced by integrin activation and this
creates a binding site for the Src family kinases. This action causes the recruitment
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of another adaptor protein, p130Cas. Its interaction occurs via a SH3 domain which 
is mediated by phosphorylation by FAK and Src. Tyrosine phosphorylation of 
p130Cas is an integral event for the recruitment of additional molecules and the 
release of docking sites for Crk and Nek. The Crk molecule is phosphorylated at 
T221 by p130Cas, an important event for its localisation to the focal adhesion and for 
Rac activation. The interaction of p130Cas and FAK with Src is crucial for the 
targeting of Src to the focal adhesion. Src mediated phosphorylation of Y861 and 
Y925 creates docking sites for Grb2 which is an important molecule in the MAPK 
signalling pathway. Src can phosphorylate FAK at Y925 which induces focal 
adhesion turnover (Frame, Fincham et al. 2002). Focal adhesions mature further 
with the recruitment of zyxin, an actin scaffold protein (Figure 22A). The zyxin protein 
is only present in late focal adhesions and it considered a differentiating marker of 
focal complexes from focal adhesions (Hirata, Tatsumi et al. 2008).
Integrin-linked kinase (ILK) is a non-receptor serine/threonine kinase with a principle 
role as an adaptor protein. Its principle binding partner is PINCH (Chiswell, Zhang et 
al. 2008). The ILK-PINCH complex binds to parvin, to form the ILK/PINCH/parvin 
complex. There are 3 isoforms of parvin, however the a-parvin isoform is the only 
parvin to be expressed ubiquitously (Wickstrom, Lange et al.). ILK is able to bind pi 
and P3 tails of integrins. Downstream of integrins, the parvins regulate cell spreading 
and actin cytoskeleton organisation. The a-parvin can bind paxillin at focal adhesions 
(Yoshimi, Yamaji et al. 2006; Lorenz, Vakonakis et al. 2008). The ILK/PINCH/parvin 
interaction with integrins enhances the physical interaction of the integrin with the 
ECM. This complex has an important signalling role and can activate the Akt 
pathway in a number of cell types (Figure 22B).
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Mutational analysis of ILK showed a disruption of the a-parvin-ILK interaction, which 
subsequently disrupted the localisation of FAK to focal adhesions (Attwell, Mills et al.
2003). The functionality of ILK has also been highlighted by ILK-null fibroblasts which 
exhibit reduced cell spreading and migration due to delayed formation of focal 
adhesions, and a poorly organised actin cytoskeleton (Sakai, Li et al. 2003).
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F ig u r e  22 . Overview of focal adhesion formation and maturation. A , Numbered 1-7  is 
the sequence of events in recruitment of proteins to the cell-matrix adhesive 
structure. B , The ILK/PINCH/parvin complex forming adhesive complex by interacting 
with integrins and paxillin.
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C) Actin filaments forming the basis of cell movement
Actin filaments function as structural scaffolds and as motors for cell movement by 
creating forward thrust. The assembly and disassembly of actin filaments are 
regulated by over a hundred actin binding proteins. Actin binding proteins can 
mediate actin filament dynamics by nucleating, capping, stabilizing, severing, 
polymerisation, depolymerisation, cross-linking, bundling and sequestering actin 
(Goley et al. 2006).
At the cell front, the actin assembly drives the extension of membrane protrusions, 
so called lamellipodia and finger like projections called filopodia. At the leading edge 
of the lamellipodium adhesive contacts are formed which connect the ECM to the 
actin cytoskeleton. The anchoring of actin protrusions to the ECM through adhesive 
structures results in the cell body traction. Forward motion requires the polarisation 
of actin filaments at the leading edge and depolarisation at the rear. This process is 
termed actin treadmilling. Actin filaments can grow by the process of polymerisation, 
which occurs when the actin end is exposed to monomeric actin, and depolarisation 
induces actin filament stabilisation of actin structures.
The key molecule controlling the formation of the actin protrusions is the Arp2/3 
complex which induces branching of actin filaments (Mullins, Heuser et al. 1998). 
The Arp2/3 complex forms the machinery required for actin-based motility (Welch
1999). Branching of actin filaments at the cell front induces new actin filament 
formation producing an actin filament network which pulls the plasma membrane 
forward. The Arp2/3 complex localises only to the leading edge of cells and inhibition 
of Arp2/3 leads to attenuation of lamellipodia formation (Goley and Welch 2006).
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Cofilin (also called ADF) is integral to this process and is localised at the 
lamellipodium, but not at the leading edge (Svitkina and Borisy 1999). Upon 
polymerisation, actin hydrolyses ATP creating a difference in concentration at the 
ATP-bound barbed end of the filament and the ADP-bound pointed end. Cofilin binds 
the ADP bound actin filaments altering the structure resulting in an increase in the 
pointed end depolymerisation (Carlier, Laurent et al. 1997). This depolymerisation 
causes an increase in the concentration of monomeric actin and stabilisation of actin 
structures.
The small GTPases Rho, Rac and cdc42 are prime regulators of actin filament 
based movement. They act as molecular switches which cycle between an inactive 
GDP-bound state and an active GTP-bound state, stimulated by external factors 
such as growth factors, mechanical stress, integrin signalling and G-protein coupled 
receptor signalling. Cycling between inactive GDP-bound to active GTP-bound 
states is induced by GEFs and GTPase-activating proteins (GAPs).
The action of Rho, Rac and cdc42 are tightly regulated in conjunction so that actin 
polarisation occurs in a controlled manner. Both cdc42 and Rac mediate movement 
at the leading edge of the cell, by regulating the formation of membrane protrusions 
whilst Rho regulates the rear of the cell by stimulating the formation of stress fibers 
critical for actin-myosin mediated cell contraction (Wu, Suetsugu et al. 2004). The 
formation of stress fibres associated with focal adhesions induces retraction of the 
rear of the cell. There is interplay between stress fibres and adhesive structures 
where the formation of focal adhesions initiate the elongation of stress fibres. The 
tension generated by the stress fibres induces growth of focal adhesions. RhoA 
activates ROCK which in turn phosphorylates myosin II light chain (MLC). 
Phosphorylation of MLC is elevated by inhibition of MLC phosphatise by ROCK. This
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action assembles the myosin II into myosin filaments and interacts with actin 
filaments to form the actin contractile stress fibres (Burridge and Wennerberg 2004).
The Arp2/3 complex regulates actin protrusions at the cell front. This complex is 
activated by the WASP family of proteins. The WASP family is categorised into three 
groups, WASPs (WASP and N-WASP), WAVEs (WAVE 1-3), WASH, WHAMM and 
JMP (Insall and Machesky 2009). The WASP protein was first to be identified in 
Wiscott-Alrich Syndrome, and is restricted to the haemopoitic system (Ochs and 
Thrasher 2006). N-WASP is the near ubiquitously expressed homolog of WASP 
which functions downstream of cdc42 and Rac (Rohatgi, Ma et al. 1999). N-WASP is 
localised to the leading edge of lamellipodia in carcinoma cells (Lorenz, Yamaguchi 
et al. 2004), highlighting its role in cell migration. Also functioning downstream of 
Rac1, the WAVE proteins are also important activators of the Arp2/3 complex since 
they are localised at the leading edge of the cell (Insall and Machesky 2009). 
Whereas N-WASP is regulated by an autoinhibition mechanism, the WAVE proteins 
are fully active, and their main function is to activate the Arp2/3 complex during 
membrane protrusions and cell migration.
LIM kinase (LIMK) which functions down-stream of Rho and Rac inactivates cofilin 
by phosphorylation. Indeed, LIMK is essential regulator of Rho dependent stress 
fibre/focal adhesion formation and Rac dependent lamellipodia formation (Sumi, 
Matsumoto et al. 1999). Downstream of Rac activation, LIMK is phosphorylated by 
PAK1 which inactivates cofilin by phosphorylation (Edwards, Sanders et al. 1999). 
This thereby inactivates the actin depolymerisaton process at the lamellipodium.
Downstream of Rho are the Rho kinases (ROCKs) which function as serine 
threonine kinases. ROCKS exist as two isoforms, ROCKI and ROCKII. The latter is
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largely restricted to the brain and muscle tissues (Riento and Ridley 2003). ROCKI 
also phosphorylates LIMK to enhance the phosphorylation and subsequent 
inactivation of cofilin leading to an increase in actin filament production (Maekawa, 
Ishizaki et al. 1999) (Figure 23).
Cortactin is an actin filament binding protein which is enriched at the leading edge of 
lamellipodia where it co-localises with actin and Arp2/3 (Uruno, Liu et al. 2001). It 
forms an important link between the actin cytoskeleton and signalling events which 
regulate cell adhesion and cell migration (Le Clainche and Carlier 2008). The direct 
binding to Arp2/3 induces conformational changes to facilitate actin nucleation and 
filament elongation (Welch and Mullins 2002). N-WASP can cooperate with cortactin 
to stimulate Arp2/3 and actin assembly. The phosphorylation of cortactin enhances 
the activation of N-WASP. Cortactin does not have a role in the initial formation of 
lamellipodia but rather has a role in inducing the focal adhesive contacts formulated 
after lamellipodia formation (Yamaguchi and Condeelis 2007).
Taken together, cell movement on a 2-Dimensional substrate involves actin 
protrusion at the leading edge, the formation of new focal complexes at the leading 
edge. This is followed by formation of contractile stress fibres which forms between 
focal adhesions. This provides the forward thrust required for forward movement. 
The final step requires the detraction from the rear, allowing the cell to move in a 
forward direction. There is a tight interplay between formation of adhesive structures 
and actin protrusive force (Figure 24).
The 2-dimensional study of cell migration and invasion can differ in the morphology, 
cell-substrate and cell-cell interactions compared to a 3-dimensional environment 
(Birgersdotter, Sandberg et al. 2005). The importance of 3D ECM has been
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highlighted for epithelial cells, where 3D environments promote normal epithelial 
polarity and differentiation (Roskelley and Bissell 1995).
Studies conducted with fibroblasts have shown marked differences between 
analysing cell migration on 2D substrates and 3D environments. On a 2D substrate 
fibroblasts display classical focal and fibrillar adhesions. However in 3-dimensional 
environment, paxillin and a5 integrin were shown to colocalise to unusual cell-matrix 
attachments parallel to FN-containing extracellular fibres. These distinctive 3D-matrix 
adhesions were observed on mesenchymal and migrating mouse neural crest cells. 
Whereas adhesive structures can form on a 2D-substrate lacking FN, formation of 
3D-adhesive structures require FN (Green and Yamada 2007). In addition, the avP3 
integrin present in 2D fibrillar adhesions is absent from the 3D-matrix adhesions.
Phosphorylation of FAK has been studied in 2D settings as an early step in integrin 
signaling. In a cell-derived 3D environment, phosphorylation of FAK in cell adhesions 
is virtually absent from human fibroblasts. Instead, phosphorylation appears to be 
reduced more than 4-fold and confined to mini focal adhesions (Cukierman, Pankov 
et al. 2001). The activity level of the Rac GTPase is reduced for fibroblasts within a 
3D matrix, giving the cell increased directional movement (Pankov, Endo et al. 
2005).
Although 2-dimensional analysis of cell migration is informative, there are clear 
differences when analysing cell migration in a 3D environment. The 3-dimensional 
environment allows for greater complexity and may offer greater accuracy to in vivo 
tumour environment. However, effective study of 3D environments requires 
advanced imaging techniques, and the experimentation of 3-dimensional cell 
substrates is a relatively novel area.
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F ig u r e  23 . Overview of RhoGTP family signalling during cytoskeletal rearrangement. Rho 
family of GTPases can be activated by extracellular stimuli signalling through integrins, 
receptor tyrosine kinases, G-protein coupled receptors or mechanical stress. The stimuli act 
upon guanine-nucleotide-exchange factors (GEFs) and GTPase-activating proteins (GAPs). 
Activation of the Rho family of GTPases induces actin polymerisation and formation of acto- 
myosin stress fibres. Red lines indicate inhibition, black lines indicate activation.
137
RacPolymerised actin 
protrusion
tdc42
PROTRUSION
ADHESION
Formation of new 
focal adhesion at the 
leading edge
Focal Adhesion
Actin/
Focal complex 
Acto-Myosin
contraction
Acto-myosin contraction
promoting translocationRho
TRANSLOCATION
Detraction from 
the rear
RETRACTION
Figure 24. Overview of cell movement on a 2D substrate. At the leading edge actin 
protrusions are formed. Protruded actin forms new focal complex adhesions, which stabilise 
and mature into focal complexes. Acto-myosin contractile forces mediate retraction at the 
rear of the cell.
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D) Cell-cell interactions
Epithelial architecture is maintained through a number of cell-cell junctions. 
Adherence and tight junctions form the main adhesive contacts between epithelial 
cells.
Adherence junctions initiate and stabilise cell-cell contacts, regulate the actin 
cytoskeleton and intracellular signalling. The adherence junction includes the 
interactions among the cadherin transmembrane glycoproteins and the catenin 
family which associate to formulate, maintain and regulate the function of adherence 
junctions. The ‘classical’ cadherin family includes E- (epithelial), N- (neural) and P- 
(placental) cadherin. The structure consists of five extracellular domains, a single 
transmembrane domain and two cytoplasmic domains. The cytoplasmic domain is 
highly conserved in the cadherin family, and associates with the catenin family of 
proteins (a-, p-, and y-catenin).
E-cadherin is a prime mediator of epithelial architecture and adhesion. It forms a 
homodimer by binding another E-cadherin molecule on an adjacent cell. The 
localisation is specific to specialised zonula adherens-type. The down-regulation of 
E-cadherin expression in epithelial tumours has been demonstrated. This may occur 
through a number of mechanimsms including mutation, DNA methylation and 
transcriptional control. The loss of E-cadherin expression has been found in a 
number of tumours including breast, colon, esophangeal, gastric, pancreatic and a 
number of others cancers. Downregulation of E-cadherin is an essential process 
during development and involves EMT promoting cell migration (Barbera MJ et al. 
2004).
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P-catenin associates with the cytoplasmic domain of E-cadherin, and a-catenin binds 
to p-catenin to link the cadherins to the actin cytoskeleton. Cells lacking a-catenin 
are unable to form stable adherence junctions despite normal expression of E- 
cadherin. Cytoplasmic p-catenin is regulated by a protein complex consisting of 
adenomatous polyposis coli (APC), casein kinase la (CKIa), axin and GSK-3p which 
primes p-catenin for degradation. APC binds to RGS domain of axin and GSK-3P 
and CKIa interacts with different sites of axin as does p-catenin. Both axin and APC 
act as scaffold proteins in the destruction complex. This destruction complex acts to 
degrade P-catenin through phosphorylation at specific amino-terminal Ser and Thr 
residues (Ser33, Ser37, Thr41 and Ser45) (Mosimann, Hausmann et al. 2009). This 
leads to ubiquination of P-catenin promoting its degradation by the ubiquitin- 
proteosome pathway. The pathway mediates the rapid degradation and elimination 
of regulatory proteins, and is prevalent within the Wnt signalling pathway. Proteins 
tagged for proteolysis are ligated by multiple ubiquitin molecules in a multimeric 
chain (Aberle, Bauer et al. 1997). Disruption of E-cadherin, a cadherin expressed in 
epithelial cells can alter the cell morphology increasing migratory and invasiveness 
of cells. Translocation of cytoplasmic p-catenin to the nucleus induces binding to the 
Tcf/Lcf transcription factor to initiate transcription of numerous genes.
A second catenin, p120-catenin also binds to E-cadherin at the plasma membrane to 
formulate cell-cell junctions, and is required for increased adhesiveness (Hartsock 
and Nelson 2008). It also performs a stabilising role preventing internalization of 
cadherins (Davis, Ireton et al. 2003). It also has a role in cell migration where over­
expression leads to formation of actin protrusions and migration in a Rac and cdc42 
dependant manner (Noren, Liu et al. 2000) and targeted down-regulation of p12-
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catenin leads to attenuated migration and invasiveness (Macpherson, Hooper et al. 
2007).
Tight junctions (TJ) are integral to maintain epithelial architecture. They are 
comprised of several transmembrane proteins and associated intracellular 
molecules. Perhaps the most extensively studied TJ surface molecule is occludin 
along with claudins and the junctional adhesion molecule (JAM) families. They also 
control the passage of ions and solutes between cells (Hartsock and Nelson 2008).
Occludin was one of the first proteins identified as a component of tight junctions. 
There are two isoforms of occludin; however no differences in structure or function 
have been reported. Structurally it comprised of 2 extracellular loops, an intracellular 
turn, N-terminus and C-terminus domains. The C-terminus domain contains serine, 
threonine and tyrosine residues allowing for phosphorylation events to take place 
(Sakakibara, Furuse et al. 1997). It can associate with the actin cytoskeleton by 
binding to actin directly or indirectly with adapter proteins such as ZO and cingulin. 
The carboxy-terminus cytoplasmic tail of occludin associates with ZO-1, ZO-2 and 
ZO-3. These ZO proteins interact together to anchor claudins, occludin and JAMS to 
the actin cytoskeleton. They therefore act as scaffolds for protein interactions at the 
tight junction. In addition both ZO-1 and ZO-2 have a capacity to bind a-catenin, and 
ZO-3 is able to bind p120-catenin. The ZO proteins not only act as linkers to the 
cytoskeleton, but as scaffold providing a link between tight and adherence junctions.
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4.3.2.3 Proteolysis
A) Matrix Metalloproteinases
The ECM is a network of proteins which fill intracellular spaces between cells.
Ultimately secreted by cells, the ECM forms a structural scaffold offering mechanical
support with participation in a number of cellular functions. Comprised of
polysaccharide glycoaminoglycans (GAG) and fibrous proteins the ECM is formed by
the secretion of macromolecules. Components of the ECM include collagen,
proteoglycans, elastin, fibronectin and laminin. Malignant tumours have a requisite
desire to grow, invade and metastasise, and the ECM acts as a barrier against this.
To overcome the ECM barrier, transformed malignant cells secrete proteases which
degrade the ECM to promote cell invasion and/or tumour angiogenesis. Matrix
metalloproteinases represent a major group of enzymes which regulate ECM
composition (Visse and Nagase 2003). Classified as matrixins, MMPs are a family of
zinc-binding endopeptidases which are known to cleave numerous components of
the ECM. MMPs are grouped into a number of categories some of which include,
collagenases, gelatinases, stromelysins, matrilysins and membrane bound (Nagase,
Visse et al. 2006). 23 MMPs have been identified in humans where all share
common structural and functional domains. Structurally MMPs differ depending on
which domains are present. All the members have a conserved propeptide domain
containing the cysteine switch and a catalytic domain. The catalytic domain contains
the zinc binding motif and methionine, with zinc and calcium ions, integral for stability
and enzymatic activity (Nagase, Visse et al. 2006). Most MMPs are secreted
however; six of the MMPs have transmembrane domains which restrict their
expression to the cell membrane. MMPs which are secreted are released latent
enzymes and as such require cleavage of the propeptide domain to become active
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enzymes. Membrane bound MMPs such as MT1-MMP contain a furin-like enzyme 
recognition motif which allows activation by intracellular proteinases before reaching 
the cell membrane. For MMP-2 activation, MT1-MMP located at the cell surface is 
inhibited by the N-terminal domain of Tissue Inhibitor of Metalloproteinases 2 (TIMP-
2). The C-terminus of TIMP-2 acts as a receptor for the latent proMMP-2 hemopexin 
domain. A second adjacent uninhibited MT1-MMP molecule cleaves and activates 
the tethered proMMP-2 (Itoh and Seiki 2004). The residual propeptide domain left 
behind following activation is then cleaved by an active MMP-2 molecule. Low 
expression of TIMP-2 promotes the activation of MMP-2, whilst a higher level of 
TIMP-2 expression saturates free MT1-MMPs that are required for MMP-2 activation 
(Strongin, Collier et al. 1995). The gelatinases A and B (MMP-2 and MMP-9 
respectively) contain three repeats of a fibronectin type II motif within the catalytic 
domain which mediate the binding to collagens. Both MMP-2 and MMP-9 cleave 
gelatin, and type IV, V and XI collagens (Nagase, Visse et al. 2006). The presence 
and activity of MMPs is increased in malignant cancers with the greatest expression 
highlighted in invasive areas of the tumour. Several MMPs have been implicated in 
key molecules associated with tumour invasion, metastasis and angiogenesis. In 
melanoma, elevated levels of MMP-9 correlated with increased progression, poor 
survival and metastasis (Deryugina and Quigley 2006). In MMP deficient mice 
susceptible to carcinogenesis MMP-9 was found to be crucial for the promotion of 
angiogenesis and tumour vasculature. Within the tumour environment, MMP-2 is 
upregulated through an OPN dependent manner via interaction with integrin avp3
(Rupp, Visconti et al. 2008). In thyroid lesions MMP-2 was readily detected in 
malignant thyroid lesions (Cho Mar, Eimoto et al. 2006). MMP-9 has addition roles in 
promoting angiogenesis by regulating the bioavailiability of VEGF, a potent mediator
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of angiogenesis (Bergers, Brekken et al. 2000). Inhibition of MT1-MMP, MMP-2 and 
MMP-9 attenuates angiogenesis and lymph node metastasis (Nakamura, Koizumi et 
al. 2004).
B) Urokinase Plasminogen Activator System
The urokinase plasminogen activator (uPA)/urokinase plasminogen activator 
receptor (uPAR) system has a role in tumour progression (Andreasen, Egelund et al.
2000). This system comprises of uPA, plasminogen activator inhibitors (PAI’s) and 
uPAR, the G-protein coupled uPA binding receptor. uPA, a serine proteinase is 
activated by cleavage following the binding to uPAR. The cleavage of uPA is induced 
by the action of plasmin. uPA generates active plasmin from plasminogen, thus 
creating a positive feedback loop for uPA activation and plasmin activation (Dass, 
Ahmad et al. 2008). Plasmin also facilitates the degradation of ECM components 
including FN, gelatinase, fibrin, laminin and latent collagenases (Fisher, Mackie et al.
2001). This forms the basis of the pro-angiogenic functions of this system. PAI’s are 
anti-proteases which inhibit the action of uPA. PAI-1 binds to active uPA/uPAR 
complex and induces internalisation of this uPA/uPAR/PAI-1 complex (Figure 25). 
The internalisation results in the degradation of uPA/PAI-1 by lysosomes, whilst 
uPAR is recycled and transported back to the cell membrane. In human cancers the 
plasminogen system has been well established. In epithelial breast cancer, increase 
in invasiveness was induced in an OPN-uPA dependent manner (Tuck, Hota et al. 
2001). OPN upregulates metastatic behaviour through the upregulation of MMP-2 
and uPA in an avp3 integrin dependent manner. The binding of OPN to avp3 integrin 
activates Integrin Linked Kinase which induces upregulation of the transcription
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factor AP-1 and subsequent upregulation of MMP-2 and uPA. In human mammary 
epithelial cells where OPN was ectopically expressed resulted in an increase in 
invasion which was dependant on uPA.
ECM Degradation
uPA
Plasminogen
uPAR
Plasminogen Receptor
Plasmii
PAI2
PAI1
Plasma Membrane
F ig u r e  25 . The Urokinase Plasminogen Activator System. uPA binds to its receptor, uPAR 
which activates uPA. Activated uPA generates plasmin from plasminogen to induce ECM  
degradation.
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4.4 Aims, Objectives and Experimental Strategy
Following selection of candidate markers the second major aim of this thesis was to 
define their role in thyroid tumour invasion. To carry out this aim I focused on 2 
genes, Slug and OPN which are over-expressed in PTC. With the use of thyroid 
cancer cell lines, I investigated the role of these genes in the process of tumour 
invasion. This effectively defined the processes regulated by these genes, and 
provided an indication of how they mediate invasion. For this work I utilised thyroid 
cancer lines, with a view to extending the work to primary models. Using stable 
shRNA knockdown experiments I conducted experiments to define the role of these 
markers in tumour invasion. I hypothesised that these selected markers would affect 
a number of mechanisms.
Study the role of Slug and OPN in thyroid tumour invasion
1) Define invasive capability in thyroid cancer cell lines and the expression 
profile of Slug and OPN.
This work indicates if the expression of Slug or OPN is linked to invasive behaviour. 
To do this the flowing objectives were completed:
1. Characterise invasive capability in a panel of thyroid cancer cell lines
2. Characterise expression of OPN and Slug in a panel of cancer cell lines
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2) Conduct knock-down of Slug and OPN
Both Slug and OPN are over-expressed in PTC. To establish the role of these genes 
in tumour invasion, I hypothesised that shRNA mediated knock-down of expression 
would confer invasive tumour cells with a non-invasive epithelial phenotype. To 
achieve this goal the following objectives were carried out:
1. Prepare lentiviruses for the shRNA mediated knock-down of Slug and OPN
2. Conduct the shRNA mediated knockdown of Slug and OPN in a highly invasive 
cell line over-expressing Slug and OPN
3. Validate the knock-down of Slug and OPN
3) Determine if shRNA mediated knock-down of Slug and OPN affects 
invasive capability
This would provide evidence that expression of Slug or OPN directly mediates an 
invasive phenotype. To conduct this aim the following objective was completed:
1. Conduct invasion assays to determine if there is significant reduction in invasive 
capability.
4) Investigate the invasive mechanisms mediated by Slug and OPN which 
confers an invasive phenotype
This aim elucidates the mechanisms which Slug and OPN regulate to induce an 
invasive phenotype. As tumour invasion is a collection of cellular processes, 
investigations into the roles of extracellular matrix remodelling by proteinases, cell 
motility, cell-cell adhesion and cell-matrix adhesions were conducted. This provided
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direct evidence of Slug and OPN in PTC invasion with an indication of their
therapeutic value. To carry out these aims the following objectives were conducted:
Study of Extracellular matrix remodelling by proteinases
1. Investigate if the down-regulation of Slug and OPN impacts the urokinase 
activator system or activity of matrix metalloproteinases.
Study of cell motility
1. Investigate how the down-regulation of Slug and OPN impacts the actin based 
machinery which is required for cell motility
2. Investigate how the down-regulation of Slug and OPN impacts the motile 
behaviour of cells.
3. Investigate the role of Hepatocyte Growth Factor in motile behaviour, and the 
regulation by Slug and OPN.
4. Analyse if variant isoforms of CD44 are a contributing factor mediating HGF- 
dependant motility.
Study of cell-cell interactions to investigate if the down-regulation of Slug and 
OPN confer mesenchymal to epithelial transition
1. Investigate how the down-regulation of Slug and OPN impacts tight junction 
regulation
2. Investigate if the down-regulation of Slug and OPN regulates adherence junctions
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3. Investigate how the down-regulation of Slug and OPN affects cell-matrix 
interactions and how this relates to motile behaviour.
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5.0 Materials and
Methods
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5.1 Cell culture
For the culture of cell lines, cells were grown in a humidified atmosphere containing 
20 % O2, 5 % CO2 at 37°C. Cells were either grown in RMPI, DuIbecco’s modified 
Eagles’ medium or the 1:1 mixture of Dulbecco’s modified Eagles’ medium and 
Hams’ F12. All were supplemented with 10% foetal calf serum, Penicillin and 
Streptomycin with glutamine (Table 5.0).
5.2 Preparation of Lentiviral supernatants
The Lentiviral vectors used in my investigations were the MISSION™ Slug shRNA 
and MISSION™ OPN shRNA both in a pLK0.1-puro vector (both purchased from 
Sigma-Aldrich, UK) (Table 5.1). For each transfection sample DNA-Lipofectamine™ 
2000 complexes were prepared. This involved diluting 9pg of the ViraPower™ 
Packaging Mix (Invitrogen, Paisley, UK) and 3pg of shRNA plasmid DNA (12pg total) 
in 1.5mL of Opti-MEM® medium without serum. This was gently mixed. In a separate 
sterile 5 mL tube, Lipofectamine™ 2000 was mixed gently before use and 36pL 
diluted in 1.5mL of Opti-MEM® medium without serum. This was followed by gently 
mixing and incubating for 5 minutes at room temperature. After a 5 minute 
incubation, the diluted DNA with the diluted Lipofectamine™ 2000 was combined 
and gently mixed. This mixture was incubated for 20 minutes at room temperature to 
allow the DNA-Lipofectamine ™ 2000 complexes to form.
Whilst the DNA-Lipofectamine complexes were forming, 293FT cells were 
trypsinised and resuspened at a density of 1.2x106 cells/mL in 10mL of growth 
medium containing serum without antibiotics. The DNA-Lipofectamine™ complexes
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were added to a 10cm tissue culture plate containing 5mL of Opti-MEM® Medium 
with serum and without antibiotics. To this 5mL of the 293FT cell suspension (6x106 
total cells) was added to the plate. The plate was mixed by rocking the plate back 
and forth and incubated overnight at 37°C in a humidified 5% C02 incubator. The 
following day the medium was removed and replaced with 10mL complete culture 
medium without antibiotics. This was left to incubate at 37°C in a humidified 5% C02 
incubator. Virus-containing supernatants were harvested after 48 hours post­
transfection by removing medium into to a 15mL sterile, capped, conical tube. This 
was centrifuged at 10OOg for 15 minutes at 4°C to pellet debris. Viral supernatants 
were stored at -80°C using cryovials in 1ml_ aliquots.
Lentiviral infection of cells was conducted according to the materials and methods 
section in Part I (2.2.3)
Oncogene/plasmid Producer cells Selection
SlugshRNApLKO. 1 -puro 293FT Puromycin
OPNshRNApLKO. 1 -puro 293FT Puromycin
Table 5.1. Lentiviral plasmids with producer cells used and corresponding selection
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Cells Source Growing media Usage
Primary human 
thyroid epithelial cells
Normal human thyroid tissue 1:1 mixture of Dulbecco's modified Eagles’ medium and 
Hams’ F12 medium supplemented with 10% fetal calf 
serum.
Identification of candidate genes using Microarray
ORI-3 Human primary thyroid follicular epithelial cells immortalized by 
SV40
RPMI medium, supplemented with 10% fetal calf serum Thyroid negative control for invasion assays
Negative control for the study of Slug and OPN in
invasion
Characterisation of B-Raf isoforms
K1 Human papillary thyroid carcinoma cell line 1:1 mixture of Dulbecco’s modified Eagles' medium and 
Hams' F12 medium supplemented with 10% fetal calf 
serum.
Characterisation of B-Raf isoforms 
Positive control for tumour invasion 
Positive control for the study of Slug and OPN in invasion
FTC133 Human follicular thyroid carcinoma cell line RPMI medium supplemented with 10% fetal calf serum. Characterisation of B-Raf isoforms 
Study of tumour invasion
FTC236 Human follicular thyroid carcinoma cell line derived from the 
metastasis of FTC133
1:1 mixture of Dulbecco’s modified Eagles’ medium and 
Hams’ F12 medium supplemented with 10% fetal calf 
serum.
Characterisation of B-Raf isoforms 
Study of tumour invasion
Hth74 Human anaplastic thyroid carcinoma cell line 1:1 mixture of Dulbecco’s modified Eagles’ medium and 
Hams' F12 medium supplemented with 10% fetal calf 
serum.
Characterisation of B-Raf isoforms 
Study of tumour invasion
SW1736 Human anaplastic thyroid carcinoma cell line 1:1 mixture of Dulbecco’s modified Eagles’ medium and 
Hams' F12 medium supplemented with 10% fetal calf 
serum.
Characterisation of B-Raf isoforms
TT Human medullary thyroid carcinoma cell line 1:1 mixture of Dulbecco’s modified Eagles’ medium and 
Hams’ F12 medium with 15% fetal calf serum.
Characterisation of B-Raf isoforms
K5 Human follicular thyroid carcinoma cell line 1:1 mixture of Dulbecco's modified Eagles’ medium and 
Hams’ F12 medium supplemented with 10% fetal calf 
serum.
Characterisation of B-Raf isoforms
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UCLA-R082
Human follicular thyroid carcinoma cell line 1:1 mixture of Dulbecco’s modified Eagles’ medium and 
Hams’ F12 medium supplemented with 10% fetal calf 
serum.
Characterisation of B-Raf isoforms
BCPAP Human papillary thyroid carcinoma cell line 1:1 mixture of Dulbecco’s modified Eagles’ medium and 
Hams’ F12 medium supplemented with 10% fetal calf 
serum.
Characterisation of B-Raf isoforms 
Study of tumour invasion
A431 epidermoid carcinoma cell line RPMI medium, supplemented with 10% fetal calf serum 
supplemented with 10% fetal calf serum.
Positive control for adherence junctions
MCF7 Human breast carcinoma cell line RPMI medium, supplemented with 10% fetal calf serum Control cell line used in the study of Slug and OPN in 
invasion
MDAMB231 Human breast carcinoma cell line Dulbecco’s modified Eagles’ medium with 10% fetal calf 
serum
Control cell line used in the study of Slug and OPN in 
invasion
293FT Human kidney cell line Dulbecco's modified Eagles’ high glucose medium, 
(supplemented with 10% fetal calf serum depending on 
experimental conditions)
Production of lentiviruses
Phoenix Amphotrophic retrovirus packaging cell line Dulbecco's modified Eagles' medium with 10% fetal calf 
serum
Production of BRAFV600E retroviruses
'F-CRIP doej RASV12 retrovirus producer cell line Dulbecco's modified Eagles’ medium with 10% fetal calf 
serum
Production of RASV12 retroviruses
'F-CRIP RET/PTC1 RET/PTC1 retrovirus producer cell line Dulbecco's modified Eagles' medium with 10% fetal calf 
serum
Production of RET/PTC1 retroviruses
Table 5.0. Cells with corresponding culture conditions, source and usage.
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5.3 Cell Lysis
Cells were grown to 70% confluence and scraped into 1mL STE buffer (10mM Tris 
pH 8.0, 150mM NaCI, 1mM EDTA pH 8.0) and centrifuged at 1000rpm at 4°C for 5 
minutes. After discarding supernatant cells were lysed for 5 minutes on ice in 2.5 
times the volume of lysis buffer (150mM NaCI, 50mM Tris, 5mM EDTA and 1% 
NP40 with 30pL/mL PMSF, 10pL/mL protease inhibitor cocktail (Calbiochem, 
Nottingham, UK) and 10pL/mL phosphatase inhibitor cocktail (Calbiochem, 
Nottingham, UK). The lysed cell mixture was centrifuged at 56,000rpm at 4°C for 30 
minutes. The supernatant was removed and stored at -20°C for future use.
5.4 Protein Quantification
To determine protein concentration the Bradford method of quantification was 
utilised. Bovine Serum Albumin (BSA) standards (Pierce Ltd, UK) were prepared in 
triplicate at concentrations of 100pg/mL, 200pg/mL, 300pg/mL and 400pg/mL by 
diluting 2mg/mL BSA in 1/10 diluted lysis buffer. Protein samples were diluted 1/10 in 
water and 40pL of each standard and sample was aliquoted into 1.6mL semi-micro 
cuvettes to which 1mL of Bradford Coomassie Plus Protein Assay reagent (Thermo 
Fisher Scientific, Rockford, IL, USA) was added. Using the 1/10 diluted lysis buffer 
as a reference, the standards and samples were read on a spectrophotometer at a 
wavelength of 595nm. Protein concentrations were calculated from the colorimetric 
values obtained by producing a standard curve.
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5.5 Sodium Dodecyl Sulfate (SDS) Polyacrylamide Gel Electrophoresis (PAGE) 
Western Immunoblotting
Samples were prepared by addition of 3X loading buffer (300pL 0.5M Tris pH 6.8, 
300pL Glycerol, 300pL 10% SDS, 60pL 1% bromophenol blue and 30pL 2- 
mercaptoethanol) followed by boiling for 5 minutes. The Precision Plus Molecular 
Weight Marker (Bio-Rad, Hertfordshire, UK) was also prepared in the same way. 
Electrophoresis was performed using an SE-250 mini-vertical electrophoresis unit 
(GE Heathcare Life Sciences, Buckinghamshire, UK) at 100V until the desired 
separation had occurred. Prior to the transfer of proteins onto a Polyvinylidene 
Fluoride (PDVF) membrane (Millipore, Billerica, MA, USA), the membrane was 
equilibriated in methanol. The transfer of proteins was performed using a TE-22 Mini­
tank transfer unit (GE Heathcare Life Sciences, Buckinghamshire, UK) overnight at 
10V.
For immunoprobing, the membranes were blocked according to antibody conditions 
for 4 hours at 4°C on a shaker. Primary antibodies were diluted according to 
antibody conditions and probed at 4°C overnight on a roller (Table 5.2). Secondary 
antibodies were either anti-mouse Horseradish Peroxidase, anti-rabbit Horseradish 
Peroxidase or anti-goat HorseRadish Peroxidase. This was dependant on the 
antibody being used. Membranes were washed several times with 1XTBS 0.2% 
Tween20 after antibody incubations. For chemiluminicent detection ECL Plus 
reagent (GE Heathcare Life Sciences, Buckinghamshire, UK) was used. For 
detection membranes were ultimately developed onto ECL-film.
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5.6 Zymogram Analysis
Samples were prepared by growing cells in a T75 tissue culture flask to 80% 
confluence, aspirating the medium and replenishing with serum-free medium. These 
were incubated overnight at 37°C in a humidified 5% CO2 incubator. The following 
day, the medium was harvested, centrifuged at 1000rpm for 5 minutes to remove 
any cell debris and stored at -20°C for future use.
Gelatin 10% Ready Gel Zymogram Gels were commercially obtained (Biorad 
laboratories). Samples were thawed to which 2x Tris-Glycine SDS buffer was added 
at a ratio of 1:1. The buffer consisted of 2.5 mL 0.5M Tris-HCI, pH 6.8, 2 ml_ 
Glycerol, 4mL 10% (w/v) SDS, 0.5mL 0.1% Bromophenol Blue and H20 to 10mL. 
Samples were applied to the gel using the same conditions as SDS-PAGE. The gel 
was then incubated in Renaturing Buffer, which consisted of 2.5% Triton-X-100 (v/v) 
in H20 for 30 minutes with gentle agitation. The Renaturing Buffer was decanted and 
placed in the Developing Buffer (50mM Tris-base, 0.2M NaCI, 5mM CaCI2, 0.7mg 
ZnCI2, 0.02% NaN3 and H20 to 1L) for 5 hours at 37°C. The final step consisted of 
staining with Coomassie Blue R-250 (500mg Coomassie Blue R-250, 225mL 
methanol, 225mL deionised H20, 50mL Acetic acid) for 30 minutes and destained 
using methanol : acetic acid : H20 (50:10:40) Destaining solution until clear bands 
were visible.
157
5.7 OPN Enzyme-linked immunosorbent assay (ELISA)
Human OPN quantikine immunoassay was commercially obtained (R&D Systems). 
To each well of the micro-plate, 100pL of Assay Diluent RD1-6 was added, followed 
by the addition of 50pL of standard, control, or sample per well. Each standard, 
control and sample was analysed in duplicate. This was covered with the supplied 
adhesive strip. The plate was then incubated for 2 hours at room temperature. Each 
well of the plate was aspirated and washed by filling each well with Wash Buffer 
(400pL) using a squirt bottle, with the process repeated three times for a total of four 
washes. After the last wash, any remaining Wash Buffer was removed by aspiration 
and decanting, followed by blotting against clean paper towels. To each well, 200pL 
of OPN conjugate was added and the plate covered by a new adhesive strip. This 
was incubated for 2 hours at room temperature. Using the Wash Buffer, the wash 
step was then repeated. To each well 200pL of substrate solution was added, which 
was then incubated for 30 minutes at room temperature in the dark. To stop the 
reaction, 50pL of Stop Solution was added to each well. The optical density of each 
well was determined within 30 minutes using a FLUOstar OPTIMA microplate reader 
(BMG Labtech, Germany) set to 450nm. Readings at 540 nm were also determined 
and these were subtracted from the readings at 450 nm. This subtraction corrected 
the optical imperfections in the plate.
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5.8 Immunofluorescence
Cells were grown on glass coverslips (RA Lamb, Lauda-Konlgshofen, Germany) and 
fixed in 4% paraformaldehyde and rinsed three times with 1XPBS. 
Paraformaldehyde fixed cells were permabilised with 0.2% Triton-X-100 for 20 
minutes at room temperature, and were blocked in goat serum (1:20 in 1XPBS) for 1 
hour. Primary antibodies were incubated overnight at 4°C. All antibodies were diluted 
and washed with 1XPBS 0.001% Tween20. Secondary antibodies were diluted in 
PBS and incubated at room temperature for 1 hour. Coverslips were counterstained 
with 20pL DRAQ5 (Biostatus Ltd, Shepshed, UK) or DAPI nuclear stain for 10 
minutes and mounted on glass slides using Prolong Gold Antifade reagent 
(Invitrogen, Paisley, UK) and sealed with clear nail varnish.
Details regarding antibodies, company, and concentrations are detailed in Table 5.2.
5.9 Phalloidin Staining
Cells grown on coverslips were washed twice with 1xPBS. Cells were fixed with 4% 
paraformaldehyde and washed 3 times with 1xPBS. Cells were permebilised with 
0.1% Triton-X-100 for 20 minutes and rinsed 3 times with 1xPBS. Cells were 
incubated for 20 minutes in the dark with a phalloidin-FITC (Sigma-Aldrich, UK) 
antibody (50pg/mL). Coverslips were washed with 1xPBS and counterstained with 
DAPI for 10 minutes. Coverslips were mounted on glass slides using Prolong Gold 
Antifade reagent (Invitrogen, Paisley, UK) and sealed with clear nail varnish.
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Application Protein name 1° Antibody Antibody source Specificity Cone. Blacking solution Z°
Antibody
Cone.
Phospho-
Cortactin
(Y466) Abeam H, M 1:500 10%FCS/PBS Alexa
Fluor
568
1:500
E-cadherin (HECD-1) Abeam H 1:100 10%FCS/PBS Alexa
Fluor
488
1:500
Vinculin (sc73614) Santa-Cruz
Biotechnology
Inc
H 1:100 10%FCS/PBS Alexa
Fluor
488
1:500
WAVE! G ift from Prof. 
W . Jiang
H 1:250 10%FCS/PBS Alexa
Fluor
568
1:500
LL
N-WASP G ift from Prof. 
W . Jiang
H 1:250 10%FCS/PBS Alexa
Fluor
568
1:500
Slug (G18) Santa-Cruz
Biotechnology
Inc
H 1:200 10%FCS/PBS Alexa
Fluor
488
1:500
(3-catenin (610154) BD
Transduction
Laboratories
H, M 1:50 10%FCS/PBS Alexa
Fluor
568
1:500
Pan-cadherin (CH-19) Abeam H, M 1:100 5%FCS/PBS Alexa
Fluor
488
1:500
lntegrinP3 (BV4) Abeam H 1:100 5%FCS/PBS Alexa
Fluor
488
1:500
CD44 (156-3C 11) Cell signalling 
Technology
H 1:400 20%FCS/PBS/
Triton-X
Alexa
Fluor
568
1:500
Snail (L70G2) Cell signalling 
Technology
H, M 1:1000 5%
milk/lxTBS/0.1%
Tween
RAM 1:2000
Slug (G18) Santa-Cruz
Biotechnology
Inc
H 1:1000 5%
milk/lxTBS/0.1%
Tween
RAG 1:2000
B-Raf (24462) Upstate
Biotechnology
H lpg /m l 5%
milk/lxTBS/0.1%
Tween
GAR 1:2000
W
B (3-catenin (610154) BD
Transduction
Laboratories
H, M 0.25
pg/ml
5%
BSA/lxTBS/0.1%
Tween
RAM 1:2000
Occludin (33-150) Invitrogen H ,M 1 pg/ml 5%
milk/lxTBS/0.1%
Tween
GAR 1:2000
M T1-MM P (EP1264Y) Abeam H, M 1:2000 5%
BSA/lxTBS/0.1%
Tween
RAM 1:2000
Actin (048K4861) Sigma-Aldrich H 1:750 5%
milk/lxTBS/0.1%
Tween
RAG 1:2000
Table 5.2. Antibodies used for Immunofluorescence (IF) and Western Blot analysis (WB). 
(RAM; Rabbit anti-mouse, GAR;Goat anti-rabbit, RAG;Rabbit anti-goat, H;Human, 
M;Mouse). WAVE1 and N-WASP antibodies were a gift from Prof. Wen Jiang (Department 
of Surgery, Anaesthetics, Obstetrics & Gynaecology, Cardiff University)
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5.10 Mini-preparation of plasmid DNA
MISSION™ Bacterial glycerol stocks containing Slug shRNA or OPN shRNA in a 
pLK0.1-puro vector were commercially obtained (Sigma-Aldrich, UK). The glycerol 
stocks were streaked onto agar-carbenicillin (200pL carb/100ml_ LB) plates and left to 
incubate at 37°C overnight. Colonies were picked and inoculated in 5mL LB-carbenicillin 
and incubated at 37°C overnight with agitation. Mini-preps were conducted of the 
inoculated LB were conducted using the PureLink™ Quick Plasmid Miniprep Kit 
(Invitrogen, Paisley, UK).
The bacterial culture was pelleted and the medium removed from the cell pellet. This 
was completely resuspended in 250pL Resuspension Buffer (R3) with RNase A making 
sure no cell clumps remained. To the resuspended bacterial pellet, 250pL Lysis Buffer 
(L7) was added to cells and mix gently by inverting the capped tube 5 times. This was 
followed by a 5 minute incubation at room temperature. After the incubation, 350pL 
Precipitation Buffer (N4) was added. This was mixed immediately by inverting the tube 
until the solution was homogeneous. The mixture was centrifuged at 12,000g for 10 
minutes at room temperature using a microcentrifuge to clarify the lysate from lysis 
debris. The supernatant was then loaded onto a spin column. The Spin Column with 
supernatant was placed into a 2mL Wash Tube. This was centrifuged at 12,000g for 1 
minute. The flow-through was discarded and the column placed back into the Wash 
Tube. Next, 500pL Wash Buffer (W10) with ethanol was added to the column and 
incubated for 1 minute at room temperature. This was then centrifuged at 12,000g for 1 
minute. The flow-through was again discarded and the column placed back into the
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Wash Tube. Following this step, 700pL Wash Buffer (W9) with ethanol was added to 
the column. The column was centrifuged at 12,000g for 1 minute. The flow-through was 
discarded and the column placed back into the Wash Tube. To remove any residual 
Wash Buffer (W9), the column was centrifuged at 12,000g for 1 minute and the flow­
through discarded. The Spin Column was placed in a clean 1.5mL Recovery Tube to 
which 50pL of TE Buffer (TE) was added to the centre of the column. The column was 
incubated for 1 minute at room temperature, followed by centrifugation at 12,000g for 2 
minutes. The Recovery Tube contained the purified plasmid DNA.
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5.11 cDNA synthesis and Reverse Transcription Polymerase Chain Reaction (RT- 
PCR)
Following RNA extraction, 1(jg of RNA was combined with 2pL (1pg/pL) Random 
Primers (Invitrogen, Paisley, UK) and 8pL sterile water and incubated for 10 minutes at 
70°C. To this 4pL 5X buffer, 2pL 0.1 M DTT, 1pL10m dNTP, 1pL Superscript II and 1pL 
RNaseOUT™ (All from Invitrogen, Paisley, UK) were added and incubated for 1 hour at 
42°C. This was followed by conventional PCR.
Primers dedicated to each target were designed and ordered through a commercial 
company (MWG-Biotech). PCR program was conducted according to Table 5.3. 
GAPDH primers which were commercially obtained (Biomol, Germany). The PCR 
program was conducted according to Table 5.4.
For the conventional PCR, 2pL of the cDNA, 8.5pL H20, 5pL 10x Buffer, 1pL dNTPs, 
0.5pL Taq polymerase, 3pL Magnesium Chloride (all from Thermo-Fisher, UK) with 
2.5pL of forward and reverse primer (10 pmol/pL) was used. Primer sequences are 
detailed in Table 5.5.
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PCR Program 
Step
Temperature Time Number of 
Cycles
Initial denaturing 94°C 2 minutes
<-
---
---
---
---
---
--►
25 
Cy
cle
s
Denaturing 94°C 15
seconds
Annealing Primer
dependant
30
seconds
Elongation 72°C 3 minutes
Final Elongation 72°C 10 minutes
MWG primers
Table 5.3. PCR program for primers ordered through MWG. Annealing temperature is primer 
dependant.
PCR Program 
Step
Temperature Time Number of 
Cycles
Initial denaturing 94°C 2 minutes
<-
---
---
---
---
---
-►
25 
Cy
cle
s
Denaturing 94° C 15
seconds
Annealing 55°C 30
seconds
Elongation 72°C 3 minutes
Final Elongation 72°C 10 minutes
GAPDH primers
Table 5.4. PCR program for GAPDH primers ordered from Biomol. PCR program was 
conducted according to manufacturer instructions.
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Length
(bp)
Primer Sequences 
(5'-3'; a, forward; b, reverse)
Cycles Annealing 
Tempertaure (°C)
B-Raf exon 
8-18
1598 a- CCAATTGGTTGGGACACTG 
b- GTTCTGATGCACTGCGGTG
25 56
B-Raf exon 
1 0 -1 8
922 a- GCCTCATTACCTGGCTCAC 
b- GTTCTGATGCACTGCGGTG
25 56
E-cadherin 612 a- TGGGCTGGACCGAGAGAGTT 
b- ATCTCCAGCCAGTTGGCAGT
25 55
Osteopontin a-450
b-408
c-369
a- AGCCAAACGCCGACCAAG 
b- GGT CCGTGGG AAAAT CAGT G
25 56
Slug 258 a- AGAT GCAT ATTCGGACCCAC 
b- CCTCATGTTTGTGCAGGAGA
25 57
uPA 199 a- ACT ACTACG GCT CT GAAGT CACCA 
b- GAAGTGT GAG ACT CTCGTGT AG AC
25 50
uPAR 157 a- CTG G AGCTT G AAAAT CTGCCG 
b- GGI I I I ICGGTTCGTGAGTGC
25 50
MT1-MMP 221 a- GGATACCCAATGCCCATTGGCCA 
b- CCATT GGGCAT CCAGAAGAGAGC
25 51
MMP-2 225 a- AGAT CTT CTT CTT CAAGG ACCGGTT 
b- GGCTGGTCAGTGGCTTGGGGTA
25 51
CD44s 157 a- AAAGG AGCAGCACTT CAG GA 
b- TGTGTCTTGGTCTCTGGTAGC
25 51
CD44v6 175 a- AACT GATATT CTTCT C AC AG 
b- CTT GTT AAACCAT CCATTACCAG
25 50
CD44v7 200 a- CT CAAACT G CAT GGTCACAG 
b- AAAATCTCAGAGGCTATTAC
25 50
CD44v10 310 a- CT GATTCCACCT CCACACAG 
b- GATAATAAATGCCAAATTACCTG
25 50
GAPDH 240 a- T GAT G ACAT CAAGAAG GTGGT GAAG 
b- TCCTTGGAGGCCATGTGGGCCAT
25 55
Table 5.5. Primer sequences detailing product size, number of cycles and melting temperature.
6.0 Results
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6.1 The role of Slug and OPN in Thyroid Tumour Invasion
The differential diagnosis between follicular adenoma and follicular carcinoma is 
difficult to determine following major histological examination after thyroidectomy 
(Davis, Gordon et al. 1991). The identification of additional biomarkers of invasion 
would greatly facilitate in the differential diagnosis, and further provide opportunities 
for identifying new therapeutic targets.
Our laboratory has established a primary model representing FA, and two additional 
models representing PTC. Using these I conducted a Microarray gene profiling 
experiment to identify novel candidate genes which may regulate an invasive 
phenotype. In parallel, I had conducted a literature analysis to identify additional 
biomarkers. From this analysis I identified two genes, Slug and Osteopontin (OPN) 
which are implicated in thyroid cancer.
Osteopontin, a secreted phosphoprotein regulates numerous processes pertaining to 
tumour invasion and metastasis. OPN is overexpressed and enhances PTC 
invasiveness in RET/PTC transformed rat thyroid cells and correlates with 
aggressive clinicopathological features of PTC (Guarino, Faviana et al. 2005). OPN- 
integrin binding directly mediates migration and invasion of tumour cells, and is 
known to enhance thyroid papillary carcinoma invasiveness. This includes increasing 
cell migration, motility and extracellular matrix degradation. The mechanistic 
explanation of how OPN regulates thyroid tumour invasion requires further 
investigation. The overexpression of OPN and its implication in invasion has already 
been elucidated. However, the precise mechanisms regulating the invasive program 
mediated by OPN in thyroid cancer requires further investigation.
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The Slug transcription factor has been implicated in papillary carcinoma. Down- 
regulation of E-cadherin mediated by Slug has been demonstrated in thyroid 
carcinoma (Hardy, Vicente-Duenas et al. 2007). However, it is unclear if other 
invasive processes are affected by the overexpression of Slug.
We therefore hypothesised that OPN and Slug may regulate multiple invasive 
processes. I therefore aimed to assess upstream regulators and downstream 
effectors of these nominated candidates. To achieve this overall aim, lentiviral 
mediated shRNA knockdown of Slug and OPN was used.
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6.2 Characterising the invasive behaviour across a panel of thyroid cancer cell 
lines.
To investigate invasive behaviour in vitro, I used a modified in vitro boyden chamber 
invasion assay utilising reconstituted growth factor reduced basement membrane 
matrix. The reconstituted basement membrane matrix acts as a barrier which 
invasive cells have to pass through. This effectively reflects the in vivo situation of 
tumour invasion. The cell lines analysed in this study were from different thyroid 
tumours (Table 6.0) and the invasive potential of each cell line was analysed. 
Determining the thyroid cell lines which display the greatest degree of invasive 
behaviour was important aim as it establishes the experimental controls to assess 
possible roles of Slug and OPN in tumour invasion.
Cell
line
Source
ORI-3 Normal epithelium transformed with SV40
K1 Human papillary thyroid carcinoma cell line
BCPAP Human papillary thyroid carcinoma cell line
FTC133 Human follicular thyroid carcinoma cell line derived from the primary tumour of apatient
FTC236 Human follicular thyroid carcinoma cell line derived from the metastasis of theprimary tumour (FTC 133)
Hth74 Human anaplastic thyroid carcinoma cell line
Table 6.G. The thyroid cell lines and their source used for the characterisation of invasive
behaviour.
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Primarily, I optimised the invasion assay by conducting the assay under a gradient of 
0%-10% serum conditions. The gradient provides a chemo-attractant for cells to 
migrate and invade the Matrigel. This is a common method to study cell invasion, 
however in my studies this resulted in invasion of the ORI-3 cell line. This cell line, 
derived from normal epithelium was used as a negative control for invasion. I 
therefore chose to conduct invasion assays using low serum conditions (1% Foetal 
calf serum) without the addition of chemoattractants, therefore only invasive cells 
would invade through the matrix. The invasion assay therefore provides an accurate 
representation of the invasive potential of the respective cell line. Each assay was 
conducted in triplicate and on three separate occasions. The chambers were fixed 
and stained with GIEMSA and the total number of invaded cells counted in 5 
different fields of each chamber and the average across the triplicate experiments 
compiled (Figure 26).
I used low serum conditions and reduced growth factor Matrigel for the invasion 
assay since growth factors and mitogens can attenuate the assay. In addition, 
replication allows for increased accuracy and addition of error bars to the graphical 
results. The results from the invasion assay clearly show that for each cell line 
analysed, there is an increase in the number of invasive cells after 48 hours. The 
ORI-3 cell line, which represents normal epithelium, displayed the least degree of 
invasion, a result which was to be expected. Both the K1 and FTC236 cell lines 
displayed the greatest degree of invasion after 24 hours, even more so after 48 
hours. This was followed by BCPAP an FTC133 which also displayed significant 
invasion. The Hth74 cell line did not display significant invasion of the matrix. The 
increase in invasion after 48 hours may be due to cell proliferation and not cell 
invasion. Taken together, the papillary carcinoma cell line, K1 and the metastasis of
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follicular carcinoma, FTC236 displayed the greatest degrees of invasion. This 
enabled the characterisation of both negative (ORI-3) and positive control (K1 and 
FTC236) for future experiments.
These results show the invasive potential of thyroid cell lines. In particular, the ORI-3 
cell line displayed basal levels of invasion a result which was expected since this cell 
line is derived from normal epithelium, and therefore is not expected to invade, and 
also shows the invasion assay is functioning properly. This clearly marks this cell 
line as the negative control for future experiments. From the carcinoma cell lines, the 
K1 cell acted as the superior positive control, as it displayed the greatest degree of 
invasion both after 24 hours and 48 hours.
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Figure 26. The invasive potential of cell lines derived from different thyroid pathologies using 
the Boyden chamber system. Invasion assays displaying percentage of invaded cells after 
24 hours (blue) and 48 hours (red) respectively. Cells were seeded at a density of 
3x105/insert. Each cell line was assayed three times, each time in triplicate Boyden 
chambers. After 24 and 48 hours respectively, invaded cells were visualised using GIEMSA 
stain, and 5 different fields of view for each were photographed and the average amount of 
cells counted. (A) Actual cell numbers of invaded cells. T-test analysis was conducted by 
comparing ORI-3 cells with each of the cell lines at 24 and 48 hours respectively. Significant 
p-values are indicated above the bars together with black stars. (B) Cell numbers were 
converted into percentages and graphically presented. 100% invasion was assumed at the 
48 hour time point of the K1 sample.
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6.3 Characterising the role of Slug and OPN in tumour invasion
My expression profile of Slug and OPN revealed an increased expression in the 
RASV12 model. This FA model also displayed prominent invasive capability. This 
may be linked to the up-regulation of these respective genes. Indeed, the up- 
regulation of both Slug and OPN has been highlighted in the literature in a number of 
tumours including PTC.
Literature analysis revealed OPN to be over-expressed in human PTC samples 
compared with normal epithelium, FA and multinodular goiters. Also, OPN was 
shown to induce invasiveness in PTC cell lines (Guarino, Faviana et al. 2005). 
Details regarding molecular mechanisms, processes, phenotypic effects and up­
stream regulators and down-stream effectors of OPN require further investigation to 
further elucidate the role of OPN in thyroid tumourigenesis.
Similarly Slug, a transcriptional repressor has been implicated in thyroid 
tumourigenesis. Its expression was detailed in a number of thyroid cell lines. 
Expression of Slug is minimal in the ORI-3 cell line, a cell line which is derived from 
normal thyroid epithelium, and it is over-expressed in cell lines derived from thyroid 
carcinomas (Hardy et al. 2007). Morphologically, cells expressing the transcription 
repressor Slug did not form close contacts and Slug was deemed functionally active 
based on the localised nuclear expression. Although the work did establish an 
implication of Slug in thyroid carcinogenesis, there was limited experimental data on 
the background mechanisms of Slug and its link with carcinogenesis. Slug is a 
known transcriptional repressor of E-cadherin, and E-cadherin down-regulation is 
associated with the induction of EMT. This study will reflect on the previous work 
pertaining to Slug and its role in cell-cell contact, but also its role in cell-substrate
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interaction. In addition, the section details the expression of Slug and OPN in thyroid 
cell lines, their impact on the invasion, with detailed molecular background 
surrounding the impact.
6.3.1 Characterisation of Slug in thyroid cell lines
To assess if the expression of Slug correlates with the level of invasion, I determined 
expression of Slug in a range of thyroid cell lines derived from different tumours. 
Real-time PCR (qPCR) was used to quantify Slug mRNA within each cell line. The 
method entailed extracting total RNA from sub-confluent cells using Trizol which was 
subsequently processed by Dr. Claudia Consoli from CBS who performed the real­
time reverse transcription of Slug using GAPDH as a loading control. The qPCR 
analysis revealed ORI-3 cells to have no Slug mRNA. However, K1 cells had ~250 
units of normalised expression whist in the other cell lines the quantity was 
considerably less at ~50 units of normalised expression (Figure 27A).
In parallel, I extracted protein lysates from sub-confluent dishes of each of the 
respective cell line. Samples were quantified and SDS-PAGE western blot analysis 
was conducted. The lysate samples were ran on a 10% acrylamide gel and 
transferred to a PVDF membrane. The membrane was then probed with a Slug 
specific antibody and re-probed with actin, as a loading control for the western blot.
Contrasting with the qPCR analysis, the western blot analysis revealed basal Slug 
expression in ORI3 cells. The FTC133, FTC236 and Hth74 cell lines also had similar 
expression levels of Slug. The most protein was detected in the papillary carcinoma
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cell lines K1 and BCPAP respectively, with less detected in the BCPAP cell line 
(Figure 27C).
To observe cellular localisation of Slug and a qualitative measure of Slug expression 
immunofluorescence was utilised. For immunofluorescence, cells were grown onto 
glass coverslips, fixed in 4% paraformaldehyde, permeabilised with 0.1% Triton-X 
and probed with a Slug specific antibody. Nuclei were counter-stained using the 
DRAQ5 stain.
Immunofluorescence analysis revealed the Slug to be localised at the nucleus, a 
result consistent with previous studies (Hardy et al. 2007). In addition the signal 
intensity of Slug can be used a qualitative measure of Slug expression. The K1 cell 
line had the greatest signal intensity which indicates an increased expression of Slug 
in this cell line (Figure 28). This work details the expression of Slug in a range of 
thyroid cell lines derived from different pathologies. Slug was detected at basal levels 
in ORI-3 cells, whilst in the PTC cell line K1, Slug was detected at significantly higher 
levels.
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F ig u r e  2 7 . Characterisation of Slug in thyroid cell lines A , qPCR of Slug in thyroid cell lines 
normalised to GAPDH. Total RNA was extracted from each cell line and quantified in 
triplicate. B, Ct values of Slug (blue bars) and GAPDH (red bars) obtained from the qPCR  
analysis. C, Western Blot analysis of Slug in each cell line using a Slug specific antibody. 
Molecular weight markers are highlighted in red. The membrane was stripped and re-probed 
with actin to observe loading.
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Slug Draq5 Merge
Figure 28. Immunofluorescent analysis of Slug expression in cell lines derived from various 
thyroid pathologies. Cells were stained with Slug (red) and counterstained with DRAQ5 
nuclear stain (blue). Scale bar indicates 50pm and is applicable to all images.
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6.3.2 Characterisation of OPN in thyroid cell lines
To assess a possible role of OPN with invasion, OPN expression was assessed in 
the same panel of cell lines used to assess Slug expression. To quantify OPN mRNA 
content, qPCR was used. I extracted total RNA using Trizol from matched samples 
that were used for the ELISA analysis. The qPCR showed a massive increase in 
OPN mRNA in the K1 cells compared with the other cell lines. In ORI-3 cells, OPN 
was undetectable indicating minimal expression of the OPN protein. In the K1 cells 
however, OPN was highly expressed. The other cell lines had basal level expression 
of OPN (Figure 29A).
An OPN ELISA was used to detect OPN protein expression. Cells were grown to 
80% confluence and the conditioned media was collected from the cells after 48 
hours and analysed by a commercially available Enzyme-linked immunosorbent 
assay (ELISA) assay directed towards OPN. The ELISA was conducted in triplicate 
and the absorbance’s averaged. The results correlated with the mRNA content with 
K1 displaying the highest absorbance. This target could potentially regulate invasion 
of K1 cells and further experiments were conducted to elucidate this theory (Figure 
29C).
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Figure 29. Characterisation of Osteopontin in thyroid cell lines. A, qPCR was conducted on 
thyroid cell lines using RNA extracted from each cell line. Quantification was conducted in 
triplicate from a single sample normalised to GAPDH. B. Ct values of OPN (blue bars) and 
GAPDH (red bars) obtained from the qPCR analysis. C, ELISA was conducted on matched 
samples using a commercially available assay system. In triplicate, conditioned media was 
collected from matched samples and analysed with the ELISA assay system. T-test analysis 
was conducted by comparing ORI-3 cells with each of the cell lines at 24 and 48 hours 
respectively. Significant p-values are indicated above the bars together with black stars.
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6.4 The shRNA mediated knockdown of Slug and OPN
Since I had successfully highlighted a link between Slug and OPN expression with 
invasive capability I next sought to investigate if this was the case. To achieve this 
aim I genetically manipulated Slug and OPN expression in the K1 cell line by 
conducting knock-down experiments.
Plasmid glycerol stock targeting Slug was obtained from Sigma-Alrich from their 
MISSION™ shRNA archive. The 293FT cell line was used to generate high-titer Slug 
lentivirus with the use of the ViraPower™ Lentiviral Expression System. 
Subconfluent dishes of K1 cells were infected with lentiviral particles expressing 
shRNA directed towards Slug and OPN respectively. Cells infected with the shRNA 
were puromycin resistant.
Using the K1 lysate as a positive control, western blot analysis detected Slug 
expression in the clones expressing the Slug shRNA. This confirmed the most 
prevalent knockdown of Slug in clone 10 (Figure 30A). Further confirmation of the 
knockdown was conducted using protein lysates, along with ORI-3 (negative control) 
and K1 (positive control). This re-confirmed the knockdown of Slug expression in 
clone 10 (Figure 30B). This clone was selected for future experiments and so was 
named Slug Sh.
Observing mRNA content reconfirmed the western result of Slug knockdown in K1 
cells (Figure 30C).
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Figure 30. Confirmation of shRNA mediated Slug knockdown. A, Confirmation of shRNA 
knockdown of Slug. Western blot of K1 (positive control) and Slug knockdown clones 
observing Slug expression. B, Western blot analysis re-confirming Slug knockdown in K1 
cells with expression of Slug in OPN Sh. ORI-3 (negative control) and K1 (positive control) to 
reconfirm knockdown of Slug in K1 cells with actin as a loading control. C, RT-PCR was 
conducted using Slug specific primers and reverse transcriptase to semi-quantify mRNA 
content of Slug in cell lines. MCF7 and MDAMB231 were used as additional controls.
In parallel to the shRNA knockdown of Slug, OPN expression was also knocked 
down using the same method previously detailed. The system of commercially 
available glycerol stock of shRNA directed towards OPN was obtained and used. 
The ViraPower™ Lentiviral Expression System with the 293FT cell line was used to 
package the lentiviral shRNA into particles. The OPN protein is typically secreted, 
therefore conditioned media was obtained from OPN clones. Briefly, the OPN clones 
were grown to sub-confluence and the conditioned media collected and analysed by 
ELISA. The results show as previously a high level of OPN in K1 cells with basal 
level of OPN in ORI3 cells. All OPN ShRNA clones showed a dramatic reduction of 
OPN, highlighting efficient knockdown of OPN. Any of the clones could be suitable 
for future experiments; however clone 2 was selected (Figure 31A), and was referred 
to as OPN Sh for future experiments. Using conditioned media with an OPN specific 
antibody, western blot analysis revealed a decrease in OPN in clone 2 (Figure 31B). 
Interestingly, the detection of OPN with western blot and ELISA did not correlate with 
each other, but this may be due to the sensitivity of the assays or experimental 
procedures. Since conditioned media was utilised in the western blot, an appropriate 
loading control could not be gained. In ORI-3, MCF7 and MDAMB231 cells there 
was basal level expression (Figure 31C). Observing OPN mRNA content, there are 
clearly 2 dominant OPN isoforms identified. The shRNA targets all the OPN 
isoforms, and this was confirmed as OPN mRNA was not detected in OPN Sh. 
Consistent with both the ELISA and western blot analysis ORI-3 cells displayed little 
or no OPN. The RT-PCR analysis of OPN detected isoforms A and B of OPN, but 
this detection method failed to detect isoform C. The mRNA content in OPN Sh cells 
showed no detectable OPN isoforms (Figure 31C). OPN mRNA was only detectable 
in K1 cells and Slug Sh cells.
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Figure 31. Confirmation of shRNA mediated knockdown of OPN. A, ELISA was conducted 
using a commercially available assay system. Conditioned media was collected from clones, 
with K1 and analysed with the ELISA assay system. Each sample was analysed in triplicate. 
ORI-3 is a negative control, K1 acts as a positive control and remaining samples depict cells 
with knockdown of Osteopontin. T-test analysis was conducted by comparing ORI-3 cells 
with each sample. Only the K1 cell line displayed significance (p=0.004) indicated above the 
bar together with a black star. B, Western blot using conditioned media loaded equally. C, 
RT-PCR was conducted using OPN primers which are able to detect all isoforms of OPN. 
GAPDH acts as a loading control for the PCR experiment. MCF7 and MDAMB231 were 
used as additional controls. ORI-3 was the thyroid negative control and K1 the thyroid 
positive control.
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I next aimed to determine if the knockdown of Slug or OPN affected the invasive 
capability of the K1 cell line. I used the same in vitro invasion assay system with the 
same experimental conditions. The assays like previous were scored at 24 hours 
and 48 hours post invasion, and the results summarised as number of invaded cells 
and percentage invasion.
The K1 cell line at the 48 hour time point displayed the highest degree of invasive 
behaviour and was taken as 100% invasion. The Slug Sh and OPN Sh timepoints 
were calculated as the percentage of invasion by comparing with K1 at 48 hours.
After a period of 48 hours in ORI-3 cells, the invasion assays showed minimal 
invasion with less than 2% of invaded cells detected. In K1 cells, there was 
prominent invasion after 24 hours with 57% invaded cells, with maximum invasion 
after 48 hours. With the Slug Sh sample, there was a dramatic decrease in invasion 
both after 24 hours and 48 hours with 6.5% invaded cells detected after 24 hours 
with an increase to 20% cells after 48 hours. This result provides a link between Slug 
expression and the invasive behaviour of cells (Figure 32).
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Figure 32. The invasive potential of the Slug Sh cell line. Invasion assays displaying A) 
average total invaded cell number and B) percentage of invaded cells. Invasion assays were 
taken after 24 hours (blue) and 48 hours (red) respectively. Each cell line was assayed three 
times in triplicate Boyden chambers. Invaded cells were visualised using GIEMSA stain, and 
5 different fields of view for each were photographed and the average amount of cells 
counted. Values were then converted into percentages and graphically presented. At the 48 
hour time point, 100% total invasion in the K1 cell was assumed. The other samples were 
calculated for percentage invasion from the total invasion of K1. T-test analysis was 
conducted comparing ORI-3 with either K1 or Slug Sh at 24 hours and 48 hours respectively. 
Significance is shown as black stars above the bar with the p-value.
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To establish if OPN expression was linked to invasive behaviour, invasion assays 
were conducted. After a period of 24 hours ORI-3 cells like previous results 
displayed minimal invasion with 6.2% invaded cells detected after 48 hours. In K1 
cells, there was prominent invasion after 24 hours (p=0.003) with 47% invaded cells 
with maximum invasion after 48 hours (p=0.02). The knockdown of OPN had a 
dramatic effect on invasive behaviour as 21% invaded cells were detected after 24 
hours (p=0.001) with 36% after 48 hours (p=0.009). This experimental data, like the 
data of Slug Sh provided an interesting link of OPN regulating the invasive behaviour 
of the papillary carcinoma cell line, K1. (Figure 33).
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Figure 33. The invasive potential of the OPN Sh cell line. Invasion assays displaying A) 
average total invaded cell number and B) percentage of invaded cells. Invasion assays were 
taken after 24 hours (blue) and 48 hours (red) respectively. Each cell line was assayed three 
times in triplicate Boyden chambers. Invaded cells were visualised using GIEMSA stain, and 
5 different fields of view for each were photographed and the average amount of cells 
counted. Values were then converted into percentages and graphically presented. At the 48 
hour time point, 100% total invasion in the K1 cell was assumed. The other samples were 
calculated for percentage invasion from the total invasion of K1. T-test analysis was 
conducted comparing ORI-3 with either K1 or OPN Sh at 24 Hours and 48 hours 
respectively. Significance is shown as black stars above the bar with the p-value.
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6.5 Summary
To study tumour invasion cell lines derived from various thyroid cancers were used 
due to their unlimited proliferative potential and their representation of tumour 
pathology. This work was initially carried out in cell lines with a view to conduct 
experiments on primary models. An in vitro invasion assay system was utilised to 
study the concept of tumour invasion. High serum conditions attenuate the assay 
and induces invasion in non invasive cell lines including ORI-3 and MCF10A (data 
not shown). Therefore, invasion assays were conducted using growth factor reduced 
Matrigel with low serum culture conditions to limit the effect of growth factors and 
stimulants. The reconstituted basement membrane matrix offered a consistent 
representation of the basement membrane for the analysis of tumour invasion.
The thyroid cell lines analysed included the PTC cell lines K1 and BCPAP, which 
carry the BRAFV600E mutation. This mutation is associated with increased 
aggressiveness (Kebebew, Weng et al. 2007). The invasive capability of the K1 cell 
line correlates with the aggressiveness of in vivo tumours. ORI-3 cells are derived 
from normal epithelium and do not show an invasive capability, which is consistent 
with primary tumours. The FTC133 cell line derived from FTC, displayed increased 
invasion, but its metastasis FTC236 displayed a significant increase in invasive 
potential. This would be expected as metastatic cells would phenotypically have a 
higher potential to invade the basement membrane. This also highlights the invasion 
assay was functioning as it should with degrees of invasion displayed by the cell 
lines analysed. The anaplastic cell line, Hth74 displayed a low degree of invasion 
implying an anomalous result, as anaplastic carcinomas are highly invasive and 
aggressive and induce fatality within a year (Sherman 2003). The Hth74 cell line may
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display a high degree of invasive behavior and may have invaded through the 
Matrigel before the 24 hour time point.
I next investigated if either Slug or OPN were involved in regulating an invasive 
phenotype. To achieve this aim, the expression of Slug and OPN was characterised 
across the same panel of cell lines. Both genes had increased expression in the K1 
PTC cell line, recapitulating evidence presented in other studies. Literature analysis 
has previously eluded the potential role of these two genes in PTC. Over expression 
of OPN was demonstrated in primary PTC samples and was involved with the 
invasive phenotype of PTC (Guarino, Faviana et al. 2005). Slug has also been 
highlighted in PTC cell lines (Hardy, Vicente-Duenas et al. 2007).
Taken together, the K1 cell line displayed the highest expression of both Slug and 
OPN together with the highest degree of invasive behavior. The ORI-3 cell line which 
displayed minimal invasion displayed basal level of expression of Slug and OPN. 
This indicates prominent expression of both Slug and OPN may be linked to 
increased invasive ability.
To investigate the role of Slug and OPN in tumour invasion, I chose to genetically 
manipulate gene expression by knocking down expression in the K1 cell line. To 
conduct shRNA-mediated knockdown of I purchased glycerol stocks of shRNA and 
prepared the lentiviral particles to transduce into the K1 cell line. Lentiviral vectors 
were chosen as lentiviruses can target both dividing and non-diving cells. To 
determine effective knock-down, expression of Slug and OPN was re-characterised 
allowing me to select clones displaying reduced expression of Slug and OPN. These 
clones were termed Slug Sh and OPN Sh respectively.
Observing OPN mRNA in OPN Sh by RT-PCR revealed the identification of multiple 
isoforms of OPN. In a separate study of mesothelioma, OPN isoforms were
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assessed for their tumourigenic properties. The OPN gene produces three RNA 
isoforms which encode three protein isoforms. Isoform-A is the full length isoform of 
OPN, isoform-B excluding exon 4 and isoform-C which excludes 3. In mesothelioma, 
isoforms-A and -B were up regulated, whilst isoform C was not. Isoforms-A and -B 
induced tumourigenic phenotypes including proliferation, migration, invasion and 
colony formation (Ivanov, Ivanova et al. 2009). Isoform-C was not detected in the 
RT-PCR analysis, but considering the role of OPN in mesothelioma this isoform can 
be deemed insignificant in terms of its tumourigenic activity.
Interestingly in K1 cells, isoform-A was more abundant in K1 cells, and following 
lenti-viral knockdown of OPN, no isoform of OPN was detected by RT-PCR with 
reduced expression detected by western blot. In Slug Sh, the mRNA content of OPN 
was increased. Currently there is no documented link between Slug and OPN. The 
down-regulation of OPN mRNA in Slug Sh and up-regulated Slug mRNA in OPN Sh 
indicates a possible interaction of Slug and OPN. The results showed an increase of 
mRNA content in Slug Sh compared to K1 cells. This could be due to slight unequal 
loading during the RT-PCR analysis, or it may be caused by a direct regulatory link 
between Slug and OPN which results in the increased expression of OPN. To 
provide evidence for a direct link between Slug and OPN, OPN Sh cells were 
analysed for Slug expression.
To study the effect of reducing expression of Slug and OPN on invasive behavior, I 
conducted invasion assays using K1 as a positive control and ORI-3 cells as the 
negative control. Overall, the invasive behavior was significantly reduced for both 
OPN Sh and Slug Sh. This strongly suggests the expression of Slug and OPN is 
linked to invasive behavior. The K1 cell line displayed increased invasive behavior
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with the ORI-3 cell line displaying minimal invasive behavior. This recapitulates the 
data which was obtained earlier.
191
6.6 Invasive processes mediated by Slug and OPN
After establishing a role for Slug and OPN in thyroid tumour invasion, I sought to 
investigate the cellular mechanisms mediated by Slug and OPN which induce 
invasion.
6.6.1 Proteinase activity mediated by Slug and OPN
Proteinase activity has been highly regarded as mechanism which aids invasive 
behaviour of tumours. To investigate the effect of proteinase activity in thyroid 
tumour invasion and the relation to the expression of Slug and OPN, I conducted RT- 
PCR analysis using specific primers targeting the urokinase plasminogen activator, 
its receptor, MMP-2 and MT1-MMP. In parallel, MTI-MMP protein expression was 
analysed by western blot. To assess MMP activity, gelatin zymogram analysis was 
conducted to observe MMP-2 and MMP-9 pro- and active forms.
The ORI-3 cell line displayed basal level detection of uPA and uPAR. MT1-MMP was 
not detected, whilst MMP-2 was. Since ORI-3 does not display an invasive 
capability, MMP-2 mRNA alone is not sufficient to induce invasion. In the K1 cell line, 
MT1-MMP mRNA content was the highest compared to the other cell lines. The uPA 
receptor was detected considerably more in K1 cells compared with ORI-3 cells. This 
may indicate a potential role of the uPAR in the invasive capability of K1 cells, 
although this would require further investigation to ascertain if this is the case. The 
Slug Sh and OPN Sh cells displayed a comparable mRNA content of uPAR to the K1 
cell line. The mRNA content of uPA was detected at basal levels in both ORI-3 and 
K1 cells, indicating the plasminogen activator system is not applicable in these cells.
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In Slug Sh and OPN Sh the content of uPA was increased compared to K1 cells. 
Since uPA requires the binding to uPAR for plasminogen activation, it implies the 
system does not contribute to the invasive potential, and indicates that in PTC the 
urokinase plasminogen activation system does not have a role in invasion (Figure 
34 A).
Western blot analysis of MT1-MMP expression correlated with mRNA content. The 
K1 cell line displayed the highest degree of expression, with ORI-3 and MCF7 the 
lowest. MT1-MMP expression in the Slug Sh cells was apparently reduced. This 
indicates a potential regulatory mechanism involving MT1-MMP and Slug. MT1-MMP 
protein expression in OPN Sh cells was not significantly altered, although the mRNA 
content of MT1-MMP was reduced (Figure 34B).
The Gelatin zymogram analysis was conducted to observe MMP-2 and MMP-9 
activity using conditioned media collected from samples which were used for the 
western blot analysis. To conduct this assay the zymogram was loaded with 
conditioned media, electrophoresed and stained using coomassie blue. Based upon 
size, the digested areas in the gel represent latent and active forms of MMP-2 and 
MMP-9. For my study, only MMP-2 and MMP-9 pro-enzymes were detected in the 
cell lines, indicating MMP-2 and MMP-9 activity does not contribute to the invasive 
process in Slug or OPN mediated invasion (Figure 34C).
193
MT1-MMP
MMP-2
GAPDH
.1 0 0  k D a  
>75 k D a
'5 0  k D a
.3 7  k D a
MMP-9
pro-enzyme
MMP-2
pro-enzyme
92kDa
72kDa
Figure 34. Analysis of proteinase activity in Slug Sh and OPN Sh. A. RT-PCR using specific 
primers directed to uPAR, uPA, MT1-MMP and MMP-2 with GAPDH as a loading control. B. 
Western blot of MT1-MMP using cell lysates with actin as the loading control. C. Zymogram 
analysis using conditioned media from matched protein samples detecting MMP-2 and 
MMP-9 pro-enzymes only.
6.6.1.1 Summary
Matrix metalloproteinases (MMPs) are a family of zinc-binding end peptidases which 
are known to degrade the majority of components of the ECM, which their 
expression prevalent in malignant tumours. Membrane bound MMPs have a C- 
terminus hydrophobic domain which anchors the MMP to the cell membrane, thereby 
restricting its activity to the cell surface. MT1-MMP acts as a master activator of 
MMP-2, an MMP which degrades type IV collagen in the basement membrane (Sato, 
Takino et al. 1994). In addition, MT1-MMP expression has been shown to correlate 
with tumour growth and angiogenesis via the up-regulation of VEGF in 
adenocarcinoma (Sounni, Devy et al. 2002).
Expression of MT1-MMP was reduced in both the Slug Sh and OPN Sh cells, 
confirmed by RT-PCR and western blot. This indicates that OPN and Slug may 
possibly have a role in the regulation of MT1-MMP. In mesothelioma, expression of 
Slug correlates with the levels of MT1-MMP, MMP-2 and MMP-9 (Sivertsen, Hadar 
et al. 2006). Additionally in lung cancer, Slug mediated an increase in invasion, 
suppression of E-cadherin and regulation of MMP-2 expression and activity. The 
authors failed to analyse MT1-MMP expression (Shih, Tsai et al. 2005). For MMP-2 
to become active, an MT1-MMP dimer is required. In my investigation, Slug Sh 
showed a reduction of MT1-MMP. Preliminary zymogram analysis did not reveal 
active forms of MMP-2 or MMP-9 in K1 cells, indicating that these cell lines do not 
possess an active MMP-2 or MMP-9 enzyme. The lack of these enzymes in K1 
indicates that MMP-2 and MMP-9 do not have a role in invasion. However, this 
assay was only conducted once and so a repeat experiment is required. In addition, 
the experimental conditions may require further optimisation to observe active MMP- 
2 and MMP-9 enzymes.
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The evidence presented indicates the reduction in MT1-MMP expression in Slug Sh 
cells which may imply a regulatory mechanism involving Slug and MT1-MMP, and 
this may in part explain why Slug Sh cells have a reduced invasive capacity.
In mammary cancer cells, OPN is able to confer an invasive phenotype by up- 
regulating MMP-2 and uPA (Mi, Guo et al. 2006). In addition, in murine melanoma 
cells, OPN induced MT1-MMP expression and activation of pro-MMP-2 (Philip, 
Bulbule et al. 2001). MT1-MMP down-regulation in OPN Sh confirmed a role of OPN 
in the induction of MT1-MMP expression.
Taken together it appears that MT1-MMP is directly regulated by Slug and OPN. In 
migrating cells MT1-MMP is re-localised to the lamellipodia and invadopodia 
(Nakahara, Howard et al. 1997; Mori, Tomari et al. 2002). This displays the dynamic 
regulation of MT1-MMP which can occur during cell invasion and migration. It is 
unclear if this occurs in K1 cells, and requires further investigation. MT1-MMP is 
able to interact with a wide range of proteins including ECM components, CD44 and 
av integrins (Gingras and Beliveau. 2010). Since CD44 and av integrins are ligands 
for OPN, the downregulation of MT1-MMP in OPN Sh may influence the binding of 
CD44 and av integrins to OPN. For OPN-mediated invasion, CD44 and/or av integrin 
interaction with MT1-MMP may be a pre-requisite for OPN mediated-cell invasion. 
The down-regulation of MT1-MMP in both Slug Sh and OPN Sh may be influence 
the production of VEGF. MT1-MMP is known to up-regulate VEGF production 
(Sounni, Devy et al. 2002). VEGF is a pro-angiogenic factor when upregulation is 
associated with enhanced tumour growth, and invasion in thyroid cancer (Lin and 
Chao 2005).
The urokinase activator system has a prominent role in tumour progression. The 
mRNA content was unaltered in Slug Sh and OPN Sh, which indicates that both
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OPN and Slug do not regulate the uPAR mRNA levels. Reduced uPAR would result 
in a decrease of uPA activation, since the binding of uPA to the receptor is required. 
The mRNA content of uPA was increased in Slug Sh and OPN Sh compared with K1 
cells. As Slug Sh and OPN Sh displayed a reduction in invasive behaviour, the 
increase in uPA mRNA does not have impact on invasion.
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6.6.2 Cell migration
6.6.2.1 Analysis of the actin cytoskeleton during cell migration
Cell motility is a complex and an integral process for invasion requiring the cell to 
regulate cell-cell adhesion, cell-matrix adhesion and regulation of the cell 
cytoskeleton. Forward motility requires the formation of actin membrane protrusions 
coupled with regulation of cell adhesion and retraction from the rear of the cell. Cells 
move by rearranging the actin cytoskeleton with regulation of cell-matrix interactions 
to mediate the processes of cell migration and motility.
To investigate cell motility and the role of Slug and OPN in mediating this process I 
conducted an immunofluorescence time course experiment. This involved growing 
cells to confluence on coverslips and creating a ‘wound’ in the monolayer of cells. At 
each indicated timepoint the cells were fixed and stained for F-actin and DAPI by 
immunofluorescence. This experiment effectively observed wound closure and the 
distribution of filamentous actin in cells at the leading edge of the wound.
The K1 cells displayed accelerated wound closure at -12 hours. Both Slug Sh and 
OPN Sh closed the wound at -24 hours. At the 4 hour time point, K1 cells have a 
concentration of F-actin at the leading edge of the wound (Figure 35, red arrows).
Observing actin at each time point revealed the cell size of OPN Sh at the leading 
edge appeared more expanded compared to K1. For all the samples, actin appeared 
to be concentrated at the cell membrane.
The cells at the leading edge of OPN Sh displayed an interesting result in that the 
staining for actin was decreased, highlighting a lack of F-actin stress fibres (Figure 
35, white arrows). This is an indication of actin cytoskeleton impairment. In addition,
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as the wound closes in OPN Sh, the cell body at the leading edge increase in size. 
This is evident at the 8 hour time point. The cell body of both K1 and Slug Sh at the 
leading edge did not increase in size like OPN Sh (Figure 35).
This experiment essentially observed cell motility at selected time points. To expand 
on this, I conducted time-lapse analysis to observe cell motility over a period of time 
and not just at selected time points, thereby providing further details of possible 
mechanisms which regulate invasion.
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Figure. 35. Immunofluorescent timecourse observing wound closure with F-actin staining. Cells were grown to confluence on coverslips, 
wounded and after 3 hours fixed and stained at selected time points for F-actin (green) with DAPI to observe the nucleus (blue). Red arrows 
indicate concentration of actin. White arrows indicate the enlargement of cells and lack of actin stress fibres. Scale bar is equal to 50pm, and is 
applicable to all the images.
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6.6.2.2 Analysis of cell motility
An integral requirement for transformed tumour cells to invade through the basement 
membrane and metastasis, not only relies upon adhesion dynamics but also a motile 
phenotype. The time-lapse capture of tumour cells allows for the analysis of cell 
movement, motility together with interactions between cells and the cell-substrate 
contact on a 2-dimensional substrate. To conduct time-lapse analysis, K1, Slug Sh 
and OPN Sh were used. The time-lapse is useful to study the effect of knocking 
down expression of Slug and OPN on cell migration, motility and interactions 
between cells and with the substrate, all of which have never been studied in this 
manner before.
The time-lapse study was conducted by capturing images of three fields from each 
cell line every 15 minutes for a period of 48 hours. The cells were plated at a low 
confluency to account for cell density effects which can attenuate cell 
migration/motility.
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6.6.2.2.1 The effect of Slug and OPN down-regulation on cell growth
The time-lapse camera was used to collect images every 5 hours. The cell number 
was determined for each image and the data graphically shown. The increase in cell 
number over time provided an indication of cell proliferation for K1, Slug Sh and OPN 
Sh. From the analysis, K1 cells displayed the greatest rate of cell number over time 
totalling -550 cells over 48 hours, a result which was expectant of a tumour cell line 
with high invasive capability. The Slug Sh cells had a decreased growth rate at -410 
cells over 48 hours. OPN Sh was further decreased with an even slower growth rate 
at -370 cells (Figure 36). These results recapitulate the in vitro observations.
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Figure 36. Growth curve to measure the number of K1, Slug Sh and OPN Sh cells every 5 
hours. The total number of cells on each field was counted every 5 hours and the data 
averaged to obtain an average cell number per cell line (K1;blue, Slug Sh;red, OPN 
Sh;green).
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Details regarding cell cycle can also be determined using time-lapse, where the time 
taken between cell division is defined as the ‘inter-mitotic time’ (IMT). The ‘inter- 
mitotic distance’ (IMD) is defined as the total distance travelled in the time between 
cell division. The inter-mitotic times and distances were defined from a total of 15 
cells per cell lines which were tracked using the Metamorph software suite 
(Molecular devices; http://www.moleculardevices.com). which generated up to 3 
generations. Cells which could not be tracked in 48 hours were subsequently 
removed from the analysis.
For every inter-mitotic time track, the corresponding average distance travelled by 
the cell was determined, and the data graphically summarised by plotting the inter- 
mitotic times against inter-mitotic distances (Figure 37). This effectively provided a 
distribution of cell division and distance travelled.
From the results, the K1 cells travelled the greatest distance with a heterogeneous 
distributed pattern across 3 generations. Interestingly, only the K1 cells had 
complete tracks in the 3rd generation indicating a faster inter-mitotic time compared 
to both Slug Sh and OPN Sh. Although Slug Sh contained outliers, the overall 
distribution of the tracks is indicative of a longer mitotic time with a shorter distance 
travelled. OPN Sh showed the greatest homogeneous distribution compared with K1 
cells with distance limited to 125pm, with an inter-mitotic time comparable to Slug 
Sh.
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Figure 37. Inter-mitotic time Vs. inter-mitotic distance for each complete generation of K1, 
Slug Sh and OPN Sh cells. Blue diamonds correspond to the 1st generation of cells, Red 
triangles correspond to 2nd generation cells and green squares refer to the 3rd generation 
cells. K1, Slug Sh and OPN Sh are represented as individual graphs.
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6.6.2.2.2 Random walk analysis
The movement or motility of cells on a 2D surface can be characterized through 
random walk analysis, allowing the various distribution patterns (both temporal and 
spatial) to be mathematically recast. This type of analysis is particularly suited to 
cellular tracking for both (un)perturbed systems and can inform numerically and 
analytically assign well-known statistical measures to the individual or population 
(Selmeczi et al. 2005). In this study, we employ only a few statistical measures to 
quantify population movement of the differing cell-lines, namely, the asphericity a 
parameter derived from the radius of gyration tensor and the diffusion coefficient 
(motility) determined from numerical fitting of the averaged mean square traverse of 
the population as a function of time (Codling et al. 2008). This particular analysis was 
conducted by Dr. Martyn Brown, who used the MATLAB programming suite 
(http ://www. math works .co.uk) to conduct this analysis.
Below, is a brief overview describing how these statistical measures are extracted 
from the time-lapse data files. From the tracking datasets the X and Y coordinates of 
individual cells were recorded at each sampling point over the time-course of the 
experiment. These values were averaged to form the following covariance matrix:
r
T =
\
(x2)-{xY iw)~(x)(y) W-m (y2)-(yY.
here the angular brackets, ( ), refer to an ensemble average.
The matrix in (1) is next diagonalised to reveal the magnitude of the square of the 
two characteristic orthogonal eigenvalues, Ri. These values are then comparable to 
the major and minor axis of an ellipse that describing the average movement of the
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cellular population. This analysis thus far gives an overall extent of the random walk 
but does not account for the shape. The Asphericity parameter, A2, is combination of 
the derived eigenvalues of the covariance matrix, given by the expression:
Here, d refers to the spatial dimension considered, two in this planar study.
The value of A2 is bounded to the unit interval [0 1]. For a walk which is spherical, 
the value is 0. For walks which are highly asymmetric, i.e. the R1 »  R2, A2 tends to 
unity. Therefore, the magnitude of A2 can give a direct quantitative value for the 
averaged cellular traverse as a function of time, i.e. generation.
The lesser the value of asphericity is an indication of increased movement from the 
cells. This is an indicative result due the overlap of the cell tracks at the starting point 
of 0pm. Individual tracks cannot be sufficiently resolved; therefore the asphericity 
value cannot be taken as absolute, but merely as an indication of movement. In the 
1st generation Slug Sh cells surprisingly had the lowest asphericity value which can 
be visually observed by the extent of the random walk, and this walk is also 
comparable to the K1 cells. Most interestingly, the OPN Sh cells displayed a highly 
spherical random walk signified visually by the walk centred on 0pm with an 
asphericity value of 0.788. The 2nd generation is particularly interesting as in general 
all the cells displayed a spherical random walk compared with the 1st generation. 
The K1 cells had an asphericity value of 0.691, which is highly comparable to Slug 
Sh cells with a value of 0.651. The OPN Sh cells did not alter their respective 
random walk pattern with increased asphericity of 0.837. In the 3rd generation 
asphericity was not significantly altered with K1 slightly increasing in asphericity to
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0.720 by both Slug Sh and OPN Sh decreasing in asphericity, however visually the 
random walk seems less random-like (Figure 38).
6.6.2.2.3 Analysis of velocity during cell migration
The velocity of the cell can be used as a measure of cell movement, where a slower 
velocity would equate to less movement, and increased velocity with increased 
motility. To investigate and analyse cellular velocity, the Metamorph suite collects 
velocity values during the tracking of cells. The same cells which were tracked for 
their inter-mitotic times, distance and their random walk were analysed for their 
average velocity across each generation. Analysis of each generation was 
conducted separately to investigate the effect of cell proliferation on cell movement. 
Incomplete tracks were defined as cells which migrated from the field of view. These 
incomplete tracks were included in this particular analysis.
The results show K1 to be the quickest. Following the pattern of random walk and 
inter-mitotic distance, Slug Sh displayed decreased velocity with OPN Sh even more 
so. After the 1st generation all the cells had a decreased velocity which may be 
attributed to cellular proliferation, and lack of space for the cell to move into. Overall 
the 2nd generation velocity decreased compared with the 1st generation. The average 
velocities of K1 and Slug Sh in the 2nd generation closely followed each other at a 
velocity of 10 pm/hour at 6 hours, whilst OPN Sh remained the slowest at 10 
pm/hour. Surprisingly in the 3rd generation, Slug Sh cells had the most velocity, with 
an exponential increase in the space of 2 hours at the end point of analysis (Figure 
39).
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Figure 38. Generational Random Walk analysis for K1, Slug Sh and OPN Sh. A measure of 
the asphericity of the random walk is defined by the value given in each panel. The closer 
the value to 0 indicates a spherical random walk, indicating less movement of the cells. A 
value closer to 1 indicates more movement.
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Figure 39. Preliminary experiment displaying the average velocity for each generation of K1, 
Slug Sh and OPN Sh cells. Each graph represents each generation of 15 cells. Dashed lines 
represent actual values, whilst solid lines represent average values. K1 is highlighted by 
blue, Slug Sh as red and OPN Sh as black.
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6.6.2.3 Summary
Cell motility, an inherent quality of invasion was investigated by time-lapse 
microscopy. This method is useful in investigating altogether proliferation; cell-cell 
interactions, cell-substrate interactions and how the cells move across a 2D 
substrate. By tracking cells from K1, Slug Sh and OPN Sh vital statistics including 
position, time and speed were determined. Simply determining the amount of cells at 
each time point effectively determined the cellular growth. Since invasive capability is 
impaired in both Slug Sh and OPN Sh, an expectant result would be an overall affect 
on motility. From this investigation, over time, Slug Sh had a decreased cell number 
with OPN Sh having a further decrease in cell number compared to the PTC cell line, 
K1. The attenuated cellular growth may be a phenotypic alteration which ultimately 
affects invasive capability. Although the cellular context is different, in human 
gliomas Slug was shown to promote cell growth and invasion (Yang et al. 2010). 
Here, knockdown of Slug decreased cell growth, and is consistent with Yang et al. 
The mechanism of how cell growth is affected by Slug requires further investigation. 
OPN Sh displayed a significant decrease in cell number/time, and this finding 
correlates with other studies, where OPN overexpression is linked to cell growth and 
tumour invasion (Philip et al. 2001).
Tracking individual cell lineages of K1, Slug Sh and OPN Sh cells allowed the 
movement and inter-mitotic times to be investigated. This analysis revealed 
phenotypical alterations which the Slug Sh or OPN Sh induce. The distance Vs. time 
analysis revealed a wide distribution in K1 cells. For Slug Sh cells, the distance 
travelled was decreased and there was a further decrease in movement for OPN Sh 
cells. K1 cells had the fastest inter-mitotic time with the greatest degree of
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movement. Slug displayed a decreased inter-mitotic time with a lower degree of 
distribution of movement/time. OPN knockdown displayed the greatest alteration with 
a severely restricted movement. Linking with the invasive capacity of the knockdown 
clones, there is a reduction of movement. The process of movement is integral to 
invasion, without it cells would not display an invasive capability. This work provided 
evidence of phenotypic alterations to cell migration and this correlates with the 
reduction of invasion. Further investigation of individual generations by random walk 
analysis provided a visual representation of movement. Over the entire time course 
when cells proliferate, the free space available for cells to move becomes restricted. 
This means the results from generation 2 onwards are skewed as free space is a 
limiting variable which is inherent to the experiment. Observation of the 1st 
generation alone provides an experiment devoid from this limiting variable. The 
determination of asphericity is in itself not an absolutely accurate method. This 
method does not have a high degree of resolution where cell tracks overlap each 
other, which therefore affect the asphericity values. The effect of proliferation is also 
evidenced by the data pertaining to average velocity. As cells divide the free space 
to move becomes less, and so less movement correlates with reduced velocity. 
Interestingly OPN Sh displayed the most reduced velocity even though space and 
proliferation in the 1st generation was not a factor affecting velocity. Analysing the 1st, 
2nd and 3rd generation individually allows cell proliferation and cell density to be 
analysed across each generation and how this impacts cell movement and motility.
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6.7 Epithelial Mesenchymal Transition
The process of EMT is prominent in tumour invasion. Tumour cells utilise EMT to 
further their progression in invasion, metastasis and survival. EMT brings about a 
change in cellular morphology to allow cells to have a migratory phenotype. 
Alteration of an epithelial cell to have mesenchymal properties requires 
morphological, architecture, adhesion and migratory changes. Normal epithelial cells 
form a tight monolayer and their movement is restricted and provide tissues with 
mechanical rigidity. The presence of cell-cell junctions and adhesive molecules holds 
the cells tightly together and inhibits the movement of individual cells. In contrast, 
mesenchymal cells do not possess the junctions and adhesive properties like 
epithelial cells, but their adhesive properties are less strong allowing for greater 
motile capacity. They form structures which are irregular in shape and not uniform in 
structure or density. The morphology of mesenchymal cells is irregular as they 
possess leading edge polarity (Chambers et al. 2002; Hugo et al. 2007). The 
alteration from epithelial to mesenchymal cells defines an essential dynamic process 
for tumour progression. An EMT transition involves a change in the adhesive 
qualities of the cell, remodelling of the cytoskeleton, and proteolytic degradation of 
the extracellular matrix.
In my investigation I aimed to study if reversal of EMT occurs in Slug Sh and OPN 
Sh. We hypothesised that down-regulation of Slug and OPN would convey an 
increased epithelial phenotype in terms of cell motility, cell-cell adhesions and cell- 
matrix adhesions. This in effect would provide reasoning as to why invasive 
capability was reduced in Slug Sh and OPN Sh.
213
6.7.1 WAVE and N-WASP in actin-based cell movement
The actin filament system regulates cell movement. The WASP family of proteins 
including N-WASP and WAVE1 activate the Arp2/3 complex which mediates the 
formation of lamellipodia and filopodia. Formation of lamellipodia and filopodia are 
integral for cell movement. Signalling upstream to WAVE1 and N-WASP are the 
small GTPases Rho, Rac and cdc42.
To investigate if this system of actin protrusion formation is affected by the knock­
down of Slug and OPN, I immunofluorescently stained cells for WAVE1 and N- 
WASP. Cells were grown to confluence and wounded. After 3 hours the cells were 
fixed and probed for WAVE1 and N-WASP using immunofluorescence. This enabled 
me to visualise the localisation of these proteins.
WAVE1 expression was localised in the nucleus and cytoplasm in ORI-3 cells but at 
basal levels. In K1 cells, there is a significant increase in signal intensity. Perinuclear 
staining of WAVE1 was demonstrated in Slug Sh cells. Interestingly OPN Sh cells 
have an intense nuclear and perinuclear staining of WAVE1. However this may be 
non-specific artefacts (Figure 40). The N-WASP protein in both the Slug Sh and 
OPN Sh cells displayed reduced signal intensity in comparison to K1 cells (Figure 
41). The localisation of WAVE1 and N-WASP is important as expression at the 
leading edge of cells would indicate a role in lamellipodia and filopodia mediated cell 
movement.
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Actin WAVE1 Merge
Figure 40. Immunofluorescent analysis of F-actin and WAVE1 expression in Slug Sh and 
OPN Sh cells. Cells were stained with F-actin (green) and co-immunostained with WAVE1 
(red) followed with counterstaining with DAPI nuclear stain (blue). Fluorescence was 
observed with a fluorescent microscope. Scale bar is equal to 50pm, and is applicable to all 
the images.
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Actin N-WASP Merge
Figure 41. Immunofluorescent analysis of F-actin and N-WASP expression in Slug Sh and 
OPN Sh cells. Cells were stained with F-actin (green) and co-immunostained with N-WASP 
(red) followed with counterstaining with DAPI nuclear stain (blue). Fluorescence was 
observed with a fluorescent microscope. Scale bar is equal to 50pm, and is applicable to all 
the images.
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6.7.2 Summary
The actin network and the formation of actin-based protrusions are important for cell 
migration as they regulate the forward thrust required for cell movement along with 
the dynamic regulation of cell contacts. The lamellipodia and filopodia are types of 
membrane protrusions which generate forward thrust facilitating cell movement. 
Movement involves a process where actin filaments polymerise at the leading edge 
and depolarise at the rear resulting in a forward motion. Central to the formation of 
these protrusions are the Rho family of GTPases, Rho, Rac and cdc42. Both cdc42 
and Rac regulate the leading edge of the cell by inducing the formation of membrane 
protrusions including filopodia lamellipodia. Rho regulates the rear of the cell by 
stimulating the formation of stress fibers, inducing actin-mediated cell contraction 
(Wu et al. 2004). The formation of new actin filaments produces an actin filament 
network which pushes the plasma membrane forward.
It appears OPN Sh have an impaired actin network in terms of movement. Since Rho 
functions to formulate stress fibres, the evidence presented in this section implies 
Rho activity is impaired in OPN Sh. In OPN Sh, Rac and cdc42 are functional, 
promoting forward movement at the leading edge of the cell. Impaired Rho activity 
would perhaps result in reduced formation of actin stress fibres, increased cell 
attachment to the substrate at the rear of the cell, and reduced contractile movement 
at the rear of cell. Indeed in this thesis, lack of stress fibres has been observed in 
OPN Sh. To observe if this is the case conducting a Rho activity assay is a crucial 
experiment. I attempted this experiment by growing K1, Slug Sh and OPN Sh cells to 
maximum confluency in tissue culture flasks. I next ‘wounded’ the cell monolayer by 
scratching with a pipette tip and this was left to incubate for 30 minutes. I harvested 
each cell line by scraping and used the Rho binding domain (RBD) of the Rho
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effector protein, Rhotekin to determine RhoA activity. The RBD motif has been 
shown to bind specifically to the GTP-bound form of RhoA which results in a 
significantly reduced intrinsic and catalytic rate of GTP hydrolysis. Using a GST 
fusion protein containing the Rhotekin residues 7-89 allowed the "pull-down" the 
Rhotekin-RBD/Rho-GTP complex with glutathione affinity beads. The amount of 
activated RhoA is determined by a western blot using a RhoA specific antibody. I 
could not determine RhoA activity, and my method requires further optimisation for 
Rho activity to be determined.
Functioning downstream of Rac and cdc42 are WAVE1 and N-WASP. WAVE1 is 
specifically activated by cdc42. WAVE stabilises the interactions of the lamellipodium 
to the substrate (Yamazaki et al. 2005). WAVE 1-deficient cells result in an increase 
in extension speed and lamellipodia, with a decrease in the cell-matrix interactions at 
the lamellipodium.
Immunofluorescent analysis of WAVE1 could only be used as a qualitative measure 
of activity it implies the upstream activator of WAVE1, cdc42 is impaired. However, 
further investigations are required to determine if this is the case. If WAVE1 is in fact 
impaired then the adhesive contacts which formed at the lamellipodium would be 
reduced, restricting the migratory ability of the cells.
N-WASP is specifically activated by cdc42. Although a quantitative measure, 
immunofluorescent staining of N-WASP revealed a strong signal in ORI-3 and K1 
cells. Interestingly, both the Slug Sh and OPN Sh cells displayed a diffuse signal. 
This indicates that the activation of the Arp2/3 by N-WASP would be decreased, and 
the formation of lamellipodia and filopodia impaired.
Functioning downstream to WAVE1 and N-WASP is the Arp2/3 complex (Welch 
1999). The Arp2/3 complex localises to the leading edge of cells, and inhibition of
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Arp2/3 leads to attenuation of lamellipodia formation (Goley and Welch 2006). 
Therefore, impairment of the upstream elements WAVE1 and N-WASP would result 
in decreased Arp2/3 activity, attenuating lamellipodia formation.
Taken together, the N-WASP low signal intensity implies a possible impairment of 
the actin machinery regulating the leading edge of the cell. In this thesis I sought to 
address this by observing focal adhesion assembly at the leading edge.
6.8 The role of HGF in Slug and OPN-mediated cell migration
I next investigated the role of HGF in cell invasion using scratch wound analysis with 
time-lapse capture. HGF stimulation is known to induce OPN expression, and is a 
contributing factor of tumour growth and metastasis (Ariztia et al. 2003).
To investigate this hypothesis, cells were grown to confluence and a wound inflicted 
in the monolayer with a p200 pipette tip. The closure of the wound was captured by 
time-lapse analysis. This directed wound closure experiment was analysed with and 
without the addition of HGF at a concentration of 1pg/mL in the culture medium. This 
effectively allowed me to determine if HGF has a role in invasion, and if this role is 
mediated by Slug or OPN.
Using the same experimental conditions, the time-lapse capture K1, Slug Sh and 
OPN Sh cells was conducted and analysed for capacity of the cells to close the 
inflicted wound over a period of 48 hours. The IMT, IMD and average velocity 
measurements were collected by tracking cells every 15 minutes using the 
Metamorph software suite. However, in this instance only the 1st generation could be
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analysed since all cells failed to complete a 2nd generation in the given time frame of 
48 hours.
In the K1 cell line the effect of HGF is apparent. Without HGF treatment average IMT 
for the tracked cells was clustered at 27 hours and at an IMD of 75pm. The addition 
of HGF resulted in a more heterogeneous pattern with an increase in inter-mitotic 
time and distance. The Slug Sh displayed a minimal change in IMD with HGF 
treatment. However, the IMT was increased from 20 hours to 27 hours following 
HGF treatment. For OPN Sh cells without HGF treatment, the IMT was clustered at 
~20 hours. Following treatment with HGF, the IMT increased to ~32 hours, however, 
the distance travelled did not increase (Figure 42). The average velocity of K1 cells 
after HGF treatment increased, whilst both Slug Sh and OPN Sh displayed a 
decrease in velocity following HGF treatment (Figure 43). This velocity data does not 
correlate with the previous results (Figure 39), where Slug Sh and OPN Sh had 
reduced velocity compared to K1 cells. This may be due to conducting the HGF- 
induced migration in a scratch wound assay. In addition, differences within the cells 
may be more difficult to visualise in this setting.
Taken together, this indicates a probable role of HGF in Slug and OPN mediated 
invasion, since the knockdown of Slug and OPN did not alter IMD or velocity like K1 
after HGF treatment. To further this investigation, I sought to analyse the mRNA 
content of CD44v, and surface localisation of CD44 as CD44 has a documented role 
in HGF mediated invasion (Ariztia et al. 2003).
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Figure 42. Preliminary experiment displaying Inter-mitotic time Vs. inter-mitotic distance for 
K1, Slug Sh and OPN Sh cells in a wound closure experiment. Cells were treated with and 
without HGF. Cells were tracked for 1 complete generation, with the IMD and IMT 
calculated. Blue diamonds correspond to cells with HGF treatment and red squares 
correspond to cells without HGF treatment. K1, Slug Sh and OPN Sh are represented as 
individual graphs.
221
0.3
o 0.05
l With HGF 
i W ithout HGF
K1 Slug Sh OPN Sh
F ig u r e  4 3 . Average velocity for the 1st generation of K1, Slug Sh and OPN Sh cells in a 
wound closure experiment. Cells were treated with HGF (1pg/mL) and without HGF. Blue 
bars correspond to cells with HGF treatment and red bars correspond to cells without HGF 
treatment.
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6.8.1 Assessment of CD44v and the implication for HGF-mediated invasion
Overexpression of OPN induces an increased migratory phenotype in epithelial cells, 
with the cMet-hepatocyte growth factor (HGF) system playing an integral role. The 
Met tyrosine kinase receptor is predominantly expressed on epithelial and 
endothelial cells, its ligand HGF is produced by motile mesenchymal cells. The 
interaction leads to a metastatic-invasive phenotype promoting EMT (Ariztia et al. 
2003). HGF, in vitro is a potent stimulus for cell growth, motility and morphogenesis 
(Birchmeier and Gherardi 1998). OPN is a transcriptional target of HGF and CD44v 
can bind OPN with cooperation from p1 integrins to mediate HGF-mediated tumour 
invasion and metastasis (Orian-Rousseau et al. 2002). From the directed cell motility 
analysis there is an implication role for Slug and OPN in HGF-mediated cell 
migration.
To investigate the role of CD44v in HGF mediated invasion, the mRNA content of 
CD44 isoforms was determined by RT-PCR. The isoforms analysed included CD44s, 
CD44v6, CD44v7 and CD44v10. To do this I extracted total RNA from sub-confluent 
dishes and using the process of RT-PCR. Specific fragments of CD44 standard 
(CD44S), CD44v6, v7 and v10 were amplified with specific primers. MCF7 acted as 
a negative control for the experiment, whilst ORI-3 acted as a normal thyroid 
epithelium negative control. CD44s expression was highlighted in all cell lines, but 
only the negative controls, MCF7 and ORI-3 displayed decreased mRNA content. 
The other cell lines displayed equal amounts of the CD44S mRNA. There is clear 
increased expression of CD44v6, v7 and v10 mRNA in K1 cells. This indicates a 
potential role of CD44 variants in invasive ability and tumour progression in this cell 
line and therefore papillary carcinoma. In Slug Sh and OPN Sh a reduction of CD44 
variant mRNA is observed (Figure 44).
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Observing CD44 surface expression with immunofluorescent analysis, the results 
show continuous localisation at the leading edge in OPN Sh. Cells at the leading 
edge of Slug Sh displayed no specific CD44 localisation. In ORI-3 cells, the surface 
expression of CD44 was punctate, with no localisation at the leading edge. K1 cells 
displayed a similar CD44 localisation to ORI-3 cells, however, with a more diffuse 
surface expression (Figure 45). This indicates a possible OPN-CD44 role in 
regulating motile/invasive behaviour.
CD44S
CD44v6
CD44v7
CD44v10
GAPDH
/V W  & 4
F ig u re  4 4 . Analysis of CD44 variants in Slug Sh and OPN Sh cells. RT-PCR was conducted 
using specific primers directed towards individual isoforms of CD44S, CD44v6, CD44v7 and 
CD44v10 in 3 independent experiments. GAPDH was utilised as a loading control. MCF7 
and ORI-3 cells acted as negative controls and MDAMB231 and K1 cells as positive 
controls.
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Actin CD44 200%
Figure 45. Surface expression of CD44 (all isoforms) in Slug Sh and OPN Sh cells. Cells 
were grown to confluence on coverslips wounded for 3 hours and fixed with 
paraformaldehyde. Cells were stained with F-actin (green), CD44 (red) and counterstained 
with DAPI nuclear stain (blue). Cells were non-permeabilised to visualise surface expression 
of CD44. Fluorescence was observed with a fluorescent microscope. Images are presented 
as F-actin, CD44 merged with DAPI for each cell line analysed. Areas were selected 
(signified by white squares) and enlarged by 200% to provide further intricate detail. Scale 
bars are equal to 50pm, and each scale bar is applicable to its column.
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6.8.2 Summary
One of the mechanisms in which OPN confers a migratory phenotype in tumour cells 
is through the cMet-HGF system. OPN is prominent in HGF-dependent 
tumourigenesis, and inhibition of OPN expression attenuates the HGF-invasiveness 
demonstrated in vitro and in vivo (Medico et al. 2001; Ariztia et al. 2003). It appears 
that both OPN and Slug have roles in HGF-mediated invasion. With HGF treatment 
there was an increase in inter-mitotic time, however, there was no increase in 
distance travelled. This means the expression of Slug and OPN is important for HGF 
mediated invasion.
To investigate this further I assessed the status of CD44v. CD44v are able to amplify 
HGF induced invasion (Smith et al. 1999). OPN can interact with CD44v in 
conjunction with (31 integrins to induce receptor pair clustering (van der Voort et al. 
1999). The CD44v6, CD44v7 and CD44v10 have been shown to bind to OPN to 
enhance the migratory phenotype of rat fibrosarcoma cells (Katagiri et al. 1999).
Observing CD44s mRNA revealed no alteration in Slug Sh and OPN Sh. This means 
this isoform is not regulated by either Slug or OPN and has no role in PTC tumour 
invasion. However, the mRNA content of CD44v6, CD44v7 and CD44v10 were 
possibly decreased in both Slug Sh and OPN Sh. This implies there is direct 
regulation by Slug and OPN. Based on literature, this evidence links with the HGF 
treatment since HGF-mediated invasion may occur via CD44v signalling. Down- 
regulation of Slug and OPN directly regulates CD44v which impairs HGF-mediated 
invasion.
A functional interaction between CD44v and Slug was established in a manner that 
is dependent on CD44v and partially dependent on NFkB and Slug to induce cell
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invasion, stimulates by high molecular weight hyaloronic acid, the natural ligand for 
CD44 (Craig et al. 2009). This is the only study to correlate CD44 and Slug with 
invasion. Consistent with the evidence presented here, this interaction depends on 
variant isoforms of CD44, and not CD44s.
Since HGF-mediated invasion by OPN requires CD44v and p1 integrins, the down- 
regulation of CD44v mRNA would mean that p i integrins are not sufficient to induce 
HGF-mediated invasion.
Observation of endogenous CD44 by immunofluorescence indicated role of OPN in 
regulating CD44 surface expression. In melanoma, OPN expression increases CD44 
surface expression together with MMP-2 secretion (Samanna et al. 2006). A change 
in surface expression of CD44 in OPN Sh implies a role of OPN mediating CD44 
localisation. This may relate to an invasive mechanism regulated by OPN. It would 
be interesting to observe surface expression of specific CD44v on the cell surface 
and possible co-localisation with pi integrins. These investigations will elucidate the 
interacting role of OPN and CD44v in HGF stimulated invasion.
Since OPN Sh has an impaired migratory ability, I sought to investigate the formation 
of focal adhesions during migration. Focal adhesions are essential to the movement 
of the cell, the dynamic regulation of adhesions is integral to cell migration and 
invasive behaviour.
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6.9 Analysis of focal adhesion formation during cell migration
In addition to cell-cell interactions, cell-matrix interactions also have a prominent role 
in EMT. The cell matrix interactions are important for mediating the protractive force 
required for cellular movement (Harburger and Calderwood 2009). This is conducted 
through cell-matrix interactions which form, disassemble or mature at the leading 
edge of the cell and disassemble at the rear of the cell. The adaptor protein vinculin 
is expressed at focal adhesions (Harburger and Calderwood 2009). The amount and 
size of focal adhesions is an indication of the motile state of cells, where smaller a 
fewer adhesions are present on more motile cells.
6.9.1 Analysis of Vinculin and Cortactin
I aimed to assess the localisation of focal adhesions by conferring a migratory 
phenotype. The localisation and size of the focal contacts are important when 
considering motile behaviour. The analysis of focal contacts in Slug Sh and OPN Sh 
may elucidate the mechanism which regulates the reduction in invasive behaviour.
Cells were grown to confluency on coverslips and wounded. After 3 hours 
incubation, cells were fixed and immunofluorescently stained with specific 
antibodies. To observe focal adhesions, cells were co-immunostained for vinculin, an 
adaptor protein present at focal adhesions, along with phosphorylated-cortactin 
observe the focal adhesions at the leading edge. Cortactin functions at the focal 
adhesive sites at the leading edge following the formation of lamellipodia. 
Immunofluorescent staining of vinculin in ORI-3 cells showed distinct focal adhesive 
sites distinguished by the intense green signal. These sites are pronounced and
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substantial with a particular localisation at the leading edge of cells, whilst in K1 cells 
the vinculin staining is punctate, which may indicate smaller focal adhesions. In 
addition, the staining of vinculin is prominent at the leading edge of the wound. Slug 
Sh cells have a slight increase in the size of focal adhesion as indicated by the 
staining of vinculin, but remain localised around the leading edge of the cells. OPN 
Sh cells follow a different pattern with large focal adhesions reminiscent of ORI-3 
cells. Interestingly, these are localised around the cell membranes of a majority of 
cells. The expression of cortactin by definition should localise at focal adhesions at 
the leading edge present in migratory cells. Cortactin expression was localised to the 
outer edge of cells for the K1 cell line and Slug Sh. There was decreased cortactin 
expression for the OPN Sh and ORI-3 cell line (Figure 46).
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F igu re  46. Co-immunostaining to detect vinculin and phosphorylated-cortactin expression in 
ORI-3, K1, Slug Sh and OPN Sh cells. Cells were grown to confluence on coverslips 
wounded for 3 hours and fixed with paraformaldehyde. Cells were co-stained with vinculin 
(green) and phosphorylated-cortactin followed by counterstaining with the DAPI nuclear stain 
(blue). Fluorescence was observed with a fluorescent microscope with an x40 objective 
lense. Images are presented as vinculin alone (green), phosphorylated-cortactin (red), 
merged vinculin and phosphorylated-cortactin with DAPI, and selected areas enlarged by 
200% (signified by white boxes). Scale Bars indicate 50pm and are applicable to all images.
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6.9.2 The regulation of Integrin 03 localisation by Slug and OPN
Integrinp3 is important for cell proliferation, survival, invasion and migration (Kiosses 
et al. 2001). In migrating fibroblasts, Integrin av03 is localised at the leading edge of 
migrating cells over FN and vitronectin ECM components (Woods et al. 2004). This 
localisation is due to Rac activation which recruits integrin03 (Danen et al. 2005). 
Overexpression of integrin av03 increases Rac activity and lamellipodium formation, 
increasing actin stress fibre formation.
To investigate this I immunofluorescently probed integrinp3 to observe if Slug or 
OPN have roles in mediating integrinp3 localisation. This was conducted on 
coverslips where cells were grown to confluency, wounded and after 3 hours fixed 
and immunofluorescent stained.
The immunofluorescence analysis of integrinp3 in ORI-3 cells failed to detect 
integrinP3. At the leading edge of K1 cells, integrinp3 was localised at the cell 
periphery and within the cytoplasm. The localisation was focused at points along the 
leading edge. This indicates probable formation of lamellipodia at these points 
(Figure 47).
In Slug Sh localisation of integrinP3 at the leading edge was focused at points, 
however, more sparsely then K1 cells. OPN Sh displayed increased localisation of 
integrinp3 at the leading edge with no concentrated points of staining, which was 
observed in Slug Sh and K1 cells (Figure 47). This implies a lack of movement, with 
no formation of actin protrusions. The continuous staining may relate to the lack of 
stress fibres which would impair the acto-myosin contractility required for the 
retraction of the rear.
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Integrin-p3 Merge 200%
Figure 47. Integrin(33 localisation in ORI-3, K1, Slug Sh and OPN Sh cells. Cells were grown 
to confluence on coverslips wounded for 3 hours and fixed with paraformaldehyde. Cells 
were stained with integrin (33 (green) and counterstained with DAPI nuclear stain (blue). 
Fluorescence was observed with a fluorescent microscope. Images are presented as 
integrin p3 alone, integrin (33 merged with DAPI and an area enlarged by 200%. Scale bars 
are equal to 50pm, and each scale bar is applicable to its column.
6.9.3 Summary
Directional movement of cells requires the formation of membrane protrusions 
coupled with cell adhesion. Integrins are central and function as a bridge between 
the ECM and the actin cytoskeleton of the cell. Integrins with additional proteins form 
a multi-protein complex to form cell-matrix adhesions (Wiesner et al. 2005). These 
adhesions are formulated around activated integrin clusters, and these are essential 
for cell motility and migration. The adhesions are able to mature and disassemble 
allowing for dynamic regulation of the cell-matrix interaction.
For migration to occur, adhesion structures must form, disassemble or mature at the 
leading edge of the cell and disassemble at the rear of the cell for the cell to conduct 
cell migration. Early adhesions mature into focal complexes localised at the border 
between lamellipodia and lamella. These mature further into focal adhesions with the 
recruitment of vinculin, a adaptor protein which is always contained within the focal 
adhesion of the cell (Galbraith et al. 2002). These dynamic structures are found at 
the cell periphery and in more central areas and are associated with actin stress 
fibres (Wozniak et al. 2004).
Cells with depleted amounts of vinculin have decreased adhesion and increased 
migratory ability with smaller and fewer adhesive contacts (Saunders et al. 2006). In 
addition, vinculin-null cells exhibit increased motility with fewer and smaller focal 
adhesions, a phenotype prevalent in motile cells (Subauste et al. 2004).
This recapitulates the situation in my investigation. ORI-3 cells display decreased 
migratory ability, and possess larger focal contacts. K1 cells are highly invasive and 
possess smaller contacts localised at the leading edge. Slug Sh, revealed 
localisation of vinculin around the cell membrane and OPN Sh displayed fewer
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fcontacts containing vinculin, and these were situated around the cell membrane. 
Since vinculin can be present in early focal contacts, further analysis is required to 
elucidate the type of adhesion present.
Cortactin is an actin filament binding protein which localises at the leading edge of 
lamellipodia (Uruno et al. 2001). It mediates the activation of Arp2/3 in a synergistic 
manner with N-WASP. It is therefore implicated in the formation of lamellipodia, and 
is associated with a migratory phenotype. A reduction in adhesions containing 
cortactin implies the activity of Arp2/3 would be impaired in OPN Sh. It also indicates 
the formation of lamellipodia is restricted. This reduced lamellipodia formation may 
explain the reduced migratory phenotype and subsequent invasive capability of OPN 
Sh. In Slug Sh, there was not any significant alteration in integrinP3 localisation 
compared to K1. This indicates that in Slug Sh the lamellipodia formation is 
functioning in migration.
The localisation of integrinp3 was assessed to see if either Slug or OPN down- 
regulation impacts the function of integrinP3. In migrating cells, integrinP3 is localised 
to the cell edges (Kiosses et al. 2001).
The immunofluorescence analysis showed integrinp3 localisation concentrated at 
points along the leading edge in K1 cells. In Slug Sh, localisation at the leading edge 
was also concentrated at points of the leading edge, but more sparsely. In addition, 
in OPN Sh there was intense localisation along the entire leading edge. This 
evidence indicates a potential role of integrinp3 in regulating migration and invasion.
This is particularly interesting since integrinp3 is a ligand for OPN. Integrinp3 may 
act in a cooperative manner with other integrins or CD44 to exert OPN dependent 
migration. However, since the down-regulation of OPN did not impact the localisation 
of integrinp3 it appears OPN-dependent cell migration does not involve integrinp3.
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Integrin|33 also has a prominent role in focal adhesion assembly, and the intense 
staining concentrated at the leading edges may in fact be focal adhesions. In K1 
cells which are highly motile, there needs to be a dynamic regulation of adhesive 
structures at the leading edge. Knockdown of slug may have reduced the number of 
focal adhesions, attenuating cell migration. The continuous localisation of integrinp3 
at the leading edge in OPN Sh may be a continuous focal adhesion assembly which 
causes the cell to be attached to the substrate in a manner which would cause 
reduced migration. This hypothesis is confirmed by the analysis of vinculin and 
cortactin, which in OPN Sh showed the focal adhesions to be present around the cell 
periphery.
Taken together, there seems to be a prominent role of integrinP3 regulating a motile 
phenotype, either by focal adhesion assembly or formation of actin protrusions.
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6.10 Analysis of cell-cell adhesion mediated by Slug and OPN knockdown
6.10.1 Tight Junctions
Epithelial cells are joined to each other by a set of intracellular junctions which 
include GAP junctions, desmosomes, adherence junctions and tight junctions. Tight 
junctions are formulated from occludin, claudin, and junctional adhesion molecules 
(JAMs). Tight junctions function to provide signalling capabilities and cell-cell 
adhesion aiding the maintenance of epithelial architecture. Recent reports have 
highlighted the tight junction down-regulation correlates with staging, invasiveness, 
and metastatic potential of epithelial tumours (Kominsky et al. 2003).
Downregulation of the tight junction protein, occludin is observed in poorly 
differentiated gastrointestinal adenocarcinomas (Kimura et al. 1997). This maybe 
important as it may be related to the progression of the cancer.
In addition, Slug is a known repressor of occludin expression in Pa4 (rat parotid 
gland) epithelial cells. Knockdown of Slug in these cells restored expression of 
occludin (Wang et al. 2007).
I sought to investigate if Slug mediates expression of occludin expression in thyroid 
cancer. In addition, I also investigated the role of OPN on the regulation of tight 
junction regulation, as there is no literature pertaining to OPN with occludin 
expression. To investigate this aim, I determined the expression of occludin in 
thyroid cell lines using SDS-PAGE western analysis. Occludin expression was 
highlighted in the ORI-3 cell line. Expression was also detected in the FTC cell line 
FTC133, and its metastasis, FTC236 and anaplastic carcinoma, Hth74. In the PTC 
cell lines, K1 and BCPAP occludin expression was not detected (Figure 48A).
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Western blot analysis of Slug Sh and OPN Sh also did not reveal occludin 
expression (Figure 48B).
Figure 48. Analysis of tight junctions by Slug Sh and OPN Sh. SDS-PAGE western blot 
analysis was conducted to assess occludin expression. A, Thyroid cell lines were analysed 
for occludin expression using western blot analysis B, Using positive (ORI-3) and negative 
(K1) controls for occludin expression the knockdown clones of Slug and OPN were analysed 
for expression. Occludin is indicated by the black arrow. Remaining bands are non-specific.
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6.10.2 Adherence junctions
Classical cadherins are transmembrane proteins which formulate the adherence 
adhesive junctions. They formulate intercellular contact through the interaction with 
opposing cadherins on neighbouring cells. In general, cadherins are complexed with 
other cytoplasmic proteins to regulate intracellular signalling. Functionally, 
adherence junctions initiate and stabilise cell-cell junctions to regulate the actin 
cytoskeleton. Epithelial cells highly express E-cadherin, whilst other cadherins are 
expressed by mesenchymal cells. In a large number of epithelial tumours E-cadherin 
is downregulated, and is linked to tumour progression. Slug is a well known 
transcriptional repressor of E-cadherin (Hajra et al. 2002; Uchikado et al. 2005). In 
the knockdown of Slug I would expect re-expression of E-cadherin.
To investigate this hypothesis, I conducted RT-PCR analysis to determine E- 
cadherin mRNA content in Slug Sh and OPN Sh. This experiment aimed to 
determine if Slug or OPN regulate E-cadherin expression. I conducted RT-PCR 
using MCF7 and MDAMB231 as additional controls. E-cadherin mRNA was only 
detected in the MCF7 cell line. It was not detectable in the ORI-3 cell line, a result 
that is surprising since ORI-3 cells are derived from a normal epithelial origin (Figure 
49A). This indicates that E-cadherin is not present in thyroid cell lines.
I next performed immunofluorescence analysis to observe the localisation of E- 
cadherin (Figure 50). This method was used to re-confirm the results seen with the 
RT-PCR analysis. This was conducted using A431 and ORI3 cells as positive 
controls for E-cadherin expression. E-cadherin was only detected in the A431 cell 
line. Expression was localised to the cell-cell contacts, which is consistent with the 
normal localisation of E-cadherin. In the thyroid cell lines there was no detection of
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E-cadherin, a result which is consistent with the RT-PCR analysis. This result 
concludes further experiments regarding E-cadherin as there is no E-cadherin 
mRNA in thyroid.
The cytoplasmic tails of cadherin molecules bind to catenin molecules. The p-catenin 
molecule links the cadherin to the actin cytoskeleton of the cell. Indeed, the 
localisation of p-catenin is crucial to the signalling activities of the Wnt pathway.
I next investigated the expression and localisation of P-catenin to assess whether it 
is localised to the cell membrane. The overall expression of p-catenin was analysed 
using western blot analysis and to observe specific p-catenin localisation the 
technique of immunofluorescence was utilised (Figure 57B). Western blot analysis 
showed the expression of p-catenin to be increased in both Slug Sh and OPN Sh. P- 
catenin expression was also detected in the ORI-3 and K1 cell lines.
Immunofluorescence analysis showed p-catenin to be localised at the cell 
membrane. The immunofluorescence also showed that A431 positively expressed E- 
cadherin. This effectively showed that p-catenin is tethered to E-cadherin at the cell 
membrane. Taken together, the localisation of P-catenin at the cell membrane of the 
thyroid cell lines suggests that in the thyroid cell lines of ORI-3, K1, Slug Sh and 
OPN Sh P-catenin must be tethered to another cadherin family member (Figure 
49B). To further this investigation, I utilised a pan-cadherin antibody to assess 
localisation of caderin molecules. This antibody is useful in detecting all cadherin 
members and would show the presence and localisation of cadherins, but it cannot 
differentiate the type of cadherin. To investigate the localisation of cadherin 
molecules, sub-confluent cells plated on cover slips were fixed with 
paraformaldehyde and immunofluorescently stained for pan-cadherin (Figure 51).
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T h e  results showed intense pan-cadherin  expression localised at the cell m em brane  
in the O R I-3  cell line. This is typical of an epithelial cells which have adherence  
junctions as part of their morphology. In K1 cells, pan-cadherin  w as detected at the  
cell m em brane and cytoplasm , implying a disorganised cadherin expression. This  
indicates the presence of a cadherin m em ber which m ay m ediate  the invasive 
phenotype observed in K1 cells. T h e  Slug Sh cells displayed postive pan-cadherin  
expression at the cell-cell contacts, in a highly organised structure, consistant with 
epithelial architecture. T h e  O P N  Sh cells displayed a disorgainsed pan-cadherin  
expression, localised at the cell m em brane and the cytoplasm.
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Figure 49. Analysis of E-cadherin expression and mRNA content. RT-PCR was conducted 
on subconfluent cells. Cells were lysed with Trizol and total RNA extracted, converted to 
cDNA using reverse transcriptase and an E-cadherin fragment amplified with the use of 
specific primers. (3-catenin expression was analysed by western blot with actin acting as a 
loading control for the western.
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E-Cadherin p-Catenin Merge
Figure 50. Immunofluorescent analysis of E-cadherin and P-catenin expression. Cells were 
stained with E-cadherin (green) and co-immunostained with p-catenin (red) followed with 
counterstaining with DAPI nuclear stain (blue). Fluorescence was observed with a 
fluorescent microscope. Scale bar represents 50pm, and is applicable to all images.
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Pan-cadherin x200%
Figure 51. Pan-cadherin expression in ORI-3, K1, Slug Sh and OPN Sh cells. Cells were 
grown to confluence on coverslips wounded for 3 hours and fixed with paraformaldehyde. 
Cells were stained with Pan-cadherin (green) and counterstained with DAPI nuclear stain 
(blue). Fluorescence was observed with a fluorescent microscope with an x40 objective 
lense. Images are presented as Pan-cadherin merged with DAPI for each cell line analysed. 
Areas were selected (signified by white squares) and enlarged by 200% to provide further 
intricate detail. Scale bars represents 50pm for each column.
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6.10.3 Summary
Epithelial architecture is maintained by tightly packed cells which adhere to one 
another through different types of junctions, which include tight junctions, adherence 
junctions GAP junctions and desmosomal junctions.
Slug functions as a transcription repressor of the adherence junctional protein E- 
cadherin. It also represses other junctional proteins including ZO-1 and occludin 
(Bolos et al. 2003; Ikenouchi et al. 2003; Ohkubo and Ozawa 2004) Overexpression 
of Slug has been shown to correlate with the dysregulation of occludin in a Raf-1 
dependent manner (Wang et al. 2007).
Expression of occludin was absent from the K1 cell line, and in the Slug Sh and OPN 
Sh cells there was no alteration in occludin expression. Experimental evidence did 
indicate that occludin is absent from PTC. The difference in the morphology of these 
cells may account for this.
Although I have shown that tight junctions are not regulated as a mechanism of 
invasion, I analysed the possibility that adherence junctions may be down-regulated 
as an invasive mechanism. The loss of E-cadherin expression represents a key 
mechanism which occurs in EMT. Observed in thyroid cancer, Slug is a known 
repressor of E-cadherin expression (Hardy et al. 2007). In normal conditions, E- 
cadherin is associated with P-catenin, an integral constituent of the Wnt signalling 
pathway. The localisation of p-catenin is crucial to determining the cellular fate and 
transcription of genes regulating which may have roles in regulating an invasive 
phenotype, namely Slug. E-cadherin mRNA content was analysed in a number of 
cell lines with the adenocarcinoma cell line, MCF7 acting as an experimental control. 
In contrast to other studies, ORI-3 cells did not have any E-cadherin mRNA content 
(Hardy et al. 2007). A probable explanation causing the loss of E-cadherin
243
expression may involve the extensive culturing. Recently investigated in prostate 
cancer, OPN was shown to mediate an up regulation of P-catenin expression in the 
nucleus in an Akt-dependent manner (Robertson and Chellaiah).
In OPN Sh and Slug Sh cells, the western blot analysis revealed an increase in P- 
catenin expression. Immunofluorescent analysis revealed increased organised 
expression at the cell-cell borders in Slug Sh and OPN Sh, with minimal expression 
in the nucleus.
The localisation of p-catenin at the cell membrane indicates the presence of a 
cadherin molecule mediating the adherence junction between cells. Obviously this 
cannot be E-cadherin since this was devoid in the thyroid cell lines. The use of a 
pan-cadherin antibody was useful in investigating if there is in fact a cadherin 
present at the cell membrane. From the immunofluorescence analysis, there was 
intense staining at the cell membrane of ORI-3 and, somewhat K1 cells. Perhaps 
most interesting is the increased organised nature of the cadherin staining at the cell 
membrane for Slug Sh, a morphology consistent with normal epithelial cells. It 
appears down-regulating Slug confers an organised epithelial structure. In OPN Sh, 
the localisation of pan-cadherin was chaotic, and indicates that OPN does not 
regulate the adherence junctions as an invasive mechanism.
To summarise, the highly organised nature of the cell-cell-contacts indentified by the 
intense p-catenin and pan-cadherin staining in the knockdown of Slug which implies 
that there is restoration of the cell-cell contacts which are evident in normal 
epithelium.
Cell-cell contact is crucial to maintaining an epithelial architecture, and this forms the 
basis of explaining how Slug mediates an invasive phenotype.
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7.0 General 
Discussion and Future
Work
246
Thyroid cancer is the most common endocrine malignancy, with its incidence 
increasing worldwide. Fine needle aspiration (FNA) is the preferred preoperative 
diagnostic tool which can diagnose papillary carcinoma (PTC) with high reliability. 
FNA cannot differentiate follicular adenoma (FA) from FTC as these lesions have 
overlapping pathological features. The diagnosis relies upon histological examination 
and is an invasive technique.
This thesis contained 2 major aims, firstly, to identify novel markers of tumour 
invasion, and secondly to characterise their therapeutic value. To conduct this 
research my group had previously established in vitro models of follicular adenoma 
(FA) and papillary carcinoma (PTC). The respective oncogenes, RASV12, 
RET/PTC1, BRAFV600E were introduced into primary thyrocytes (Bond et al. 1994). 
These formed the in vitro models of FA (RASV12), and PTC (RET/PTC1 and 
BRAFV600E). Studies concerning these particular models and invasion remained a 
novel aspect which had not been previously investigated.
For the first major aim of my thesis, I primarily focused my investigation on the 
BRAFV600E oncogene and characterising the B-Raf oncogenic mutation in thyroid cell 
lines. B-Raf can undergo alternative splicing providing different levels of signalling 
which may lead to a specific cellular effect. Mutated B-Raf conveys a dramatic 
increase in kinase activity and is implicated in aggressive PTC tumours (Namba et 
al. 2003; Palona et al. 2006).The detection of BRAFV600E in both the full length and 
shorter isoforms in thyroid cell lines was important for future experiments and 
highlights the complexity of oncogenic signalling events. All the PTC cell lines which 
were analysed had the BRAFV600E mutation. It would be interesting to firstly 
investigate the kinase activity of the shorter isoforms, and the contribution to the
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oncogenic ability and secondly, compare the kinase activity of the full length 
BRAFV600E which I used in my experiments with the other shorter isoforms.
Following on from this work, I formed my in vitro models for use on a microarray 
platform. Since I aimed to identify candidate genes involved with tumour invasion 
and define their therapeutic value, I characterised the invasive capability of the in 
vitro models in parallel to the genetic profiling for the identification of novel markers.
The FA model displayed a high degree of invasive behaviour, unexpected since 
RASV12 is associated with FA tumours. This may in part be due to culture 
conditions, where the serum may contain growth factors that induce invasive 
behaviour. The other PTC models also displayed an invasive phenotype.
This therefore limited the initial purpose of the microarray study. Since all the models
displayed an invasive phenotype, the comparison of an invasive model versus a non-
invasive model was not possible. The gene profiling study was reframed to
determine the overlapping expression associated with or attributed to invasion for
each of the models. The further aim was to identify specific processes, pathways and
genes which may cause the invasive behaviour of the RASV12 model. A number of
genes were identified which other studies suggest may convey the invasive
phenotype seen in the RASV12 model. These genes included VEGF, FN, EGFR,
MMP-9 and Rho genes. The gene expression profiles of each model showed that
these genes were not up-regulated in the PTC models. The oncogenic events of
BRAFV600E, RASV12 and RET/PTC1 are mutually exclusive. Therefore the genetic
profile, processes and pathways are specific to the model. These genes were only
analysed using the microarray platform and so to be accurate with any profiling
study, it is necessary to validate the results to observe expression at the
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transcriptional level (Northern blot) and protein level (SDS-PAGE) is essential. To 
investigate the role of serum on inducing invasive behaviour, culturing the cells in 
low serum conditions may result in a reduction of invasive ability in RASV12. Using 
the same conditions for the microarray study genetic profiling of models cultured in 
low serum conditions would provide a comparison of how low serum culture 
conditions affect gene expression. Ultimately, adjusting the culture conditions may 
provide a more suitable model to investigate the concept of thyroid tumour invasion.
An alternative explanation of why the RASV12 model displayed an invasion 
phenotype are the high proliferative sub-culture of epithelial like cells (Bond et al. 
1993). Investigating the phenotypic heterogeneity and sustainability in culture needs 
to be carried out. The isolation of the subculture and RASV12-infected epithelial cells 
and study of their invasive behaviour using invasion assays would determine if the 
invasion observed in my studies is actually RASV12-infected epithelial cells. Also, 
mapping cells with epithelial or mesenchymal markers before and after conducting 
invasion assays would provide further experimental evidence of which cells are 
invading. However, this may prove challenging as cells undergo complex 
morphogenic changes during Matrigel cell invasion which may make identifying 
cellular markers difficult.
The invasion assay itself was conducted using growth factor reduced Matrigel. 
Thyroid invasion is defined as cell invasion through the thyroid capsule. The capsule 
is comprised of a mixture of components including collagen and fibrous tissue. To 
represent this Matrigel invasion assays could be adapted to incorporate these 
elements to make the invasion assay experimental technique more accurate to the in 
vivo setting.
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From the microarray study and background literature analysis a number of 
candidates were identified. This formed the second main aim of the thesis. 
Osteopontin (OPN) and Slug were selected as they were both implicated in tumour 
progression (Cano et al. 2000; Hajra et al. 2002; Wai and Kuo 2004; Hardy et al. 
2007), and investigations of these genes in thyroid cancers remained limited and 
could be expanded upon. OPN is over-expressed and enhances papillary carcinoma 
invasiveness in RET/PTC transformed rat thyroid cells (Guarino et al. 2005). In 
thyroid tumours, OPN expression correlates with aggressive clinicopathological 
features of papillary carcinoma, presence of lymph node metastases and tumour 
size (Guarino et al. 2005). Mechanisms of how increased OPN gene expression 
enhances invasion and which invasive processes and pathways are involved in 
thyroid cancer remains unclear. Slug is a known transcriptional repressor of E- 
cadherin (Hajra et al. 2002) and induces epithelial to mesenchymal transition (EMT) 
(Savagner et al. 1997). In thyroid, Hardy et al. showed increased detection of Slug in 
PTC cell lines, with basal level expression in normal thyroid tissue or normal tissue 
derived cell lines. Mechanistic evidence of the invasive processes mediated by Slug 
in thyroid cancer can also be investigated further.
To investigate Slug and OPN in thyroid cancer invasion I began by characterising a 
panel of thyroid cancer cell lines for their invasive capability and expression of Slug 
and OPN. The expression of both Slug and OPN correlated with enhanced invasion 
of the PTC cell line, K1. Thus, indicating of roles for Slug and OPN in thyroid cancer.
To investigate the potential role of Slug and OPN in tumour invasion, shRNA- 
mediated knockdown was conducted using the K1 cell line. Producing the 
knockdown clones and re-analysing the invasive behaviour revealed a dramatic
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reduction in invasive behaviour. This provided direct evidence that correlated Slug 
and OPN expression with tumour invasion. This evidence was consistent with other 
studies where different cancers displayed increased expression or Slug or OPN 
which correlated with malignancy (Wai and Kuo 2004; Shih et al. 2005).
Details regarding the mechanisms of how Slug and OPN regulate invasion remain to 
be elucidated. Since invasion consists of multiple processes which combine and 
initiate invasion, a multi-step analysis focussing on proteolysis, cell-cell adhesion, 
cell motility and cell-matrix adhesion were conducted.
Proteinases degrade ECM components to promote angiogenesis and promote 
invasion. I sought to analyse if proteinase activity is regulated by either Slug or 
OPN. Expression of MT1-MMP mRNA was reduced in both the Slug and OPN 
knockdown clones. This indicates that both OPN and Slug may have a role in the 
regulation of MT1-MMP. This membrane bound MMP promotes tumour growth and 
angiogenesis through the induction of vascular endothelial growth factor (Sounni et 
al. 2002). In addition, MMP-2 activation may be impaired in Slug and OPN 
knockdown clones since activation of MMP-2 requires 2 molecules of MT1-MMP. 
The first MT1-MMP molecule binds to the latent MMP-2 and the second cleaves and 
activates the latent enzyme.
The zymogram analysis revealed latent pro-enzymes of MMP-2 and MMP-9; 
however, it is probable that the concentration of MMP-2 and MMP-9 in the samples 
was not efficient to detect the active enzymes. In addition, analysis by western blot 
or ELISA using concentrated conditioned media could identify the pro- and active 
forms of MMP-2 and MMP-9. This would confirm the results of the zymogram.
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MT1-MMP was shown to collaborate with integrinp3 to promote MMP-2 activation in 
breast carcinoma cells (Deryugina et al. 2001). Analysing the expression of 
integrinp3 would elucidate what the effect of MT1-MMP down-regulation is in the 
knock-down clones. Since MT1-MMP is membrane bound, using 
immunofluorescence to analyse localisation, it would be interesting to observe if 
integrinp3 co-localises with MT1-MMP.
The urokinase activation system did not have a role in invasion mediated by Slug or 
OPN since decrease in mRNA content of uPAR was not seen. Further investigation 
would involve observing expression of uPAR and uPA using western blots to 
observe expression at the protein level. In addition, detection of uPA by RT-PCR 
does not differentiate between the active and inactive forms of uPA in the samples. 
To confirm this evidence presented, an assay testing for uPA activity would need to 
be conducted.
The 2nd aspect of investigation was the investigation of cell-cell interactions. 
Epithelial cells are joined to each other by a set of intracellular junctions including 
adherence and tight junctions to give the typical epithelial architecture. In a tumour 
setting these junctions are down-regulated, and Slug is a main instigator of down- 
regulating cell junctions (Hajra et al. 2002; Bolos et al. 2003). E-cadherin is found 
expressed at epithelial adherence junctions, and down-regulation is associated with 
EMT. My investigation of E-cadherin expression was in contrast to Hardy et al. The 
ORI-3 cell line, derived from normal epithelium was used as a positive control for E- 
cadherin expression. In my hands E-cadherin was absent in this cell line, and this 
was true of all the thyroid cell lines. However, this down-regulation of E-cadherin did 
not affect the invasive behaviour. Hardy et al. found the same ORI-3 cell line to
252
possess E-cadherin. Continuous culture of the ORI-3 cell line may have resulted in 
the loss of E-cadherin.
Using a pan-cadherin antibody which detects all cadherin molecules, results showed 
that there is expression of cadherin molecules at the cell junctions, and this was 
confirmed with the analysis of p-catenin which was also localised at the cell 
junctions.
Analysing the knock-down clone of Slug using the pan-cadherin antibody revealed a 
highly organised localisation of cadherin at the cell membrane. This type of 
localisation is consistent with a normal epithelial monolayer. To investigate this 
further, determining which class of cadherin is expressed would be advantageous. 
Class switching of cadherins may be a mechanism which may be regulated by Slug 
(Kuphal and Bosserhoff 2006).
The third aspect of this investigation observed cell motility. In a tumour environment, 
cells possess a motile phenotype in order to invade. Motility is dependent on the 
formation of actin protrusions (lamellipodia and filopodia) and cell-matrix adhesive 
contacts which all combine to generate forward thrust (Insall and Machesky 2009).
Time-lapse analysis tracking cells and conducting random walk analysis revealed 
phenotypic changes resulting from the knock-down of Slug or OPN. In Slug Sh and 
OPN Sh cells, proliferation and the distance travelled were both decreased. In 
addition, the actin time course wound closure experiment revealed a slower wound 
closure time for the knockdown clones. Random walk analysis revealed decreased 
migration of Slug, however more so of the OPN knockdown clone. This evidence 
provided an implication that cell migration is impaired when Slug or OPN are
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knocked down. These results clearly showed an impaired motile ability in the 
knockdown clones.
The formation of actin-based protrusions are important for cell migration, and N- 
WASP and WAVE1 are important to this. Immunofluorescence analysis of N-WASP 
in both the Slug and OPN knockdown clones revealed decreased N-WASP signal, 
an indication of decreased N-WASP activity. This work would greatly benefit from 
western blot analysis to confirm the indication. Detection of WAVE1 also revealed 
decreased expression in the Slug knockdown. This evidence indicates the activation 
of the Arp2/3 complex may be impaired, affecting the formation of lamellipodia and 
filopodia. N-WASP is activated by cdc42 (Wu et al. 2004), and Rac functions 
upstream of WAVE1 (Schwartz 2004). Both cdc42 and Rac function at the leading 
edge of the cell whereas Rho acts at the rear of the cell (Popoff and Geny 2009). 
GST-fusion assays to examine Rac and Rho activity were conducted using the Rac 
binding domain of PAK1 and the Rho binding domain of Rhotekin. However, the 
assay requires optimisation and so did not provide any meaningful results. A GST- 
pull down assay testing for cdc42 activity would also be advantageous to see if these 
GTPases are regulated by Slug or OPN.
The Rho GTPase regulates movement at the rear of the cell by forming stress fibres 
(Maekawa et al. 1999). The OPN knock-down clone displayed a lack of stress fibres 
and in a wound closure environment the cell body was stretched implying the 
movement at the rear of the cell is impaired. Analysis of Rho activity would elucidate 
if this is the case, and if OPN regulates Rho activity.
Fundamental for cell movement are the formation of focal adhesions, the size and
localisation of which is dependent on the migratory status of the cell.
Immunofluorescence analysis of vinculin, a protein present in mature focal
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adhesions revealed cell-matrix interactions in the knockdown clones. 
Phosphorylated-cortactin was co-stained, which is particularly important in cells with 
a migratory phenotype. Cortactin is an actin filament binding protein localised at the 
leading edge of lamellipodia. Cortactin and N-WASP synergistically cooperate to 
stimulate Arp2/3 and actin assembly. When cortactin is phosphorylated, activation of 
N-WASP is enhanced. In the K1 PTC cell line, cortactin was localised around the cell 
periphery and Slug knockdown displayed a similar pattern. Although phosphorylated- 
cortactin was detectable in the OPN knockdown there was decreased expression of 
cortactin around the cell periphery.
There is circumstantial evidence of increased size of focal adhesions in the 
knockdown clones. This evidence links the cell-matrix adhesions with a migratory 
phenotype where cells with decreased vinculin expression have fewer cell-matrix 
adhesive structures with an increased migratory ability (Subauste et al. 2004). The 
partial restoration of focal adhesions in the knockdown clones for Slug and OPN 
links focal adhesion size with cell migration and therefore invasion. To further this 
work other proteins involved with cell-matrix adhesions would determine the type of 
adhesive contacts present. The integral focal adhesion adaptor protein paxillin has 
many binding partners, and performs a central role in the formation of focal contacts. 
Since focal adhesions remain an active site for actin polymerisation, zyxin, an 
adaptor protein which serves as a scaffold protein at focal adhesions has been 
shown to regulate actin polymerisation, and is a protein which is only present in 
mature focal adhesions (Beckerle 1997).
FAK is an tyrosine kinase which is present only in focal adhesions (Brakebusch and 
Fassler 2003). The carboxyl terminus of FAK contains the focal adhesion targeting
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(FAT) domain, which displays homology to vinculin (Arold et al. 2002), and contains 
binding sites for paxillin and talin. Integrin-linked kinase (ILK) is a non-receptor 
serine/threonine kinase with a principle role as an adaptor protein. The functionality 
of ILK has been highlighted by ILK-null fibroblasts which exhibit reduced cell 
spreading, migration, due to delayed formation of focal adhesions, and a poorly 
organised actin cytoskeleton (Sakai et al. 2003). Investigating the expression and 
localisation of paxillin, zyxin, ILK and FAK would elucidate the role of focal adhesions 
with actin assembly/disassembly inducing cell contractility and subsequent cell 
migration. Formation of adhesive structures is a dynamic process during cell 
migration, and so observing localisation and expression of other associated proteins 
may provide additional mechanistic detail explaining how OPN and Slug affect the 
formation of cell-matrix adhesions.
Other experiments to consider would be to analyse the upstream inducers of Slug 
and OPN. Highlighted in the background chapter, HGF-dependent tumourigenesis 
and inhibition of OPN expression attenuates the HGF-invasiveness in vitro and in 
vivo (Medico et al. 2001; Ariztia et al. 2003). This is an indication that OPN is a 
necessity for HGF-induced tumour invasion. Using time-lapse analysis I found that 
both Slug and OPN knockdown clones did not respond to HGF treatment in terms of 
movement. Interestingly, in the Slug Sh and OPN Sh cells the time between cell 
division was increased in response to HGF treatment. This indicates that HGF may 
have a role in Slug and OPN-mediated invasion. To expand on this further I would 
conduct invasion assays with and without HGF treatment. This would therefore 
confirm the action of HGF in mediating invasion via Slug and OPN. Within the 
literature Slug is reported to be highly up-regulated in response to HGF, and this is
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an early event preceding EMT (Leroy and Mostov 2007). The authors suggest Slug 
may act as a survival factor in response to HGF.
Variant isoforms of CD44 (CD44v) are able to amplify HGF-mediated invasion (Smith 
et al. 1999) and are able to bind OPN. The interaction of CD44v with integrinpi can 
lead to enhanced cell motility and chemotaxis (Katagiri et al. 1999). I therefore would 
like to assess the localisation of integrinpi and see if co-localisation with CD44v 
occurs. With regard to CD44v analysis of expression and localisation of CD44v 
would confirm the findings presented and elucidate the role of HGF in Slug and 
OPN-mediated invasion. There is a good indication that CD44v have a role since 
CD44v6, v7 and v10 mRNA was down-regulated by both Slug and OPN in the 
knockdown clones.
Craig et al., showed that interaction between Slug and CD44 induced cell invasion. 
This is the only study to correlate CD44 and Slug with tumour invasion. This 
interaction depends solely on variant isoforms of CD44, a finding consistent with my 
experiments. The down-regulation of Slug expression correlates with the reduced 
mRNA content of CD44v6, v7 and v10. This interaction can be investigated in more 
detail. It would be interesting to observe if the introduction of CD44v in Slug Sh or 
OPN Sh induces a restoration of invasive ability.
An interesting investigation would be to investigate the upstream events of both Slug 
and OPN. The over-expression of OPN has been correlated with the presence of 
BRAFV600E and RET/PTC1 (Guarino et al. 2005). It would be interesting to see if the 
B-Raf oncogene regulates the expression of Slug and OPN to induce invasion.
Since this knockdown work has had a phenotypic response in a cell line model, 
carrying this work forward with primary models of PTC would give an indication of
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the role Slug and OPN in an in vivo situation. The evidence presented in this thesis 
implies that both Slug and OPN respectively are sufficient alone to initiate tumour 
invasion. It is unclear how knockdown of either Slug or OPN would affect the gross 
morphology of an in vivo tumour. Since growth rates are reduced along with cell 
migration, it would imply reduced sized tumours with a decreased capacity to invade. 
This would not be an absolute ablation of invasion since residual invasion was 
observed in the experiments conducted with the K1 cell line. However it suggests 
that these may provide valid candidates as therapeutic targets since in this thesis 
direct targeting of Slug and OPN alone severely reduced invasion, implying that 
these genes have a master role in mediating invasion. In other cancers targeting 
these genes in vivo situation reduced tumour invasion and tumour size (Yang et al. ; 
Zhao et al. 2008). The research presented in other studies together with the 
evidence presented in this thesis strongly indicates that targeting either Slug or OPN 
in vivo would have a strong therapeutic effect.
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Figure 1. t-test analysis of genotype-specific changes in gene expression. Hierarchical 
clustering displaying the genotype specific transcriptional changes of 705 differentially 
regulated probe sets in RASV12 compared to BRAFV600Eand RET/PTC1 oncogene infected 
thyrocytes. The columns correspond to the oncogene and the rows to each gene transcript. 
Red signifies up-regulation and green signifies down-regulation.
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9. Hypoxia response regulation
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16. Lipid Biosynthesis and regulation
17. Nuclear receptor signaling 
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I 28. Cholesterol and bile acid homeostasis 
I 29. Neurotransmission
30. Vitamin and cofactor metabolism and 
its regulation
31. Nucleotide metabolism and its 
|_ regulation
I 32. Cell cycle and its regulation 
33. Aminoacid metabolism and its 
regulation
RASV12 BRAFV600E RET/PTC1
Figure 2. Enrichment analysis of pathway folders identified in t-test cluster 1. The 
enrichment method was subjected to an FDR of 0.05. A, The order of map folders is based 
on their significance in the cluster. The dark orange bars dictate significance set at 0.05%. 
Although the light/orange bars are displayed they are not discussed due to the possibility of 
false positive results. For the t-test cluster 1, there were 33 map folders identified with 10 of 
significance. B, The corresponding heatmap of the t-test cluster 1, displaying an overall 
expression pattern of 334 up-regulated probes in RASV12 and median/down-regulation in 
both BRAFV600E and RET/PTC1. The columns correspond to the oncogenic condition and 
the rows to each gene transcript. Red signifies up-regulation and green signifies down- 
regulation, whilst median expression is signified by black.
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F ig u r e  3. Enrichment analysis of pathway folders identified in t-test cluster 2. The 
enrichment method was subjected to an FDR of 0.05. A , The order of map folders is based 
on their significance in the cluster. The dark orange bars dictate significance set at 0.05%. 
Although the light/orange bars are displayed they are not discussed due to the possibility of 
false positive results. For the t-test cluster 2, there were 33 map folders identified with 5 of 
significance. B , The corresponding heatmap of the t-test cluster 2, displaying an overall 
expression pattern of 334 down-regulated probes in RASV12 and median/up-regulation in 
both BRAFV600E and RET/PTC1. The columns correspond to the oncogenic condition and 
the rows to each gene transcript. Red signifies up-regulation and green signifies down- 
regulation, whilst median expression is signified by black.
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Table 1.0 T-test cluster 1
# Gene Symbol Protein name Object type
1 ACP1 Low molecular weight phosphotyrosine protein 
phosphatase
Protein phosphatase
2 ACSL3 Long-chain-fatty-acid--CoA ligase 3 Generic enzyme
3 ADM ADM Receptor ligand
4 AE01 Neuroblastoma breakpoint family member 9 Generic protein
5 AK3L1 Adenylate kinase isoenzyme 4, mitochondrial Generic kinase
6 AKAP10 A kinase anchor protein 10, mitochondrial Generic binding protein
7 AKAP12 A-kinase anchor protein 12 Generic binding protein
8 AMN1 Protein AMN1 homolog Generic binding protein
9 AMPD3 AMP deaminase 3 Generic enzyme
10 ANKRD37 Ankyrin repeat domain-containing protein 37 Generic binding protein
11 ANKRD50 Ankyrin repeat domain-containing protein 50 Generic protein
12 AP1S1 AP-1 complex subunit sigma-1A Transporter
13 APLP2 Amyloid-like protein 2 Generic binding protein
14 ARG2 Arginase-2, mitochondrial Generic enzyme
15 ARHGAP18 Rho GTPase-activating protein 18 Regulators (GDI, GAP, 
GEF etc.)
16 ARHGAP22 Rho GTPase-activating protein 22 Regulators (GDI, GAP, 
GEF etc.)
17 ARHGAP5 Rho GTPase-activating protein 5 Regulators (GDI, GAP, 
GEF etc.)
18 ARL1 ADP-ribosylation factor-like protein 1 RAS superfamily
19 ASMTL N-acetylserotonin O-methyltransferase-like 
protein
Generic enzyme
20 ATM Serine-protein kinase ATM Protein kinase
21 ATP13A5 Probable cation-transporting ATPase 13A5 Generic binding protein
22 ATP1A1 Sodium/potassium-transporting ATPase subunit 
alpha-1
Generic channel
23 ATP1B1 Sodium/potassium-transporting ATPase subunit 
beta-1
Generic binding protein
24 ATP2C1 Calcium-transporting ATPase type 2C member 1 Generic channel
25 B4GALT7 Beta-1,4-galactosyltransferase 7 Generic enzyme
26 BAT2L2 BAT2 domain-containing protein 1 Generic protein
27 BBS2 Bardet-Biedl syndrome 2 protein Generic binding protein
28 BNC2 Zinc finger protein basonuclin-2 Generic binding protein
29 C13orf36 Uncharacterized protein C13orf36 Generic protein
30 C13orf37 UPF0582 protein C13orf37 Generic protein
31 C18orf19 Uncharacterized protein C18orf19 Generic protein
32 C18orf32 UPF0729 protein C18orf32 Generic protein
33 C20orf 199 RNA
34 C21orf91 Protein EURL homolog Generic protein
35 C6orf62 Uncharacterized protein C6orf62 Generic protein
36 CALR Calreticulin Generic binding protein
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37 CAMK2D Calcium/calmodulin-dependent protein kinase 
type II delta chain
Protein kinase
38 CAV2 Caveolin-2 Generic binding protein
39 CCNG1 Cyclin-G1 Generic binding protein
40 CD274 Programmed cell death 1 ligand 1 Generic binding protein
41 CD302 CD302 antigen Generic binding protein
42 CD44 CD44 antigen Generic receptor
43 CD46 Membrane cofactor protein Generic receptor
44 CDC42SE2 CDC42 small effector protein 2 Generic binding protein
45 CEP57 Centrosomal protein of 57 kDa Generic binding protein
46 CEP63 Centrosomal protein of 63 kDa Generic binding protein
47 CLASP1 CLIP-associating protein 1 Generic binding protein
48 CLEC11A C-type lectin domain family 11 member A Receptor ligand
49 CLK4 Dual specificity protein kinase CLK4 Protein kinase
50 CNN3 Calponin-3 Generic binding protein
51 CNOT1 CCR4-NOT transcription complex subunit 1 Generic binding protein
52 COG6 Conserved oligomeric Golgi complex subunit 6 Generic binding protein
53 CPD Carboxypeptidase D Generic protease
54 CRTAP Cartilage-associated protein Generic binding protein
55 CUL3 Cullin-3 Generic binding protein
56 DCBLD2 Discoidin, CUB and LCCL domain-containing 
protein 2
Generic binding protein
57 DCUN1D4 DCN1-like protein 4 Generic protein
58 DDX17 Probable ATP-dependent RNA helicase DDX17 Generic enzyme
59 DFNA5 Non-syndromic hearing impairment protein 5 Generic binding protein
60 DRAM2 DNA damage-regulated autophagy modulator 
protein 2
Generic protein
61 DSE Dermatan-sulfate epimerase Generic enzyme
62 EEF1A1 Elongation factor 1-alpha 1 Generic binding protein
63 EEF1B2 Elongation factor 1-beta Generic binding protein
64 EEF1B4
65 EGFR Epidermal growth factor receptor Receptor with enzyme 
activity
66 EIF2S2 Eukaryotic translation initiation factor 2 subunit 2 Generic binding protein
67 EIF3E Eukaryotic translation initiation factor 3 subunit E Generic binding protein
68 EIF4B Eukaryotic translation initiation factor 4B Generic binding protein
69 ELL2 RNA polymerase II elongation factor ELL2 Generic binding protein
70 EPRS Bifunctional aminoacyl-tRNA synthetase Generic enzyme
71 ERAP1 Endoplasmic reticulum aminopeptidase 1 Metalloprotease
72 ERN1 Serine/threonine-protein 
kinase/endoribonuclease IRE1
Protein kinase
73 ER01L EROI-like protein alpha Generic enzyme
74 ERP44 Endoplasmic reticulum resident protein ERp44 Generic binding protein
75 ETV3 ETS translocation variant 3 Transcription factor
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76 EXD3 Probable exonuclease mut-7 homolog, isoform 5 Generic enzyme
Probable exonuclease mut-7 homolog Generic binding protein
77 FAM13A Protein FAM13A Generic protein
78 FAM162A UPF0389 protein FAM162A Generic protein
79 FAM167A UPF0484 protein FAM167A Generic protein
80 FAM43A Protein FAM43A Generic protein
81 FN1 Fibronectin Receptor ligand
82 FNDC3A Fibronectin type-lll domain-containing protein 3a Generic protein
83 FRG1 Protein FRG1 T ransporter
84 FRG1B Protein FRG1B Generic protein
85 FUBP1 Far upstream element-binding protein 1 Transcription factor
86 FXR1 Fragile X mental retardation syndrome-related 
protein 1
Generic binding protein
87 GALNT12 Polypeptide N-acetylgalactosaminyltransferase 
12
Generic enzyme
88 GALNT5 Polypeptide N-acetylgalactosaminyltransferase 5 Generic enzyme
89 GAS5 RNA
90 GLS Glutaminase kidney isoform, mitochondrial Generic enzyme
91 GNA13 Guanine nucleotide-binding protein subunit 
alpha-13
G-alpha
92 GOLGB1 Golgin subfamily B member 1 Generic binding protein
93 GUSB Beta-glucuronidase Generic enzyme
94 HEY1 Hairy/enhancer-of-split related with YRPW motif 
protein 1
Transcription factor
95 HLTF Helicase-like transcription factor Generic binding protein
96 HNRNPD Heterogeneous nuclear ribonucleoprotein DO Generic binding protein
97 HNRPDL Heterogeneous nuclear ribonucleoprotein D-like Generic binding protein
98 HOMER1 Homer protein homolog 1 Generic binding protein
99 HSP90B1 Endoplasmin Generic binding protein
100 HSPA2 Heat shock-related 70 kDa protein 2 Generic binding protein
101 HSPA5 78 kDa glucose-regulated protein Generic binding protein
102 IAH1 Isoamyl acetate-hydrolyzing esterase 1 homolog Generic enzyme
103 IER3IP1 Immediate early response 3-interacting protein 1 Generic binding protein
104 IER5L Immediate early response gene 5-like protein Generic protein
105 IGFBP3 Insulin-like growth factor-binding protein 3 Generic binding protein
106 IL17RB Interleukin-17 receptor B Generic receptor
107 M lnterleukin-8 Receptor ligand
108 INSIG2 Insulin-induced gene 2 protein Generic binding protein
109 INTS6 Integrator complex subunit 6 Generic enzyme
110 IRS2 Insulin receptor substrate 2 Generic binding protein
111 ITGA4 Integrin alpha-4 Generic receptor
112 ITGB1 Integrin beta-1 Generic receptor
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113 I IVNS1ABP Influenza virus NS1A-binding protein Generic binding protein
114 JARID2 Protein Jumonji Generic binding protein
115 KCNMA1 Calcium-activated potassium channel subunit 
alpha-1
Voltage-gated ion- 
channel
116 KDM5B Lysine-specific demethylase 5B Transcription factor
117 KIAA1143 Uncharacterized protein KIAA1143 Generic protein
118 KIAA1244 Brefeldin A-inhibited guanine nucleotide- 
exchange protein 3
Regulators (GDI, GAP, 
GEF etc.)
119 KIAA1245 KIAA1245 Generic protein
120 KISS1R KiSS-1 receptor GPCR
121 LAPTM4A Lysosomal-associated transmembrane protein 
4A
Generic protein
122 LAYN Layilin Generic receptor
123 LCORL Ligand-dependent nuclear receptor corepressor­
like protein
Generic binding protein
124 LEMD1 LEM domain-containing protein 1 Generic protein
125 LEPR Leptin receptor Generic receptor
126 LGALS8 Galectin-8 Receptor ligand
127 LIPG Endothelial lipase Generic phospholipase
128 LMAN1 Protein ERGIC-53 Generic binding protein
129 LOC100133315 Putative short transient receptor potential 
channel 2-like protein
Generic binding protein
130 LOC100134091
131 LOC149832
132 LOC151162
133 LOC387763 Protein Ag2 homolog Generic protein
134 LOC399959
135 LOC440957 UPF0640 protein Generic binding protein
136 LOC550643 Putative uncharacterized protein LOC550643 Generic protein
137 LOC642236
138 LOC643837 RNA
139 LOC653380 TBC1 domain family member 3C-like protein 
ENSP00000341742
Regulators (GDI, GAP, 
GEF etc.)
140 LOC727820
141 LOC729082
142 LOC729222
143 LOC730510
144 LONP2 Peroxisomal Lon protease homolog 2 Generic protease
145 MAN2A1 Alpha-mannosidase 2 Generic enzyme
146 MAP3K2 Mitogen-activated protein kinase kinase kinase 2 Protein kinase
147 MAP4K4 Mitogen-activated protein kinase kinase kinase 
kinase 4
Protein kinase
148 MAPK6 Mitogen-activated protein kinase 6 Protein kinase
149 MBNL2 Muscleblind-like protein 2 Generic binding protein
150 MED21 Mediator of RNA polymerase II transcription 
subunit 21
Generic binding protein
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151 MIB1 E3 ubiquitin-protein ligase MIB1 Generic enzyme
152 MIR21 RNA
153 MLH3 DNA mismatch repair protein Mlh3 Generic binding protein
154 MPHOSPH6 M-phase phosphoprotein 6 Generic binding protein
155 MPZL2 Myelin protein zero-like protein 2 Generic binding protein
156 MRI1 Methylthioribose-1 -phosphate isomerase Generic binding protein
157 MT1A Metallothionein-1A Generic binding protein
158 MT1E Metallothionein-1E Generic binding protein
159 MT1H Metallothionein-1H Generic binding protein
160 MT1M Metallothionein-1M Generic binding protein
161 MT1P2 MT-1H-like protein Generic protein
162 MXI1 MAX-interacting protein 1 Transcription factor
163 N4BP2L2 NEDD4-binding protein 2-like 2 Generic protein
164 NACA Nascent polypeptide-associated complex subunit 
alpha
Generic binding protein
165 NAP1L1 Nucleosome assembly protein 1-like 1 Generic binding protein
166 NBAS Neuroblastoma-amplified sequence Generic protein
167 NBPF1 Neuroblastoma breakpoint family member 1 Generic protein
168 NBPF10 Neuroblastoma breakpoint family member 10 Generic protein
169 NBPF11 Neuroblastoma breakpoint family member 11 Generic protein
170 NBPF14 Neuroblastoma breakpoint family member 14 Generic protein
171 NBPF15 Neuroblastoma breakpoint family member 15 Generic protein
172 NBPF16 Neuroblastoma breakpoint family member 16 Generic protein
173 NBPF3 Neuroblastoma breakpoint family member 3 Generic protein
174 NBPF8 Neuroblastoma breakpoint family member 21 Generic protein
Neuroblastoma breakpoint family member 8 Generic protein
175 NBPF9 Neuroblastoma breakpoint family member 20 Generic protein
176 NCRNA00219 Putative uncharacterized protein TIGA1 Generic protein
177 NDP Norrin Receptor ligand
178 NDUFB5 NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 5, mitochondrial
Generic enzyme
179 NDUFS4 NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 4, mitochondrial
Generic enzyme
180 NFIB Nuclear factor 1 B-type Transcription factor
181 NFXL1 NF-X1-type zinc finger protein NFXL1 Generic binding protein
182 NGLY1 Peptide-N(4)-(N-acetyl-beta- 
glucosaminyl)asparagine amidase
Generic enzyme
183 NMD3 60S ribosomal export protein NMD3 Generic binding protein
184 NOL3 Nucleolar protein 3 Generic binding protein
185 NOL7 Nucleolar protein 7 Generic protein
186 NOTCH2NL Notch homolog 2 N-terminal-like protein Generic binding protein
187 NT5E 5-nucleotidase Generic phosphatase
188 NUCB2 Nucleobindin-2 Generic binding protein
189 OCIAD1 OCIA domain-containing protein 1 Generic protein
190 P4HA2 Prolyl 4-hydroxylase subunit alpha-2 Generic enzyme
191 PABPC1L Polyadenylate-binding protein 1-like Generic binding protein
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192 PAM Peptidyl-glycine alpha-amidating 
monooxygenase
Generic enzyme
193 PAQR5 Membrane progestin receptor gamma Generic receptor
194 PCNP PEST proteolytic signal-containing nuclear 
protein
Generic binding protein
195 PCNX Pecanex-like protein 1 Generic protein
196 PDCD6 Programmed cell death protein 6 Generic binding protein
197 PDGFC Platelet-derived growth factor C Receptor ligand
198 PDIA6 Protein disulfide-isomerase A6 Generic enzyme
199 PECI Peroxisomal 3,2-trans-enoyl-CoA isomerise Generic enzyme
200 PER3 Period circadian protein homolog 3 Generic binding protein
201 PGCP Plasma glutamate carboxypeptidase Generic protease
202 PHF20 PHD finger protein 20 Generic binding protein
203 PLCG2 1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase gamma-2
Generic phospholipase
204 PLEKHA3 Pleckstrin homology domain-containing family A 
member 3
Generic binding protein
205 PLLP Plasmolipin Generic channel
206 PMPCB Mitochondrial-processing peptidase subunit beta Metalloprotease
207 PNN Pinin Transcription factor
208 PPARA Peroxisome proliferator-activated receptor alpha Transcription factor
209 PPFIBP1 Liprin-beta-1 Generic binding protein
210 PPIL3 Peptidyl-prolyl cis-trans isomerase-like 3 Generic enzyme
211 PPP1R9A Neurabin-1 Generic binding protein
212 PRKRA Interferon-inducible double stranded RNA- 
dependent protein kinase activator A
Generic binding protein
213 PRUNE2 Protein prune homolog 2 Generic protein
BNIP2 motif-containing molecule at the C- 
terminal region 1
Generic protein
214 PTEN Phosphatidylinositol-3,4,5-trisphosphate 3- 
phosphatase and dual-specificity protein 
phosphatase PTEN
Lipid phosphatase
215 PTENP1 phosphatase and tensin homolog (mutated in 
multiple advanced cancers 1), pseudogene 1
Protein phosphatase
216 PURA Transcriptional activator protein Pur-alpha Transcription factor
217 PYROXD1 Pyridine nucleotide-disulfide oxidoreductase 
domain-containing protein 1
Generic enzyme
218 QPCT Glutaminyl-peptide cyclotransferase Generic enzyme
219 RAB11FIP3 Rab11 family-interacting protein 3 Regulators (GDI, GAP, 
GEF etc.)
220 RAB13 Ras-related protein Rab-13 RAS superfamily
221 RAP2B Ras-related protein Rap-2b RAS superfamily
222 RARS2 Probable arginyl-tRNA synthetase, mitochondrial Generic enzyme
223 RBM12 RNA-binding protein 12 Generic binding protein
224 RBM5 RNA-binding protein 5 Generic binding protein
225 RBM6 RNA-binding protein 6 Generic binding protein
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226 RBPJ Recombining binding protein suppressor of 
hairless
Transcription factor
227 RGS10 Regulator of G-protein signaling 10 Regulators (GDI, GAP, 
GEF etc.)
228 RGS5 Regulator of G-protein signaling 5 Regulators (GDI, GAP, 
GEF etc.)
229 RIMKLB Ribosomal protein S6 modification-like protein B Generic enzyme
230 RNASE4 Ribonuclease 4 Generic enzyme
231 RNF160 RING finger protein 160 Generic binding protein
232 RP11-9412.2 neuroblastoma breakpoint family, member 11- 
like
Generic protein
233 RPL14 60S ribosomal protein L14 Generic binding protein
234 RPL14P1
235 RPL17 60S ribosomal protein L17 Generic binding protein
236 RPL17P6
237 RPL22 60S ribosomal protein L22 Generic binding protein
238 RPL3 60S ribosomal protein L3 Generic binding protein
239 RPL30 60S ribosomal protein L30 Generic binding protein
240 RPL31 60S ribosomal protein L31 Generic binding protein
241 RPL36A 60S ribosomal protein L36a Generic binding protein
242 RPL36AP37 similar to large subunit ribosomal protein L36a Generic protein
243 RPL9 60S ribosomal protein L9 Generic binding protein
244 RPS10 40S ribosomal protein S10 Generic binding protein
245 RPS15A 40S ribosomal protein S15a Generic binding protein
246 RPS15AP19
247 RPS7 40S ribosomal protein S7 Generic binding protein
248 RSBN1 Round spermatid basic protein 1 Generic binding protein
249 RTTN Rotatin Generic binding protein
250 S100A10 Protein S100-A10 Receptor ligand
251 SAT2 Diamine acetyltransferase 2 Generic enzyme
252 SC65 Synaptonemal complex protein SC65 Generic protein
253 SCAMP1 Secretory carrier-associated membrane protein 
1
Generic binding protein
254 SCD Putative uncharacterized protein PR01933 Generic protein
Acyl-CoA desaturase Generic enzyme
255 SDC2 Syndecan-2 Generic receptor
256 SEC22B Vesicle-trafficking protein SEC22b Generic binding protein
257 SEC62 Translocation protein SEC62 Generic receptor
258 SEL1L Protein sel-1 homolog 1 Generic binding protein
259 SELK Selenoprotein K Generic binding protein
260 SEPT8 Septin-8 Generic binding protein
261 SFRS11 Splicing factor, arginine/serine-rich 11 Generic binding protein
262 SGK3 Serine/threonine-protein kinase Sgk3 Protein kinase
263 SH3KBP1 SH3 domain-containing kinase-binding protein 1 Generic binding protein
264 SLAMF7 SLAM family member 7 Generic receptor
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265 SLC25A36 Solute carrier family 25 member 36 T ransporter
266 SLC2A3 Solute carrier family 2, facilitated glucose 
transporter member 3
Transporter
267 SLC5A3 Sodium/myo-inositol cotransporter T ransporter
268 SMAD9 Mothers against decapentaplegic homolog 9 Transcription factor
269 SNHG5 RNA
270 SNHG6
271 SNHG8
272 SNORD50A RNA
273 SNORD50B
274 SNX21 Sorting nexin-21 Generic binding protein
275 SNX3 Sorting nexin-3 Generic binding protein
276 SNX5 Sorting nexin-5 Generic binding protein
277 SOX4 Transcription factor SOX-4 Transcription factor
278 SPAG4 Sperm-associated antigen 4 protein Generic binding protein
279 SRGAP2P1 SLIT-ROBO Rho GTPase activating protein 2 
pseudogene 1
Generic protein
280 SSR1 Translocon-associated protein subunit alpha Generic binding protein
281 ST3GAL6 Type 2 lactosamine alpha-2,3-sialyltransferase Generic enzyme
282 SYNE2 Nesprin-2 Generic binding protein
283 SYTL2 Synaptotagmin-like protein 2 Generic binding protein
284 TAF1D TATA box-binding protein-associated factor RNA 
polymerase I subunit D
Generic binding protein
285 TALD01 Transaldolase Generic enzyme
286 TAX1BP1 Taxi-binding protein 1 Generic binding protein
287 TBC1D3 TBC1 domain family member 3E/3F Generic protein
288 TBC1D3C TBC1 domain family member 3C/3D Regulators (GDI, GAP, 
GEF etc.)
289 TBC1D3F TBC1 domain family member 3 Regulators (GDI, GAP, 
GEF etc.)
290 TBC1D3G TBC1 domain family member 3G Regulators (GDI, GAP, 
GEF etc.)
291 TBC1D3H TBC1 domain family member 3-like protein 
LOC729837
Regulators (GDI, GAP, 
GEF etc.)
TBC1 domain family member 3E/3F Generic protein
292 TFB1M Dimethyladenosine transferase 1, mitochondrial Generic enzyme
293 THBD Thrombomodulin Generic receptor
294 TKT Transketolase Generic enzyme
295 TM4SF1 Transmembrane 4 L6 family member 1 Generic receptor
296 TM4SF4 Transmembrane 4 L6 family member 4 Generic receptor
297 TM9SF3 Transmembrane 9 superfamily member 3 Generic binding protein
298 TMED10 Transmembrane emp24 domain-containing 
protein 10
Generic binding protein
299 TMEM45B Transmembrane protein 45B Generic protein
300 TMEM49 Transmembrane protein 49 Generic protein
301 TMEM9 Transmembrane protein 9 Generic protein
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302 TMTC2 Transmembrane and TPR repeat-containing 
protein 2
Generic binding protein
303 TPP1 Tripeptidyl-peptidase 1 Generic protease
304 TRPM8 Transient receptor potential cation channel 
subfamily M member 8
Generic channel
305 TTC3 Tetratricopeptide repeat protein 3 Generic binding protein
306 TXNIP Thioredoxin-interacting protein Generic binding protein
307 UBE2I SUMO-conjugating enzyme UBC9 Generic enzyme
308 US01 General vesicular transport factor p115 Transporter
309 VAMP4 Vesicle-associated membrane protein 4 Generic protein
310 VEGFA Vascular endothelial growth factor A Receptor ligand
311 VKORC1 Vitamin K epoxide reductase complex subunit 1 Generic enzyme
312 VLDLR Very low-density lipoprotein receptor Generic receptor
313 WDR66 WD repeat-containing protein 66 Generic binding protein
314 WSB1 WD repeat and SOCS box-containing protein 1 Generic binding protein
315 XI ST RNA
316 XYLT2 Xylosyltransferase 2 Generic enzyme
317 YME1L1 ATP-dependent metalloprotease YME1L1 Metalloprotease
318 ZAK Mitogen-activated protein kinase kinase kinase 
MLT
Protein kinase
319 ZMYM2 Zinc finger MYM-type protein 2 Generic binding protein
320 ZNF12 Zinc finger protein 12 Generic binding protein
321 ZNF57 Zinc finger protein 57 Generic binding protein
322 ZNF804A Zinc finger protein 804A Generic binding protein
323 ZNF84 Zinc finger protein 84 Generic binding protein
324 ZNF91 Zinc finger protein 91 Transcription factor
325 hCG 19809
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Table 2.0 T-test cluster 2
# Gene Symbol Protein name Object type
1 ABCF2 ATP-binding cassette sub-family F member 2 Transporter
2 ACAP3 Arf-GAP with coiled-coil, ANK repeat and PH 
domain-containing protein 3
Regulators (GDI, GAP, 
GEF etc.)
3 ACIN1 Apoptotic chromatin condensation inducer in the 
nucleus
Generic binding protein
4 ACSL5 Long-chain-fatty-acid--CoA ligase 5 Generic enzyme
5 ACTBP9
6 ADAMTSL4 ADAMTS-like protein 4 Metalloprotease
7 ADRM1 Proteasomal ubiquitin receptor ADRM1 Generic binding protein
8 AFG3L2 AFG3-like protein 2 Metalloprotease
9 AGRN Agrin Generic binding protein
10 AKIRIN2 Akirin-2 Generic binding protein
11 AKT1 RAC-alpha serine/threonine-protein kinase Protein kinase
12 ANKRD40 Ankyrin repeat domain-containing protein 40 Generic protein
13 ANXA7 Annexin A7 Generic binding protein
14 AP1M1 AP-1 complex subunit mu-1 T ransporter
15 APOA1BP Apolipoprotein A-l-binding protein Generic binding protein
16 APRT Adenine phosphoribosyltransferase Generic enzyme
17 ARF3 ADP-ribosylation factor 3 RAS superfamily
18 ARID1A AT-rich interactive domain-containing protein 1A Generic binding protein
19 ARID3A AT-rich interactive domain-containing protein 3A Transcription factor
20 ARL2BP ADP-ribosylation factor-like protein 2-binding 
protein
Generic binding protein
21 ARPC4 Actin-related protein 2/3 complex subunit 4 Generic binding protein
22 ATF6 Cyclic AMP-dependent transcription factor ATF- 
6 alpha
Transcription factor
23 ATP6V0C V-type proton ATPase 16 kDa proteolipid 
subunit
Generic protein
24 ATP6V0D1 V-type proton ATPase subunit d 1 Transporter
25 ATXN1L Ataxin-1-like Generic binding protein
26 BAG5 BAG family molecular chaperone regulator 5 Generic binding protein
27 BAT1 Spliceosome RNA helicase BAT1 Generic enzyme
28 BRMS1 Breast cancer metastasis-suppressor 1 Generic binding protein
29 C18orf10 Tubulin polyglutamylase complex subunit 2 Generic protein
30 C19orf21 Uncharacterized protein C19orf21 Generic protein
31 C1orf85 Lysosomal protein NCU-G1 Generic protein
32 C20orf 108 Transmembrane protein C20orf108 Generic protein
33 C20orf29 Uncharacterized protein C20orf29 Generic protein
34 C2orf29 Uncharacterized protein C2orf29 Generic protein
35 C7orf49 Modulator of retrovirus infection homolog Generic protein
36 C9orf167 Torsin family protein C9orf167 Generic binding protein
37 CABIN 1 Calcineurin-binding protein cabin-1 Generic binding protein
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38 CALM1 Calmodulin Generic binding protein
39 CALM2 Calmodulin Generic binding protein
40 CALM3 Calmodulin Generic binding protein
41 CAPRI N1 Caprin-1 Generic binding protein
42 CAPZB F-actin-capping protein subunit beta Generic binding protein
43 CBS Cystathionine beta-synthase Generic enzyme
44 CC2D1A Coiled-coil and C2 domain-containing protein 
1A
Generic binding protein
45 CCDC109A Coiled-coil domain-containing protein 109A Generic protein
46 CCDC85C Coiled-coil domain-containing protein 85C Generic protein
47 CCDC90A Coiled-coil domain-containing protein 90A, 
mitochondrial
Generic protein
48 CCDC97 Coiled-coil domain-containing protein 97 Generic protein
49 CDS2 Phosphatidate cytidylyltransferase 2 Generic enzyme
50 CEACAM1 Carcinoembryonic antigen-related cell adhesion 
molecule 1
Generic protein
51 CENPB Major centromere autoantigen B Generic binding protein
52 CISH Cytokine-inducible SH2-containing protein Generic binding protein
53 CLN3 Batten in Generic binding protein
54 CLPTM1 Cleft lip and palate transmembrane protein 1 Generic protein
55 CNN3 Calponin-3 Generic binding protein
56 CNP 2')3'-cyclic-nucleotide 3-phosphodiesterase Generic enzyme
57 COMMD4 COMM domain-containing protein 4 Generic binding protein
58 COX5A Cytochrome c oxidase subunit 5A, mitochondrial Generic enzyme
59 CSNK1E Casein kinase I isoform epsilon Protein kinase
60 CTBP1 C-terminal-binding protein 1 Generic binding protein
61 CTDSP1 Carboxy-terminal domain RNA polymerase II 
polypeptide A small phosphatase 1
Protein phosphatase
62 CYB5B Cytochrome b5 type B Transporter
63 DCTN1 Dynactin subunit 1 Generic binding protein
64 DDX28 Probable ATP-dependent RNA helicase DDX28 Generic enzyme
65 DDX56 Probable ATP-dependent RNA helicase DDX56 Generic enzyme
66 DID01 Death-inducer obliterator 1 Generic binding protein
67 DMWD Dystrophia myotonica WD repeat-containing 
protein
Generic protein
68 ONAJB6 DnaJ homolog subfamily B member 6 Generic binding protein
69 DNAJC14 DnaJ homolog subfamily C member 14 Generic binding protein
70 DULLARD Serine/threonine-protein phosphatase dullard Generic phosphatase
71 E2F4 Transcription factor E2F4 Transcription factor
72 EAPP E2F-associated phosphoprotein Generic protein
73 EIF3B Eukaryotic translation initiation factor 3 subunit 
B
Generic binding protein
74 EIF4G1 Eukaryotic translation initiation factor 4 gamma 
1
Generic binding protein
75 ERBB2 Receptor tyrosine-protein kinase erbB-2 Receptor with enzyme 
activity
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76 ESRRA Steroid hormone receptor ERR1 Transcription factor
77 EVC Ellis-van Creveld syndrome protein Generic protein
78 EVI5L EVI5-like protein Regulators (GDI, GAP, 
GEF etc.)
79 EWSR1 RNA-binding protein EWS Generic binding protein
80 EXOC6B Exocyst complex component 6B Generic protein
81 EXOC7 Exocyst complex component 7 Generic protein
82 FAM100A Protein FAM100A Generic protein
83 FAM21A Protein FAM21A Generic phosphatase
84 FAM21B Protein FAM21B Generic protein
85 FAM21C Protein FAM21C Generic phosphatase
86 FAM21D Protein FAM21D Generic protein
87 FAM38A Protein FAM38A Generic protein
88 FAM53C Protein FAM53C Generic protein
89 FAM86B1 Protein FAM86B1 Generic protein
90 FARS2 Phenylalanyl-tRNA synthetase, mitochondrial Generic enzyme
91 FBXL14 F-box/LRR-repeat protein 14 Generic binding protein
92 FBX07 F-box only protein 7 Generic binding protein
93 FKBP1A Peptidyl-prolyl cis-trans isomerase FKBP1A Generic binding protein
94 FKRP Fukutin-related protein Generic enzyme
95 FLNA Filamin-A Generic binding protein
96 FUT1 Galactoside 2-alpha-L-fucosyltransferase 1 Generic enzyme
97 G3BP1 Ras GTPase-activating protein-binding protein 1 Generic enzyme
98 GAMT Guanidinoacetate N-methyltransferase Generic enzyme
99 GAS2L1 GAS2-like protein 1 Generic protein
100 GBA Glucosylceramidase Generic enzyme
101 GBAP
102 GCN1L1 Translational activator GCN1 Generic binding protein
103 GNA11 Guanine nucleotide-binding protein subunit 
alpha-11
G-alpha
104 GNAI2 Guanine nucleotide-binding protein G(i), alpha-2 
subunit
G-alpha
105 GOLGA6L4 Putative golgin subfamily A member 6-like 
protein 4
Generic protein
106 GPS2 G protein pathway suppressor 2 Regulators (GDI, GAP, 
GEF etc.)
107 GRINA Glutamate [NMDA] receptor-associated protein 
1
Ligand-gated ion- 
channel
108 GSPT1 Eukaryotic peptide chain release factor GTP- 
binding subunit ERF3A
Generic binding protein
109 GTF2F1 General transcription factor IIF subunit 1 Transcription factor
110 H1FX Histone H1x Generic binding protein
111 H2AFV Histone H2A.V Generic binding protein
112 HDGF Hepatoma-derived growth factor Generic binding protein
113 HEXIM1 Protein HEXIM1 Generic binding protein
114 HIST1H2BC Histone H2B type 1-C/E/F/G/l Generic binding protein
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115 HIST1H2BE Histone H2B type 1-C/E/F/G/l Generic binding protein
116 HIST1H2BF Histone H2B type 1-C/E/F/G/l Generic binding protein
117 HIST1H2BG Histone H2B type 1-C/E/F/G/l Generic binding protein
118 HIST1H2BI Histone H2B type 1-C/E/F/G/l Generic binding protein
119 HMG20A High mobility group protein 20A Transcription factor
120 HMGB3 High mobility group protein B3 Generic binding protein
121 HN1 Hematological and neurological expressed 1 
protein
Generic protein
122 HNRNPH2 Heterogeneous nuclear ribonucleoprotein H2 Generic binding protein
123 HNRNPU Heterogeneous nuclear ribonucleoprotein U Generic binding protein
124 ICOSLG ICOS ligand Generic receptor
125 ICT1 Immature colon carcinoma transcript 1 protein Generic binding protein
126 IFIT5 Interferon-induced protein with tetratricopeptide 
repeats 5
Generic binding protein
127 IFNGR2 Interferon-gamma receptor beta chain Generic receptor
128 ILF2 Interleukin enhancer-binding factor 2 Transcription factor
129 INO80E INO80 complex subunit E Generic protein
130 INTS5 Integrator complex subunit 5 Generic binding protein
131 IP04 lmportin-4 Transporter
132 IRF9 Interferon regulatory factor 9 Transcription factor
133 ISY1 Pre-mRNA-splicing factor ISY1 homolog Generic protein
134 KDM3B Lysine-specific demethylase 3B Generic enzyme
135 KIAA0196 Strumpellin Generic protein
136 KIAA0226 Uncharacterized protein KIAA0226 Generic protein
137 KIAA0284 Protein KIAA0284 Generic protein
138 KIAA1279 KIF1-binding protein Generic binding protein
139 KIAA1737 Uncharacterized protein KIAA1737 Generic protein
140 KLF13 Krueppel-like factor 13 Transcription factor
141 KRT7 Keratin, type II cytoskeletal 7 Generic binding protein
142 LARP1 La-related protein 1 Generic binding protein
143 LASP1 LIM and SH3 domain protein 1 Transporter
144 LDOC1L Protein LDOC1L Generic protein
145 LEMD2 LEM domain-containing protein 2 Generic protein
146 LIMK2 LIM domain kinase 2 Protein kinase
147 LOC100128612
148 LOC150776 Putative uncharacterized protein FLJ41352 Generic protein
149 LSM12 Protein LSM12 homolog Generic binding protein
150 MAD1L1 Mitotic spindle assembly checkpoint protein 
MAD1
Generic binding protein
151 MAP4 Microtubule-associated protein 4 Generic binding protein
152 MARK2 Serine/threonine-protein kinase MARK2 Protein kinase
153 MARVELD1 Putative MARVEL domain-containing protein 1 Generic protein
154 MAT2A S-adenosylmethionine synthetase isoform type- 
2
Generic enzyme
155 MCOLN1 Mucolipin-1 Generic channel
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156 MED22 Mediator of RNA polymerase II transcription 
subunit 22
Generic binding protein
157 METTL13 Methyltransferase-like protein 13 Generic enzyme
158 MFN2 Mitofusin-2 Generic binding protein
159 MICALL1 MICAL-like protein 1 Generic binding protein
160 MIIP Migration and invasion-inhibitory protein Generic protein
161 MINK1 Misshapen-like kinase 1 Protein kinase
162 MKL1 MKL/myocardin-like protein 1 Generic binding protein
163 MLLT6 Protein AF-17 Generic binding protein
164 MON1A Vacuolar fusion protein MON1 homolog A Generic protein
165 MPDU1 Mannose-P-dolichol utilization defect 1 protein Generic binding protein
166 MPRIP Myosin phosphatase Rho-interacting protein Generic binding protein
167 MSL1 Male-specific lethal 1 homolog Generic binding protein
168 MY018A Myosin-XVIIIa Generic binding protein
169 NACC1 Nucleus accumbens-associated protein 1 Generic binding protein
170 NADK NAD kinase Generic kinase
171 NAPA Alpha-soluble NSF attachment protein Transporter
172 NBL1 Neuroblastoma suppressor of tumorigenicity 1 Generic binding protein
173 NCOA5 Nuclear receptor coactivator 5 Generic binding protein
174 NECAP1 Adaptin ear-binding coat-associated protein 1 Generic binding protein
175 NKIRAS2 NF-kappa-B inhibitor-interacting Ras-like protein 
2
RAS superfamily
176 NOC4L Nucleolar complex protein 4 homolog Generic binding protein
177 NUP50 Nucleoporin 50 kDa Generic channel
178 NUP62 Nuclear pore glycoprotein p62 Generic channel
179 OPTN Optineurin Generic binding protein
180 OR7E104P
181 PACS2 Phosphofurin acidic cluster sorting protein 2 Generic protein
182 PAIP1 Polyadenylate-binding protein-interacting 
protein 1
Generic binding protein
183 PARP9 Poly [ADP-ribose] polymerase 9 Generic enzyme
184 PATZ1 POZ-, AT hook-, and zinc finger-containing 
protein 1
Generic binding protein
185 PBRM1 Protein polybromo-1 Generic binding protein
186 PCNXL3 Pecanex-like protein 3 Generic protein
187 PCYT1A Choline-phosphate cytidylyltransferase A Generic enzyme
188 PEBP1 Phosphatidylethanolamine-binding protein 1 Generic binding protein
189 PEF1 Peflin Generic binding protein
190 PFN1 Profilin-1 Generic binding protein
191 PGAP2 Post-GPI attachment to proteins factor 2 Generic binding protein
192 PGLS 6-phosphogluconolactonase Generic enzyme
193 PGRMC2 Membrane-associated progesterone receptor 
component 2
Generic receptor
194 PHF12 PHD finger protein 12 Generic binding protein
195 PHLDA3 Pleckstrin homology-like domain family A 
member 3
Generic binding protein
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196 PI4KA Phosphatidylinositol 4-kinase alpha Lipid kinase
197 PI4KAP1 Putative phosphatidylinositol 4-kinase alpha-like 
protein P1
Lipid kinase
198 PI4KAP2 Putative phosphatidylinositol 4-kinase alpha-like 
protein P2
Generic protein
199 PIP5K1C Phosphatidylinositol-4-phosphate 5-kinase type- 
1 gamma
Generic kinase
200 PISD Phosphatidylserine decarboxylase proenzyme Generic enzyme
201 PITPNA Phosphatidylinositol transfer protein alpha 
isoform
T ransporter
202 PLOD3 Procollagen-lysine,2-oxoglutarate 5- 
dioxygenase 3
Generic enzyme
203 PMEPA1 Transmembrane prostate androgen-induced 
protein
Generic binding protein
204 PML Probable transcription factor PML Transcription factor
205 PNMA1 Paraneoplastic antigen Ma1 Generic binding protein
206 PNPO Pyridoxine-5'-phosphate oxidase Generic enzyme
207 POLDIP2 Polymerase delta-interacting protein 2 Generic binding protein
208 POLRMT DNA-directed RNA polymerase, mitochondrial Generic enzyme
209 POM121 Nuclear envelope pore membrane protein POM 
121
Generic channel
210 POM121B Putative nuclear envelope pore membrane 
protein POM 121B
Generic protein
211 POM121C Nuclear envelope pore membrane protein POM 
121C
Generic channel
212 PPM1K Protein phosphatase 1K, mitochondrial Protein phosphatase
213 PPP1R10 Serine/threonine-protein phosphatase 1 
regulatory subunit 10
Generic binding protein
214 PPP1R9B Neurabin-2 Generic binding protein
215 PPP4R1 Serine/threonine-protein phosphatase 4 
regulatory subunit 1
Generic binding protein
216 PPP5C Serine/threonine-protein phosphatase 5 Protein phosphatase
217 PRCC Proline-rich protein PRCC Generic protein
218 PREB Prolactin regulatory element-binding protein Generic binding protein
219 PRIC285 Peroxisomal proliferator-activated receptor A- 
interacting complex 285 kDa protein
Generic binding protein
220 PRICKLE1 Prickle-like protein 1 Generic binding protein
221 PRKD2 Serine/threonine-protein kinase D2 Protein kinase
222 PSMB2 Proteasome subunit beta type-2 Generic protease
223 PSMB6 Proteasome subunit beta type-6 Generic protease
224 PSMD3 26S proteasome non-ATPase regulatory subunit 
3
Generic binding protein
225 PSME3 Proteasome activator complex subunit 3 Generic binding protein
226 PTBP1 Polypyrimidine tract-binding protein 1 Generic binding protein
227 PTPN9 Tyrosine-protein phosphatase non-receptor type 
9
Protein phosphatase
228 PTPRJ Receptor-type tyrosine-protein phosphatase eta Generic receptor
229 PYG02 Pygopus homolog 2 Generic binding protein
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230 RANBP10 Ran-binding protein 10 Generic protein
231 RAVER1 Ribonucleoprotein PTB-binding 1 Generic binding protein
232 RBBP4 Histone-binding protein RBBP4 Generic enzyme
233 RBM12 RNA-binding protein 12 Generic binding protein
234 RBMS1 RNA-binding motif, single-stranded-interacting 
protein 1
Generic binding protein
235 RCE1 CAAX prenyl protease 2 Generic protease
236 RHOG Rho-related GTP-binding protein RhoG RAS superfamily
237 RNF144B E3 ubiquitin-protein ligase RNF144B Generic enzyme
238 RNF19B E3 ubiquitin-protein ligase RNF19B Generic binding protein
239 RNF220 RING finger protein 220 Generic binding protein
240 RNF31 RING finger protein 31 Generic binding protein
241 RNF40 E3 ubiquitin-protein ligase BRE1B Generic enzyme
242 RNFT1 RING finger and transmembrane domain- 
containing protein 1
Generic binding protein
243 RRBP1 Ribosome-binding protein 1 Generic receptor
244 S100A2 Protein S100-A2 Generic binding protein
245 SAE1 SUMO-activating enzyme subunit 1 Generic enzyme
246 SARNP SAP domain-containing ribonucleoprotein Generic binding protein
247 SBF1 Myotubularin-related protein 5 Protein phosphatase
248 SENP3 Sentrin-specific protease 3 Generic protease
249 SF1 Splicing factor 1 Generic binding protein
250 SFRS1 Splicing factor, arginine/serine-rich 1 Generic binding protein
251 SFRS15 Splicing factor, arginine/serine-rich 15 Generic binding protein
252 SFRS2B Splicing factor, arginine/serine-rich 2B Generic binding protein
253 SFT2D2 Vesicle transport protein SFT2B Generic protein
254 SGPL1 Sphingosine-1-phosphate lyase 1 Generic enzyme
255 SGSH N-sulphoglucosamine sulphohydrolase Generic enzyme
256 SH2D3A SH2 domain-containing protein 3A Generic binding protein
257 SIK3 Serine/threonine-protein kinase SIK3 Protein kinase
258 SIRT6 NAD-dependent deacetylase sirtuin-6 Generic enzyme
259 SIVA1 Apoptosis regulatory protein Siva Generic binding protein
260 SLC35C1 GDP-fucose transporter 1 Transporter
261 SLC4A2 Anion exchange protein 2 Transporter
262 SLC4A5 Electrogenic sodium bicarbonate cotransporter 
4
T ransporter
263 SMARCA4 Probable global transcription activator SNF2L4 Generic enzyme
264 SMG5 Protein SMG5 Generic binding protein
265 SMG7 Protein SMG7 Generic binding protein
266 SMPD4 Sphingomyelin phosphodiesterase 4 Generic enzyme
267 SPATA24 Testis protein T6441 homolog Generic protein
268 SPHK2 Sphingosine kinase 2 Lipid kinase
269 SPOP Speckle-type POZ protein Generic binding protein
270 SPTAN1 Spectrin alpha chain, brain Generic binding protein
271 SRI Sorcin Generic binding protein
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272 STAT3 Signal transducer and activator of transcription 
3
Transcription factor
273 STAT6 Signal transducer and activator of transcription 
6
Transcription factor
274 STOML1 Stomatin-like protein 1 Generic binding protein
275 STRN4 Striatin-4 Generic binding protein
276 STUB1 STIP1 homology and U box-containing protein 1 Generic enzyme
277 SUPT6H Transcription elongation factor SPT6 Transcription factor
278 SYNCRIP Heterogeneous nuclear ribonucleoprotein Q Generic binding protein
279 TAGLN2 Transgelin-2 Generic protein
280 TBC1D25 TBC1 domain family member 25 Regulators (GDI, GAP, 
GEF etc.)
281 TBCC Tubulin-specific chaperone C Generic binding protein
282 TCEB3 Transcription elongation factor B polypeptide 3 Generic binding protein
283 TENC1 Tensin-like C1 domain-containing phosphatase Generic binding protein
284 TEX261 Protein TEX261 Generic protein
285 TFE3 Transcription factor E3 Transcription factor
286 TGOLN2 Trans-Golgi network integral membrane protein 
2
Generic binding protein
287 TH1L Negative elongation factor C/D Generic binding protein
288 TIAF1 TGFB1-induced anti-apoptotic factor 1 Generic binding protein
289 TIMM23 Mitochondrial import inner membrane 
translocase subunit Tim23
Generic protein
290 TMEM139 Transmembrane protein 139 Generic protein
291 TMEM160 Transmembrane protein 160 Generic protein
292 TMEM185B Transmembrane protein 185B Generic protein
293 TMEM199 Transmembrane protein 199 Generic protein
294 TMEM201 Transmembrane protein 201 Generic protein
295 TNRC18 Trinucleotide repeat-containing gene 18 protein Generic binding protein
296 TNRC6C Trinucleotide repeat-containing gene 6C protein Generic binding protein
297 TOPORS E3 ubiquitin-protein ligase Topors Generic enzyme
298 TRAF4 TNF receptor-associated factor 4 Generic binding protein
299 TRIM34 Tripartite motif-containing protein 34 Generic binding protein
300 TRIM6 Tripartite motif-containing protein 6 Generic binding protein
301 TRIM6-TRIM34 interferon-responsive finger protein 1 long form Generic protein
302 TRIM65 Tripartite motif-containing protein 65 Generic binding protein
303 TRIM69 Tripartite motif-containing protein 69 Generic binding protein
304 TSPAN14 Tetraspanin-14 Generic receptor
305 TSPYL5 Testis-specific Y-encoded-like protein 5 Generic protein
306 TSSC4 Protein TSSC4 Generic protein
307 TSTA3 GDP-L-fucose synthetase Generic enzyme
308 TTLL3 Tubulin monoglycylase TTLL3 Generic enzyme
309 UBA1 Ubiquitin-like modifier-activating enzyme 1 Generic enzyme
310 UBAP2L Ubiquitin-associated protein 2-like Generic binding protein
311 UBE2A Ubiquitin-conjugating enzyme E2 A Generic enzyme
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312 UBE2D2 Ubiquitin-conjugating enzyme E2 D2 Generic enzyme
313 UBE2M NEDD8-conjugating enzyme Ubc12 Generic enzyme
314 UBE2N Ubiquitin-conjugating enzyme E2 N Generic enzyme
315 UBE3C Ubiquitin-protein ligase E3C Generic enzyme
316 UMPS Uridine 5'-monophosphate synthase Generic enzyme
317 UQCRC1 Cytochrome b-c1 complex subunit 1, 
mitochondrial
Generic binding protein
318 URM1 Ubiquitin-related modifier 1 homolog Generic protein
319 VAPB Vesicle-associated membrane protein- 
associated protein B/C
Generic binding protein
320 VDR Vitamin D3 receptor Transcription factor
321 WDR18 WD repeat-containing protein 18 Generic protein
322 WDR5 WD repeat-containing protein 5 Generic binding protein
323 WDR77 Methylosome protein 50 Generic binding protein
324 WIZ Protein Wiz Generic binding protein
325 WWC1 Protein WWC1 Generic binding protein
326 YWHAB 14-3-3 protein beta/alpha Generic binding protein
327 YWHAH 14-3-3 protein eta Generic binding protein
328 ZDHHC12 Probable palmitoyltransferase ZDHHC12 Generic enzyme
329 ZDHHC3 Palmitoyltransferase ZDHHC3 Generic enzyme
330 ZDHHC8 Probable palmitoyltransferase ZDHHC8 Generic enzyme
331 ZFAND3 AN 1-type zinc finger protein 3 Generic binding protein
332 ZNF532 Zinc finger protein 532 Generic binding protein
333 ZNF592 Zinc finger protein 592 Generic binding protein
334 ZNF593 Zinc finger protein 593 Generic binding protein
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Used correlation distance metric, 
average linkage clustering, on logcen data.
Figure 4. ANOVA of genotype-specific changes in gene expression. Hierarchical clustering 
displaying the genotype specific transcriptional changes of 690 differentially regulated 
probesets in RASV12, BRAFV600E and RET/PTC1 oncogene infected thyrocytes. The 
columns correspond to the oncogene and the rows to each gene transcript. Red signifies up- 
regulation and green signifies down-regulation.
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Figure 5. Enrichment analysis of pathway folders identified in ANOVA cluster 1. The 
enrichment method was subjected to an FDR of 0.05. A, The order of map folders is based 
on their significance in the cluster. The dark orange bars dictate significance set at 0.05%. 
Although the light/orange bars are displayed they are not discussed due to the possibility of 
false positive results. For the ANOVA cluster 1, there were 21 map folders identified withl of 
significance. B, The corresponding heamap of the ANOVA cluster 1, displaying an overall 
expression pattern of 121 median/down-regulated probes in RASV12, down-regulated 
probes in RET/PTC1 and high/up-regulation in BRAFV600E. The columns correspond to the 
oncogenic condition and the rows to each gene transcript. Red signifies up-regulation and 
green signifies down-regulation, whilst median expression is signified by black.
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Figure 6. Enrichment analysis of pathway folders identified in ANOVA cluster 2. The 
enrichment method was subjected to an FDR of 0.05. A, The order of map folders is based 
on their significance in the cluster. The dark orange bars dictate significance set at 0.05%. 
Although the light/orange bars are displayed they are not discussed due to the possibility of 
false positive results. For the ANOVA cluster 2, there were 32 map folders identified with 1 of 
significance. B, The corresponding heamap of the ANOVA cluster 2, displaying an overall 
expression pattern of 96 median/down-regulated probes in RASV12, and BRAFV600E and 
high/up-regulated probes in RET/PTC1. The columns correspond to the oncogenic 
condition and the rows to each gene transcript. Red signifies up-regulation and green 
signifies down-regulation, whilst median expression is signified by black.
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Figure 7. Enrichment analysis of pathway folders identified in ANOVA cluster 3. The 
enrichment method was subjected to an FDR of 0.05. A, The order of map folders is based 
on their significance in the cluster. The dark orange bars dictate significance set at 0.05%. 
Although the light/orange bars are displayed they are not discussed due to the possibility of 
false positive results. For the ANOVA cluster 3, there were 32 map folders identified with 9 of 
significance. B, The corresponding heamap of the ANOVA cluster 3, displaying an overall 
expression pattern of 142 up-regulated/highly expressed probes in RET/PTC1, and 
downregulaed/low expression in RASV12 and median expression in BRAFV600E. The 
columns correspond to the oncogenic condition and the rows to each gene transcript. Red 
signifies up-regulation and green signifies down-regulation, whilst median expression is 
signified by black.
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Figure 8. Enrichment analysis of pathway folders identified in ANOVA cluster 4. The 
enrichment method was subjected to an FDR of 0.05. A, The order of map folders is based 
on their significance in the cluster. The dark orange bars dictate significance set at 0.05%. 
Although the light/orange bars are displayed they are not discussed due to the possibility of 
false positive results. For the ANOVA cluster 4, there were 32 map folders identified with 5 of 
significance. B, The corresponding heamap of the ANOVA cluster 4, displaying an overall 
expression pattern of 209 high/up-regulated probes in RASV12, median expression in 
BRAFV600E and median/low down-regulated probes in RET/PTC1. The columns correspond 
to the oncogenic condition and the rows to each gene transcript. Red signifies up-regulation 
and green signifies down-regulation, whilst median expression is signified by black.
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Figure 9. Enrichment analysis of pathway folders identified in ANOVA cluster 5. The 
enrichment method was subjected to an FDR of 0.05. A, The order of map folders is based 
on their significance in the cluster. The dark orange bars dictate significance set at 0.05%. 
Although the light/orange bars are displayed they are not discussed due to the possibility of 
false positive results. For the ANOVA cluster 5, there were 18 map folders identified with no 
significant maps. B, The corresponding heamap of the ANOVA cluster 5, displaying an 
overall expression pattern of 34 high/up-regulated probes in RASV12, median expression 
in RET/PTC1 and low/d own-regulated probes in BRAFV600E. The columns correspond to 
the oncogenic condition and the rows to each gene transcript. Red signifies up-regulation 
and green signifies down-regulation, whilst median expression is signified by black.
312
Table 3.0 ANOVA Cluster 1
# Gene Symbol Protein name Object type
1 ABL2 Tyrosine-protein kinase ABL2 Protein kinase
2 ADAMTS18 A disintegrin and metalloproteinase with 
thrombospondin motifs 18
Metalloprotease
3 AJAP1 Adherens junction-associated protein 1 Generic binding protein
4 ARID3A AT-rich interactive domain-containing protein 3A Transcription factor
5 BOK Bcl-2-related ovarian killer protein Generic binding protein
6 C1orf38 Protein THEMIS2 Generic enzyme
7 C2orf54 Uncharacterized protein C2orf54 Generic protein
8 CA2 Carbonic anhydrase 2 Generic enzyme
9 CALCOCOI Calcium-binding and coiled-coil domain- 
containing protein 1
Generic binding protein
10 CD9 CD9 antigen Receptor ligand
11 CDC42EP1 Cdc42 effector protein 1 Generic binding protein
12 CDSN Corneodesmosin Generic binding protein
13 CDYL Chromodomain Y-like protein Generic binding protein
14 CGN Cingulin Generic binding protein
15 CGNL1 Cingulin-like protein 1 Generic binding protein
16 CLCF1 Cardiotrophin-like cytokine factor 1 Receptor ligand
17 CLDN6 Claudin-6 Generic binding protein
18 CLSTN2 Calsyntenin-2 Generic binding protein
19 CLTB Clathrin light chain B Generic binding protein
20 CNKSR1 Connector enhancer of kinase suppressor of ras 
1
Generic binding protein
21 COROIB Coronin-1B Generic binding protein
22 CPPED1 Calcineurin-like phosphoesterase domain- 
containing protein 1
Generic enzyme
23 CYP4F11 Cytochrome P450 4F11 Generic enzyme
24 DBNDD2 Dysbindin domain-containing protein 2 Generic binding protein
25 DHRS9 Dehydrogenase/reductase SDR family member 
9
Generic enzyme
26 DIRC2 Disrupted in renal carcinoma protein 2 Generic protein
27 DOPEY2 Protein dopey-2 Generic protein
28 DUSP10 Dual specificity protein phosphatase 10 Protein phosphatase
29 DUSP5 Dual specificity protein phosphatase 5 Protein phosphatase
30 ELF3 ETS-related transcription factor Elf-3 Transcription factor
31 EPS8L1 Epidermal growth factor receptor kinase 
substrate 8-like protein 1
Generic binding protein
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32 ERBB3 Receptor tyrosine-protein kinase erbB-3 Receptor with enzyme 
activity
33 ESAM Endothelial cell-selective adhesion molecule Generic binding protein
34 F11R Junctional adhesion molecule A Generic binding protein
35 FAM150B Protein FAM150B Generic protein
36 FAM83A Protein FAM83A Generic protein
37 FAM83H Protein FAM83H Generic protein
38 FAM84B Protein FAM84B Generic binding protein
39 GNAL Guanine nucleotide-binding protein G(olf) 
subunit alpha
G-alpha
40 HCG22
41 HDGF Hepatoma-derived growth factor Generic binding protein
42 HOMER2 Homer protein homolog 2 Generic binding protein
43 HPGD 15-hydroxyprostaglandin dehydrogenase [NAD+] Generic enzyme
44 HSD17B2 Estradiol 17-beta-dehydrogenase 2 Generic enzyme
45 IL1RN lnterleukin-1 receptor antagonist protein Receptor ligand
46 ITGA2 Integrin alpha-2 Generic receptor
47 ITPKC Inositol-trisphosphate 3-kinase C Generic kinase
48 IVL Involucrin Generic binding protein
49 JUP Junction plakoglobin Generic binding protein
50 KCNF1 Potassium voltage-gated channel subfamily F 
member 1
Voltage-gated ion- 
channel
51 KIF1A Kinesin-like protein KIF1A Generic binding protein
52 KLF6 Krueppel-like factor 6 Transcription factor
53 KLHDC3 Kelch domain-containing protein 3 Generic binding protein
54 KLK10 Kallikrein-10 Generic protease
55 KLK6 Kallikrein-6 Generic protease
56 KLK7 Kallikrein-7 Generic protease
57 L1CAM Neural cell adhesion molecule L1 Generic binding protein
58 LAMC2 Laminin subunit gamma-2 Receptor ligand
59 LCN2 Neutrophil gelatinase-associated lipocalin Transporter
60 LPIN1 Lipin-1 Generic binding protein
61 LYPLA1 Acyl-protein thioesterase 1 Generic enzyme
62 MEAF6 Chromatin modification-related protein MEAF6 Generic protein
63 MED15 Mediator of RNA polymerase II transcription 
subunit 15
Generic binding protein
64 METRN Meteorin Generic protein
65 MFI2 Melanotransferrin Generic binding protein
66 MMP10 Stromelysin-2 Metalloprotease
67 MUC20 Mucin-20 Generic binding protein
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68 MYCN N-myc proto-oncogene protein Transcription factor
69 MY01C Myosin-lc Generic binding protein
70 MY01D Myosin-ld Generic binding protein
71 NDFIP1 NEDD4 family-interacting protein 1 Generic binding protein
72 NDRG4 Protein NDRG4 Generic protein
73 PHYHIPL Phytanoyl-CoA hydroxylase-interacting protein­
like
Generic protein
74 PI3 Elafin Generic binding protein
75 PLA2G2F Group IIF secretory phospholipase A2 Generic phospholipase
76 PLEKHA7 Pleckstrin homology domain-containing family A 
member 7
Generic binding protein
77 PPL Periplakin Generic binding protein
78 PRPS1 Ribose-phosphate pyrophosphokinase 1 Generic kinase
79 PRSS22 Brain-specific serine protease 4 Generic protease
80 PRSS37 Probable inactive trypsin-X2 Generic protein
81 PRSS8 Prostasin Generic protease
82 PSG1 Pregnancy-specific beta-1-glycoprotein 1 Generic protein
83 PSG4 Pregnancy-specific beta-1-glycoprotein 4 Generic protein
84 PSG9 Pregnancy-specific beta-1-glycoprotein 9 Generic protein
85 RAB11FIP1 Rab11 family-interacting protein 1 Generic binding protein
86 RAB15 Ras-related protein Rab-15 RAS superfamily
87 RALBP1 RalA-binding protein 1 Regulators (GDI, GAP, 
GEF etc.)
88 RNF14 E3 ubiquitin-protein ligase RNF14 Generic enzyme
89 RNF39 RING finger protein 39 Generic binding protein
90 RP1-21018.1 Kazrin Generic protein
91 RRAS2 Ras-related protein R-Ras2 RAS superfamily
92 RTN2 Reticu Ion-2 Generic binding protein
93 SCNN1A Amiloride-sensitive sodium channel subunit 
alpha
Generic protein
94 SDCBP2 Syntenin-2 Generic binding protein
95 SEC14L2 SEC 14-like protein 2 Transporter
96 SERPINB1 Leukocyte elastase inhibitor Generic binding protein
97 SIRPA Tyrosine-protein phosphatase non-receptor type 
substrate 1
Generic binding protein
98 SLC12A6 Solute carrier family 12 member 6 Transporter
99 SLC4A11 Sodium bicarbonate transporter-like protein 11 T ransporter
100 SMURF1 "1 E3 ubiquitin-protein ligase SMURF1 Generic enzyme
101 SMURF2 E3 ubiquitin-protein ligase SMURF2 Generic enzyme
102 SOX17 Transcription factor SOX-17 Transcription factor
103 SPRR1A Cornifin-A Generic binding protein
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104 SPRR1B Cornifin-B Generic binding protein
105 ST8SIA4 CMP-N-acetylneuraminate-poly-alpha-2,8-
sialyltransferase
Generic enzyme
106 SULT2B1 Sulfotransferase family cytosolic 2B member 1 Generic enzyme
107 SVIL Supervillin Generic binding protein
108 SYS1-DBNDD2
109 THSD7A Thrombospondin type-1 domain-containing 
jDrotein 7A
Generic protein
110 TICAM1 TIR domain-containing adapter molecule 1 Generic binding protein
111 TJP3 Tight junction protein ZO-3 Generic binding protein
112 TM7SF2 Delta(14)-sterol reductase Generic enzyme
113 TMCC3 Transmembrane and coiled-coil domains protein 
3
Generic protein
114 TSHZ1 Teashirt homolog 1 Generic binding protein
115 TTC9 Tetratricopeptide repeat protein 9A Generic binding protein
116 UCA1
117 UXS1 UDP-glucuronic acid decarboxylase 1 Generic enzyme
118 WDR45 WD repeat domain phosphoinositide-interacting 
protein 4
Generic protein
119 WNT9A Protein Wnt-9a Receptor ligand
120 ZADH2 Zinc-binding alcohol dehydrogenase domain- 
containing protein 2
Generic enzyme
121 ZDHHC13 Probable palmitoyltransferase ZDHHC13 Generic enzyme
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Table 4.0 ANOVA Cluster 2
# Gene Symbol Protein name Object type
1 ACSL6 Long-chain-fatty-acid--CoA ligase 6 Generic enzyme
2 APOL1 Apolipoprotein L1 Receptor ligand
3 BDNF Brain-derived neurotrophic factor Receptor ligand
4 BTN3A2 Butyrophilin subfamily 3 member A2 Generic protein
5 BTN3A3 Butyrophilin subfamily 3 member A3 Generic protein
6 C11orf82 Nitric oxide-inducible gene protein Generic protein
7 C12orf4 Uncharacterized protein C12orf4 Generic protein
8 C1S Basic proline-rich peptide IB-1 Generic binding protein
Complement C1s subcomponent Generic protease
9 C3 Complement C3 Generic binding protein
10 C3orf14 Uncharacterized protein C3orf14 Generic protein
11 CASP1 Caspase-1 Generic protease
12 CCNA2 Cyclin-A2 Generic binding protein
13 CCNB2 G2/mitotic-specific cyclin-B2 Generic binding protein
14 CD74 HLA class II histocompatibility antigen gamma 
chain
Generic receptor
15 CDC25B M-phase inducer phosphatase 2 Protein phosphatase
16 CD01 Cysteine dioxygenase type 1 Generic enzyme
17 COQ3 Hexaprenyldihydroxybenzoate 
methyltransferase, mitochondrial
Generic enzyme
18 COX6A1 Cytochrome c oxidase subunit 6A1, 
mitochondrial
Generic enzyme
19 CPXM1 Probable carboxypeptidase X1 Generic protease
20 CTSS Cathepsin S Generic protease
21 CXCL11 C-X-C motif chemokine 11 Receptor ligand
22 DKC1 H/ACA ribonucleoprotein complex subunit 4 Generic enzyme
23 DPY19L2 Protein dpy-19 homolog 2 Generic protein
24 DPY19L2P1 Protein dpy-19 homolog 2-like 1 Generic protein
25 DPY19L2P2 dpy-19-like 2 pseudogene 2 (C. elegans) Generic protein
26 DPY19L2P4 dpy-19-like 2 pseudogene 4 (C. elegans) Generic protein
27 ERP27 Endoplasmic reticulum resident protein ERp27 Generic protein
28 FAM163A UPF0417 protein FAM163A Generic binding protein
29 FARSB Phenylalanyl-tRNA synthetase beta chain Generic enzyme
30 FAS Tumor necrosis factor receptor superfamily 
member 6
Generic receptor
31 FKBP5 FK506-binding protein 5 Generic binding protein
32 GBP1 Interferon-induced guanylate-binding protein 1 Generic binding protein
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33 GBP3 Guanylate-binding protein 3 Generic enzyme
34 GGH Gamma-glutamyl hydrolase Generic protease
35 GLIPR1 Glioma pathogenesis-related protein 1 Generic protein
36 GNAS Guanine nucleotide-binding protein G(s) subunit 
alpha isoforms short
G-alpha
Neuroendocrine secretory protein 55 Generic enzyme
Protein ALEX G-alpha
Guanine nucleotide-binding protein G(s) subunit 
alpha isoforms XLas
G-alpha
37 GPER G-protein coupled estrogen receptor 1 GPCR
38 HIST1H2BK Histone H2B type 1-K Generic binding protein
39 IFI16 Gamma-interferon-inducible protein lfi-16 Generic binding protein
40 IFI30 Gamma-interferon-inducible lysosomal thiol 
reductase
Generic enzyme
41 IFITM2 Interferon-induced transmembrane protein 2 Generic binding protein
42 IGFBP5 Insulin-like growth factor-binding protein 5 Generic binding protein
43 IL10RB Interleukin-10 receptor beta chain Generic receptor
44 IL1R2 lnterleukin-1 receptor type II Generic receptor
45 IRF1 Interferon regulatory factor 1 Transcription factor
46 KIF16B Kinesin-like protein KIF16B Generic binding protein
47 KLF4 Krueppel-like factor 4 Transcription factor
48 KYNU Kynureninase Generic enzyme
49 LGALS1 Galectin-1 Receptor ligand
50 LOC100131642
51 LOC653879
52 ME1 NADP-dependent malic enzyme Generic enzyme
53 MKI67 Antigen KI-67 Generic binding protein
54 MLKL Mixed lineage kinase domain-like protein Protein kinase
55 NCOA7 Nuclear receptor coactivator 7 Generic binding protein
56 NID2 Nidogen-2 Generic binding protein
57 NMI N-myc-interactor Generic binding protein
58 NQ01 NAD(P)H dehydrogenase [quinone] 1 Generic enzyme
59 PCDH19 Protocadherin-19 Generic binding protein
60 PIK3R2 Phosphatidylinositol 3-kinase regulatory subunit 
beta
Generic binding protein
61 PML Probable transcription factor PML Transcription factor
62 PN01 RNA-binding protein PN01 Generic binding protein
63 POP5 Ribonuclease P/MRP protein subunit POP5 Generic enzyme
64 PSMB9 Proteasome subunit beta type-9 Generic protease
65 PSMC5 26S protease regulatory subunit 8 Generic enzyme
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66 PSME2 Proteasome activator complex subunit 2 Generic binding protein
67 PTN Pleiotrophin Receptor ligand
68 RAP1B Ras-related protein Rap-1 b RAS superfamily
69 RARRES3 Retinoic acid receptor responder protein 3 Generic protein
70 RNF5 E3 ubiquitin-protein ligase RNF5 Generic enzyme
71 RPLP0P1
72 SAMD9L Sterile alpha motif domain-containing protein 9- 
like
Generic protein
73 SERPING1 Plasma protease C1 inhibitor Generic binding protein
74 SFRS2 Splicing factor, arginine/serine-rich 2 Generic binding protein
75 SLC15A3 Solute carrier family 15 member 3 Transporter
76 SLC25A12 Calcium-binding mitochondrial carrier protein 
Aralarl
Transporter
77 SNRPF Small nuclear ribonucleoprotein F Generic binding protein
78 SP140L Nuclear body protein SP140-like protein Generic binding protein
79 STAMBPL1 AMSH-like protease Metalloprotease
80 STRN3 Striatin-3 Generic binding protein
81 TAP1 Antigen peptide transporter 1 Transporter
82 TAP2 Antigen peptide transporter 2 Transporter
83 TARP
84 TFRC Transferrin receptor protein 1 Generic receptor
85 TLR3 Toll-like receptor 3 Generic receptor
86 TMEM60 Transmembrane protein 60 Generic protein
87 TMEM97 Transmembrane protein 97 Generic protein
88 TRGV3 T-cell receptor gamma chain V region PT- 
gamma-1/2
Generic receptor
89 TRGV5 T cell receptor gamma variable 5 Generic receptor
90 TRIM22 E3 ubiquitin-protein ligase TRIM22 Transcription factor
91 UBFD1 Ubiquitin domain-containing protein UBFD1 Generic protein
92 UCHL1 Ubiquitin carboxyl-terminal hydrolase isozyme 
L1
Generic protease
93 VEGFC Vascular endothelial growth factor C Receptor ligand
94 XPR1 Xenotropic and polytropic retrovirus receptor 1 GPCR
95 ZNF236 Zinc finger protein 236 Transcription factor
96 hCG 1757335 Ras-related protein Rap-1 b-like protein RAS superfamily
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Table 5.0 ANOVA Cluster 3
# Gene Symbol Protein name Object type
1 ACIN1 Apoptotic chromatin condensation inducer in the 
nucleus
Generic binding protein
2 AGRN Agrin Generic binding protein
3 AKAP2 A-kinase anchor protein 2 Generic binding protein
4 AKT1 RAC-alpha serine/threonine-protein kinase Protein kinase
5 ANXA1 Annexin A1 Generic binding protein
6 BMP1 Bone morphogenetic protein 1 Metalloprotease
7 BRMS1 Breast cancer metastasis-suppressor 1 Generic binding protein
8 C14orf156 SRA stem-loop-interacting RNA-binding protein, 
mitochondrial
Generic binding protein
9 C17orf71 Protein SMG8 Generic binding protein
10 C19orf28 Uncharacterized MFS-type transporter C19orf28 Generic protein
11 C1orf43 Uncharacterized protein C1orf43 Generic protein
12 C2orf29 Uncharacterized protein C2orf29 Generic protein
13 CALM1 Calmodulin Generic binding protein
14 CALM2 Calmodulin Generic binding protein
15 CALM3 Calmodulin Generic binding protein
16 CBR3 Carbonyl reductase [NADPH] 3 Generic enzyme
17 CC2D1A Coiled-coil and C2 domain-containing protein 1A Generic binding protein
18 CCDC85C Coiled-coil domain-containing protein 85C Generic protein
19 CCND3 G1/S-specific cyclin-D3 Generic binding protein
20 CDC6 Cell division control protein 6 homolog Generic binding protein
21 CDS2 Phosphatidate cytidylyltransferase 2 Generic enzyme
22 CHCHD3 Coiled-coil-helix-coiled-coil-helix domain- 
containing protein 3, mitochondrial
Generic binding protein
23 CNN3 Calponin-3 Generic binding protein
24 CSNK1E Casein kinase I isoform epsilon Protein kinase
25 CSRP2BP Cysteine-rich protein 2-binding protein Generic binding protein
26 DDX58 Probable ATP-dependent RNA helicase DDX58 Generic enzyme
27 DTX3L E3 ubiquitin-protein ligase DTX3L Generic binding protein
28 EIF3B Eukaryotic translation initiation factor 3 subunit B Generic binding protein
29 EPSTI1 Epithelial-stromal interaction protein 1 Generic protein
30 EXOC7 Exocyst complex component 7 Generic protein
31 FAM100A Protein FAM100A Generic protein
32 FAM125A Multivesicular body subunit 12A Generic binding protein
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33 FAM38A Protein FAM38A Generic protein
34 FAM53C Protein FAM53C Generic protein
35 FBX04 F-box only protein 4 Generic binding protein
36 FILIP1L Filamin A-interacting protein 1-like Generic protein
37 FKRP Fukutin-related protein Generic enzyme
38 GDPD3 Glycerophosphodiester phosphodiesterase 
domain-containing protein 3
Generic enzyme
39 HAS3 Hyaluronan synthase 3 Generic enzyme
40 HEXIM1 Protein HEXIM1 Generic binding protein
41 HNRNPAB Heterogeneous nuclear ribonucleoprotein A/B Generic binding protein
42 HNRNPM Heterogeneous nuclear ribonucleoprotein M Generic binding protein
43 HSPA9 Stress-70 protein, mitochondrial Generic binding protein
44 IFI44L Interferon-induced protein 44-like Generic protease
45 IFIT3 Interferon-induced protein with tetratricopeptide 
repeats 3
Generic binding protein
46 IFITM1 Interferon-induced transmembrane protein 1 Generic binding protein
47 IFITM3 Interferon-induced transmembrane protein 3 Generic protein
48 ILF3 Interleukin enhancer-binding factor 3 Transcription factor
49 INO80C INO80 complex subunit C Generic protein
50 IRF1 Interferon regulatory factor 1 Transcription factor
51 KDM3B Lysine-specific demethylase 3B Generic enzyme
52 KIF23 Kinesin-like protein KIF23 Generic binding protein
53 KLF13 Krueppel-like factor 13 Transcription factor
54 KLF6 Krueppel-like factor 6 Transcription factor
55 KPNA2 Importin subunit alpha-2 Transporter
56 LAMP3 Lysosome-associated membrane glycoprotein 3 Generic protein
57 LAP3 Cytosol aminopeptidase Generic protease
58 LARP1 La-related protein 1 Generic binding protein
59 LMF2 Lipase maturation factor 2 Generic protein
60 LOC388796
61 LOC652147
62 LOC727996
63 LOC728216
64 LOC728438
65 LSG1 Large subunit GTPase 1 homolog Generic binding protein
66 LSM12 Protein LSM12 homolog Generic binding protein
67 MARVELD1 Putative MARVEL domain-containing protein 1 Generic protein
68 MAT2A S-adenosylmethionine synthetase isoform type-2 Generic enzyme
69 MCM3 DNA replication licensing factor MCM3 Generic binding protein
70 MED22 Mediator of RNA polymerase II transcription 
subunit 22
Generic binding protein
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71 MGST2 Microsomal glutathione S-transferase 2 Generic enzyme
72 MICALL1 MICAL-like protein 1 Generic binding protein
73 MRPL4 39S ribosomal protein L4, mitochondrial Generic binding protein
74 MSL1 Male-specific lethal 1 homolog Generic binding protein
75 MUC1 Mucin-1 Generic binding protein
76 MX1 Interferon-induced GTP-binding protein Mx1 Generic enzyme
77 MX2 Interferon-induced GTP-binding protein Mx2 Generic enzyme
78 NACC1 Nucleus accumbens-associated protein 1 Generic binding protein
79 NLRC5 Protein NLRC5 Generic binding protein
80 OAS1 2'-5'-oligoadenylate synthetase 1 Generic enzyme
81 OAS2 2'-5'-oligoadenylate synthetase 2 Generic enzyme
82 OAS3 2'-5'-oligoadenylate synthetase 3 Generic enzyme
83 OR7E104P
84 PACS2 Phosphofurin acidic cluster sorting protein 2 Generic protein
85 PALM2 Paralemmin-2 Generic kinase
86 PALM2-AKAP2 OTTHUMP00000063892 Generic binding protein
87 PARP1 Poly [ADP-ribose] polymerase 1 Generic enzyme
88 PARP9 Poly [ADP-ribose] polymerase 9 Generic enzyme
89 PCGF5 Polycomb group RING finger protein 5 Generic binding protein
90 PCNT Pericentrin Generic binding protein
91 PCNXL3 Pecanex-like protein 3 Generic protein
92 PDCD11 Protein RRP5 homolog Generic binding protein
93 PFN1 Profilin-1 Generic binding protein
94 PIGU Phosphatidylinositol glycan anchor biosynthesis 
class U protein
Generic binding protein
95 PLK2 Serine/threonine-protein kinase PLK2 Protein kinase
96 PPIL5 Peptidylprolyl isomerase-like 5 Generic enzyme
97 PPP2CA Serine/threonine-protein phosphatase 2A 
catalytic subunit alpha isoform
Protein phosphatase
98 RAN GTP-binding nuclear protein Ran RAS superfamily
99 RBBP4 Histone-binding protein RBBP4 Generic enzyme
100 RHOB Rho-related GTP-binding protein RhoB RAS superfamily
101 ROR1 Tyrosine-protein kinase transmembrane receptor 
ROR1
Receptor with enzyme 
activity
102 RYR1 Ryanodine receptor 1 Ligand-gated ion- 
channel
103 SAMD9 Sterile alpha motif domain-containing protein 9 Generic protein
104 SELI Ethanolaminephosphotransferase 1 Generic enzyme
105 SEPHS1 Selenide, water dikinase 1 Generic kinase
106 SFRS1 Splicing factor, arginine/serine-rich 1 Generic binding protein
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107 SFRS3 Splicing factor, arginine/serine-rich 3 Generic binding protein
108 SGPL1 Sphingosine-1 -phosphate lyase 1 Generic enzyme
109 SLC25A20 Mitochondrial carnitine/acylcarnitine carrier 
protein
Transporter
110 SLC38A7 Putative sodium-coupled neutral amino acid 
transporter 7
Generic binding protein
111 SMARCA4 Probable global transcription activator SNF2L4 Generic enzyme
112 SP110 Sp110 nuclear body protein Generic binding protein
113 SRRT Serrate RNA effector molecule homolog Generic binding protein
114 STAT1 Signal transducer and activator of transcription 
1 -alpha/beta
Transcription factor
115 STEAP3 Metalloreductase STEAP3 Generic enzyme
116 SYNCRIP Heterogeneous nuclear ribonucleoprotein Q Generic binding protein
117 TACC3 Transforming acidic coiled-coil-containing protein 
3
Generic binding protein
118 TAGLN2 Transgelin-2 Generic protein
119 TEAD4 Transcriptional enhancer factor TEF-3 Transcription factor
120 TEX261 Protein TEX261 Generic protein
121 TGOLN2 Trans-Golgi network integral membrane protein 
2
Generic binding protein
122 THBS1 Thrombospondin-1 Receptor ligand
123 TIMM22 Mitochondrial import inner membrane 
translocase subunit Tim22
Transporter
124 TK1 Thymidine kinase, cytosolic Generic kinase
125 TMEM140 Transmembrane protein 140 Generic protein
126 TMEM173 Transmembrane protein 173 Generic protein
127 TMEM201 Transmembrane protein 201 Generic protein
128 TMPO Lamina-associated polypeptide 2, isoform alpha Generic binding protein
Lamina-associated polypeptide 2, isoforms 
beta/gamma
Generic binding protein
129 TPX2 Targeting protein forXklp2 Generic binding protein
130 TRAFD1 TRAF-type zinc finger domain-containing protein 
1
Generic binding protein
131 TRIM21 52 kDa Ro protein Generic binding protein
132 TRIM26 Tripartite motif-containing protein 26 Generic binding protein
133 TRIM69 Tripartite motif-containing protein 69 Generic binding protein
134 TRIP13 Thyroid receptor-interacting protein 13 Generic binding protein
135 UBE3C Ubiquitin-protein ligase E3C Generic enzyme
136 UHRF1 E3 ubiquitin-protein ligase UHRF1 Generic enzyme
137 UMPS Uridine 5-monophosphate synthase Generic enzyme
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138 USP18 Ubl carboxyl-terminal hydrolase 18 Generic protease
139 WDR77 Methylosome protein 50 Generic binding protein
140 XAF1 XIAP-associated factor 1 Generic binding protein
141 YWHAB 14-3-3 protein beta/alpha Generic binding protein
142 ZWINT ZW10 interactor Generic binding protein
Table 6.0 ANOVA Cluster 4
# Gene Symbol Protein name Object type
1 ADAMTS1 A disintegrin and metalloproteinase with 
thrombospondin motifs 1
Metalloprotease
2 AGPAT9 Glycerol-3-phosphate acyltransferase 3 Generic enzyme
3 AHNAK2 Protein AHNAK2 Generic binding protein
4 AKAP12 A-kinase anchor protein 12 Generic binding protein
5 AKAP13 A-kinase anchor protein 13 Regulators (GDI, GAP, 
GEF etc.)
6 ALOX5 Arachidonate 5-lipoxygenase Generic enzyme
7 ANKRD37 Ankyrin repeat domain-containing protein 37 Generic binding protein
8 AP1S1 AP-1 complex subunit sigma-1A Transporter
9 APBB2 Amyloid beta A4 precursor protein-binding family 
B member 2
Generic binding protein
10 ARG2 Arginase-2, mitochondrial Generic enzyme
11 ARHGAP22 Rho GTPase-activating protein 22 Regulators (GDI, GAP, 
GEF etc.)
12 ARHGAP5 Rho GTPase-activating protein 5 Regulators (GDI, GAP, 
GEF etc.)
13 ARL1 ADP-ribosylation factor-like protein 1 RAS superfamily
14 ARL4C ADP-ribosylation factor-like protein 4C RAS superfamily
15 ATP1B1 Sodium/potassium-transporting ATPase subunit 
beta-1
Generic binding protein
16 BHLHE40 Class E basic helix-loop-helix protein 40 Transcription factor
17 BTBD7 BTB/POZ domain-containing protein 7 Generic binding protein
18 C12orf76 Uncharacterized protein C12orf76 Generic protein
19 C13orf36 Uncharacterized protein C13orf36 Generic protein
20 C18orf19 Uncharacterized protein C18orf19 Generic protein
21 C4orf47 UPF0602 protein C4orf47 Generic protein
22 C4orf49 Uncharacterized protein C4orf49 Generic protein
23 C7orf68 Hypoxia-inducible gene 2 protein Generic binding protein
24 CAMK2D Calcium/calmodulin-dependent protein kinase 
type II delta chain
Protein kinase
25 CBFA2T2 Protein CBFA2T2 Transcription factor
26 CCNG1 Cyclin-G1 Generic binding protein
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27 CD44 CD44 antigen Generic receptor
28 CD46 Membrane cofactor protein Generic receptor
29 CD55 Complement decay-accelerating factor Generic binding protein
30 CEP57 Centrosomal protein of 57 kDa Generic binding protein
31 CHPT1 Cholinephosphotransferase 1 Generic enzyme
32 CLEC11A C-type lectin domain family 11 member A Receptor ligand
33 CPD Carboxypeptidase D Generic protease
34 CTBS Di-N-acety Ich itobiase Generic enzyme
35 CTSB Cathepsin B Generic protease
36 CTTN Src substrate cortactin Generic binding protein
37 CXCR4 C-X-C chemokine receptor type 4 GPCR
38 DCBLD2 Discoidin, CUB and LCCL domain-containing 
protein 2
Generic binding protein
39 DCUN1D4 DCN1-like protein 4 Generic protein
40 DPY30 Protein dpy-30 homolog Generic binding protein
41 DRAM2 DNA damage-regulated autophagy modulator 
protein 2
Generic protein
42 EGFR Epidermal growth factor receptor Receptor with enzyme 
activity
43 EHF ETS homologous factor Transcription factor
44 EIF3D Eukaryotic translation initiation factor 3 subunit D Generic binding protein
45 EIF3E Eukaryotic translation initiation factor 3 subunit E Generic binding protein
46 ELTD1 EGF, latrophilin and seven transmembrane 
domain-containing protein 1
GPCR
47 EPRS Bifunctional aminoacyl-tRNA synthetase Generic enzyme
48 ERN1 Serine/threonine-protein 
kinase/endoribonuclease IRE1
Protein kinase
49 ER01L EROI-like protein alpha Generic enzyme
50 ERP44 Endoplasmic reticulum resident protein ERp44 Generic binding protein
51 ETNK1 Ethanolamine kinase 1 Generic kinase
52 ETV3 ETS translocation variant 3 Transcription factor
53 FAM110C Protein FAM110C Generic protein
54 FAM162A UPF0389 protein FAM162A Generic protein
55 FAM167A UPF0484 protein FAM167A Generic protein
56 FAM45A Protein FAM45A Generic protein
57 FAM45B Protein FAM45B Generic protein
58 FIBCD1 Fibrinogen C domain-containing protein 1 Generic binding protein
59 FNTA Protein
farnesyltransferase/geranylgeranyltransferase 
type-1 subunit alpha
Generic enzyme
60 FOXL1 Forkhead box protein L1 Transcription factor
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61 FXR1 Fragile X mental retardation syndrome-related 
protein 1
Generic binding protein
62 FZD10 Frizzled-10 GPCR
63 G0S2 Putative lymphocyte G0/G1 switch protein 2 Generic protein
64 GALNT5 Polypeptide N-acetylgalactosaminyltransferase 5 Generic enzyme
65 GALNTL2 Polypeptide N-acetylgalactosaminyltransferase- 
like protein 2
Generic enzyme
66 GJC1 Gap junction gamma-1 protein Generic channel
67 GLS Glutaminase kidney isoform, mitochondrial Generic enzyme
68 GLT8D1 Glycosyltransferase 8 domain-containing protein 
1
Generic enzyme
69 GOLGB1 Golgin subfamily B member 1 Generic binding protein
70 GOLT1A Vesicle transport protein GOT1A Generic binding protein
71 GPR155 Integral membrane protein GPR155 Generic receptor
72 GYS2 Glycogen [starch] synthase, liver Generic enzyme
73 HLTF Helicase-like transcription factor Generic binding protein
74 HOMER1 Homer protein homolog 1 Generic binding protein
75 HSP90B1 Endoplasmin Generic binding protein
76 IGFBP3 Insulin-like growth factor-binding protein 3 Generic binding protein
77 ING2 Inhibitor of growth protein 2 Generic binding protein
78 I NSC Protein inscuteable homolog Generic binding protein
79 INSIG2 Insulin-induced gene 2 protein Generic binding protein
80 INTS6 Integrator complex subunit 6 Generic enzyme
81 IRF6 Interferon regulatory factor 6 Transcription factor
82 IVNS1ABP Influenza virus NS1A-binding protein Generic binding protein
83 JARID2 Protein Jumonji Generic binding protein
84 KDM3A Lysine-specific demethylase 3A Generic enzyme
85 KDM5B Lysine-specific demethylase 5B Transcription factor
86 KIAA0430 Limkain-b1 Generic binding protein
87 KIAA1143 Uncharacterized protein KIAA1143 Generic protein
88 KIAA1244 Brefeldin A-inhibited guanine nucleotide- 
exchange protein 3
Regulators (GDI, GAP, 
GEF etc.)
89 KISS1R KiSS-1 receptor GPCR
90 KLHL24 Kelch-like protein 24 Generic binding protein
91 LAMB3 Laminin subunit beta-3 Receptor ligand
92 LAMC2 Laminin subunit gamma-2 Receptor ligand
93 LAPTM4A Lysosomal-associated transmembrane protein 
4A
Generic protein
94 LEMD1 LEM domain-containing protein 1 Generic protein
95 LEPR Leptin receptor Generic receptor
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96 LGR5 Leucine-rich repeat-containing G-protein coupled 
receptor 5
GPCR
97 LIMA1 LIM domain and actin-binding protein 1 Generic binding protein
98 LIPG Endothelial lipase Generic phospholipase
99 LMAN1 Protein ERGIC-53 Generic binding protein
100 LOC149832
101 LOC387763 Protein Ag2 homolog Generic protein
102 LOC554202 Putative uncharacterized protein LOC554202 Generic protein
103 LOC729082
104 LOC729222
105 LOX Protein-lysine 6-oxidase Generic enzyme
106 LRRC16A Leucine-rich repeat-containing protein 16A Generic binding protein
107 LRRFIP1 Leucine-rich repeat flightless-interacting protein 
1
Transcription factor
108 LTA4H Leukotriene A-4 hydrolase Generic enzyme
109 MAN2A1 Alpha-mannosidase 2 Generic enzyme
110 MAP2 Microtubule-associated protein 2 Generic binding protein
111 MAP4K4 Mitogen-activated protein kinase kinase kinase 
kinase 4
Protein kinase
112 MAST4 Microtubule-associated serine/threonine-protein 
kinase 4
Protein kinase
113 MBOAT2 Lysophospholipid acyltransferase 2 Generic enzyme
114 METTL5 Methyltransferase-like protein 5 Generic enzyme
115 MIB1 E3 ubiquitin-protein ligase MIB1 Generic enzyme
116 MPZL2 Myelin protein zero-like protein 2 Generic binding protein
117 MREG Melanoregulin Generic protein
118 MRI1 Methylthioribose-1 -phosphate isomerase Generic binding protein
119 MTSS1 Metastasis suppressor protein 1 Generic binding protein
120 MXI1 MAX-interacting protein 1 Transcription factor
121 NCRNA00201
122 NCRNA00219 Putative uncharacterized protein TIGA1 Generic protein
123 NDRG1 Protein NDRG1 Generic binding protein
124 NFKBIZ NF-kappa-B inhibitor zeta Generic binding protein
125 NGLY1 Peptide-N(4)-(N-acetyl-beta- 
glucosaminyl)asparagine amidase
Generic enzyme
126 NOTCH2NL Notch homolog 2 N-terminal-like protein Generic binding protein
127 NRIP3 Nuclear receptor-interacting protein 3 Generic binding protein
128 NT5E 5'-nucleotid,ase Generic phosphatase
129 OPN3 Opsin-3 GPCR
130 PAM Peptidyl-glycine alpha-amidating 
monooxygenase
Generic enzyme
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131 PDGFC Platelet-derived growth factor C Receptor ligand
132 PECI Peroxisomal 3,2-trans-enoyl-CoA isomerase Generic enzyme
133 PHF20 PHD finger protein 20 Generic binding protein
134 PHLDA1 Pleckstrin homology-like domain family A 
member 1
Generic binding protein
135 PIK3CB Phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit beta isoform
Lipid kinase
136 PLAT Tissue-type plasminogen activator Generic protease
137 PLCG2 1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase gamma-2
Generic phospholipase
138 PPFIBP1 Liprin-beta-1 Generic binding protein
139 PPP1R3B Protein phosphatase 1 regulatory subunit 3B Protein phosphatase
140 PRKRA Interferon-inducible double stranded RNA- 
dependent protein kinase activator A
Generic binding protein
141 PRUNE2 Protein prune homolog 2 Generic protein
BNIP2 motif-containing molecule at the C- 
terminal region 1
Generic protein
142 PSG1 Pregnancy-specific beta-1-glycoprotein 1 Generic protein
143 PTEN Phosphatidylinositol-3,4,5-trisphosphate 3- 
phosphatase and dual-specificity protein 
phosphatase PTEN
Lipid phosphatase
144 QPCT Glutaminyl-peptide cyclotransferase Generic enzyme
145 RAB13 Ras-related protein Rab-13 RAS superfamily
146 RAP2B Ras-related protein Rap-2b RAS superfamily
147 RBM5 RNA-binding protein 5 Generic binding protein
148 RBM6 RNA-binding protein 6 Generic binding protein
149 RBPJ Recombining binding protein suppressor of 
hairless
Transcription factor
150 RGS20 Regulator of G-protein signaling 20 Regulators (GDI, GAP, 
GEF etc.)
151 RNASE4 Ribonuclease 4 Generic enzyme
152 RPL22 60S ribosomal protein L22 Generic binding protein
153 RPL31 60S ribosomal protein L31 Generic binding protein
154 RPL31P10
155 RPL31P17
156 RPL31P18
157 RPL31P39
158 RPL31P4 similar to ribosomal protein L31 Generic protein
159 RPL5 60S ribosomal protein L5 Generic binding protein
160 RRAS2 Ras-related protein R-Ras2 RAS superfamily
161 SAT1 Diamine acetyltransferase 1 Generic enzyme
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162 SATB1 DNA-binding protein SATB1 Transcription factor
163 SCAMP1 Secretory carrier-associated membrane protein 
1
Generic binding protein
164 SCD Acyl-CoA desaturase Generic enzyme
Putative uncharacterized protein PR01933 Generic protein
165 SDC2 Syndecan-2 Generic receptor
166 SEL1L Protein sel-1 homolog 1 Generic binding protein
167 SERTAD2 SERTA domain-containing protein 2 Generic binding protein
168 SH3YL1 SH3 domain-containing YSC84-like protein 1 Generic binding protein
169 SLAMF7 SLAM family member 7 Generic receptor
170 SLC2A14 Solute carrier family 2, facilitated glucose 
transporter member 14
T ransporter
171 SLC2A3 Solute carrier family 2, facilitated glucose 
transporter member 3
T ransporter
172 SLC5A3 Sodium/myo-inositol cotransporter T ransporter
173 SNX21 Sorting nexin-21 Generic binding protein
174 SPAG4 Sperm-associated antigen 4 protein Generic binding protein
175 SPIRE1 Protein spire homolog 1 Generic binding protein
176 SPON1 Spondin-1 Generic binding protein
177 SPRY2 Protein sprouty homolog 2 Generic binding protein
178 SRGAP2P1 SLIT-ROBO Rho GTPase activating protein 2 
pseudogene 1
Generic protein
179 SSTR1 Somatostatin receptor type 1 GPCR
180 TAF1D TATA box-binding protein-associated factor RNA 
polymerase I subunit D
Generic binding protein
181 TAF9B Transcription initiation factor TFIID subunit 9B Generic binding protein
182 TCEA3 Transcription elongation factor A protein 3 Generic binding protein
183 TFB1M Dimethyladenosine transferase 1, mitochondrial Generic enzyme
184 IG Thyroglobulin Generic binding protein
185 THBD Thrombomodulin Generic receptor
186 THSD4 Thrombospondin type-1 domain-containing 
protein 4
Generic protease
187 TLE1 Transducin-like enhancer protein 1 Generic binding protein
188 TMEM106B Transmembrane protein 106B Generic protein
189 TMEM117 Transmembrane protein 117 Generic protein
190 TMEM49 Transmembrane protein 49 Generic protein
191 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 Generic binding protein
192 TPP1 Tripeptidyl-peptidase 1 Generic protease
193 TRPM8 Transient receptor potential cation channel 
subfamily M member 8
Generic channel
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194 TSHZ1 Teashirt homolog 1 Generic binding protein
195 TXNIP Thioredoxin-interacting protein Generic binding protein
196 UBE2B Ubiquitin-conjugating enzyme E2 B Generic enzyme
197 UBE2I SUMO-conjugating enzyme UBC9 Generic enzyme
198 USOI General vesicular transport factor p115 Transporter
199 USP10 Ubiquitin carboxyl-terminal hydrolase 10 Generic protease
200 VAMP1 Vesicle-associated membrane protein 1 Generic binding protein
201 VEGFA Vascular endothelial growth factor A Receptor ligand
202 VLDLR Very low-density lipoprotein receptor Generic receptor
203 WSB1 WD repeat and SOCS box-containing protein 1 Generic binding protein
204 XIST RNA
205 XYLT2 Xylosyltransferase 2 Generic enzyme
206 YPEL4 Protein yippee-like 4 Generic protein
207 ZMYM2 Zinc finger MYM-type protein 2 Generic binding protein
208 ZNF185 Zinc finger protein 185 Generic binding protein
209 ZNF804A Zinc finger protein 804A Generic binding protein
Table 7.0 ANOVA Cluster 5
# Gene Symbol Protein name Object type
1 ADM ADM Receptor ligand
2 AK3L1 Adenylate kinase isoenzyme 4, mitochondrial Generic kinase
3 ANKMY2 Ankyrin repeat and MYND domain-containing 
protein 2
Generic binding protein
4 C18orf19 Uncharacterized protein C18orf19 Generic protein
5 CDH6 Cadherin-6 Generic binding protein
6 CLU Clusterin Generic binding protein
7 DEGS1 Sphingolipid delta(4)-desaturase DES1 Generic enzyme
8 EFEMP1 EGF-containing fibulin-like extracellular matrix 
protein 1
Generic binding protein
9 EIF2S2 Eukaryotic translation initiation factor 2 subunit 2 Generic binding protein
10 EPAS1 Endothelial PAS domain-containing protein 1 Transcription factor
11 ERRFI1 ERBB receptor feedback inhibitor 1 Generic binding protein
12 FAM13A Protein FAM13A Generic protein
13 FKBP11 FK506-binding protein 11 Generic enzyme
14 HEXB Beta-hexosaminidase subunit beta Generic enzyme
15 HSPA5 78 kDa glucose-regulated protein Generic binding protein
16 HSPD1 60 kDa heat shock protein, mitochondrial Generic binding protein
17 HSPH1 Heat shock protein 105 kDa Generic binding protein
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18 JMJD6 Bifunctional arginine demethylase and lysyl- 
hydroxylase JMJD6
Generic enzyme
19 LGALS8 Galectin-8 Receptor ligand
20 ME2 NAD-dependent malic enzyme, mitochondrial Generic enzyme
21 MGC9913 MGC9913 Generic protein
22 MGST1 Microsomal glutathione S-transferase 1 Generic enzyme
23 MON2 Protein MON2 homolog T ransporter
24 P4HA2 Prolyl 4-hydroxylase subunit alpha-2 Generic enzyme
25 PAICS Multifunctional protein ADE2 Generic enzyme
26 PCYOX1L Prenylcysteine oxidase-like Generic enzyme
27 PDIA5 Protein disulfide-isomerase A5 Generic enzyme
28 PDIA6 Protein disulfide-isomerase A6 Generic enzyme
29 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6- 
biphosphatase 3
Generic enzyme
30 PGM1 Phosphoglucomutase-1 Generic enzyme
31 PPIL3 Peptidyl-prolyl cis-trans isomerase-like 3 Generic enzyme
32 SNHG1
33 SORBS2 Sorbin and SH3 domain-containing protein 2 Generic binding protein
34 TFPI2 Tissue factor pathway inhibitor 2 Generic binding protein
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